<SEC-DOCUMENT>0001654954-19-010735.txt : 20190913
<SEC-HEADER>0001654954-19-010735.hdr.sgml : 20190913
<ACCEPTANCE-DATETIME>20190913161203
ACCESSION NUMBER:		0001654954-19-010735
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		58
FILED AS OF DATE:		20190913
DATE AS OF CHANGE:		20190913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233748
		FILM NUMBER:		191092683

	BUSINESS ADDRESS:	
		STREET 1:		310 N. WESTLAKE BLVD.
		STREET 2:		SUITE 206
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		310 N. WESTLAKE BLVD.
		STREET 2:		SUITE 206
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>gtbp_s12019.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Registration No. 333-</font>&#xA0;</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Washington, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 16px">
FORM S-1</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 24px">
GT BIOPHARMA, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Exact name of registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
DELAWARE</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(State or other jurisdiction of incorporation or
organization)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
2834</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Primary Standard Industrial Classification Code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
94-1620407</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(I.R.S. Employer Identification Number)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
9350 Wilshire Blvd. Suite 203</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Beverly Hills, CA 90212</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
(800) 304-9888</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;(Address, including zip code, and telephone number, including
area code, of registrant's principal executive
offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
The Corporation Trust Company</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Corporation Trust Center</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
1209 Orange Street</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Wilmington, Delaware 19801</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Telephone: (302) 658-7581</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(Name, address, including zip code, and telephone number, including
area code, of agent for service)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Copies of Communications to:</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Gary R. Henrie, Esq.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
P.O. Box 5174</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Etna, WY 83118</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Tel: (309) 313-5092</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Email: grhlaw@hotmail.com</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Approximate date of commencement of proposed sale to
public:</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
From time to time after the effective date of this registration
statement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If any securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. [X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, check
the following box and list the Securities Act registration
statement number of the earlier effective registration statement
for the same offering. [ &#xA0;]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [
&#xA0;]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If this Form is a post-effective amendment filed pursuant to Rule
462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [
&#xA0;]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
[&#xA0; ]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If delivery of the prospectus is expected to be made pursuant to
Rule 434, please check the following box. [ &#xA0;]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; break-after: page; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CALCULATION OF REGISTRATION FEE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: bottom; width: 32%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="color: rgb(0, 0, 0); font-weight: bold; font-family: Times New Roman;">
Title of Each Class of Securities To Be
Registered</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 16%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Amount to</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
be</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Registered</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 17%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Proposed Maximum</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Offering Price</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Per Share</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 17%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Proposed Maximum</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Aggregate</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Offering Price</font></font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Amount of</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Registration Fee</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 32%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Common stock, par value $.001 per share</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 16%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
41,473,822 shares(1)</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 17%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$0.1725(2)</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 17%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$7,154,234.30</font></div>
</td>
<td style="vertical-align: bottom; width: 1%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
$867.10</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(1)&#xA0; &#xA0; The 41,473,822 common shares are being registered
for resale by Selling Stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(2)&#xA0; &#xA0; The closing price of the common shares on
September 11, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
The Registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of
1933 or until the registration statement shall become effective on
such date as the Commission, acting pursuant to said Section 8(a),
may determine.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The information in this prospectus is not complete and may be
changed. The selling stockholders may not sell these securities
until the registration statement filed with the Securities and
Exchange Commission is effective. This prospectus is not an offer
to sell these securities and the selling stockholders are not
soliciting offers to buy these securities in any state where such
offers are not permitted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Subject to completion,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
September&#xA0; _____, 2019&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font><br>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
PROSPECTUS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
41,473,822 Shares</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
GT BIOPHARMA, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are registering the resale of 41,473,822 shares of common stock
of GT Biopharma, Inc., a Delaware corporation (the "Company"), by
the Selling Stockholders. Of those shares, 36,430,505 may be
acquired upon the conversion of notes and 5,043,317 may be aquired
upon the conversion of Series J-1 Preferred Stock (the "Conversion
Shares").&#xA0;&#xA0; The Selling Stockholders will receive all of
the proceeds from the sale of the Conversion Shares. We will pay
all expenses incident to the registration of the shares under the
Securities Act of 1933, as amended.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
At the present time our common stock is listed on the OTCQB under
the symbol GTBP. The Selling Stockholders will sell the shares at
prevailing market prices or at privately negotiated
prices.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Investing in our common stock involves risks, which are described
in the "Risk Factors" section beginning on page 10 of this
prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The date of this prospectus is September _____, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
TABLE OF CONTENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
You should rely only on the information contained in this
prospectus. We have not authorized any person to provide you with
any information or represent anything not contained in this
prospectus, and, if given or made, any such other information or
representation should not be relied upon as having been authorized
by us. The selling stockholders are not offering to sell, or
seeking offers to buy, our common stock in any jurisdiction where
the offer or sale is not permitted. You should not assume that the
information provided in this prospectus is accurate as of any date
other than the date on the front cover of this
prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 91%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Page</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#prospectus"><font style="font-family: Times New Roman; font-size: 13px;">PROSPECTUS
SUMMARY</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#prospectus"><font style="font-family: Times New Roman; font-size: 13px">2</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#risk"><font style="font-family: Times New Roman; font-size: 13px;">RISK
FACTORS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#risk"><font style="font-family: Times New Roman; font-size: 13px">7</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#use"><font style="font-family: Times New Roman; font-size: 13px;">USE OF
PROCEEDS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#use"><font style="font-family: Times New Roman; font-size: 13px">22</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#market"><font style="font-family: Times New Roman; font-size: 13px;">MARKET FOR OUR
COMMON STOCK AND RELATED STOCKHOLDER
MATTERS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#market"><font style="font-family: Times New Roman; font-size: 13px">22</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#managements"><font style="font-family: Times New Roman; font-size: 13px;">MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#managements"><font style="font-family: Times New Roman; font-size: 13px">23</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#description"><font style="font-family: Times New Roman; font-size: 13px;">DESCRIPTION OF
BUSINESS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#description"><font style="font-family: Times New Roman; font-size: 13px">27</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#management"><font style="font-family: Times New Roman; font-size: 13px;">MANAGEMENT</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#management"><font style="font-family: Times New Roman; font-size: 13px">43</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#executive"><font style="font-family: Times New Roman; font-size: 13px;">EXECUTIVE
COMPENSATION</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#executive"><font style="font-family: Times New Roman; font-size: 13px">44</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#voting"><font style="font-family: Times New Roman; font-size: 13px;">VOTING SECURITIES
AND PRINCIPAL HOLDERS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#voting"><font style="font-family: Times New Roman; font-size: 13px">46</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#selling"><font style="font-family: Times New Roman; font-size: 13px;">SELLING
STOCKHOLDERS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#selling"><font style="font-family: Times New Roman; font-size: 13px">48</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#plan"><font style="font-family: Times New Roman; font-size: 13px;">PLAN OF
DISTRIBUTION</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#plan"><font style="font-family: Times New Roman; font-size: 13px">49</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#capitalstock"><font style="font-family: Times New Roman; font-size: 13px;">DESCRIPTION OF
CAPITAL STOCK</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#capitalstock"><font style="font-family: Times New Roman; font-size: 13px">51</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#legal"><font style="font-family: Times New Roman; font-size: 13px;">
LEGAL MATTERS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#legal"><font style="font-family: Times New Roman; font-size: 13px">53</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#disclosure"><font style="font-family: Times New Roman; font-size: 13px;">DISCLOSURE OF
COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT
LIABILITIES</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#disclosure"><font style="font-family: Times New Roman; font-size: 13px">53</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#experts"><font style="font-family: Times New Roman; font-size: 13px;">EXPERTS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#experts"><font style="font-family: Times New Roman; font-size: 13px">53</font></a></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#where"><font style="font-family: Times New Roman; font-size: 13px;">
WHERE YOU CAN FIND MORE INFORMATION</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#where"><font style="font-family: Times New Roman; font-size: 13px">53</font></a></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 91%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: rgb(64, 90, 237);"><a href="#Financials"><font style="font-family: Times New Roman; font-size: 13px;">INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS</font></a></font></div>
</td>
<td style="vertical-align: top; width: 9%">
<div style="text-align: center"><a href="#Financials"><font style="font-family: Times New Roman; font-size: 13px">54</font></a></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ABOUT THIS PROSPECTUS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
This prospectus is part of a registration statement on Form S-1
that we filed with the Securities and Exchange Commission utilizing
a &#x201C;shelf&#x201D; registration process. Under this shelf
registration process, the selling stockholders may offer from time
to time up to an aggregate of 41,473,822 shares of common stock in
one or more offerings. The registration statement of which this
prospectus is a part is being filed in accordance with the
registration rights agreement, dated as of August 14, 2019, by and
among GT Biopharma, Inc. and the selling stockholders party
thereto. Pursuant to the registration rights agreement, we have
agreed to indemnify and hold harmless, to the extent permitted by
law, each of the selling stockholders party to the registration
rights agreement and each of such selling stockholder&#x2019;s
directors, officers, partners, members, employees, agents,
representatives of and each other person, if any, who controls such
selling stockholder within the meaning of the Securities Act of
1933, as amended (the &#x201C;Securities Act&#x201D;), from and
against certain losses, claims, damages and liabilities, including
certain liabilities under the Securities Act.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
You should rely only on the information contained in this
prospectus and any free writing prospectus prepared by or on behalf
of us that we have referred you to. We take no responsibility for,
and can provide no assurance as to the reliability of, any other
information that others may give you. No person has been authorized
to give any information or make any representations in connection
with this offering other than those contained or incorporated by
reference in this prospectus, any accompanying prospectus
supplement and any related issuer free writing prospectus in
connection with the offering described herein and therein. Neither
this prospectus nor any prospectus supplement nor any related
issuer free writing prospectus shall constitute an offer to sell or
a solicitation of an offer to buy offered securities in any
jurisdiction in which it is unlawful for such person to make such
an offering or solicitation. This prospectus does not contain all
of the information included in the registration statement. For a
more complete understanding of the offering of the securities, you
should refer to the registration statement, including its
exhibits.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
No action is being taken in any jurisdiction outside the United
States to permit a public offering of common stock or possession or
distribution of this prospectus in that jurisdiction. Persons who
come into possession of this prospectus in jurisdictions outside
the United States are required to inform themselves about and to
observe any restriction as to this offering and the distribution of
this prospectus applicable to those jurisdictions.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unless otherwise indicated, information contained in this
prospectus concerning our industry and the markets in which we
operate, including our general expectations and market position,
market opportunity and market share, is based on information from
our own management estimates and research, as well as from industry
and general publications and research, surveys and studies
conducted by third parties. Management estimates are derived from
publicly available information, our knowledge of our industry and
assumptions based on such information and knowledge, which we
believe to be reasonable. In addition, assumptions and estimates of
our and our industry&#x2019;s future performance are necessarily
subject to a high degree of uncertainty and risk due to a variety
of factors, including those described in &#x201C;Risk
Factors.&#x201D; These and other factors could cause our future
performance to differ materially from our assumptions and
estimates. See &#x201C;Cautionary Note Regarding Forward-Looking
Statements.&#x201D;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
This prospectus contains summaries of certain provisions contained
in some of the documents described herein, but reference is made to
the actual documents for complete information. All of the summaries
are qualified in their entirety by the actual documents. Copies of
some of the documents referred to herein have been filed, or will
be filed as exhibits to the registration statement of which this
prospectus is a part, and you may obtain copies of those documents
as described below under the heading &#x201C;Where You Can Find
Additional Information.&#x201D;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
All references to the number of shares issued or outstanding in
this prospectus, and all per share and other similar data, reflect
a 1for 300 reverse stock split that we effected on August 21,
2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
All product and company names are trademarks of their respective
owners. Solely for convenience, trademarks and trade names referred
to in this prospectus, including logos, artwork and other visual
displays, may appear without the &#xAE; or TM symbols, but such
references are not intended to indicate, in any way, that their
respective owners will not assert, to the fullest extent under
applicable law, their rights thereto. We do not intend our use or
display of other companies&#x2019; trade names or trademarks to
imply a relationship with, or endorsement or sponsorship of us by,
any other companies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Throughout this prospectus, the terms &#x201C;we,&#x201D;
&#x201C;us,&#x201D; &#x201C;our,&#x201D; and &#x201C;our company&#x201D;
refer to GT Biopharma, Inc., a Delaware corporation and its related
subsidiaries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #FF0000; font-family: Times New Roman; font-size: 13px">
The information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is effective. This preliminary prospectus is not an
offer to sell these securities and it is not soliciting an offer to
buy these securities in any state or jurisdiction where the offer
or sale is not permitted.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #FF0000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUBJECT TO COMPLETION, DATED SEPTEMBER 3, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #FF0000; font-family: Times New Roman; font-size: 13px">
PRELIMINARY PROSPECTUS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="prospectus"></a></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PROSPECTUS SUMMARY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
This summary highlights certain information about us, this offering
and selected information contained elsewhere in or incorporated by
reference in this prospectus. Because this is only a summary, it
does not contain all of the information that may be important to
you or that you should consider before investing in our common
stock. You should read the entire prospectus carefully, especially
&#x201C;Risk Factors&#x201D; set forth in this prospectus, the other
information incorporated by reference in this prospectus, and the
information included in any free writing prospectus that we have
authorized for use in connection with this offering. This
prospectus contains forward-looking statements, based on current
expectations and related to future events and our future financial
performance, that involve risks and uncertainties. Our actual
results may vary materially from those discussed in the
forward-looking statements as a result of various factors,
including, without limitation, those set forth in &#x201C;Risk
Factors&#x201D; as well as other matters described in this
prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immuno-oncology products
based off our proprietary Tri-specific Killer Engager (TriKE),
Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody
Drug Conjugate (ADC) technology platforms. Our TriKE and TetraKE
platforms generate proprietary moieties designed to harness and
enhance the cancer killing abilities of a patient&#x2019;s own
natural killer, or NK, cells. Once bound to a NK cell, our moieties
are designed to enhance the NK cell and precisely direct it to one
or more specifically-targeted proteins (tumor antigens) expressed
on a specific type of cancer, ultimately resulting in the cancer
cell&#x2019;s death. TriKEs and TetraKEs are made up of recombinant
fusion proteins, can be designed to target any number of tumor
antigens on hematologic malignancies, sarcomas or solid tumors and
do not require patient-specific customization. They are designed to
be dosed in a common outpatient setting similar to modern antibody
therapeutics and are expected to have reasonably low cost of goods.
Our ADC platform generates product candidates that are bi-specific,
ligand-directed single-chain fusion proteins that, we believe,
represent the next generation of ADCs.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our TriKE product candidates are single-chain, tri-specific scFv
recombinant fusion proteins composed of the variable regions of the
heavy and light chains (or heavy chain only) of anti-CD16
antibodies, wild-type or a modified form of IL-15 and the variable
regions of the heavy and light chains of an antibody that precisely
targets a specific tumor antigen. We utilize the NK stimulating
cytokine human IL-15 as a crosslinker between the two scFvs which
provides a self-sustaining signal that leads to the proliferation
and activation of NK cells thus enhancing their ability to kill
cancer cells mediated by antibody-dependent cell-mediated
cytotoxicity (ADCC) via the highly potent CD16 activating receptor
on our moieties. Our second TriKE product candidate, GTB-C3550, is
a next-generation version of GTB-3550 containing a modified CD16
component.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our TetraKE product candidates are single-chain fusion proteins
composed of human single-domain anti-CD16 antibody, wild-type IL-15
and the variable regions of the heavy and light chains of two
antibodies that target two specific tumor antigens expressed on
specific types of cancer cells. An example of a TetraKE product
candidate is GTB-1615 which targets EpCAM and CD133 positive solid
tumors. EpCAM is found on many solid tumor cells of epithelial
origin and CD133 is a marker for cancer stem cells. GTB-1615 is
designed to enable a patient&#x2019;s NK cells to kill not only the
heterogeneous population of cancer cells found in many solid tumors
but also kill the cancer stem cells that are typically responsible
for recurrences. We intend to initiate human clinical testing for
certain of our solid tumor product candidates in 2020.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our TriKEs and TetraKEs act by binding to a patient&#x2019;s NK cell
and a specific tumor antigen enabling an immune synapse between the
now IL-15-enhanced NK cell and the targeted cancer cell. The
formation of this immune synapse induces NK cell activation leading
to the death of the cancer cell. The self-sustaining signal caused
by our IL-15 cross-linker enables prolonged and enhanced
proliferation and activation of NK cells similar to the increased
proliferation of T-cells caused by 41BB-L or CD28 intracellular
domains in CAR-T therapy but without the need to enhance the
patient&#x2019;s NK cells ex vivo.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are using our TriKE and TetraKE platforms with the intent to
bring to market multiple immuno-oncology products that can treat a
wide range of hematologic malignancies, sarcoma and solid tumors.
The platforms are scalable and we are putting processes in place to
be able to produce IND-ready moieties in approximately 90-120 days
after a specific TriKE or TetraKE conceptual design. After
conducting market and competitive research, specific moieties can
then be rapidly advanced into the clinic on our own or through
potential collaborations with larger companies. We are currently
evaluating over a dozen moieties and intend to announce additional
clinical product candidates in the second half of 2019. We believe
our TriKEs and TetraKEs will have the ability, if approved for
marketing, to be used on a stand-alone basis, augment the current
monoclonal antibody therapeutics, be used in conjunction with more
traditional cancer therapy and potentially overcome certain
limitations of current chimeric antigen receptor, or CAR-T,
therapy.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We also believe our bi-specific, ligand-directed single-chain
fusion proteins represents the next generation of ADCs. Our lead
bi-specific ADC, GTB-1550, which targets CD19+ and/or CD22+
hematological malignancies is currently in a Phase 2 trial being
conducted at the University of Minnesota Masonic Cancer Center in
patients with relapsed/refractory B-cell leukemias or lymphomas. We
believe GTB-1550 has certain properties that could result in
competitive advantages over recently approved ADC products
targeting leukemias and lymphomas. In a Phase 1 trial, of nine
patients that achieved adequate blood levels, we saw a durable
complete response, or CR, in two heavily pretreated patients. One
patient, who had failed multiple previous treatment regimens, has
been cancer free since early 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our initial work has been conducted in collaboration with the
Masonic Cancer Center at the University of Minnesota under a
program led by Dr. Jeffrey Miller, the Deputy Director. Dr. Miller
is a recognized leader in the field of NK cell and IL-15 biology
and their therapeutic potential. We have exclusive rights to the
TriKE and TetraKE platforms and are generating additional
intellectual property around specific moieties.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Also, in connection with the acquisition of Georgetown
Translational Pharmaceuticals on September 1, 2017, we acquired a
portfolio of in-process research and development central nervous
system assets consisting of innovative reformulations and/or
repurposing of existing therapies. These CNS assets address disease
states such as chronic neuropathic pain, myasthenia gravis and
motion sickness. We are currently pursuing out-licensing
opportunities related to these assets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Immuno-Oncology Product Candidates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1550</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1550 is a bispecific scFv recombinant fusion protein-drug
conjugate composed of the variable regions of the heavy and light
chains of anti-CD19 and anti-CD22 antibodies and a modified form of
diphtheria toxin (DT390) as its cytotoxic drug payload. CD19 is a
membrane glycoprotein present on the surface of all stages of
B-lymphocyte development and is also expressed on most B-cell
mature lymphoma cells and leukemia cells. CD22 is a glycoprotein
expressed on B-lineage lymphoid precursors, including precursor
acute lymphoblastic leukemia, and often is co-expressed with CD19
on mature B-cell malignancies such as lymphoma.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1550 targets cancer cells expressing the CD19 receptor or CD22
receptor or both receptors. When GTB-1550 binds to cancer cells,
the cancer cells internalize GTB-1550, and are killed due to the
action of drug&#x2019;s cytotoxic diphtheria toxin payload. GTB-1550
has completed a Phase 1 human clinical trial in patients with
relapsed/refractory B-cell lymphoma or leukemia.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The initial Phase 1 study enrolled 25 patients with mature or
precursor B-cell lymphoid malignancies expressing the CD19 receptor
or CD22 receptor or both receptors. All 25 patients received at
least a single course of therapy. The treatment at the higher doses
produced objective tumor responses with one patient in continuous
partial remission and the second in complete remission. A Phase 2
trial of GTB-1550 is underway in patients with ALL/NHL. The
FDA-approved clinical trial is being conducted at the University of
Minnesota's Masonic Cancer Center. There are currently 18 patients
enrolled in this clinical trial. Patients in this trial are given
an approved increased dosage and schedule of GTB-1550.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We began enrolling patients in Phase 2 trial of GTB-1550 during the
first quarter of 2017 and the first patient began dosing in April
2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-3550</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-3550 is our first TriKE product candidate. It is a
single-chain, tri-specific scFv recombinant fusion protein
conjugate composed of the variable regions of the heavy and light
chains of anti-CD16 and anti-CD33 antibodies and a modified form of
IL-15. We intend to study this anti-CD16-IL-15-anti-CD33 TriKE in
CD33 positive leukemias, a marker expressed on tumor cells in acute
myelogenous leukemia, or AML, myelodysplastic syndrome, or MDS, and
other hematopoietic malignancies. CD33 is primarily a myeloid
differentiation antigen with endocytic properties broadly expressed
on AML blasts and, possibly, some leukemic stem cells. CD33 or
Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3,
gp67, p67) is a transmembrane receptor expressed on cells of
myeloid lineage. It is usually considered myeloid-specific, but it
can also be found on some lymphoid cells. The anti-CD33 antibody
fragment that will be used for these studies was derived from the
M195 humanized anti-CD33 scFV and has been used in multiple human
clinical studies. It has been exploited as target for therapeutic
antibodies for many years. We believe the recent approval of the
antibody-drug conjugate gemtuzumab validates this targeted
approach.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The GTB-3550 IND will focus on AML, the most common form of adult
leukemia with 21,000 new cases expected in 2018 alone (American
Cancer Society). These patients typically receive frontline
therapy, usually chemotherapy, including cytarabine and an
anthracycline, a therapy that has not changed in over 40 years.
About half will have relapses and require alternative therapies. In
addition, MDS incidence rates have dramatically increased in the
population of the United States from 3.3 per 100,000 individuals
from 2001-2004 to 70 per 100,000 annually, MDS is especially
prevalent in elderly patients that have a median age of 76 years at
diagnosis. The survival of patients with MDS is poor due to
decreased eligibility, as a result of advanced age, for allogeneic
hematopoietic cell transplantation (Allo- HSCT), the only curative
MDS treatment (Cogle CR. Incidence and Burden of the
Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015;
10(3):272-281). We believe GTB-3550 could serve as a relatively
safe, cost-effective, and easy-to-use therapy for
resistant/relapsing AML and could also be combined with
chemotherapy as frontline therapy thus targeting the larger
market.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The IND for GTB-3550 was filed in June 2017 by the University of
Minnesota. FDA requested that additional preclinical toxicology be
conducted prior to initiating clinical trials. The FDA also
requested some additional information and clarifications on the
manufacturing (CMC) and clinical packages. The requested additional
information and clarifications were completed and incorporated by
us into the IND in eCTD format. We filed the IND amendment in June
2018 and announced on November 1, 2018 that we had received
notification from the FDA that the IND was open and the Company was
authorized to initiate a first-in-human Phase 1 study with GTB-3550
in AML, MDS and severe mastocytosis.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-C3550</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-C3550 is a next-generation, follow-on, to our lead TriKE,
GTB-3550. GTB-C3550 contains a modified CD16 moiety which has
improved binding characteristics and enhanced tumor cell killing
based on functional assays and animal models of AML. Using our
platform technology, we substituted the anti-CD16 scFv arm in
GTB-3550 with a novel humanized single-domain anti-CD16 antibody to
create this second-generation molecule which may have improved
functionality. Single-domain antibodies, such as GTB-C3550,
typically have several advantages, including better stability and
solubility, more resistance to pH changes, can better recognize
hidden antigenic sites, lack of a VL portion thus preventing VH/VL
mispairing and are suitable for construction of larger molecules.
GTB-C3550 induced a potent increase in NK cell degranulation,
measured by CD107a expression against HL-60 AML tumor targets when
compared to our first- generation TriKE (70.75&#xB1;3.65% vs.
30.75&#xB1;5.05%). IFN production was similarly enhanced
(29.2&#xB1;1.8% vs. 6.55&#xB1;1.07%). GTB-C3550 also exhibited a
robust increase in NK cell proliferation (57.65&#xB1;6.05% vs.
20.75&#xB1;2.55%). GTB-3550 studies will help inform the
development of GTB-C3550 which we expect will de-risk the GTB-C3550
program as data will be generated to make an informed decision on
which, or both, will be brought into later phase
studies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;&#xA0;&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1615</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1615 is an example of our first-generation TetraKEs designed
for the treatment of solid tumors. It is a single-chain fusion
protein composed of CD16-IL15-EpCAM-CD133. EpCAM is found on many
solid tumor cells of epithelial origin and CD133 is a marker for
cancer stem cells. This TetraKE is designed to target not only the
heterogeneous population of cancer cells found in solid tumors but
also the cancer stem cells that are typically responsible for
recurrences. We intend to initiate human clinical testing for
certain of our solid tumor product candidates in 2020.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Central Nervous System</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our CNS portfolio consists of in-process R&amp;D
(&#x201C;IPR&amp;D&#x201D;) assets acquired in connection with the
acquisition of Georgetown Translational Pharmaceuticals
(&#x201C;GTP&#x201D;) on September 1, 2017, consisting of innovative
reformulations and/or repurposing of existing therapies. These CNS
assets address disease states such as chronic neuropathic pain
(product candidate PainBrake, utilizing AccuBreak technology),
myasthenia gravis (product candidate GTP-004) and motion sickness
(product candidate GTP-011).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In the 3rd quarter of 2018, the Company experienced changes in key
senior management. These changes resulted in the prioritization of
immuno-oncology development candidates relative to the CNS
development candidates acquired from Georgetown Translational
Pharmaceuticals. In conjunction with these strategic changes,
limited internal resources have delayed the development of the CNS
IPR&amp;D assets. The limited resources, changes in senior
leadership, and favorable market conditions for immuno-oncology
development candidates have resulted in the Company choosing to
focus on development of its immuno-oncology portfolio. We are
assessing our options to realize value from the CNS IPR&amp;D
assets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Summary Risk Factors</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Investing in our common stock involves a high degree of risk.
Before deciding whether to invest in our securities, you should
consider carefully the risks and uncertainties discussed under the
section titled &#x201C;Risk Factors&#x201D; beginning on page 10, as
well as any amendments thereto reflected in subsequent filings with
the SEC, which are incorporated by reference into this prospectus
in their entirety, together with other information in this
prospectus, the documents incorporated by reference and any free
writing prospectus that we may authorize for use in connection with
a specific offering.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Our Offices</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our principal executive offices are located at 9350 Wilshire Blvd.
Suite 203, Beverly Hills, CA 90212, and our telephone number is
(800) 304&#xAC;9888.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Our Website</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our website is located at www.gtbiopharma.com. Information
contained on or accessible through our website is not, and should
not be considered, part of, or incorporated by reference into, this
prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
THE OFFERING</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
Securities offered by the selling stockholders</font><font style="color: #000000">: Up to 41,473,822 shares of common
stock.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
Offering Price</font><font style="color: #000000">: Fixed prices,
at prevailing market prices at the time of the sale, at varying
prices determined at the time of sale, or at negotiated
prices.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
Use of proceeds</font><font style="color: #000000">: We will not
receive any proceeds from the sale of common stock by the selling
stockholders.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
OTC Markets symbol</font><font style="color: #000000">:</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">GTBP</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unless otherwise indicated, all information contained in this
prospectus gives effect to a 1-for-300 reverse stock split that we
effected on August 21, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Risk factors:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The purchase of our common stock involves a high degree of risk.
You should carefully review and consider "Risk Factors" beginning
on page 10.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We will pay all expenses incident to the registration of the shares
under the Securities Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Summary Financial Information</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The tables and information below are derived from the Company's
unaudited consolidated financial statements as of June 30, 2019,
and for the six months ended June 30, 2019 and 2018 and also as of
December 31, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"></font></div>
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman">&#xA0;</font></font></div>
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 11px"><font style="color: #000; font-weight: bold; font-family: Times New Roman"><font style="font-size: 13px">
Balance Sheet Summary (in thousands)</font></font></font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">June
30,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2019</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2018</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">Cash
and cash equivalents $</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">264</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,707</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,731</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,976</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,370</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;Statement of Operations Summary (in thousands except per
share data)</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">June
30,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2019</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">June
30,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2018</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Revenue</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Selling,
general and administrative expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,347</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,593</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">988</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
from operations</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,335</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(12,317</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,299</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(19,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per share &#x2013; basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.14</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.38</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The tables and information below are derived from the Company's
audited consolidated financial statements for the years ended
December 31, 2018 and 2017.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="padding-bottom: 2px;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Balance Sheet Summary (in thousands)</font></div>
</div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2018</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2017</font></font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">Cash
and cash equivalents $</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">254,368</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,370</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">251,689</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;Statement of Operations Summary (in thousands except per
share data)</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2018</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31,</font></font></div>
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2017</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Revenue</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Selling,
general and administrative expenses</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,487</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">134,502</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,067</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,068</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
from operations</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(250,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(135,570</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(259,186</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(144,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per share &#x2013; basic and diluted</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(5.16</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="risk">R</a>ISK FACTORS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Investment in our securities involves risks. Prior to making a
decision about investing in our securities, you should consider
carefully the risk factors, together with all of the other
information contained or incorporated by reference in this
prospectus and any prospectus supplement, including any additional
specific risks described in the section entitled &#x201C;Risk
Factors&#x201D; contained in any supplements to this prospectus, as
updated by annual, quarterly and other reports and documents we
file with the SEC after the date of this prospectus and that are
incorporated by reference herein or in the applicable prospectus
supplement. Each of these risk factors could have a material
adverse effect on our business, results of operations, financial
position or cash flows, which may result in the loss of all or part
of your investment.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Risks Related to Our Business</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000">
Our business is at an early stage of development and we may not
develop therapeutic products that can be
commercialized.</font><font style="color: #000000; font-size: 13px">&#xA0;</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Our business is at an early stage of development. We do not have
immune-oncology products in late stage clinical trials and have
only recently begun clinical trials for our CNS product candidates.
We are still in the early stages of identifying and conducting
research on potential therapeutic products. Our potential
therapeutic products will require significant research and
development and pre-clinical and clinical testing prior to
regulatory approval in the United States and other countries. We
may not be able to obtain regulatory approvals, enter clinical
trials for any of our product candidates, or commercialize any
products. Our product candidates may prove to have undesirable and
unintended side effects or other characteristics adversely
affecting their safety, efficacy or cost effectiveness that could
prevent or limit their use. Any product using any of our technology
may fail to provide the</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">intended therapeutic benefits or achieve
therapeutic benefits equal to or better than the standard of
treatment at the time of testing or production.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We have a history of operating losses and we expect to continue to
incur losses for the foreseeable future and we may never generate
revenue or achieve profitability.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of June 30, 2019, we had an accumulated deficit of approximately
$536 million. We have not generated any significant revenue to date
and are not profitable, and have incurred losses in each year since
our inception. We do not expect to generate any product sales or
royalty revenues for at least four years. We expect to incur
significant additional operating losses for the foreseeable future
as we expand research and development and clinical trial
efforts.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our ability to achieve long-term profitability is dependent upon
obtaining regulatory approvals for our products and successfully
commercializing our products alone or with third parties. However,
our operations may not be profitable even if any of our products
under development are successfully developed and produced and
thereafter commercialized. Even if we achieve profitability in the
future, we may not be able to sustain profitability in subsequent
periods.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Even if we succeed in commercializing one or more of our product
candidates, we expect to continue to incur substantial research and
development and other expenditures to develop and market additional
product candidates. The size of our future net losses will depend,
in part, on the rate of future growth of our expenses and our
ability to generate revenue. Our prior losses and expected future
losses have had and will continue to have an adverse effect on our
stockholders&#x2019; equity and working capital.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We will need additional capital to conduct our operations and
develop our products, and our ability to obtain the necessary
funding is uncertain.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have used a significant amount of cash since inception to
finance the continued development and testing of our product
candidates, and we expect to need substantial additional capital
resources in order to develop our product candidates going forward
and launch and commercialize any product candidates for which we
receive regulatory approval.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We may not be successful in generating and/or maintaining operating
cash flow, and the timing of our capital expenditures and other
expenditures may not result in cash sufficient to sustain our
operations through the next 12 months. If financing is not
sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it
could have a material adverse effect on our ability to continue to
function. The timing and degree of any future capital requirements
will depend on many factors, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
accuracy of the assumptions underlying our estimates for capital
needs in 2019 and beyond;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">scientific
and clinical progress in our research and development
programs;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
magnitude and scope of our research and development programs and
our ability to establish, enforce and maintain strategic
arrangements for research, development, clinical testing,
manufacturing and marketing;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">our
progress with pre-clinical development and clinical
trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
time and costs involved in obtaining regulatory
approvals;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
costs involved in preparing, filing, prosecuting, maintaining,
defending and enforcing patent claims; and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
number and type of product candidates that we pursue.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Additional financing through strategic collaborations, public or
private equity or debt financings or other financing sources may
not be available on acceptable terms, or at all. Additional equity
financing could result in significant dilution to our stockholders,
and any debt financings will likely involve covenants restricting
our business activities. Additional financing may not be available
on acceptable terms, or at all. Further, if we obtain additional
funds through arrangements with collaborative partners, these
arrangements may require us to relinquish rights to some of our
technologies, product candidates or products that we would
otherwise seek to develop and commercialize on our
own.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If sufficient capital is not available, we may be required to
delay, reduce the scope of or eliminate one or more of our research
or product development initiatives, any of which could have a
material adverse effect on our financial condition or business
prospects.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We have identified material weaknesses in our internal control over
financial reporting have not remedied these weaknesses. If we fail
to maintain an effective system of internal control over financial
reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, stockholders could lose
confidence in our financial and other public reporting, which would
harm our business and the trading price of our common
stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Effective internal control over financial reporting is necessary
for us to provide reliable financial reports and, together with
adequate disclosure controls and procedures, are designed to
prevent fraud. Any failure to implement required new or improved
controls, or difficulties encountered in their implementation,
could cause us to fail to meet our reporting obligations.
Ineffective internal control could also cause investors to lose
confidence in our reported financial information, which could have
a negative effect on the trading price of our common
stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have identified material weaknesses in our internal control over
financial reporting as a company. As defined in Regulation 12b-2
under the Securities Exchange Act of 1934, or the Exchange Act, a
&#x201C;material weakness&#x201D; is a deficiency, or combination of
deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material misstatement
of our annual or interim consolidated financial statements will not
be prevented, or detected on a timely basis. Specifically, we
determined that we had the following material weaknesses in our
internal control over financial reporting: (i) lack of segregation
of duties due to very small staff and significant reliance on
outside consultants, and (ii) risks of executive override also due
to lack of established policies, and small employee
staff.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of the date of this report, we have not remediated these
material weaknesses. We are continuing to adopt and implement
written policies and procedures for accounting and financial
reporting. We plan to hire additional qualified personnel to
address inadequate segregation of duties, although the timing of
such hires is largely dependent on our securing additional
financing to cover such costs. The implementation of these
initiatives may not fully address any material weakness or other
deficiencies that we may have in our internal control over
financial reporting.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Even if we develop effective internal control over financial
reporting, such controls may become inadequate due to changes in
conditions or the degree of compliance with such policies or
procedures may deteriorate, which could result in the discovery of
additional material weaknesses and deficiencies. In any event, the
process of determining whether our existing internal control over
financial reporting is compliant with Section 404 of the
Sarbanes-Oxley Act, or Section 404, and sufficiently effective
requires the investment of substantial time and resources,
including by certain members of our senior management. As a result,
this process may divert internal resources and take a significant
amount of time and effort to complete. In addition, we cannot
predict the outcome of this process and whether we will need to
implement remedial actions in order to establish effective controls
over financial reporting. The determination of whether or not our
internal controls are sufficient and any remedial actions required
could result in us incurring additional costs that we did not
anticipate, including the hiring of outside consultants. We may
also fail to timely complete our evaluation, testing and any
remediation required to comply with Section 404.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are required, pursuant to Section 404, to furnish a report by
management on, among other things, the effectiveness of our
internal control over financial reporting. However, for as long as
we are a &#x201C;smaller reporting company,&#x201D; our independent
registered public accounting firm will not be required to attest to
the effectiveness of our internal control over financial reporting
pursuant to Section 404. While we could be a smaller reporting
company for an indefinite amount of time, and thus relieved of the
above-mentioned attestation requirement, an independent assessment
of the effectiveness of our internal control over financial
reporting could detect problems that our management's assessment
might not. Such undetected material weaknesses in our internal
control over financial reporting could lead to financial statement
restatements and require us to incur the expense of
remediation.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our intellectual property may be compromised.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Part of our value going forward depends on the intellectual
property rights that we have been and are acquiring. There may have
been many persons involved in the development of our intellectual
property, and we may not be successful in obtaining the necessary
rights from all of them. It is possible that in the future, third
parties may challenge our intellectual property rights. We may not
be successful in protecting our intellectual property rights. In
either event, we may lose the value of our intellectual property,
and if so, our business prospects may suffer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If our efforts to protect the proprietary nature of the
intellectual property related to our technologies are not adequate,
we may not be able to compete effectively in our market and our
business would be harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We rely upon a combination of patents, trade secret protection and
confidentiality agreements to protect the intellectual property
related to our technologies. Any disclosure to or misappropriation
by third parties of our trade secret or other confidential
information could enable competitors to quickly duplicate or
surpass our technological achievements, thus eroding any
competitive advantage we may derive from this
information.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The strength of patents in the biotechnology and pharmaceutical
field involves complex legal and scientific questions and can be
uncertain. The patent applications we own or license may fail to
result in issued patents in the United States or in foreign
countries. Third parties may challenge the validity, enforceability
or scope of any issued patents we own or license or any
applications that may issue as patents in the future, which may
result in those patents being narrowed, invalidated or held
unenforceable. Even if they are unchallenged, our patents and
patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do
not fall within the scope of our patents. If the breadth or
strength of protection provided by the patents we hold or pursue is
threatened, our ability to commercialize any product candidates
with technology protected by those patents could be threatened.
Further, if we encounter delays in our clinical trials, the period
of time during which we would have patent protection for any
covered product candidates that obtain regulatory approval would be
reduced. Since patent applications in the United States and most
other countries are confidential for a period of time after filing,
we cannot be certain at the time of filing that we are the first to
file any patent application related to our product
candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition to the protection afforded by patents, we seek to rely
on trade secret protection and confidentiality agreements to
protect proprietary know-how that is not patentable, processes for
which patents are difficult to enforce and any other elements of
our discovery platform and drug development processes that involve
proprietary know-how, information or technology that is not covered
by patents or not amenable to patent protection. Although we
require all of our employees and certain consultants and advisors
to assign inventions to us, and all of our employees, consultants,
advisors and any third parties who have access to our proprietary
know-how, information or technology to enter into confidentiality
agreements, our trade secrets and other proprietary information may
be disclosed or competitors may otherwise gain access to such
information or independently develop substantially equivalent
information. Further, the laws of some foreign countries do not
protect proprietary rights to the same extent or in the same manner
as the laws of the United States. As a result, we may encounter
significant difficulty in protecting and defending our intellectual
property both in the United States and abroad. If we are unable to
prevent material disclosure of the trade secret intellectual
property related to our technologies to third parties, we may not
be able to establish or maintain the competitive advantage that we
believe is provided by such intellectual property, which could
materially adversely affect our market position and business and
operational results.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Claims that we infringe the intellectual property rights of others
may prevent or delay our drug discovery and development
efforts.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our research, development and commercialization activities, as well
as any product candidates or products resulting from those
activities, may infringe or be accused of infringing a patent or
other form of intellectual property under which we do not hold a
license or other rights. Third parties may assert that we are
employing their proprietary technology without authorization. There
may be third-party patents of which we are currently unaware of,
with claims that cover the use or manufacture of our product
candidates or the practice of our related methods. Because patent
applications can take many years to issue, there may be currently
pending patent applications that may later result in issued patents
that our product candidates may infringe. In addition, third
parties may obtain patents in the future and claim that use of our
technologies infringes one or more claims of these patents. If our
activities or product candidates infringe the patents or other
intellectual property rights of third parties, the holders of such
intellectual property rights may be able to block our ability to
commercialize such product candidates or practice our methods
unless we obtain a license under the intellectual property rights
or until any applicable patents expire or are determined to be
invalid or unenforceable.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Defense of any intellectual property infringement claims against
us, regardless of their merit, would involve substantial litigation
expense and would be a significant diversion of employee resources
from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages,
obtain one or more licenses from third parties, limit our business
to avoid the infringing activities, pay royalties and/or redesign
our infringing product candidates or methods, any or all of which
may be impossible or require substantial time and monetary
expenditure. Further, if we were to seek a license from the third
party holder of any applicable intellectual property rights, we may
not be able to obtain the applicable license rights when needed or
on commercially reasonable terms, or at all. The occurrence of any
of the above events could prevent us from continuing to develop and
commercialize one or more of our product candidates and our
business could materially suffer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We may desire, or be forced, to seek additional licenses to use
intellectual property owned by third parties, and such licenses may
not be available on commercially reasonable terms or at
all.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
A third party may hold intellectual property, including patent
rights, that are important or necessary to the development of our
product candidates, in which case we would need to obtain a license
from that third party or develop a different formulation of the
product that does not infringe upon the applicable intellectual
property, which may not be possible. Additionally, we may identify
product candidates that we believe are promising and whose
development and other intellectual property rights are held by
third parties. In such a case, we may desire to seek a license to
pursue the development of those product candidates. Any license
that we may desire to obtain or that we may be forced to pursue may
not be available when needed on commercially reasonable terms or at
all. Any inability to secure a license that we need or desire could
have a material adverse effect on our business, financial condition
and prospects.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
The patent protection covering some of our product candidates may
be dependent on third parties, who may not effectively maintain
that protection.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
While we expect that we will generally seek to gain the right to
fully prosecute any patents covering product candidates we may
in-license from third-party owners, there may be instances when
platform technology patents that cover our product candidates
remain controlled by our licensors. If any of our current or future
licensing partners that retain the right to prosecute patents
covering the product candidates we license from them fail to
appropriately maintain that patent protection, we may not be able
to prevent competitors from developing and selling competing
products or practicing competing methods and our ability to
generate revenue from any commercialization of the affected product
candidates may suffer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We may be involved in lawsuits to protect or enforce our patents or
the patents of our licensors, which could be expensive,
time-consuming and unsuccessful.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Competitors may infringe our patents or the patents of our current
or potential licensors. To attempt to stop infringement or
unauthorized use, we may need to enforce one or more of our
patents, which can be expensive and time-consuming and distract
management. If we pursue any litigation, a court may decide that a
patent of ours or our licensor&#x2019;s is not valid or is
unenforceable, or may refuse to stop the other party from using the
relevant technology on the grounds that our patents do not cover
the technology in question. Further, the legal systems of certain
countries, particularly certain developing countries, do not favor
the enforcement of patents, which could reduce the likelihood of
success of any infringement proceeding we pursue in any such
jurisdiction. An adverse result in any infringement litigation or
defense proceedings could put one or more of our patents at risk of
being invalidated, held unenforceable, or interpreted narrowly and
could put our patent applications at risk of not issuing, which
could limit our ability to exclude competitors from directly
competing with us in the applicable jurisdictions.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Interference proceedings provoked by third parties or brought by
the U.S. PTO may be necessary to determine the priority of
inventions with respect to our patents or patent applications or
those of our licensors. An unfavorable outcome could require us to
cease using the related technology or to attempt to license rights
to use it from the prevailing party. Our business could be harmed
if the prevailing party does not offer us a license on commercially
reasonable terms, or at all. Litigation or interference proceedings
may fail and, even if successful, may result in substantial costs
and distract our management and other employees.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If we are unsuccessful in obtaining or maintaining patent
protection for intellectual property in development, our business
and competitive position would be harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are seeking patent protection for some of our technology and
product candidates. Patent prosecution is a challenging process and
is not assured of success. If we are unable to secure patent
protection for our technology and product candidates, our business
may be adversely impacted.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, issued patents and pending international applications
require regular maintenance. Failure to maintain our portfolio may
result in loss of rights that may adversely impact our intellectual
property rights, for example by rendering issued patents
unenforceable or by prematurely terminating pending international
applications.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If we are unable to protect the confidentiality of our trade
secrets, our business and competitive position would be
harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition to seeking patents for some of our technology and
product candidates, we also rely on trade secrets, including
unpatented know-how, technology and other proprietary information,
to maintain our competitive position. We currently, and expect in
the future to continue to, seek to protect these trade secrets, in
part, by entering into confidentiality agreements with parties who
have access to them, such as our employees, collaborators, contract
manufacturers, consultants, advisors and other third parties. We
also enter into confidentiality and invention or patent assignment
agreements with our employees and consultants. Despite these
efforts, any of these parties may breach the agreements and
disclose our proprietary information, including our trade secrets,
and we may not be able to obtain adequate remedies for any such
disclosure. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some
courts inside and outside the United States are less willing or
unwilling to protect trade secrets. If any of our trade secrets
were to be lawfully obtained or independently developed by a
competitor, we would have no right to prevent them, or those to
whom they disclose the trade secrets, from using that technology or
information to compete with us. If any of our trade secrets were to
be disclosed to or independently developed by a competitor, our
competitive position would be harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If we fail to meet our obligations under our license agreements, we
may lose our rights to key technologies on which our business
depends.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our business depends in part on licenses from third parties. These
third-party license agreements impose obligations on us, such as
payment obligations and obligations to diligently pursue
development of commercial products under the licensed patents. If a
licensor believes that we have failed to meet our obligations under
a license agreement, the licensor could seek to limit or terminate
our license rights, which could lead to costly and time-consuming
litigation and, potentially, a loss of the licensed rights. During
the period of any such litigation, our ability to carry out the
development and commercialization of potential products could be
significantly and negatively affected. If our license rights were
restricted or ultimately lost, our ability to continue our business
based on the affected technology platform could be severely
adversely affected.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We will have to hire additional executive officers and employees to
operate our business. If we are unable to hire qualified personnel,
we may not be able to implement our business strategy.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We currently have only two fulltime employees. The loss of the
services of any of our key product or business development
employees could delay our product development programs and our
research and development efforts. We do not maintain key person
life insurance on any of our officers, employees or consultants. In
order to develop our business in accordance with our business
strategy, we will have to hire additional qualified personnel,
including in the areas of manufacturing, clinical trials
management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and
have commenced our search for additional key
employees.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Moreover, there is intense competition for a limited number of
qualified personnel among biopharmaceutical, biotechnology,
pharmaceutical and other businesses. Many of the other
pharmaceutical companies against which we compete for qualified
personnel have greater financial and other resources, different
risk profiles, longer histories in the industry and greater ability
to provide valuable cash or stock incentives to potential recruits
than we do. They also may provide more diverse opportunities and
better chances for career advancement. Some of these
characteristics may be more appealing to high quality candidates
than what we are able to offer as an early-stage company. If we are
unable to continue to attract and retain high quality personnel,
the rate and success at which we can develop and commercialize
product candidates will be limited.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We depend on key personnel for our continued operations and future
success, and a loss of certain key personnel could significantly
hinder our ability to move forward with our business
plan.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Because of the specialized nature of our business, we are highly
dependent on our ability to identify, hire, train and retain highly
qualified scientific and technical personnel for the research and
development activities we conduct or sponsor. The loss of one or
more key executive officers, or scientific officers, would be
significantly detrimental to us. In addition, recruiting and
retaining qualified scientific personnel to perform research and
development work is critical to our success. Our anticipated growth
and expansion into areas and activities requiring additional
expertise, such as clinical testing, regulatory compliance,
manufacturing and marketing, will require the addition of new
management personnel and the development of additional expertise by
existing management personnel. There is intense competition for
qualified personnel in the areas of our present and planned
activities. Accordingly, we may not be able to continue to attract
and retain the qualified personnel, which would adversely affect
the development of our business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
We may be subject to claims by third parties asserting that our
employees or we have misappropriated their intellectual property,
or claiming ownership of what we regard as our own intellectual
property.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Many of our employees were previously employed at universities or
other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure
that our employees do not use the proprietary information or
know-how of others in their work for us, with contractual
provisions and other procedures, we may be subject to claims that
these employees or we have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any
such employee&#x2019;s former employers. Litigation may be necessary
to defend against any such claims.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, while it is our policy to require our employees and
contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property
to us, we may be unsuccessful in executing such an agreement with
each party who in fact contributes to the development of
intellectual property that we regard as our own. Further, the terms
of such assignment agreements may be breached and we may not be
able to successfully enforce their terms, which may force us to
bring claims against third parties, or defend claims they may bring
against us, to determine the ownership of intellectual property
rights we may regard and treat as our own.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and
requirements, which could cause our business to
suffer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are exposed to the risk of employee fraud or other misconduct.
Misconduct by employees could include intentional failures to
comply with regulations of governmental authorities, such as the
FDA or the European Medicines Agency, or EMA, to provide accurate
information to the FDA or EMA, to comply with manufacturing
standards we have established, to comply with federal, state and
international healthcare fraud and abuse laws and regulations as
they may become applicable to our operations, to report financial
information or data accurately or to disclose unauthorized
activities to us. Employee misconduct could also involve the
improper use of information obtained in the course of clinical
trials, which could result in regulatory sanctions and serious harm
to our reputation. It is not always possible to identify and deter
employee misconduct, and the precautions we currently take and the
procedures we may establish in the future as our operations and
employee base expand to detect and prevent this type of activity
may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are
instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations,
including the imposition of significant fines or other
sanctions.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our reliance on the activities of our non-employee consultants,
research institutions and scientific contractors, whose activities
are not wholly within our control, may lead to delays in
development of our proposed products.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We rely extensively upon and have relationships with scientific
consultants at academic and other institutions, some of whom
conduct research at our request, and other consultants with
expertise in clinical development strategy or other matters. These
consultants are not our employees and may have commitments to, or
consulting or advisory contracts with, other entities that may
limit their availability to us. We have limited control over the
activities of these consultants and, except as otherwise required
by our collaboration and consulting agreements to the extent they
exist, can expect only limited amounts of their time to be
dedicated to our activities. These research facilities may have
commitments to other commercial and non-commercial entities. We
have limited control over the operations of these laboratories and
can expect only limited amounts of time to be dedicated to our
research goals.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
It may take longer to complete our clinical trials than we project,
or we may not be able to complete them at all.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
For budgeting and planning purposes, we have projected the date for
the commencement, continuation and completion of our various
clinical trials. However, a number of factors, including scheduling
conflicts with participating clinicians and clinical institutions,
and difficulties in identifying and enrolling patients who meet
trial eligibility criteria, may cause significant delays. We may
not commence or complete clinical trials involving any of our
products as projected or may not conduct them
successfully.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We expect to rely on medical institutions, academic institutions or
clinical research organizations to conduct, supervise or monitor
some or all aspects of clinical trials involving our products. We
will have less control over the timing and other aspects of these
clinical trials than if we conducted them entirely on our own. If
we fail to commence or complete, or experience delays in, any of
our planned clinical trials, our stock price and our ability to
conduct our business as currently planned could be
harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Clinical drug development is costly, time-consuming and uncertain,
and we may suffer setbacks in our clinical development program that
could harm our business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Clinical drug development for our product candidates is costly,
time-consuming and uncertain. Our product candidates are in various
stages of development and while we expect that clinical trials for
these product candidates will continue for several years, such
trials may take significantly longer than expected to complete. In
addition, we, the FDA, an institutional review board, or IRB, or
other regulatory authorities, including state and local agencies
and counterpart agencies in foreign countries, may suspend, delay,
require modifications to or terminate our clinical trials at any
time, for various reasons, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">discovery
of safety or tolerability concerns, such as serious or unexpected
toxicities or side effects or exposure to otherwise unacceptable
health risks, with respect to study participants;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">lack
of effectiveness of any product candidate during clinical trials or
the failure of our product candidates to meet specified
endpoints;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">delays
in subject recruitment and enrollment in clinical trials or
inability to enroll a sufficient number of patients in clinical
trials to ensure adequate statistical ability to detect
statistically significant treatment effects;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">difficulty
in retaining subjects and volunteers in clinical
trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">difficulty
in obtaining IRB approval for studies to be conducted at each
clinical trial site;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">delays
in manufacturing or obtaining, or inability to manufacture or
obtain, sufficient quantities of materials for use in clinical
trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inadequacy
of or changes in our manufacturing process or the product
formulation or method of delivery;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">delays
or failure in reaching agreement on acceptable terms in clinical
trial contracts or protocols with prospective contract research
organizations, or CROs, clinical trial sites and other third-party
contractors;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
to add a sufficient number of clinical trial sites;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">uncertainty
regarding proper formulation and dosing;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">failure
by us, our employees, our CROs or their employees or other
third-party contractors to comply with contractual and applicable
regulatory requirements or to perform their services in a timely or
acceptable manner;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">scheduling
conflicts with participating clinicians and clinical
institutions;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">failure
to design appropriate clinical trial protocols;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
or unwillingness of medical investigators to follow our clinical
protocols;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">difficulty
in maintaining contact with subjects during or after treatment,
which may result in incomplete data; or</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">changes
in applicable laws, regulations and regulatory
policies.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If we experience delays or difficulties in the enrollment of
patients in clinical trials, those clinical trials could take
longer than expected to complete and our receipt of necessary
regulatory approvals could be delayed or prevented.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We may not be able to initiate or continue clinical trials for our
product candidates if we are unable to locate and enroll a
sufficient number of eligible patients to participate in these
trials as required by U.S. Food and Drug Administration, or the
FDA, or similar regulatory authorities outside the United States.
In particular, because we are focused on patients with molecularly
defined cancers, our pool of suitable patients may be smaller and
more selective and our ability to enroll a sufficient number of
suitable patients may be limited or take longer than anticipated.
In addition, some of our competitors have ongoing clinical trials
for product candidates that treat the same indications as our
product candidates, and patients who would otherwise be eligible
for our clinical trials may instead enroll in clinical trials of
our competitors&#x2019; product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Patient enrollment for any of our clinical trials may also be
affected by other factors, including without
limitation:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
severity of the disease under investigation;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
frequency of the molecular alteration we are seeking to target in
the applicable trial;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
eligibility criteria for the study in question;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
perceived risks and benefits of the product candidate under
study;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
extent of the efforts to facilitate timely enrollment in clinical
trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
patient referral practices of physicians;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
ability to monitor patients adequately during and after treatment;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
proximity and availability of clinical trial sites for prospective
patients.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our inability to enroll a sufficient number of patients for our
clinical trials would result in significant delays and could
require us to abandon one or more clinical trials altogether.
Enrollment delays in our clinical trials may result in increased
development costs for our product candidates, and we may not have
or be able to obtain sufficient cash to fund such increased costs
when needed, which could result in the further delay or termination
of the trial.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Consistent with our general product development strategy, we intend
to design future trials for our product candidates to include some
patients with the applicable clinical characteristics, stage of
therapy, molecular alterations, biomarkers, and/or cell surface
antigens that determine therapeutic options, or are indicators of
the disease, with a view to assessing possible early evidence of
potential therapeutic effect. If we are unable to locate and
include such patients in those trials, then our ability to make
those early assessments and to seek participation in FDA expedited
review and approval programs, including breakthrough therapy and
fast track designation, or otherwise to seek to accelerate clinical
development and regulatory timelines, could be
compromised.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We have limited clinical testing and regulatory capabilities, and
human clinical trials are subject to extensive regulatory
requirements, very expensive, time-consuming and difficult to
design and implement. Our products may fail to achieve necessary
safety and efficacy endpoints during clinical trials, which may
limit our ability to generate revenues from therapeutic
products.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We cannot assure you that we will be able to invest or develop
resources for clinical trials successfully or as expediently as
necessary. In particular, human clinical trials can be very
expensive and difficult to design and implement, in part because
they are subject to rigorous regulatory requirements. The clinical
trial process is time consuming. We estimate that clinical trials
of our product candidates will take at least several years to
complete. Furthermore, failure can occur at any stage of the
trials, and we could encounter problems that cause us to abandon or
repeat clinical trials. The commencement and completion of clinical
trials may be affected by several factors, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">unforeseen
safety issues;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">determination
of dosing issues;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
to demonstrate effectiveness during clinical trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">slower
than expected rates of patient recruitment;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
to monitor patients adequately during or after treatment;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">inability
or unwillingness of medical investigators to follow our clinical
protocols.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, we or the FDA, may suspend our clinical trials at any
time if it appears that we are exposing participants to
unacceptable health risks or if the FDA finds deficiencies in our
investigational new drug application, or IND, submissions or the
conduct of these trials.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We are subject to extensive regulation, which can be costly and
time consuming and can subject us to unanticipated delays. even if
we obtain regulatory approval for some of our products, those
products may still face regulatory difficulties.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
All of our potential products, processing and manufacturing
activities, are subject to comprehensive regulation by the FDA in
the United States and by comparable authorities in other countries.
The process of obtaining FDA and other required regulatory
approvals, including foreign approvals, is expensive and often
takes many years and can vary substantially based upon the type,
complexity and novelty of the products involved. In addition,
regulatory agencies may lack experience with our technologies and
products, which may lengthen the regulatory review process,
increase our development costs and delay or prevent their
commercialization.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If we violate regulatory requirements at any stage, whether before
or after we obtain marketing approval, the FDA may take enforcement
action(s) against us, which could include issuing a warning or
untitled letter, placing a clinical hold on an ongoing clinical
trial, product seizure, enjoining our operations, refusal to
consider our applications for pre-market approval, refusal of an
investigational new drug application, fines, or even civil or
criminal liability, any of which could materially harm our
reputation and financial results. Additionally, we may not be able
to obtain the labeling claims necessary or desirable for the
promotion of our products. We may also be required to undertake
postmarketing trials to provide additional evidence of safety and
effectiveness. In addition, if we or others identify side effects
after any of our adoptive therapies are on the market, or if
manufacturing problems occur, regulators may withdraw their
approval and reformulations, additional clinical trials, changes in
labeling of our products, and additional marketing applications may
be required.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Any of the following factors, among others, could cause regulatory
approval for our product candidates to be delayed, limited or
denied:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
product candidates require significant clinical testing to
demonstrate safety and effectiveness before applications for
marketing approval can be filed with the FDA and other regulatory
authorities;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">data
obtained from pre-clinical and nonclinical animal testing and
clinical trials can be interpreted in different ways, and
regulatory authorities may not agree with our respective
interpretations or may require us to conduct additional
testing;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">negative
or inconclusive results or the occurrence of serious or unexpected
adverse events during a clinical trial could cause us to delay or
terminate development efforts for a product candidate;
and/or</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">FDA
and other regulatory authorities may require expansion of the size
and scope of the clinical trials.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Any difficulties or failures that we encounter in securing
regulatory approval for our product candidates would likely have a
substantial adverse impact on our ability to generate product
sales, and could make any search for a collaborative partner more
difficult.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Obtaining regulatory approval even after clinical trials that are
believed to be successful is an uncertain process.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Even if we complete our planned clinical trials and believe the
results were successful, obtaining regulatory approval is a
lengthy, expensive and uncertain process, and the FDA or other
regulatory agencies may delay, limit or deny approval of any of our
applications for pre-market approval for many reasons,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">we
may not be able to demonstrate to the FDA&#x2019;s satisfaction that
our product candidates are safe and effective for any
indication;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
results of clinical trials may not meet the level of statistical
significance or clinical significance required by the FDA for
approval;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may disagree with the number, design, size, conduct or
implementation of our clinical trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may not find the data from pre-clinical studies and clinical
trials sufficient to demonstrate that the clinical and other
benefits of our product candidates outweigh their safety
risks;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may disagree with our interpretation of data from pre-clinical
studies or clinical trials, or may not accept data generated at our
clinical trial sites;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
data collected from pre-clinical studies and clinical trials of our
product candidates may not be sufficient to support the submission
of applications for regulatory approval;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may have difficulties scheduling an advisory committee meeting
in a timely manner, or the advisory committee may recommend against
approval of our application or may recommend that the FDA require,
as a condition of approval, additional pre-clinical studies or
clinical trials, limitations on approved labeling, or distribution
and use restrictions;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may require development of a risk evaluation and mitigation
strategy as a condition of approval;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may identify deficiencies in the manufacturing processes or
facilities of third-party manufacturers with which we enter into
agreements for clinical and commercial supplies;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may change their approval policies or adopt new regulations
that adversely affect our applications for pre-market approval;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
FDA may require simultaneous approval for both adults and for
children and adolescents delaying needed approvals, or we may have
successful clinical trial results for adults but not children and
adolescents, or vice versa.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Before we can submit an application for regulatory approval in the
United States, we must conduct a pivotal, Phase 3 trial. We will
also need to agree on a protocol with the FDA for a clinical trial
before commencing the trial. Phase 3 clinical trials frequently
produce unsatisfactory results even though prior clinical trials
were successful. Therefore, even if the results of our Phase 2
trials are successful, the results of the additional trials that we
conduct may or may not be successful. Further, our product
candidates may not be approved even if they achieve their primary
endpoints in Phase 3 clinical trials. The FDA or other foreign
regulatory authorities may disagree with our trial design and our
interpretation of data from preclinical studies and clinical
trials. Any of these regulatory authorities may change requirements
for the approval of a product candidate even after reviewing and
providing comments or advice on a protocol for a clinical trial.
The FDA or other regulatory agencies may require that we conduct
additional clinical, nonclinical, manufacturing validation or drug
product quality studies and submit those data before considering or
reconsidering the application. Depending on the extent of these or
any other studies, approval of any applications that we submit may
be delayed by several years, or may require us to expend more
resources than we have available. It is also possible that
additional studies, if performed and completed, may not be
considered sufficient by the FDA or other regulatory
agencies.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the FDA or other regulatory agencies may also approve
a product candidate for fewer or more limited indications than we
request, may impose significant limitations related to use
restrictions for certain age groups, warnings, precautions or
contraindications or may grant approval contingent on the
performance of costly post-marketing clinical trials or risk
mitigation requirements.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We intend to pursue Section&#xA0;505(b)(2)&#xA0;regulatory approval
filings with the FDA for at least three of our product candidates.
If the FDA concludes that certain of our product candidates fail to
satisfy the requirements under Section&#xA0;505(b)(2), or if the
requirements for such product candidates under
Section&#xA0;505(b)(2)&#xA0;are not as we expect, the approval
pathway for such product candidates may take significantly longer,
cost substantially more and entail greater complications and risks
than anticipated and, in either case, may not be successful. In
addition, if under certain circumstances, exclusivity of
competitors would delay approval of our product candidates, then we
may pursue approval through the Section 505(b)(1) regulatory
pathway, which may require us to conduct additional preclinical or
clinical trials or obtain a right to reference the preclinical or
clinical data of others.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are currently developing three product candidates, GTP-004,
GTP-011 and PainBrake for which we intend to seek FDA approval
through the Section&#xA0;505(b)(2)&#xA0;regulatory pathway, and may
decide to seek FDA approval for other products through the
Section&#xA0;505(b)(2)&#xA0;regulatory pathway in the future. A
Section&#xA0;505(b)(2)&#xA0;NDA is a special type of NDA that
enables the applicant to rely, in part, on the FDA&#x2019;s findings
of safety and efficacy of an existing previously approved product,
or published literature, in support of its application.
Section&#xA0;505(b)(2)&#xA0;NDAs often provide an alternate path to
FDA approval for new or improved formulations or new uses of
previously approved products. Such filings involve significant
filing costs, including filing fees.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Reliance on existing safety findings could expedite the development
program for our product candidates by decreasing the amount of
preclinical or clinical data that we would need to generate in
order to obtain FDA approval. If the FDA does not allow us to
pursue the Section&#xA0;505(b)(2)&#xA0;regulatory pathway as
anticipated, or if the Section&#xA0;505(b)(2)&#xA0;regulatory
pathway fails to significantly decrease the amount of testing we
must conduct, we may need to conduct additional preclinical or
clinical trials, provide additional data and information and meet
additional standards to obtain regulatory approval. In such case,
the time and financial resources required to obtain FDA approval
for product candidates for which we seek approval through the
Section&#xA0;505(b)(2) pathway in the future, and complications and
risks associated with these product candidates, likely would
increase substantially. Moreover, our inability to pursue the
Section&#xA0;505(b)(2)&#xA0;regulatory pathway could prevent us
from introducing our product candidates into the market prior to
our competitors, which could harm our competitive position and
prospects. Even if the FDA allows us to pursue approval through the
Section&#xA0;505(b)(2), we cannot guarantee that it would
ultimately lead to faster product development, and our product
candidates may not receive the requisite approvals for
commercialization.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Furthermore, Section&#xA0;505(b)(2)&#xA0;NDAs are subject to
special requirements designed to protect the patent rights of
sponsors of previously approved drugs referenced in a
Section&#xA0;505(b)(2)&#xA0;NDA, and pursuing the Section 505(b)(2)
pathway could lead to patent litigation and other significant
delays if a current patent holder challenges our application for
pre-market approval. In addition, a manufacturer of an approved
referenced product to file&#xA0;a citizen petition with the FDA
seeking to delay approval of, or impose additional approval
requirements for, pending competing products. If successful, such
petitions can significantly delay, or even prevent, the approval of
the new product. However, even if the FDA ultimately denies such a
petition, the FDA may substantially delay approval while it
considers and responds to the petition.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Furthermore, award of three-year exclusivity by the FDA to a
competitor with a Section 505(b)(2) NDA could delay approval of a
product candidate of ours submitted pursuant to Section 505(b)(2)
of the Food, Drug, and Cosmetic Act if the FDA were to determine
that the products have overlapping conditions of approval, even if
our Section 505(b)(2) NDA does not rely on the competing Section
505(b)(2) NDA. Alternatively, we may pursue approval through the
Section 505(b)(1) regulatory pathway, which may require us to
conduct additional preclinical or clinical trials or obtain a right
to reference the preclinical or clinical data of others. These
alternatives may increase the time and/or financial resources
required to obtain approval.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We will continue to be subject to extensive FDA regulation
following any product approvals, and if we fail to comply with
these regulations, we may suffer a significant setback in our
business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Even if we are successful in obtaining regulatory approval of our
product candidates, we will continue to be subject to the
requirements of and review by, the FDA and comparable regulatory
authorities in the areas of manufacturing processes, post-approval
clinical data, adverse event reporting, labeling, advertising and
promotional activities, among other things. In addition, any
marketing approval we receive may be limited in terms of the
approved product indication or require costly post-marketing
testing and surveillance. Discovery after approval of previously
unknown problems with a product, manufacturer or manufacturing
process, or a failure to comply with regulatory requirements, may
result in enforcement actions such as:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">warning
letters or other actions requiring changes in product manufacturing
processes or restrictions on product marketing or
distribution;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
recalls or seizures or the temporary or permanent withdrawal of a
product from the market;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">suspending
any ongoing clinical trials;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">temporary
or permanent injunctions against our production
operations;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">refusal
of our applications for pre-market approval or an investigational
new drug application; and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">fines,
restitution or disgorgement of profits or revenue, the imposition
of civil penalties or criminal prosecution.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The occurrence of any of these actions would likely cause a
material adverse effect on our business, financial condition and
results of operations.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Many of our business practices are subject to scrutiny and
potential investigation by regulatory and government enforcement
authorities, as well as to lawsuits brought by private citizens
under federal and state laws. We could become subject to
investigations, and our failure to comply with applicable law or an
adverse decision in lawsuits may result in adverse consequences to
us. If we fail to comply with U.S. healthcare laws, we could face
substantial penalties and financial exposure, and our business,
operations and financial condition could be adversely
affected.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
While payment is not yet available from third-party payors
(government or commercial) for our product, our goal is to obtain
such coverage as soon as possible after product approval and
commercial launch in the U.S . If this occurs, the availability of
such payment would mean that many healthcare laws would place
limitations and requirements on the manner in which we conduct our
business (including our sales and promotional activities and
interactions with healthcare professionals and facilities) and
could result in liability and exposure to us. In some instances,
our interactions with healthcare professionals and facilities that
occurred prior to commercialization could have implications at a
later date. The laws that may affect our ability to operate
include, among others: (i) the federal healthcare programs
Anti-Kickback Statute, which prohibits, among other things, persons
from knowingly and willfully soliciting, receiving, offering or
paying remuneration, directly or indirectly, in exchange for or to
induce either the referral of an individual for, or the purchase,
order or recommendation of, any good or service for which payment
may be made under federal healthcare programs such as Medicare or
Medicaid, (ii) federal false claims laws which prohibit, among
other things, individuals or entities from knowingly presenting, or
causing to be presented, claims for payment from Medicare,
Medicaid, or other third-party payors that are false or fraudulent,
and which may apply to entities like us under theories of
&#x201C;implied certification&#x201D; where the government and qui
tam relators may allege that device companies are liable where a
product that was paid for by the government in whole or in part was
promoted &#x201C;off-label,&#x201D; lacked necessary approval, or
failed to comply with good manufacturing practices or other laws;
(iii) transparency laws and related reporting and/or disclosures
such as the Sunshine Act; and/or (iv) state law equivalents of each
of the above federal laws, such as anti-kickback and false claims
laws which may apply to items or services reimbursed by any
third-party payor, including commercial insurers, many of which
differ from their federal counterparts in significant ways, thus
complicating compliance efforts.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If our operations are found to be in violation of any of the laws
described above or any other governmental regulations that apply to
us, we may be subject to penalties, including civil and criminal
penalties, exclusion from participation in government healthcare
programs, damages, fines and the curtailment or restructuring of
our operations. Any penalties, damages, fines, curtailment or
restructuring of our operations could adversely affect our ability
to operate our business and our financial results. The risk of our
being found in violation of these laws is increased by the fact
that their provisions are open to a variety of evolving
interpretations and enforcement discretion. Any action against us
for violation of these laws, even if we successfully defend against
it, could cause us to incur significant legal expenses and divert
our management&#x2019;s attention from the operation of our
business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Both federal and state government agencies have heightened civil
and criminal enforcement efforts. There are numerous ongoing
investigations of healthcare pharmaceutical companies and others in
the healthcare space, as well as their executives and managers. In
addition, amendments to the Federal False Claims Act, have made it
easier for private parties to bring qui tam (whistleblower)
lawsuits against companies under which the whistleblower may be
entitled to receive a percentage of any money paid to the
government. In addition, the Affordable Care Act amended the
federal civil False Claims Act to provide that a claim that
includes items or services resulting from a violation of the
federal anti-kickback statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act. Penalties
include substantial fines for each false claim, plus three times
the amount of damages that the federal government sustained because
of the act of that person or entity and/or exclusion from the
Medicare program. In addition, a majority of states have adopted
similar state whistleblower and false-claims provision. There can
be no assurance that our activities will not come under the
scrutiny of regulators and other government authorities or that our
practices will not be found to violate applicable laws, rules and
regulations or prompt lawsuits by private citizen "relators" under
federal or state false claims laws. Any future investigations of
our business or executives, or enforcement action or prosecution,
could cause us to incur substantial costs, and result in
significant liabilities or penalties, as well as damage to our
reputation.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Laws impacting the U.S. healthcare system are subject to a great
deal of uncertainty, which may result in adverse consequences to
our business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
There have been a number of legislative and regulatory proposals to
change the healthcare system, reduce the costs of healthcare and
change medical reimbursement policies. Doctors, clinics, hospitals
and other users of our products may decline to purchase our
products to the extent there is uncertainty regarding coverage from
government or commercial payors. Further proposed legislation,
regulation and policy changes affecting third-party reimbursement
are likely. Among other things, Congress has in the past proposed
changes to and the repeal of the Patient Protection and Affordable
Care and Health Care and Education Affordability Reconciliation Act
of 2010 (collectively, the &#x201C;Affordable Care Act&#x201D;), and
lawsuits have been brought challenging aspects of the law at
various points. There have been repeated recent attempts by
Congress to repeal or replace the Affordable Care Act. At this
time, it remains unclear whether there will be any changes made to
or any repeal or replacement of the Affordable Care Act, with
respect to certain of its provisions or in its entirety. We are
unable to predict what legislation or regulation, if any, relating
to the health care industry or third-party coverage and
reimbursement may be enacted in the future at the state or federal
level, or what effect such legislation or regulation may have on
us. Denial of coverage and reimbursement of our products, or the
revocation or changes to coverage and reimbursement policies, could
have a material adverse effect on our business, results of
operations and financial condition.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We may not be successful in our efforts to build a pipeline of
product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
A key element of our strategy is to use and expand our product
platform to build a pipeline of product candidates, and progress
those product candidates through clinical development for the
treatment of a variety of different types of cancer. Even if we are
successful in building a product pipeline, the potential product
candidates that we identify may not be suitable for clinical
development for a number of reasons, including causing harmful side
effects or demonstrating other characteristics that indicate a low
likelihood of receiving marketing approval or achieving market
acceptance. If our methods of identifying potential product
candidates fail to produce a pipeline of potentially viable product
candidates, then our success as a business will be dependent on the
success of fewer potential product candidates, which introduces
risks to our business model and potential limitations to any
success we may achieve.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our product candidates may cause undesirable side effects or have
other properties that could delay or prevent their regulatory
approval, limit the commercial profile of an approved label, or
result in significant negative consequences following marketing
approval, if any.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Additionally, if one or more of our product candidates receives
marketing approval, and we or others later identify undesirable
side effects caused by such products, a number of potentially
significant negative consequences could result,
including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">regulatory
authorities may withdraw approvals of such product;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">regulatory
authorities may require additional warnings on the product&#x2019;s
label;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">we
may be required to create a medication guide for distribution to
patients that outlines the risks of such side effects;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">we
could be sued and held liable for harm caused to patients;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">our
reputation may suffer.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Any of these events could prevent us from achieving or maintaining
market acceptance of the particular product candidate, if approved,
and could significantly harm our business, results of operations
and prospects.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
We may expend our limited resources to pursue a particular product
candidate or indication that does not produce any commercially
viable products and may fail to capitalize on product candidates or
indications that may be more profitable or for which there is a
greater likelihood of success.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Because we have limited financial and managerial resources, we must
focus our efforts on particular research programs and product
candidates for specific indications. As a result, we may forego or
delay pursuit of opportunities with other product candidates or for
other indications that later prove to have greater commercial
potential. Further, our resource allocation decisions may result in
our use of funds for research and development programs and product
candidates for specific indications that may not yield any
commercially viable products. If we do not accurately evaluate the
commercial potential or target market for a particular product
candidate, we may relinquish valuable rights to that product
candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous
for us to retain sole development and commercialization rights to
such product candidate. Any such failure to improperly assess
potential product candidates could result in missed opportunities
and/or our focus on product candidates with low market potential,
which would harm our business and financial condition.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our products may be expensive to manufacture, and they may not be
profitable if we are unable to control the costs to manufacture
them.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our products may be significantly more expensive to manufacture
than we expect or than other therapeutic products currently on the
market today. We hope to substantially reduce manufacturing costs
through process improvements, development of new methods, increases
in manufacturing scale and outsourcing to experienced
manufacturers. If we are not able to make these, or other
improvements, and depending on the pricing of the product, our
profit margins may be significantly less than that of other
therapeutic products on the market today. In addition, we may not
be able to charge a high enough price for any product we develop,
even if they are safe and effective, to make a profit. If we are
unable to realize significant profits from our potential product
candidates, our business would be materially harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
For some of our products, we currently lack sufficient
manufacturing capabilities to produce our therapeutic product
candidates at commercial-scale quantities and do not have an
alternate manufacturing supply, which could negatively impact our
ability to meet any future demand for the product.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We expect that we would need to significantly expand our
manufacturing capabilities to meet potential demand for our
therapeutic product candidates, if approved. Such expansion would
require additional regulatory approvals. Even if we increase our
manufacturing capabilities, it is possible that we may still lack
sufficient capacity to meet demand.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We do not currently have any alternate supply for our products. If
our facilities where our products are currently being manufactured
or equipment were significantly damaged or destroyed, or if there
were other disruptions, delays or difficulties affecting
manufacturing capacity, including if such facilities are deemed not
in compliance with current Good Manufacturing Practice, or GMP,
requirements, future clinical studies and commercial production for
our products would likely be significantly disrupted and delayed.
It would be both time-consuming and expensive to replace this
capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Ultimately, if we are unable to supply our products to meet
commercial demand, whether because of processing constraints or
other disruptions, delays or difficulties that we experience, our
production costs could dramatically increase and sales of our
products and their long-term commercial prospects could be
significantly damaged.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
To be successful, our proposed products must be accepted by the
healthcare community, which can be very slow to adopt or
unreceptive to new technologies and products.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our proposed products and those developed by our collaborative
partners, if approved for marketing, may not achieve market
acceptance since hospitals, physicians, patients or the medical
community in general may decide not to accept and use these
products. The products that we are attempting to develop represent
substantial departures from established treatment methods and will
compete with a number of more conventional therapies manufactured
and marketed by major pharmaceutical companies. The degree of
market acceptance of any of our developed products will depend on a
number of factors, including:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">our
establishment and demonstration to the medical community of the
clinical efficacy and safety of our proposed products;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">our
ability to create products that are superior to alternatives
currently on the market;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">our
ability to establish in the medical community the potential
advantage of our treatments over alternative treatment methods;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">reimbursement
policies of government and third-party payers.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If the healthcare community does not accept our products for any of
these reasons, or for any other reason, our business would be
materially harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our business is based on novel technologies that are inherently
expensive and risky and may not be understood by or accepted in the
marketplace, which could adversely affect our future
value.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The clinical development, commercialization and marketing of
immuno-oncology therapies are at an early-stage, substantially
research-oriented, and financially speculative. To date, very few
companies have been successful in their efforts to develop and
commercialize an immuno-oncology therapeutic product. In general,
such products may be susceptible to various risks, including
undesirable and unintended side effects, unintended immune system
responses, inadequate therapeutic efficacy, or other
characteristics that may prevent or limit their approval or
commercial use. Furthermore, the number of people who may use such
therapies is difficult to forecast with accuracy. Our future
success is dependent on the establishment of a significant market
for such therapies and our ability to capture a share of this
market with our product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our development efforts with our therapeutic product candidates are
susceptible to the same risks of failure inherent in the
development and commercialization of therapeutic products based on
new technologies. The novel nature of immuno-oncology therapeutics
creates significant challenges in the areas of product development
and optimization, manufacturing, government regulation, third-party
reimbursement and market acceptance. For example, the FDA has
relatively limited experience regulating such therapies, and there
are few approved treatments using such therapy.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Our competition includes fully integrated biotechnology and
pharmaceutical companies that have significant advantages over
us.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The market for therapeutic immuno-oncology products is highly
competitive. We expect that our most significant competitors will
be fully integrated and more established pharmaceutical and
biotechnology companies or institutions, including major
multinational pharmaceutical companies, biotechnology companies and
universities and other research institutions. These companies are
developing similar products, and they have significantly greater
capital resources and research and development, manufacturing,
testing, regulatory compliance, and marketing capabilities. Many of
these potential competitors may be further along in the process of
product development and also operate large, company-funded research
and development programs. As a result, our competitors may develop
more competitive or affordable products, or achieve earlier patent
protection or product commercialization than we are able to
achieve. Competitive products may render any products or product
candidates that we develop obsolete.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Many of our competitors have substantially greater financial,
technical and other resources than we do, such as larger research
and development staff and experienced marketing and manufacturing
organizations. Additional mergers and acquisitions in the
biotechnology and pharmaceutical industries may result in even more
resources being concentrated in certain of our competitors. As a
result, these companies may be able to obtain regulatory approval
more rapidly than we can and may be more effective in selling and
marketing their products. Smaller or early-stage companies may also
prove to be significant competitors, particularly through
collaborative arrangements with large, established companies.
Competition may increase further as a result of advances in the
commercial applicability of technologies and greater availability
of capital for investment in these industries. Our competitors may
succeed in developing, acquiring or licensing drug products that
are more effective or less costly to produce or purchase on the
market than any product candidate we are currently developing or
that we may seek to develop in the future. If approved, our product
candidates will face competition from commercially available drugs
as well as drugs that are in the development pipelines of our
competitors.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Established pharmaceutical companies may invest heavily to
accelerate discovery and development of or in-license novel
compounds that could make our product candidates less competitive.
In addition, any new product that competes with an approved product
must demonstrate compelling advantages in efficacy, convenience,
tolerability and safety in order to overcome price competition and
to be commercially successful. Accordingly, our competitors may
succeed in obtaining patent protection, receiving FDA, EMA or other
regulatory approval, or discovering, developing and commercializing
medicines before we do, which would have a material adverse impact
on our business and ability to achieve profitability from future
sales of our approved product candidates, if any.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If competitors develop and market products that are more effective,
safer or less expensive than our product candidates or offer other
advantages, our commercial prospects will be limited.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our therapeutic immuno-oncology development programs face, and will
continue to face, intense competition from pharmaceutical,
biopharmaceutical and biotechnology companies, as well as numerous
academic and research institutions and governmental agencies
engaged in drug discovery activities or funding, both in the United
States and abroad. Some of these competitors are pursuing the
development of drugs and other therapies that target the same
diseases and conditions that we are targeting with our product
candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As a general matter, we also face competition from many companies
that are researching and developing cell therapies. Many of these
companies have financial and other resources substantially greater
than ours. In addition, many of these competitors have
significantly greater experience in testing pharmaceutical and
other therapeutic products, obtaining FDA and other regulatory
approvals, and marketing and selling. If we ultimately obtain
regulatory approval for any of our product candidates, we also will
be competing with respect to manufacturing efficiency and marketing
capabilities, areas in which we have limited or no
commercial-scale&#xA0;experience. Mergers and acquisitions in the
pharmaceutical and biotechnology industries may result in even more
resources&#x2019; being concentrated by our competitors. Competition
may increase further as a result of advances made in the commercial
applicability of our technologies and greater availability of
capital for investment in these fields.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Our CNS portfolio compounds also face considerable competition.
Many compounds are in development for the treatment of neuropathic
pain. Current treatments for neuropathic include narcotic
analgesics, voltage-gated sodium channel blockers, voltage-gated
calcium channel blockers, glutamate NMDA NR2B antagonists
(ketamine), drugs that increase monoamine transmission, and
cannabinoids.&#xA0;</font><font style="color: #1A1A1A">Some of the
key players operating in the global neuropathic pain market are
Depomed Inc. (NASDAQ:DEPO), Pfizer Inc. (NYSE:PFE), Johnson &amp;
Johnson (NYSE:JNJ), Bristol-Myers Squibb (NYSE:BMY), Eli Lilly and
Company (NYSE:LLY), GlaxoSmithKline PLC (NYSE:GSK), Sanofi S.A.
(NYSE:SNY), Biogen Idec Inc. (NASDAQ:BIIB), and Baxter Healthcare
Corporation (NYSE:BAX). In the field of myasthenia gravis,
pharmaceutical R&amp;D efforts focus on the discovery of a cure for
the disease. A cure would make treatment with GTP-004 obsolete. In
the field of motion sickness, research may be ongoing for better
anti-motion sickness drugs.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
If we are unable to keep up with rapid technological changes in our
field or compete effectively, we will be unable to operate
profitably.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are engaged in activities in the biotechnology field, which is
characterized by extensive research efforts and rapid technological
progress. If we fail to anticipate or respond adequately to
technological developments, our ability to operate profitably could
suffer. Research and discoveries by other biotechnology,
agricultural, pharmaceutical or other companies may render our
technologies or potential products or services uneconomical or
result in products superior to those we develop. Similarly, any
technologies, products or services we develop may not be preferred
to any existing or newly developed technologies, products or
services.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We may not be able to obtain third-party patient reimbursement or
favorable product pricing, which would reduce our ability to
operate profitably.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our ability to successfully commercialize certain of our proposed
products in the human therapeutic field may depend to a significant
degree on patient reimbursement of the costs of such products and
related treatments at acceptable levels from government
authorities, private health insurers and other organizations, such
as health maintenance organizations. Reimbursement in the United
States or foreign countries may not be available for any products
we may develop, and, if available, may be decreased in the future.
Also, reimbursement amounts may reduce the demand for, or the price
of, our products with a consequent harm to our business. We cannot
predict what additional regulation or legislation relating to the
healthcare industry or third-party coverage and reimbursement may
be enacted in the future or what effect such regulation or
legislation may have on our business. If additional regulations are
overly onerous or expensive, or if healthcare-related legislation
makes our business more expensive or burdensome than originally
anticipated, we may be forced to significantly downsize our
business plans or completely abandon our business
model.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We may be subject to litigation that will be costly to defend or
pursue and uncertain in its outcome.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our business may bring us into conflict with our licensees,
licensors or others with whom we have contractual or other business
relationships, or with our competitors or others whose interests
differ from ours. If we are unable to resolve those conflicts on
terms that are satisfactory to all parties, we may become involved
in litigation brought by or against us. That litigation is likely
to be expensive and may require a significant amount of
management&#x2019;s time and attention, at the expense of other
aspects of our business. The outcome of litigation is always
uncertain, and in some cases could include judgments against us
that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could
have a significant adverse effect on our business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We are exposed to the risk of liability claims, for which we may
not have adequate insurance.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Since we participate in the pharmaceutical industry, we may be
subject to liability claims by employees, customers, end users and
third parties. We do not currently have product liability
insurance. We intend to obtain proper insurance . however, there
can be no assurance that any liability insurance we purchase will
be adequate to cover claims asserted against us or that we will be
able to maintain such insurance in the future. We intend to adopt
prudent risk-management programs to reduce these risks and
potential liabilities. however, we have not taken any steps to
create these programs and have no estimate as to the cost or time
required to do so and there can be no assurance that such programs,
if and when adopted, will fully protect us. We may not be able to
put risk management programs in place, or obtain insurance, if we
are unable to retain the necessary expertise and/or are
unsuccessful in raising necessary capital in the future. Our
failure to obtain appropriate insurance, or to adopt and implement
effective risk-management programs, as well as any adverse rulings
in any legal matters, proceedings and other matters could have a
material adverse effect on our business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Preclinical and clinical trials are conducted during the
development of potential products and other treatments to determine
their safety and efficacy for use by humans. Notwithstanding these
efforts, when our treatments are introduced into the marketplace,
unanticipated side effects may become evident. Manufacturing,
marketing, selling and testing our product candidates under
development or to be acquired or licensed, entails a risk of
product liability claims. We could be subject to product liability
claims in the event that our product candidates, processes, or
products under development fail to perform as intended. Even
unsuccessful claims could result in the expenditure of funds in
litigation and the diversion of management time and resources, and
could damage our reputation and impair the marketability of our
product candidates and processes. While we plan to maintain
liability insurance for product liability claims, we may not be
able to obtain or maintain such insurance at a commercially
reasonable cost. If a successful claim were made against us, and we
lacked insurance or the amount of insurance were inadequate to
cover the costs of defending against or paying such a claim or the
damages payable by us, we would experience a material adverse
effect on our business, financial condition and results of
operations.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We could be subject to product liability lawsuits based on the use
of our product candidates in clinical testing or, if obtained,
following marketing approval and commercialization. If product
liability lawsuits are brought against us, we may incur substantial
liabilities and may be required to cease clinical testing or limit
commercialization of our product candidates.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We could be subject to product liability lawsuits if any product
candidate we develop allegedly causes injury or is found to be
otherwise unsuitable for human use during product testing,
manufacturing, marketing or sale. Any such product liability claims
may include allegations of defects in manufacturing, defects in
design, a failure to warn of dangers inherent in the product,
negligence, strict liability and a breach of warranties. Claims
could also be asserted under state consumer protection acts. If we
cannot successfully defend ourselves against product liability
claims, we may incur substantial liabilities or be required to
limit commercialization of our product candidates, if approved.
Even successful defense would require significant financial and
management resources. Regardless of the merits or eventual outcome,
liability claims may result in:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">decreased
demand for our product candidates;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">withdrawal
of clinical trial participants;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">initiation
of investigations by regulators;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">costs
to defend the related litigation;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">a
diversion of management&#x2019;s time and our
resources;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">substantial
monetary awards to trial participants or patients;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">product
recalls, withdrawals or labeling, marketing or promotional
restrictions;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">loss
of revenues from product sales; and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">the
inability to commercialize our product candidates.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our inability to retain sufficient product liability insurance at
an acceptable cost to protect against potential product liability
claims could prevent or inhibit the clinical testing and
commercialization of products we develop. We may wish to obtain
additional such insurance covering studies or trials in other
countries should we seek to expand those clinical trials or
commence new clinical trials in other jurisdictions or increase the
number of patients in any clinical trials we may pursue. We also
may determine that additional types and amounts of coverage would
be desirable at later stages of clinical development of our product
candidates or upon commencing commercialization of any product
candidate that obtains required approvals. However, we may not be
able to obtain any such additional insurance coverage when needed
on acceptable terms or at all. If we do not obtain or retain
sufficient product liability insurance, we could be responsible for
some or all of the financial costs associated with a product
liability claim relating to our preclinical and clinical
development activities, in the event that any such claim results in
a court judgment or settlement in an amount or of a type that is
not covered, in whole or in part, by any insurance policies we may
have or that is in excess of the limits of our insurance coverage.
We may not have, or be able to obtain, sufficient capital to pay
any such amounts that may not be covered by our insurance
policies.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We rely on third parties to conduct preclinical and clinical trials
of our product candidates. If these third parties do not
successfully carry out their contractual duties or meet expected
deadlines, we may not be able to obtain regulatory approval for or
commercialize our product candidates and our business could be
substantially harmed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We rely, and expect to continue to rely, upon third-party CROs to
execute our preclinical and clinical trials and to monitor and
manage data produced by and relating to those trials. However, we
may not be able to establish arrangements with CROs when needed or
on terms that are acceptable to us, or at all, which could
negatively affect our development efforts with respect to our drug
product candidates and materially harm our business, operations and
prospects.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We will have only limited control over the activities of the CRO we
will engaged to continue conduct our clinical trials including the
University of Minnesota for our phase 2 clinical trial for
OXS-1550. Nevertheless, we are responsible for ensuring that each
of our studies is conducted in accordance with the applicable
protocol, legal, regulatory and scientific standards, and our
reliance on any CRO does not relieve us of our regulatory
responsibilities. Based on our present expectations, we, our CROs
and our clinical trial sites are required to comply with good
clinical practices, or GCPs, for all of our product candidates in
clinical development. Regulatory authorities enforce GCPs through
periodic inspections of trial sponsors, principal investigators and
trial sites. If we or any of our CROs fail to comply with
applicable GCPs, the clinical data generated in the applicable
trial may be deemed unreliable and the FDA, EMA or comparable
foreign regulatory authorities may require us to perform additional
clinical trials before approving a product candidate for marketing,
which we may not have sufficient cash or other resources to support
and which would delay our ability to generate revenue from any
sales of such product candidate. In addition, our clinical trials
are required to be conducted with product produced in compliance
with current good manufacturing practice requirements, or cGMPs.
Our or our CROs&#x2019; failure to comply with those regulations may
require us to repeat clinical trials, which would also require
significant cash expenditures and delay the regulatory approval
process.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Agreements governing relationships with CROs generally provide
those CROs with certain rights to terminate a clinical trial under
specified circumstances. If a CRO that we have engaged terminates
its relationship with us during the performance of a clinical
trial, we would be forced to seek an engagement with a substitute
CRO, which we may not be able to do on a timely basis or on
commercially reasonable terms, if at all, and the applicable trial
would experience delays or may not be completed. In addition, our
CROs are not our employees, and except for remedies available to us
under any agreements we enter with them, we are unable to control
whether or not they devote sufficient time and resources to our
clinical, nonclinical and preclinical programs. If CROs do not
successfully carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the
quality or accuracy of the clinical data they obtain is compromised
due to a failure to adhere to our clinical protocols, regulatory
requirements or for other reasons, our clinical trials may be
extended, delayed or terminated and we may not be able to obtain
regulatory approval for, or successfully commercialize, the
affected product candidates. As a result, our operations and the
commercial prospects for the effected product candidates would be
harmed, our costs could increase and our ability to generate
revenues could be delayed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
We contract with third parties for the supply of product candidates
for clinical testing and expect to contract with third parties for
the manufacturing of our product candidates for large-scale testing
and commercial supply. This reliance on third parties increases the
risk that we will not have sufficient quantities of our product
candidates or products or such quantities at an acceptable cost,
which could delay, prevent or impair our development or
commercialization efforts.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We anticipate continuing our engagement of third parties to provide
our clinical supply as we advance our product candidates into and
through clinical development. We expect in the future to use third
parties for the manufacture of our product candidates for clinical
testing, as well as for commercial manufacture. We plan to enter
into long-term supply agreements with several manufacturers for
commercial supplies. We may be unable to reach agreement on
satisfactory terms with contract manufacturers to manufacture our
product candidates. Additionally, the facilities to manufacture our
product candidates must be the subject of a satisfactory inspection
before the FDA or other regulatory authorities approve a marketing
authorization for the product candidate manufactured at that
facility. We will depend on these third-party manufacturers for
compliance with the FDA&#x2019;s and international regulatory
authority requirements for the manufacture of our finished
products. We do not control the manufacturing process of, and are
completely dependent on, our contract manufacturers for compliance
with cGMPs. If our manufacturers cannot successfully manufacture
material that conforms to our specifications and the FDA and other
regulatory authorities&#x2019; cGMP requirements, they will not be
able to secure and/or maintain regulatory approval for their
manufacturing facilities. In addition, we have no control over the
ability of our contract manufacturers to maintain adequate quality
control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these
facilities for the manufacture of our product candidates or if it
withdraws any such approval in the future, we may need to find
alternative manufacturing facilities, which would significantly
impact our ability to develop, obtain regulatory approval for or
market our product candidates, if approved, and may subject us to
recalls or enforcement action for products already on the
market.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;If any of our product candidates are approved and contract
manufacturers fail to deliver the required commercial quantities of
finished product on a timely basis and at commercially reasonable
prices, and we are unable to find one or more replacement
manufacturers capable of production at a substantially equivalent
cost, in substantially equivalent volumes and quality and on a
timely basis, we would likely be unable to meet demand for our
products and could lose potential revenue. It may take several
years to establish an alternative source of supply for our product
candidates and to have any such new source approved by the FDA or
any other relevant regulatory authorities.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We currently have no marketing and sales force. If we are unable to
establish effective marketing and sales capabilities or enter into
agreements with third parties to market and sell our product
candidates, we may not be able to effectively market and sell our
product candidates, if approved, or generate product
revenues.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We currently do not have a marketing or sales team for the
marketing, sales and distribution of any of our product candidates
that are able to obtain regulatory approval. In order to
commercialize any product candidates, we must build on a
territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make
arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates
receive regulatory approval, we intend to establish an internal
sales and marketing team with technical expertise and supporting
distribution capabilities to commercialize our product candidates,
which will be expensive and time consuming and will require
significant attention of our executive officers to manage. Any
failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to
market. With respect to the commercialization of all or certain of
our product candidates, we may choose to collaborate, either
globally or on a territory-by-territory basis, with third parties
that have direct sales forces and established distribution systems,
either to augment our own sales force and distribution systems or
in lieu of our own sales force and distribution systems. If we are
unable to enter into such arrangements when needed on acceptable
terms or at all, we may not be able to successfully commercialize
any of our product candidates that receive regulatory approval or
any such commercialization may experience delays or limitations. If
we are not successful in commercializing our product candidates,
either on our own or through collaborations with one or more third
parties, our future product revenue will suffer and we may incur
significant additional losses.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our business and operations would suffer in the event of system
failures.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Despite the implementation of security measures, our internal
computer systems and those of our contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and
electrical failures. While we have not experienced any such system
failure, accident or security breach to date, if such an event were
to occur and cause interruptions in our operations, it could result
in a material disruption of our drug development programs. For
example, the loss of clinical trial data from completed or ongoing
or planned clinical trials could result in delays in our regulatory
approval efforts and we may incur substantial costs to attempt to
recover or reproduce the data. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or
inappropriate disclosure of confidential or proprietary
information, we could incur liability and/or the further
development of our product candidates could be
delayed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Our operations are vulnerable to interruption by natural disasters,
power loss, terrorist activity and other events beyond our control,
the occurrence of which could materially harm our
business.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Businesses located in California have, in the past, been subject to
electrical blackouts as a result of a shortage of available
electrical power, and any future blackouts could disrupt our
operations. We are vulnerable to a major earthquake, wildfire and
other natural disasters, and we have not undertaken a systematic
analysis of the potential consequences to our business as a result
of any such natural disaster and do not have an applicable recovery
plan in place. We do not carry any business interruption insurance
that would compensate us for actual losses from interruption of our
business that may occur, and any losses or damages incurred by us
could cause our business to materially suffer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
We have not held regular annual meetings in the past, and if we are
required by the Delaware Court of Chancery to hold an annual
meeting pursuant to Section 211(c) of the Delaware General
Corporation Law, or the DGCL, it could result in the unanticipated
expenditure of funds, time and other Company
resources.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Section 2.2 of our bylaws provides that an annual meeting shall be
held each year on a date and at a time designated by our board of
directors, and Section 211(b) of the DGCL provides for an annual
meeting of stockholders to be held for the election of directors.
Section 211(c) of the DGCL provides that if there is a failure to
hold the annual meeting for a period of 13 months after the latest
to occur of the organization of the corporation, its last annual
meeting or last action by written consent to elect directors in
lieu of an annual meeting, the Delaware Court of Chancery may order
a meeting to be held upon the application of any stockholder or
director. Section 211(c) also provides that the failure to hold an
annual meeting shall not affect otherwise valid corporate acts or
result in a forfeiture or dissolution of the
corporation.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have not held regular annual meetings in the past because a
substantial majority of our stock is owned by a small number of
stockholders, making it easy to obtain written consent in lieu of a
meeting when necessary. In light of our historical liquidity
constraints, handling matters by written consent has allowed our
Company to save on the financial and administrative resources
required to prepare for and hold such annual meetings. To our
knowledge, no stockholder or director has requested our
Company&#x2019;s management to hold such an annual meeting and no
stockholder or director has applied to the Delaware Court of
Chancery seeking an order directing our company to hold a meeting.
However, if one or more stockholders or directors were to apply to
the Delaware Court of Chancery seeking such an order, and if the
Delaware Court of Chancery were to order an annual meeting before
we are prepared to hold one, the preparation for the annual meeting
and the meeting itself could result in the unanticipated
expenditure of funds, time, and other Company
resources.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="use">U</a>SE OF PROCEEDS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The selling stockholders will receive all net proceeds from the
sale of the shares of common stock registered by this prospectus
and offered by any accompanying prospectus supplement. We will not
receive any proceeds from the sale of common stock by the selling
stockholders.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We, and not the selling stockholders, will pay the costs, expenses
and fees in connection with the registration of the shares covered
by this prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="market">M</a>ARKET FOR OUR COMMON STOCK AND
RELATED STOCKHOLDER MATTERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Until May 2009, our common stock was traded on the OTC Bulletin
Board (&#x201C;OTCBB&#x201D;) under the symbol &#x201C;OXIS.&#x201D;
From May 20, 2009 until March 11, 2010, our common stock was traded
on Pink OTC Markets Inc. trading platform under the symbol
&#x201C;OXIS.&#x201D; From January 2015 to August 2017, our common
stock is quoted on the OTCQB under the &#x201C;OXIS&#x201D; trading
symbol. Since August 2017, our common stock has been quoted on the
OTCQB under the &#x201C;GTBP&#x201D; trading symbol.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Trading in our common stock has fluctuated greatly during the past
eighteen months. Accordingly, the prices for our common stock
quoted on the OTCQB or Pink OTC Markets Inc. may not necessarily be
reliable indicators of the value of our common stock. The following
table sets forth the high and low bid prices for shares of our
common stock for the quarters noted, as reported on the OTCQB and
the Pink OTC Markets Inc. The following price information reflects
inter-dealer prices, without retail mark-up, mark-down or
commission and may not represent actual transactions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Fiscal Year 2019</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;High ($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;Low ($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Second
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.21</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">First
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.96</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0.30</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Fiscal Year 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fourth
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.16</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.62</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Third
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.75</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1.42</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Second
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.52</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">First
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.06</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Fiscal Year 2017</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fourth
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6.99</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.25</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Third
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">29.55</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4.66</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Second
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9.90</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3.36</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">First
Quarter</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3.81</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our common stock is also quoted on several European based exchanges
including Berlin (GTBP.BE), Frankfurt (GTBP.DE), the Euronext
(GTBP.NX) and Paris, (GTBP.PA). The foregoing trading prices
exclude trading on these foreign stock markets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">22</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Stockholders</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of September 3, 2019, there were 23 stockholders of record,
which total does not include stockholders who hold their shares in
&#x201C;street name.&#x201D; The transfer agent for our common stock
is ComputerShare, whose address is 8742 Lucent Blvd., Suite 225,
Highland Ranch, CO 80129.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#xA0;</font><font style="font-weight: bold; color: #000000">Dividends</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have not paid any dividends on our common stock to date and do
not anticipate that we will pay dividends in the foreseeable
future. Any payment of cash dividends on our common stock in the
future will be dependent upon the amount of funds legally
available, our earnings, if any, our financial condition, our
anticipated capital requirements and other factors that the Board
of Directors may think are relevant. However, we currently intend
for the foreseeable future to follow a policy of retaining all of
our earnings, if any, to finance the development and expansion of
our business and, therefore, do not expect to pay any dividends on
our common stock in the foreseeable future.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Equity Compensation Plan Information</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The information included under the heading &#x201C;Equity
Compensation Plan Information&#x201D; in &#x201C;Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder
Matters.&#x201D; is hereby incorporated by reference into this
paragraph.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="managements">M</a>ANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Some of the statements in this prospectus are forward-looking
statements about what may happen in the future. Forward-looking
statements include statements regarding our current beliefs, goals,
and expectations about matters such as our expected financial
position and operating results, our business strategy, and our
financing plans. The forward-looking statements in this prospectus
are not based on historical facts, but rather reflect the current
expectations of our management concerning future results and
events.&#xA0;&#xA0;The forward-looking statements generally can be
identified by the use of terms such as &#x201C;believe,&#x201D;
&#x201C;expect,&#x201D; &#x201C;anticipate,&#x201D;
&#x201C;intend,&#x201D; &#x201C;plan,&#x201D; &#x201C;foresee,&#x201D;
&#x201C;likely&#x201D; or other similar words or phrases. Similarly,
statements that describe our objectives, plans or goals are or may
be forward-looking statements. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause our actual results, performance or achievements to be
different from any future results, performance and achievements
expressed or implied by these statements.&#xA0;&#xA0;We cannot
guarantee that our forward-looking statements will turn out to be
correct or that our beliefs and goals will not change. Our actual
results could be very different from and worse than our
expectations for various reasons. You should review carefully all
information, including the discussion of risk factors herein and
&#x201C;Item 7: Management&#x2019;s Discussion and Analysis of
Financial Condition and Results of Operations&#x201D; of the Form
10-K for the year ended December 31, 2018.&#xA0;&#xA0;Any
forward-looking statements in this prospectus are made only as of
the date hereof and, except as may be required by law, we do not
have any obligation to publicly update any forward-looking
statements contained in this prospectus to reflect subsequent
events or circumstances.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Throughout this prospectus, the terms
&#x201C;GTBP,&#x201D;&#xA0;&#x201C;we,&#x201D;
&#x201C;us,&#x201D;&#xA0;&#x201C;our,&#x201D; &#x201C;the company&#x201D;
and &#x201C;our company&#x201D; refer to GT Biopharma, Inc., a
Delaware corporation formerly known as Oxis International, Inc.,
DDI Pharmaceuticals, Inc. and Diagnostic Data, Inc, together with
our subsidiaries.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Overview</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
We are</font><font style="color: #000000">&#xA0;a clinical stage
biopharmaceutical company focused on the development and
commercialization of novel immuno-oncology products based off our
proprietary Tri-specific Killer Engager (TriKE), Tetra-specific
Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate
(ADC) technology platforms. Our immuno-oncology portfolio is based
off a proprietary technology platform consisting of single-chain
bi-, tri- and tetra-specific scFv&#x2019;s, combined with
proprietary antibody-drug linkers and drug payloads. Constructs
include bispecific and trispecific scFv constructs, proprietary
drug payloads, bispecific targeted antibody-drug conjugates, or
ADCs, as well as tri- and tetra-specific antibody-directed cellular
cytotoxicity, or ADCC. Our proprietary tri- and tetra-specific ADCC
platform engages natural killer cells, or NK cells. NK cells are
cytotoxic lymphocytes of the innate immune system capable of immune
surveillance. NK cells mediate ADCC through the highly potent CD16
activating receptor. Upon activation, NK cells deliver a store of
membrane penetrating apoptosis-inducing molecules. Unlike T cells,
NK cells do not require antigen priming.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We also have a CNS portfolio consists of innovative reformulations
and/or repurposing of existing therapies. We believe these
therapeutic agents address certain unmet medical needs that can
lead to improved efficacy while addressing tolerability and safety
issues that tended to limit the usefulness of the original approved
drug. Our CNS drug candidates address disease states such as
chronic neuropathic pain, myasthenia gravis and vestibular
disorders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">23</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Recent Developments</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-style: italic; font-family: Times New Roman; font-size: 13px">
Financing</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Starting on August 20, 2019, GT Biopharma, Inc. (the "Company")
entered into a Securities Purchase Agreement with11 purchasers
(individually, a "Purchaser," and collectively, the "Purchasers")
pursuant to which the Company has issued to the Purchasers
Convertible Debentures in an aggregate principal amount of $975,000
(the "Debentures"), which Debentures are convertible into the
Company's common stock (the "Common Stock") at a price of $0. 20per
share. The Company and each Purchaser also entered into a
Registration Rights Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The issuance of the Debentures was made in reliance on the
exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the "Securities Act"), for the offer and sale of
securities not involving a public offering and Regulation D
promulgated under the Securities Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On May 22, 2019, GT Biopharma, Inc. (the "Company") entered into a
Securities Purchase Agreement with ten purchasers (individually, a
"Purchaser," and collectively, the "Purchasers") pursuant to which
the Company has issued to the Purchasers Convertible Debentures in
an aggregate principal amount of $1,300,000 (the "Debentures"),
which Debentures are convertible into the Company's common stock
(the "Common Stock") at a price of $0.35 per share.&#xA0; The
Company and each Purchaser also entered into a Registration Rights
Agreement.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The issuance of the Debentures was made in reliance on the
exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the "Securities Act"), for the offer and sale of
securities not involving a public offering and Regulation D
promulgated under the Securities Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On February 4, 2019, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;) with the purchasers identified on the signature
pages thereto (individually, a &#x201C;Purchaser,&#x201D; and
collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224
(the &#x201C;Notes&#x201D;), consisting of gross proceeds of
$1,052,224 and settlement of existing debt of $300,000, which Notes
shall be convertible at any time after issuance into shares (the
&#x201C;Conversion Shares&#x201D;) of the Company&#x2019;s common
stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;),
at a conversion price of $0.60 per share (the &#x201C;Conversion
Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Notes accrue interest at the rate of 10% per annum and mature
on August 2, 2019. Interest on the Notes is payable in cash or, at
a Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Notes with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Contemporaneously with the execution and delivery of the Purchase
Agreement, on February 4, 2019, the Company and certain of its
wholly-owned subsidiaries entered into a Security Agreement (the
&#x201C;Security Agreement&#x201D;) with Alpha Capital Anstalt, as
collateral agent on behalf of the Purchasers, and with the
Purchasers, pursuant to which the Purchasers have been granted a
first-priority security interest in substantially all of the assets
of the Company and such subsidiaries securing (i) an aggregate
principal amount of $1,352,224 of Notes and (ii) an aggregate
principal amount of $9,058,962 of the Company&#x2019;s 10% Senior
Convertible Debentures issued on August 2, 2018, September 7, 2018
and September 24, 2018 held by such Purchasers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Purchase Agreement contains customary representations,
warranties and covenants, including covenants, subject to certain
exceptions, that the Company, until the date on which less than 10%
of the Notes are outstanding, shall not affect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the Company entered into a registration rights
agreement (the &#x201C;Registration Rights Agreement&#x201D;) with
the Purchasers, pursuant to which the Company has agreed to file,
within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form
S-3 was filed by the Company on February 14, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">24</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Results of Operations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Comparison of the Six Months Ended June 30, 2019 and
2018</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During the six months ended June 30, 2019 and 2018, we incurred
$1.0 million and $6.7 million of research and development
expenses.&#xA0;Research and development costs decreased due
primarily to the reductions employees, consultants and preclinical
expenses. We anticipate our direct clinical costs to increase in
second half of 2019 upon the initiation of a phase one clinical
trial of our most advanced TriKe product candidate,
OXS-3550.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Selling, general and administrative expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During the six months ended June 30, 2019 and 2018, we incurred
$5.4 million and $5.6 million of selling, general and
administrative expenses.&#xA0;&#xA0;The decrease in selling,
general and administrative expenses is primarily attributable the
reduction of payroll and stock compensation expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Interest Expense</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Interest expense was $.9 million and $6.9 million for the six
months ended June 30, 2019 and 2018 respectively.&#xA0;&#xA0;The
decrease is primarily due to a decrease related to the amortization
of the original issue discount and beneficial conversion features
related to various financing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Comparison of the Fiscal Years Ended December 31, 2018 and
2017</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Research and Development Expenses</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During the years ended December 31, 2018 and 2017, we incurred $9.1
million and $1.1 million of research and development expenses,
respectively. 2018 research and development costs increased due
primarily to the addition of new employees, increased regulatory
and preclinical consultant costs to support the GTB-3550 IND,
higher costs to advance the CNS portfolio and position the assets
for licensing efforts, and higher preclinical and clinical expenses
incurred at the University of Minnesota to continue development of
our immune-oncology assets. 2018 expenses also include non-cash
compensation of $6.8 million. We anticipate our direct clinical and
preclinical costs to continue to increase throughout 2019, totaling
approximately $12 to $15 million, as we initiate a Phase 1 clinical
trial of our most advanced TriKe product candidate, GTB-3550 in the
first half of 2019, and initiate IND-enabling activities for
GTB-C3550, and GTB-1615.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Selling, general and administrative expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During the years ended December 31, 2018 and 2017, we incurred
$12.5 million and $134.5 million of selling, general and
administrative expenses, respectively. Selling, general and
administrative expenses in 2017 were driven by stock compensation
related to the acquisition of Georgetown Translational
Pharmaceuticals on September 1, 2017. Stock compensation expenses
totaled $2.3 million and $129.1 million for in 2018 and 2017,
respectively. Additional selling, general, and administrative
expenses in 2018 were due to increased spending on investor
relations campaigns to broaden awareness of the Company, and
increased legal costs primarily associated with financing efforts.
We anticipate selling, general and administrative expenses,
excluding stock compensation, to range between $1 and $2 million in
the coming quarters.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Loss on impairment</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
For the year ended December 31, 2018, the Company recorded an
intangible asset impairment charge of $228.5 million related to the
portfolio of CNS IPR&amp;D assets, which represents the excess
carrying value compared to fair value. The impairment charge was
the result of both internal and external factors. In the 3rd
quarter of 2018, the Company experienced changes in key senior
management, led by the appointment of a CEO with extensive
experience in oncology drug development. These changes resulted in
the prioritization for immuno-oncology development candidates
relative to the CNS development candidates acquired from Georgetown
Translational Pharmaceuticals. In conjunction with these strategic
changes, limited internal resources have delayed the development of
the CNS IPR&amp;D assets. The limited resources, changes in senior
leadership, and favorable market conditions for immuno-oncology
development candidates have resulted in the Company choosing to
focus on development of its immuno-oncology portfolio. We are
assessing our options to realize value from the CNS IPR&amp;D
assets. In light of this shift in market strategy, the Company
performed a commercial assessment and a valuation of the CNS
IPR&amp;D assets, both to assess fair value and support potential
future licensing efforts. Based on the results of the independent
valuation, the Company recorded the impairment charge noted
above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Interest Expense</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Interest expense was $9.1 million and $8.6 million for the years
ended December 31, 2018 and 2017, respectively. The increase is due
to an increase in non-cash amortization of debt issuance costs
associated with convertible debentures and warrants issued in
January 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">25</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Liquidity and Capital Resources</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company&#x2019;s current operations have focused on business
planning, raising capital, establishing an intellectual property
portfolio, hiring, and conducting preclinical studies and clinical
trials. The Company does not have any product candidates approved
for sale and has not generated any revenue from product sales. The
Company has sustained operating losses since inception and expects
such losses to continue over the foreseeable future. During the six
months ended June 30, 2019, the Company raised $2.4 million through
a series of issuances of convertible debentures in February and
May. Also, as noted above, the Company raised $975,000 through the
issuance of convertible notes during the time period beginning
August 20, 2019, through September 11, 2019. We anticipate that
cash utilized for selling, general, and administrative expenses
will range between $1 and $2 million in the coming quarters, while
research and development expenses will vary depending on clinical
activities.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The financial statements of the Company have been prepared on a
going-concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of
business. Accordingly, the financial statements do not include any
adjustments that might be necessary should the Company be unable to
continue in existence.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company has incurred substantial losses and negative cash flows
from operations since its inception and has an accumulated deficit
of $536 million and cash of $264 thousand as of June 30, 2019. The
Company anticipates incurring additional losses until such time, if
ever, that it can generate significant sales or revenue from
out-licensing of its products currently in development. Substantial
additional financing will be needed by the Company to fund its
operations and to commercially develop its product candidates.
These factors raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Management is currently evaluating different strategies to obtain
the required funding for future operations. These strategies may
include but are not limited to: public offerings of equity and/or
debt securities, payments from potential strategic research and
development, licensing and/or marketing arrangements with
pharmaceutical companies. Management has also implemented cost
saving efforts, including reduction in executive salaries and
reduced travel. Management believes that these ongoing and planned
financing endeavors, if successful, will provide adequate financial
resources to continue as a going concern for at least the next six
months from the date the financial statements are issued; however,
there can be no assurance in this regard. If the Company is unable
to secure adequate additional funding, its business, operating
results, financial condition and cash flows may be materially and
adversely affected.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Critical Accounting Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We consider the following accounting policies to be critical given
they involve estimates and judgments made by management and are
important for our investors&#x2019; understanding of our operating
results and financial condition.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Long-Lived Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our long-lived assets include property, plant and equipment,
capitalized costs of filing patent applications and goodwill and
other assets.&#xA0;&#xA0;We evaluate our long-lived assets for
impairment in accordance with ASC 360, whenever events or changes
in circumstances indicate that the carrying amount of such assets
may not be recoverable.&#xA0;&#xA0;Estimates of future cash flows
and timing of events for evaluating long-lived assets for
impairment are based upon management&#x2019;s
judgment.&#xA0;&#xA0;If any of our intangible or long-lived assets
are considered to be impaired, the amount of impairment to be
recognized is the excess of the carrying amount of the assets over
its fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Applicable long-lived assets are amortized or depreciated over the
shorter of their estimated useful lives, the estimated period that
the assets will generate revenue, or the statutory or contractual
term in the case of patents.&#xA0;&#xA0;Estimates of useful lives
and periods of expected revenue generation are reviewed
periodically for appropriateness and are based upon
management&#x2019;s judgment.&#xA0;&#xA0;Goodwill and other assets
are not amortized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Certain Expenses and Liabilities</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On an ongoing basis, management evaluates its estimates related to
certain expenses and accrued liabilities.&#xA0;&#xA0;We base our
estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the
results of which form the basis for making judgments about the
carrying values of liabilities that are not readily apparent from
other sources.&#xA0;&#xA0;Actual results may differ materially from
these estimates under different assumptions or
conditions.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Inflation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We believe that inflation has not had a material adverse impact on
our business or operating results during the periods
presented.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Off-balance Sheet Arrangements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have no off-balance sheet arrangements as of September 3,
2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">26</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="description">D</a>ESCRIPTION OF
BUSINESS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immuno-oncology products
based off our proprietary Tri-specific Killer Engager (TriKE),
Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody
Drug Conjugate (ADC) technology platforms. Our TriKE and TetraKE
platforms generate proprietary moieties designed to harness and
enhance the cancer killing abilities of a patient&#x2019;s own
natural killer, or NK, cells. Once bound to an NK cell, our
moieties are designed to enhance the NK cell and precisely direct
it to one or more specifically-targeted proteins (tumor antigens)
expressed on a specific type of cancer, ultimately resulting in the
cancer cell&#x2019;s death. TriKEs and TetraKEs are made up of
recombinant fusion proteins, can be designed to target any number
of tumor antigens on hematologic malignancies, sarcomas or solid
tumors and do not require patient-specific customization. They are
designed to be dosed in a common outpatient setting similar to
modern antibody therapeutics and are expected to have reasonably
low cost of goods. Our ADC platform generates product candidates
that are bi-specific, ligand-directed single-chain fusion proteins
that, we believe, represent the next generation of
ADCs.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are using our TriKE and TetraKE platforms with the intent to bring
to market immuno-oncology products that can treat a range of
hematologic malignancies, sarcoma and solid tumors. The platforms
are scalable, and we are putting processes in place to be able to
produce IND-ready moieties in a timely manner after a specific
TriKE or TetraKE conceptual design. After conducting market and
competitive research, specific moieties can then be advanced into
the clinic on our own or through potential collaborations with
larger companies. We are also evaluating, in conjunction with our
Scientific Advisory Board, additional moieties designed to target
different tumor antigens. We believe our TriKEs and TetraKEs may
have the ability, if approved for marketing, to be used on a
stand-alone basis, augment the current monoclonal antibody
therapeutics, be used in conjunction with more traditional cancer
therapy and potentially overcome certain limitations of current
chimeric antigen receptor, or CAR-T, therapy.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
also believe our bi-specific, ligand-directed single-chain fusion
proteins are examples of the next generation of ADCs. We believe
GTB-1550 has certain properties that could result in competitive
advantages over recently approved ADC products targeting leukemias
and lymphomas and/or have utility in other niche populations. In a
Phase 1 trial, of nine patients that achieved adequate blood
levels, in two heavily pretreated patients a continuous partial
remission (PR) and complete remission (CR) were observed. One of
these patients, who had failed multiple previous treatment
regimens, has been in remission since early 2015.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
initial work has been conducted in collaboration with the Masonic
Cancer Center at the University of Minnesota under a program led by
Dr. Jeffrey Miller, the Deputy Director. Dr. Miller is a recognized
leader in the field of NK cell and IL-15 biology and their
therapeutic potential. We have exclusive rights to the TriKE and
TetraKE platforms and are generating additional intellectual
property around specific moieties.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Also,
in connection with the acquisition of Georgetown Translational
Pharmaceuticals on September 1, 2017, we acquired a portfolio of
in-process research and development central nervous system
(&#x201C;CNS&#x201D;) assets consisting of innovative reformulations
and/or repurposing of existing therapies. These CNS assets address
disease states such as chronic neuropathic pain, myasthenia gravis
and motion sickness. We are currently pursuing out-licensing
opportunities related to these assets.</font></div>
&#xA0;<br>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Immuno-Oncology Platform</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Tri-specific Killer Engagers (TriKEs) and Tetra-specific Killer
Engagers (TetraKEs)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
generation of chimeric antigen receptor, or CAR, expressing T cells
from monoclonal antibodies has represented an important step
forward in cancer therapy. These therapies involve the genetic
engineering of T cells to express either CARs, or T cell receptors,
or TCRs, and are designed such that the modified T cells can
recognize and destroy cancer cells. While a great deal of interest
has recently been placed upon chimeric antigen receptor T, or
CAR-T, therapy, it has certain limitations for broad potential
applicability because it can require an individual approach that is
expensive and time consuming, and may be difficult to apply on a
large scale. We believe there is an unmet need for targeted
immuno-oncology therapies that have the potential to be dosed in a
patient-friendly outpatient setting, can be used on a stand-alone
basis, augment the current monoclonal antibody therapeutics and/or
be used in conjunction with more traditional cancer therapy. We
believe our TriKE and TetraKE constructs have this potential and
therefore we have generated, and intend to continue to generate, a
pipeline of product candidates to be advanced into the clinic on
our own or through potential collaborations with larger
companies.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">NK
cells represent an important immunotherapeutic target as they are
involved in tumor immune-surveillance, can mediate antibody-
dependent cell-mediated cytotoxicity (ADCC), contain pre-made
granules with perforin and granzyme B and can quickly secrete
inflammatory cytokines, and unlike T cells they do not require
antigen priming and can kill cells in the absence of major
histocompatibility complex (MHC) presentation.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unlike
full-length antibodies, TriKEs and TetraKEs are small single-chain
fusion proteins that bind the CD16 receptor of NK cells directly
producing a potent and lasting response, as demonstrated by
preclinical studies. An additional benefit they may have is
attractive biodistribution, as a consequence of their smaller size,
which we expect to be important in the treatment of solid tumors.
In addition to these advantages, TriKEs and TetraKEs are designed
to be non-immunogenic, have appropriate clearance properties and
can be engineered quickly to target a variety of tumor
antigens.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">27</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Background and Select Non-Clinical Data</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
conjunction with our research agreement with the Masonic Cancer
Center at the University of Minnesota, the exploration of targeting
NK cells to a variety of tumors initially focused on novel
bi-specific killer engagers, or BiKEs, composed of the variable
portions of antibodies targeting the CD16 activating receptor on NK
cells and CD33 (AML and MDS; see figure below), CD19/CD22 (B cell
lymphomas), or EpCAM (epithelial tumors (breast, colon, and lung))
on the tumor cells.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 12px; margin-right: 11px; text-indent: 0px"><img src="gtbp_bikemediatedkilling.jpg"></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Subsequently,
a tri-specific (TriKE) construct that replaced the linker molecule
between the CD16 scFv and the CD33 scFv with a modified IL-15
molecule, containing flanking sequences, was generated and tested.
Data indicate that the CD16 x IL-15 x CD33 and CD16 x IL-15 x EpCAM
TriKEs potently induce proliferation of healthy donor NK cells,
possibly greater than that induced by exogenous IL-15, which is
absent in the BiKE platform. Targeted delivery of the IL-15 through
the TriKE also resulted in specific expansion of the NK cells
without inducing T cell expansion on post-transplant patient
samples.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">When
compared to the CD16 x CD33 BiKE, the CD16 x IL-15 x CD33 TriKE is
also capable of potently restoring killing capacity of post-
transplant NK cells against CD33-expressing HL-60 Targets and
primary AML blasts. These results demonstrated the ability to
functionally incorporate an IL-5 cytokine into the BiKE platform
and also demonstrated the possibility of targeting a variety of
cytokines directly to NK cells while reducing off-target effects
and the amount of cytokines needed to obtain biologically relevant
function.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">28</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
figure below is a schematic of a BiKE construct (top) and a TriKE
construct (bottom), which has the modified IL-15 linker between the
CD16 scFv and the CD33 scFv components.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="gtbp_pic.jpg"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>&#xA0; <font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
TriKE constructs were also tested against three separate human
tumor cell lines: HL-60 (promyelocitic leukemia), Raji
(Burkitt&#x2019;s lymphoma), and HT29 (colorectal adenocarcinoma),
in addition to a model for ovarian cancer. All cell lines contained
the Luc reporter to allow for in vivo imaging of the tumors. These
systems were used to show in vivo efficacy of BiKEs (1633) and
TriKEs (GTB-3550) against relevant human tumor targets (HL-60-luc)
over an extended period of time. The system consisted of initial
conditioning of mice using radiation (250-275 cGy), followed by
injection of the tumor cells (I.V. for HL-60-luc and Raji-luc,
intra-splenic for HT29-luc and IP for ovarian for MA-148-luc), a
three-day growth phase, injection of human NK cells, and repeated
injection of the drugs of interest, BiKE and TriKE (three to five
times a week). Imaging was carried out at day 7, 14, and 21, and
extended as needed.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Figure
A below shows the results (tumor burden and mortality) when dosing
NK cells alone (top panel), the BiKE version (lacking IL-15) of
GTB-3550 (middle panel; called 1633), and the TriKE, GTB-3550
(bottom panel; then called 161533) in the above described human
tumor model, HL-60-luc. In the NK-cell-only arm, two out of the
five mice were dead by day 21 with two of the surviving mice having
extensive tumor burden as depicted by the colored images. In
contrast, all five mice in each of the BiKE and TriKE arms
survived. In addition, the tumor burden in the TriKE-treated mice
was significantly less than in the BiKE-treated mice, demonstrating
the improved efficacy from NK cells in the TriKE-treated
mice.</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">29</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 72px; margin-right: 0px; text-indent: 0px">
<div><font>&#xA0;</font></div>
<img src="gtbp_s12019000.jpg"></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Based
on these results, and others, the IND for GTB-3550 was filed in
June 2017 by the University of Minnesota. FDA requested that
additional preclinical toxicology be conducted prior to initiating
clinical trials. The FDA also requested some additional information
and clarifications on the manufacturing (CMC) and clinical
packages. The requested additional information and clarifications
were completed and incorporated by us into the IND in eCTD format.
We filed the IND amendment in June 2018 and announced on November
1, 2018 that we had received notification from the FDA that the IND
was open and the Company was authorized to initiate a
first-in-human Phase 1 study with GTB-3550 in AML, MDS and severe
mastocytosis. We expect to be in a position to begin the Phase 1
clinical trial in the first half of 2019.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Generation of humanized single-domain antibody targeting CD16 for
incorporation into the TriKE platform</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
develop second generation TriKEs, we designed a new humanized CD16
engager derived from a single-domain antibody. While scFvs consist
of a heavy and a light variable chain joined by a linker,
single-domain antibodies consist of a single variable heavy chain
capable of engaging without the need of a light chain counterpart
(see figure below).</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">30</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 240px; margin-right: 0px; text-indent: 0px">
<div><font>&#xA0;</font></div>
<img src="gtbp_s12019001.jpg">
<div><font>&#xA0;</font></div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">31</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">These
single-domain antibodies are thought to have certain attractive
features for antibody engineering, including physical stability,
ability to bind deep grooves, and increased production yields,
amongst others. Pre-clinical studies demonstrated increased
activity (NK Cell Degranulation) and functionality (NC Cell
Cytokine Production) of the single-domain CD16 TriKE (GTB-C3550)
compared to the original TriKE (GTB-3550) (see figure below). These
data were presented at the 2017 American Society of Hematology
Conference.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="gtbp_charts.jpg"></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Targeting Solid Tumors and Other Potentially Attractive
Characteristics</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unlike
full-length antibodies, TriKEs and TetraKEs are small single-chain
fusion proteins that bind the CD16 receptor of NK cells directly
producing a potentially more potent and lasting response as
demonstrated by preclinical studies. An additional benefit that
they may have is an attractive biodistribution, because of their
smaller size, which we expect to be important in the treatment of
solid tumors. In addition to these potential advantages, TriKEs and
TetraKEs are designed to be non-immunogenic, have appropriate
clearance properties and can be engineered quickly to target a
variety of tumor antigens. We believe these attributes make them an
ideal pharmaceutical platform for potentiated NK cell-based
immunotherapies and have the potential to overcome some of the
limitations of CAR-T therapy and other antibody
therapies.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Examples
of our earlier stage solid tumor targeting product candidates are
focused on EpCAM, Her2, Mesothelin (mesothelioma and lung
adenocarcinoma), and CD133 alone and in combination. We believe
certain of these constructs have the potential to target prostate,
breast, colon, ovarian, liver, and head and neck cancers. Depending
on the availability of drug supply, we hope to initiate human
clinical testing for certain of our solid tumor product candidates
in 2020.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">32</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Efficient Advancement of Potential Future Product Candidates
--Production and Scale Up</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are using our TriKE and TetraKE platforms with the intent to bring
to market multiple immuno-oncology products that can treat a range
of hematologic malignancies, sarcomas and solid tumors. The
platforms are scalable and we are currently working with several
third parties investigating the optimal expression system of the
TriKEs and TetraKE constructs which we expect to be part of a
process in which we are able to produce IND-ready moieties in
approximately 90-120 days after the construct conceptual
design.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">After
conducting market and competitive research, specific moieties can
then be rapidly advanced into the clinic on our own or through
potential collaborations with larger companies. We are currently
evaluating over a dozen moieties and intend to announce additional
clinical product candidates in the second half of
2019.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
believe our TriKEs and TetraKEs will have the ability, if approved
for marketing, to be used on a stand-alone basis, augment the
current monoclonal antibody therapeutics, or be used in conjunction
with more traditional cancer therapy and potentially overcome
certain limitations of current chimeric antigen receptor, or CAR-T,
therapy.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Bi-specific Antibody-Drug Conjugates Program</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Antibody&#x2013;drug
conjugates (ADCs) are a class of potent biopharmaceutical drugs
designed as a targeted therapy for the treatment of cancer. ADCs
combine the antitumor potency of highly cytotoxic small-molecule
drugs with the high selectivity, pharmacokinetic profile of mAbs.
These attributes allow sensitive discrimination between healthy and
diseased tissue. We believe our bi-specific, ligand-directed
single-chain fusion protein represents an example of the next
generation of ADCs.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are currently utilizing a single chain bispecific recombinant
fusion protein consisting of an anti-CD22 sFv, an anti-CD19 sFv,
and DT390 (the catalytic and translocation domains of diphtheria
toxin). It is a cytotoxic molecule produced by recombinant DNA
techniques composed of a fusion gene consisting of sequences for
DT390 and also sequences encoding two separate and distinct sFvs,
one recognizing CD22 and one recognizing CD19. The anti-CD22 sFv
comes from the monoclonal antibody RFB4 and this sFv is currently
in clinical trials involving another anti-CD22 immunotoxin called
BL22. The anti-CD19 sFv is from the monoclonal antibody HD37 that
has previously been used clinically. Published preclinical studies
have shown that the presence of both sFvs on the same single chain
molecule results in a bispecific fusion toxin that has superior
activity and anti-cancer effects compared to the monospecific
fusion toxins. Between the VL and VH regions of the sFvs, we have
introduced aggregation reducing sequences (ARL) which has produced
a product which has demonstrated better activity against scid mouse
systemic models of B cell malignancy. The action of DT2219 occurs
as a result of binding to the CD22 and/or CD19 receptors,
subsequent internalization, and enzymatic inhibition of protein
synthesis leading to cell death.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
believe that our single-chain bi-specific recombinant fusion
proteins utilizing novel linkers and innovative warheads represent
an important advance over currently marketed ADCs. Utilizing our
bi-specific ADC platform we have the ability to generate novel ADCs
with unique targets, linkers and warheads. This platform provides
us with the ability to rapidly construct novel ADCs with the
potential to treat a wide range of cancers, including hematologic
and solid tumors.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 378px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Immuno-Oncology Product Candidates</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
most advanced bi-specific ADC, GTB-1550, which targets CD19+ and/or
CD22+ hematological malignancies, is in the Phase 2 component of a
Phase 1/2 Non-Hodgins Lymphoma (NHL)/Acute Lymphocytic Leukemia
(ALL) trial which is an open-label, investigator-led study. We are
initially targeting certain hematologic malignancies as we believe
our product candidates may have certain advantages over existing
and other in-development products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
TriKE product candidates, GTB-3550 and GTB-C3550, are single-chain,
tri-specific scFv recombinant fusion proteins composed of the
variable regions of the heavy and light chains (or heavy chain
only) of anti-CD16 antibodies, wild-type or a modified form of
IL-15 and the variable regions of the heavy and light chains of an
antibody designed to precisely target a specific tumor antigen. We
utilize the NK stimulating cytokine human IL-15 as a crosslinker
between the two scFvs which is designed to provide a
self-sustaining signal leading to the proliferation and activation
of NK cells thus enhancing their ability to kill cancer cells
mediated by antibody-dependent cell-mediated cytotoxicity
(ADCC).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
TetraKE product candidates are single-chain fusion proteins
composed of human single-domain anti-CD16 antibody, wild-type IL-15
and the variable regions of the heavy and light chains of two
antibodies that are designed to target two specific tumor antigens
expressed on specific types of cancer cells. An example of a
TetraKE product candidate is GTB-1615 which is designed to target
EpCAM and CD133 positive solid tumors. EpCAM is found on many solid
tumor cells of epithelial origin and CD133 is a marker for cancer
stem cells. GTB-1615 is designed to enable a patient&#x2019;s NK
cells to kill not only the heterogeneous population of cancer cells
found in many solid tumors but also kill the cancer stem cells that
can be responsible for recurrences.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 378px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1550</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-1550
is a bispecific scFv recombinant fusion protein-drug conjugate
composed of the variable regions of the heavy and light chains of
anti-CD19 and anti-CD22 antibodies and a modified form of
diphtheria toxin (DT390) as its cytotoxic drug payload. CD19 is a
membrane glycoprotein present on the surface of all stages of
B-lymphocyte development and is also expressed on most B-cell
mature lymphoma cells and leukemia cells. CD22 is a glycoprotein
expressed on B-lineage lymphoid precursors, including precursor
acute lymphoblastic leukemia, and often is co-expressed with CD19
on mature B-cell malignancies such as lymphoma.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-1550
targets cancer cells expressing the CD19 receptor or CD22 receptor
or both receptors. When GTB-1550 binds to cancer cells, the cancer
cells internalize GTB-1550, and are killed due to the action of
drug&#x2019;s cytotoxic diphtheria toxin payload. GTB-1550 has
completed a Phase 1 human clinical trial in patients with
relapsed/refractory B-cell lymphoma or leukemia.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">33</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
initial Phase 1 study enrolled 25 patients with mature or precursor
B-cell lymphoid malignancies expressing the CD19 receptor or CD22
receptor or both receptors. All 25 patients received at least a
single course of therapy. The treatment at the higher doses
produced objective tumor responses with one patient in continuous
partial remission and the second in complete remission. A Phase 1/2
trial of GTB-1550 in 18 patients was recently completed in patients
with ALL/NHL. The FDA-approved clinical trial was conducted at the
University of Minnesota's Masonic Cancer Center. The data is
currently being analyzed. We expect to submit data from this Phase
1/2 study for presentation/publication.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-3550</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-3550
is our first TriKE product candidate. It is a single-chain,
tri-specific scFv recombinant fusion protein conjugate composed of
the variable regions of the heavy and light chains of anti-CD16 and
anti-CD33 antibodies and a modified form of IL-15. We intend to
study this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive
leukemias, a marker expressed on tumor cells in acute myelogenous
leukemia, or AML, myelodysplastic syndrome, or MDS, and other
hematopoietic malignancies. CD33 is primarily a myeloid
differentiation antigen with endocytic properties broadly expressed
on AML blasts and, possibly, some leukemic stem cells. CD33 or
Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3,
gp67, p67) is a transmembrane receptor expressed on cells of
myeloid lineage. It is usually considered myeloid-specific, but it
can also be found on some lymphoid cells. The anti-CD33 antibody
fragment that will be used for these studies was derived from the
M195 humanized anti-CD33 scFV and has been used in multiple human
clinical studies. It has been exploited as target for therapeutic
antibodies for many years. We believe the recent approval of the
antibody-drug conjugate gemtuzumab validates this targeted
approach.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The GTB-3550 IND will focus on AML, the most
common form of adult leukemia (American Cancer Society). These
patients typically receive frontline therapy, usually chemotherapy,
including cytarabine and an anthracycline, a therapy that has not
changed in over 40 years. About half will have relapses and require
alternative therapies. In addition, MDS incidence rates have
dramatically increased in the population of the United States from
3.3 per 100,000 individuals from 2001-2004 to 70 per 100,000
annually, MDS is especially prevalent in elderly patients that have
a median age of 76 years at diagnosis. The survival of patients
with MDS is poor due to decreased eligibility, as a result of
advanced age, for allogeneic hematopoietic cell transplantation
(Allo- HSCT), the only curative MDS treatment (Cogle CR. Incidence
and Burden of the Myelodysplastic Syndromes.</font> <font style="font-style: italic; color: #000000">Curr Hematol Malig
Rep</font><font style="color: #000000">. 2015; 10(3):272-281). We
believe GTB-3550 could serve as a relatively safe, cost-effective,
and easy-to-use therapy for resistant/relapsing AML and could also
be combined with chemotherapy as frontline therapy thus targeting
the larger market.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
IND for GTB-3550 was filed in June 2017 by the University of
Minnesota. FDA requested that additional preclinical toxicology be
conducted prior to initiating clinical trials. The FDA also
requested some additional information and clarifications on the
manufacturing (CMC) and clinical packages. The requested additional
information and clarifications were completed and incorporated by
us into the IND in eCTD format. We filed the IND amendment in June
2018 and announced on November 1, 2018 that we had received
notification from the FDA that the IND was open and the Company was
authorized to initiate a first-in-human Phase 1 study with GTB-3550
in AML, MDS and severe mastocytosis. We expect to be in a position
to begin the Phase 1 clinical trial in the first half of
2019.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-C3550</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-C3550
is a next-generation, follow-on, to our lead TriKE, GTB-3550.
GTB-C3550 contains a modified CD16 moiety which has improved
binding characteristics and enhanced tumor cell killing based on
functional assays and animal models of AML. Using our platform
technology, we substituted the anti-CD16 scFv arm in GTB-3550 with
a novel humanized single-domain anti-CD16 antibody to create this
second-generation molecule which may have improved functionality.
Single-domain antibodies, such as GTB-C3550, typically have several
advantages, including better stability and solubility, more
resistance to pH changes, can better recognize hidden antigenic
sites, lack of a VL portion thus preventing VH/VL mispairing and
are suitable for construction of larger molecules. GTB-C3550
induced a potent increase in NK cell degranulation, measured by
CD107a expression against HL-60 AML tumor targets when compared to
our first- generation TriKE (70.75&#xB1;3.65% vs.
30.75&#xB1;5.05%). IFN production was similarly enhanced
(29.2&#xB1;1.8% vs. 6.55&#xB1;1.07%). GTB-C3550 also exhibited a
robust increase in NK cell proliferation (57.65&#xB1;6.05% vs.
20.75&#xB1;2.55%). GTB-3550 studies will help inform the
development of GTB-C3550 which we expect will de-risk the GTB-C3550
program as data will be generated to make an informed decision on
which, or both, will be brought into later phase
studies.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
GTB-1615</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-1615
is an example of our first-generation TetraKEs designed for the
treatment of solid tumors. It is a single-chain fusion protein
composed of CD16-IL15-EpCAM-CD133. EpCAM is found on many solid
tumor cells of epithelial origin and CD133 is a marker for cancer
stem cells. This TetraKE is designed to target not only the
heterogeneous population of cancer cells found in solid tumors but
also the cancer stem cells that are typically responsible for
recurrences. Depending on the availability of drug supply, we hope
to initiate human clinical testing for certain of our solid tumor
product candidates in 2020.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Central Nervous System</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
CNS portfolio consists of in-process R&amp;D
(&#x201C;IPR&amp;D&#x201D;) assets acquired in connection with the
acquisition of Georgetown Translational Pharmaceuticals
(&#x201C;GTP&#x201D;) on September 1, 2017, consisting of innovative
reformulations and/or repurposing of existing therapies. These CNS
assets address disease states such as chronic neuropathic pain
(product candidate PainBrake, utilizing AccuBreak technology),
myasthenia gravis (product candidate GTP-004) and motion sickness
(product candidate GTP-011).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the 3rd quarter of 2018, the Company experienced changes in key
senior management. These changes resulted in the prioritization of
immuno-oncology development candidates relative to the CNS
development candidates acquired from Georgetown Translational
Pharmaceuticals. In conjunction with these strategic changes,
limited internal resources have delayed the development of the CNS
IPR&amp;D assets. The limited resources, changes in senior
leadership, and favorable market conditions for immuno-oncology
development candidates have resulted in the Company choosing to
focus on development of its immuno-oncology portfolio. We are
assessing our options to realize value from the CNS IPR&amp;D
assets.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">34</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Our Strategy</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
goal is to be a leader in immuno-oncology therapies targeting a
broad range of indications including hematological malignancies,
sarcoma and solid tumors and to generate value from our CNS product
candidates. Key elements of our strategy are to:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Expedite clinical development, regulatory approval and
commercialization of our bi-specific ADC, GTB-1550, in specific
indications with a high unmet-medical need such as patients who are
resistant or refractory to conventional treatment and also assess
fast-to- market strategies in potential orphan
indications</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Based
upon promising clinical results from the initial GTB-1550 Phase 1
study, we began enrolling patients in a Phase 2 trial during the
first quarter of 2017 for our most advanced oncology product
candidate, GTB-1550, for the treatment of patients with
relapsed/refractory B- cell leukemias or lymphomas. In the Phase 1
study, of the nine patients who received GTB-1550 at the higher
doses, two had durable complete responses in heavily pretreated
patients. One of these patients, who had failed multiple previous
treatment regimens, has been cancer free since the beginning of
2015.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">A
Phase 1/2 trial of GTB-1550 in 18 patients was recently completed
in patients with ALL/NHL. The FDA-approved clinical trial was
conducted at the University of Minnesota's Masonic Cancer Center.
The data is currently being analyzed. We expect to submit data from
this Phase 1/2 study for presentation/publication.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
will also utilize our bi-specific ADC platform to generate novel
ADCs with unique targets, linkers and warheads. We anticipate that
this platform will give us the ability to rapidly construct novel
ADCs with the potential to treat a wide range of cancers, including
hematologic and solid tumors.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Rapidly advanced our Tri-specific Killer Engagers (TriKEs),
GTB-3550 and GTB-C3550</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
TriKE and TetraKE product candidates have the potential to be
groundbreaking therapies targeting a broad range of hematologic
malignancies, sarcomas and solid tumors. We are preparing to study
GTB-3550, an anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive
leukemias, a marker expressed on tumor cells in AML, MDS and other
myeloid malignancies. We expect to begin a Phase 1 clinical trial
in the first half of 2019 in patients with relapsed/refractory AML.
The Phase 1 trial will be a dose finding study. We expect this will
be closely followed by Phase 2 trials to determine the most
efficacious dosing and cycles with the aim to maximize efficacy
while minimizing on-target, off-disease adverse
events.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-C3550
contains a humanized single-domain anti-CD16 moiety which
demonstrated improved binding characteristics and enhanced tumor
cell killing based on functional assays and animal models of
AML.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have designed GTB-3550 and GTB-C3550, if approved for marketing, to
serve as a relatively safe, cost-effective, and easy-to-use
therapies for resistant/relapsing AML or MDS which could also be
combined with chemotherapy as frontline therapy thus targeting a
broad AML/MDS market.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">GTB-C3550
is a next-generation, follow-on, to our lead TriKE, GTB-3550.
GTB-3550 studies will help inform the development of GTB-C3550. We
believe this will de-risk the GTB-C3550 program as the data being
generated will help to make informed decisions on which, or both,
will be brought into later phase studies and in which patient
populations.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Utilize our TriKE and TetraKE platform technologies to develop a
robust pipeline of targeted immuno-oncology products targeting a
wide range of hematologic malignancies, sarcomas and solid tumors
for development on our own and through potential collaborations
with larger pharmaceutical companies</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are using our TriKE and TetraKE platforms with the intent to bring
to market multiple, targeted, off-the-shelf therapies that can
treat a range of hematologic malignancies, sarcomas and solid
tumors. The platforms are scalable and we are currently working
with several third parties investigating the optimal expression
system of the TriKEs and TetraKE constructs which we expect to be
part of a process in which we are able to produce IND-ready
moieties in approximately 90-120 days after the construct
conceptual design. After conducting market and competitive
research, specific moieties can then be rapidly advanced into the
clinic on our own or through potential collaborations with larger
pharmaceutical companies.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are currently evaluating over a dozen moieties and intend to
announce additional clinical product candidates in the second half
of 2019. Depending on the availability of drug supply, we hope to
initiate human clinical testing for certain of our solid tumor
product candidates in 2020.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
believe our TriKEs and TetraKEs will have the ability, if approved
for marketing, to be used on a stand-alone basis, augment the
current monoclonal antibody therapeutics, or be used in conjunction
with more traditional cancer therapy and potentially overcome
certain limitations of current chimeric antigen receptor, or CAR-T,
therapy.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">35</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Continue our collaborative relationship with the Masonic Cancer
Center at the University of Minnesota, under a program led by Dr.
Jeffrey Miller and become the leading NK-oriented immune-oncology
company</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
believe that the TriKE and TetraKE constructs represent potentially
groundbreaking innovations in immunotherapy. In July 2016 we
entered into an exclusive license agreement with the University of
Minnesota to develop and commercialize cancer therapies using TriKE
and TetraKE technology developed by researchers at the university
to target NK cells to cancer.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
believe TriKE and TetraKE therapeutics have the potential to
significantly impact the standard of care for hematologic
malignancies, sarcomas, as well as solid tumors. The direct
engagement of the NK cell with the tumor cell via very specific
receptors may increase the efficacy while decrease the toxicity
seen with other forms of immunotherapies. If approved, we expect
the TriKEs and TetraKEs will be able to be administered at cancer
treatment facilities without the need for specialized centers or
product-specific trained staff.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
also intend to selectively evaluate and potentially acquire or
enter into licensing or other agreements for technologies and/or
product candidates that we believe would complement our oncology
product candidates and platform technologies.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Monetize our CNS programs through transactions with
commercialization-oriented pharmaceutical companies and/or other
transactions</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
CNS portfolio consists of IPR&amp;D assets acquired in connection
with the acquisition of GTP on September 1, 2017, consisting of
innovative reformulations and/or repurposing of existing therapies.
These CNS assets address disease states such as chronic neuropathic
pain, myasthenia gravis and motion sickness.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the 3rd quarter of 2018, the Company experienced changes in key
senior management, led by the appointment of a CEO with extensive
experience in oncology drug development. These changes resulted in
the prioritization of immuno-oncology development candidates
relative to the CNS development candidates acquired from Georgetown
Translational Pharmaceuticals. In conjunction with these strategic
changes, limited internal resources have delayed the development of
the CNS IPR&amp;D assets. The limited resources, changes in senior
leadership, and favorable market conditions for immuno-oncology
development candidates have resulted in the Company choosing to
focus on development of its immuno-oncology portfolio.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
expect to monetize our CNS portfolio through licensing deals with
commercialization-oriented pharmaceutical companies, which could
result in income, or enter into other transaction structures with
the intent to generate value for our shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Oncology Markets</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
B-cell Lymphomas/Leukemias</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">B-cell
lymphoma is a type of cancer that forms in B cells (a type of
immune system cell). B-cell lymphomas may be either indolent (slow-
growing) or aggressive (fast-growing). Non- Hodgkin lymphoma has an
incidence rate of 19.4 per 100,000 per year and B-cell lymphomas
make up most (about 85%) of NHL in the United States. There are
many different types of B-cell non- Hodgkin lymphomas. These
include Burkitt lymphoma, chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma,
follicular lymphoma, and mantle cell lymphoma.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; background-color: #FFFFFB; font-family: Times New Roman; font-size: 13px">
Acute Lymphoblastic Leukemia</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Acute
lymphoblastic leukemia, or ALL, is an acute form of leukemia, or
cancer of the white blood cells, characterized by the
overproduction and accumulation of immature white blood cells,
known as lymphoblasts. In persons with ALL, lymphoblasts are
overproduced in the bone marrow and continuously multiply, causing
damage and death by inhibiting the production of normal cells (such
as red and white blood cells and platelets) in the bone marrow and
by spreading (infiltrating) to other organs.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">It
is estimated that there will be 5,930 new cases of ALL reported in
the United States in 2019 (ACS Cancer Facts &amp; Figures 2019).
"Acute" is defined by the World Health Organization standards, in
which greater than 20% of the cells in the bone marrow are blasts.
Chronic lymphocytic leukemia is defined as having less than 20%
blasts in the bone marrow. Acute lymphoblastic leukemia is seen in
both children and adults; the highest incidence is seen between
ages 2 to 3 years (&gt;90 cases per 1 million per year). ALL is the
most common cancer diagnosed in children and represents
approximately 25% of cancer diagnoses among children younger than
15 years. Among children with ALL, approximately 98% attain
remission, and approximately 85% of patients aged 1 to 18 years
with newly diagnosed ALL treated on current regimens are expected
to be long-term event-free survivors, with over 90% surviving at 5
years.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">36</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Multiple Myeloma</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Multiple
myeloma is a type of cancer that forms in white blood cells and
will affect an estimated 32,110 people in 2019 in the U.S. causing
about 12,960 deaths. Multiple myeloma causes cancer cells to
accumulate in the bone marrow, where they crowd out healthy blood
cells. Multiple myeloma is also characterized by destructive lytic
bone lesions (rounded, punched-out areas of bone), diffuse
osteoporosis, bone pain, and the production of abnormal proteins
which accumulate in the urine. Anemia is also present in most
multiple myeloma patients at the time of diagnosis and during
follow-up. Anemia in multiple myeloma is multifactorial and is
secondary to bone marrow replacement by malignant plasma cells,
chronic inflammation, relative erythropoietin deficiency, and
vitamin deficiency. Plasma cell leukemia, a condition in which
plasma cells comprise greater than 20% of peripheral leukocytes, is
typically a terminal stage of multiple myeloma and is associated
with short survival.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Myeloid Leukemias</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Acute Myeloid Leukemia</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">AML
is a heterogeneous hematologic stem cell malignancy in adults with
incidence rate of 4.3% per 100,000 populations. The median age at
the time of diagnosis is 68 years. AML is an aggressive disease and
is fatal without anti-leukemic treatment. AML is the most common
form of adult leukemia with an estimated 21,450 new cases in 2019
in the U.S. These patients will require frontline therapy, usually
chemotherapy including cytarabine and an anthracycline, a therapy
that has not changed in over 40 years. Myelodysplastic syndromes
(MDS) are a heterogeneous group of myeloid neoplasms characterized
by dysplastic features of erythroid/myeloid/megakaryocytic
lineages, progressive bone marrow failure, a varying percentage of
blast cells, and enhanced risk to evolve into acute myeloid
leukemia. It is estimated that over 10,000 new cases of MDS are
diagnosed each year and there are minimal treatment options; other
estimates have put this number higher. In addition, the incidence
of MDS is rising for unknown reasons.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Solid Tumors</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the United States, in 2019, it is estimated there will be
approximately 1,762,450 new cases of cancer resulting in 606,880
deaths. Greater than 80% of these cancers will be classified as
solid tumors. The most prevalent new cases of solid tumors being
breast, lung, prostate, colorectal and bladder. (American Cancer
Society, Cancer Facts &amp; Figures 2019)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Sarcomas</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">A
sarcoma is a type of cancer that develops from certain tissues,
like bone or muscle. Bone and soft tissue sarcomas are the main
types of sarcoma. Soft tissue sarcomas can develop from soft
tissues like fat, muscle, nerves, fibrous tissues, blood vessels,
or deep skin tissues. They can be found in any part of the body.
Most of them develop in the arms or legs. They can also be found in
the trunk, head and neck area, internal organs, and the area in
back of the abdominal cavity (known as the retroperitoneum).
Sarcomas are not common tumors, and most cancers are the type of
tumors called carcinomas.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
American Cancer Society's estimates for soft tissue sarcomas in the
United States for 2019 are (these statistics include both adults
and children): about 12,750 new soft tissue sarcomas will be
diagnosed (7,240 cases in males and 5,510 cases in females). 5,270
Americans (2,840 males and 2,430 females) are expected to die of
soft tissue sarcomas. The most common types of sarcoma in adults
are undifferentiated pleomorphic sarcoma (previously called
malignant fibrous histiocytoma), liposarcoma, and leiomyosarcoma.
Certain types occur more often in certain areas of the body than
others. For example, leiomyosarcomas are the most common abdominal
sarcoma, while liposarcomas and undifferentiated pleomorphic
sarcoma are most common in legs. But pathologists (doctors who
specialize in diagnosing cancers by how they look under the
microscope), may not always agree on the exact type of sarcoma.
Sarcomas of uncertain type are very common. (American Cancer
Society, Cancer Facts &amp; Figures 2019)</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Manufacturing</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
do not currently own or operate manufacturing facilities for the
production of clinical or commercial quantities of any of our
product candidates. We rely on a small number of third-party
manufacturers to produce our compounds and expect to continue to do
so to meet the preclinical and clinical requirements of our
potential product candidates as well as for all of our commercial
needs. We do not have long-term agreements with any of these third
parties. We require in our manufacturing and processing agreements
that all third-party contract manufacturers and processors produce
active pharmaceutical ingredients, or API, and finished products in
accordance with the FDA&#x2019;s current Good Manufacturing
Practices, or cGMP, and all other applicable laws and regulations.
We maintain confidentiality agreements with potential and existing
manufacturers in order to protect our proprietary rights related to
our drug candidates.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">37</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Patents and Trademarks</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Immuno-oncology platform</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
University of Minnesota License Agreement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
(through our wholly owned subsidiary Oxis Biotech, Inc.) are party
to an exclusive worldwide license agreement with the Regents of the
University of Minnesota, to further develop and commercialize
cancer therapies using TriKE technology developed by researchers at
the university to target NK cells to cancer. Under the terms of the
agreement, we receive exclusive rights to conduct research and to
develop, make, use, sell, and import TriKE technology worldwide for
the treatment of any disease, state or condition in humans. We
shall be responsible for obtaining all permits, licenses,
authorizations, registrations and regulatory approvals required or
granted by any governmental authority anywhere in the world that is
responsible for the regulation of products such as the TriKE
technology, including without limitation the FDA in the United
States and the European Agency for the Evaluation of Medicinal
Products in the European Union. Under the agreement, the University
of Minnesota will receive an upfront license fee, royalty fees
ranging from 4% to 6%, minimum annual royalty payments of $250,000
beginning in 2022, $2,000,000 in 2025, and $5,000,000 in 2027 and
certain milestone payments totaling $3,100,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following is a list of the patent applications that we licensed
from the University of Minnesota:</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;<br></font></div>
<div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Appl. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 62/237,835</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Therapeutic compounds and its
uses</font></font></td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT
Patent Application Number PCT/US2016/055722</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Therapeutic compounds and
methods</font></font></td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Pending</font></font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>&#xA0;&#xA0;</div>
</div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Daniel A. Vallera, Ph.D. License Agreement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are party to an exclusive worldwide license agreement with Daniel
A. Vallera, Ph.D. and his co-inventor Jeffrey Lion, or jointly, Dr.
Vallera, to further develop and commercialize DT2219ARL (GTB-1550),
a novel therapy for the treatment of various human cancers. Under
the terms of the agreement, we receive exclusive rights to conduct
research and to develop, make, use, sell, and import DT2219ARL
worldwide for the treatment of any disease, state or condition in
humans. We shall be responsible for obtaining all permits,
licenses, authorizations, registrations and regulatory approvals
required or granted by any governmental authority anywhere in the
world that is responsible for the regulation of products such as
DT2219ARL, including without limitation the FDA in the United
States and the European Agency for the Evaluation of Medicinal
Products in the European Union. Under the agreement, Dr. Vallera
will receive an upfront license fee, royalty fees ranging from 3%
for net sales and 25% of net sublicensing revenues, and certain
milestone payments totaling $1,500,000.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">38</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following is a list of the patent applications and patents that
we licensed from Dr. Vallera under our license
agreements:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Pat./Pub. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 61/160,530</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Methods
and compositions for bi-specific targeting of
cd19/cd22</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 9,371,386</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Methods
and compositions for bi-specific targeting of
cd19/cd22</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 15/187,579</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Methods
and compositions for bi-specific targeting of
cd19/cd22</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
ID4 License Agreement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pursuant
to a patent license agreement with ID4, dated December 31, 2014, or
the ID4 License Agreement, we received an exclusive, worldwide
license to certain intellectual property, including intellectual
property related to treating a p62mediated disease (e.g., multiple
myeloma). The terms of this license require us to pay ID4 royalties
equal to 3% of net sales of products and 25% royalty of net
sublicensing revenues. The license will expire upon expiration of
the last patent contained in the licensed patent rights, unless
terminated earlier. We may terminate the licensing agreement with
ID4 by providing ID4 with 30 days written notice.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
will owe the following cash amounts to ID4 Pharma upon the
attainment of the following milestones:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(i)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Filing of an
investigational new drug application with a competent regulatory
authority anywhere in the world $50,000.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(ii)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Initiation of Phase
I Human Clinical Trial: $50,000.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(iii)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Initiation of Phase
II Human Clinical Trial: $100,000.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(iv)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Initiation of
pivotal Phase III Human Clinical Trial: $250,000. and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(v)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Receipt of the
first marketing approval: $250,000</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">39</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following is a list of the patent applications and patent that we
licensed from ID4 under the ID4 license agreement:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: center; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Pat./Appl. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 9,580,382</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">P62zz
chemical inhibitor</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 61/521,287</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">P62zz
chemical inhibitor</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT
Patent Application Number PCT/US2012/049911</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">P62zz
chemical inhibitor</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 14/727,710</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">P62zz
chemical inhibitor</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Chinese
Patent Application 201280048718</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">P62zz
chemical inhibitor</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Central Nervous System</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Patents for AccuBreak Tablets</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have in-licensed the rights to use the AccuBreak patents with drugs
that, like carbamazepine, are voltage-gated sodium channel blockers
in North America. The license field includes voltage gated sodium
channels inhibitors and blockers for the treatment of epilepsy,
neuropathic pain, and bipolar disorder.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Under
the agreement, AccuBreak received an upfront license fee of
$35,000, royalty fees ranging from 2.5% to 5%, minimum annual
royalty payments, and 20% of net sublicensing
revenues.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
will owe the following cash amounts to AccuBreak upon the
attainment of the following milestones:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$50,000 six months
after the first approval of the first indication by the
FDA;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$50,000 nine months
after the first approval of the first indication by the
FDA;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$100,000 12 months
after the first approval of the first indication by the
FDA;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$25,000 upon
achievement of $25,000,000 of cumulative net sales in the
world;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$50,000 upon
achievement of $50,000,000 of cumulative net sales in the world;
and</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">$100,000 upon
achievement of $75,000,000 of cumulative net sales in the
world.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">40</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Four
formulation patents protect the AccuBreak Technology:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 56px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Pat. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 7,838,031</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Method
for administering a partial dose using a segmented pharmaceutical
tablet</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 7,879,352</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Scored
pharmaceutical tablets comprising a plurality of
segments</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 8,158,148</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pharmaceutical
tablets comprising two or more unitary segments</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Number 8,231,902 (ABT- 054)</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Segmented
pharmaceutical dosage forms</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issued</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
core patent expires in 2025.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Patent Applications for GTP-004</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Four
patent applications filed by GTP in 2017 with the U.S. PTO protect
the combination of pyridostigmine or neostigmine + an antiemetic
for the treatment of myasthenia gravis. We plan to file extensions
under the Patent Cooperation Treaty, or PCT, in 2018. All patents
list below are owned by the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Pat. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 62/443,904</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Use
and composition for treating Myasthenia Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 62/449,699</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Neostigmine
combination for treating Myasthenia Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 62/536,595</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Method
and composition for treating Myasthenia Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number</font> <font style="font-family: Times New Roman; font-size: 13px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">62/536,580</font>&#xA0;<br>
</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Neostigmine
pharmaceutical combination for treating Myasthenia
Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT
Application Number PCT/US/18/12754</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Use
and composition for treating Myasthenia Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Claims
priority from US 62/443,904</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Taiwan
Application Number 107100813</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">TW</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Awaiting
FC Report</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT
Application Number PCT/US18/014700</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Neostigmine
pharmaceutical combination for treating Myasthenia
Gravis</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Claims
priority from US 62/449,699</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 14px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Taiwan
Application Number</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">TW</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Awaiting
FC Report</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">41</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Patent Application for GTP-011</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">One
patent application filed by GTP in 2017 with the U.S. PTO protects
a 72-hour patch of oxybutynin for the treatment of motion sickness.
We plan to file a PCT extension in 2018. All patents list below are
owned by the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 17px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Appl. No.</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Title</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Country</font></font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Status</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">U.S.
Patent Application Number 62/440,575</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Use
and composition for preventing and treating motion
sickness</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US
Patent Application Number 62/595,667</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Use,
method, and device for the prevention and treatment of motion
sickness</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pending*</font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT
Application Number PCT/US/17/68944</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Use
and composition for preventing and treating motion
sickness</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">PCT</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Claims
priority from US 62/440,575</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Taiwan
Application Number 107100079</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 34%;">
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">TW</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 14%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Awaiting
FC Report</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">*
This application is pending, but was used as priority document of
the PCT &#x2018;944, including its subject matter</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Employees</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
of September 3, 2019, we had two employees. Many of our activities
are outsourced to consultants who provide services to us on a
project basis. As business activities require and capital resources
permit, we will hire additional employees to fulfill our
company&#x2019;s needs.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Form and Year of Organization</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data,
Inc. was incorporated in the State of California. Diagnostic Data
changed its incorporation to the State of Delaware in 1972; and
changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and
Bioxytech S.A. and changed its name to OXIS International, Inc. On
July 17, 2017, we amended our Certificate of Incorporation for the
purpose of changing our name from Oxis International, Inc. to GT
Biopharma, Inc.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Legal Proceedings</font></div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
December 24, 2018, Empery Asset Master, Empery Tax Efficient, LP,
and Empery Tax Efficient II, LP (collectively, &#x201C;Plaintiffs)
filed in the N.Y. Supreme Court, Index No. 656408/2018, alleging
causes of action against the Company for Breach of Contract,
Liquidated Damages, Damages, and Indemnification. The claims arose
out of a securities purchase agreement entered into between
Plaintiffs and the Company pursuant to which the Company issued
convertible notes and warrants to Plaintiffs in or around January
2018. Plaintiffs allege, inter alia, that the Company failed to pay
Plaintiffs&#x2019; outstanding principal on or before the July 23,
2018 maturity date of said notes, failed to convert a portion of
said notes in response to Plaintiffs&#x2019; conversion notice, and
failed to timely adjust the exercise price of said warrants. At
issue are notes issued to Plaintiffs in the aggregate principal
amount of approximately $2.2 million and warrants representing the
right of Plaintiffs to acquire an aggregate of 480,352 shares of
common stock in the Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">42</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="management">M</a>ANAGEMENT</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table sets forth the name, age and position held by each
of our executive officers and directors as of September 30, 2019.
Directors are elected for a period of one year and thereafter serve
until the next annual meeting at which their successors are duly
elected by the stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 30%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Name</font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-family: Times New Roman;"><font style="font-weight: bold; color: #000000">Age</font></font><br></font></div>
</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 60%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-size: 11px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Position</font></font></div>
</td>
</tr><tr style="background-color: #ccedff">
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Anthony J. Cataldo</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
67</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 60%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Chief
Executive Officer and Chairman of the Board</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Steven Weldon</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
44</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 60%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Chief
Financial Officer, Principal Accounting Officer and
Director</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 21px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">Anthony J. Cataldo</font>
<font style="color: #000000">was appointed Chief Executive Officer
and Chairman on March 15, 2019. Previously he served as Vice
Chairman of the Board since January 2019. Mr. Cataldo has extensive
experience with the Company, having served on the Board of
Directors from July 2014 until November 2018, also serving as Chief
Executive Officer from November 2014 to September 2017 and
Executive Chairman of the Board from September 2017 to February
2018 during that time. Prior to joining the Company, from February
2011 until June 2013, Mr. Cataldo served as Chairman and
CEO/Founder of Genesis Biopharma, Inc. (now known as Iovance
Biotherapeutics, Inc.). Mr. Cataldo is credited with developing the
Stage Four Cancer treatment for melanoma known as Lion/Genesis
using assets acquired from the National Cancer Institute (NIH). Mr.
Cataldo also served as non-executive co-chairman of the board of
directors of MultiCell Technologies, Inc., a supplier of
functional, non-tumorigenic immortalized human hepatocytes from
February 2005 until July 2006.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">Steven Weldon</font>
<font style="color: #000000">was appointed Chief Financial Officer
and to our board of directors on March 20, 2019. Previously Mr.
Weldon was appointed to the Board of Directors of the Company in
September 2014 and as our Chief Financial Officer in November 2014
until October 2018.. Mr. Weldon has over 15 years of financial and
accounting experience. Mr. Weldon&#x2019;s financial background
includes experience in managerial, private accounting and planning.
He has served on the board of several publicly traded companies as
both, chief executive officer and chief financial officer. Mr.
Weldon was appointed as chief financial officer and as a member of
the board of directors of GB Sciences, Inc. (OTCMKTS:GBLX) in
September 2005 and served in both positions until November 2014.
Mr. Weldon also served as chief executive officer of GB Sciences
from December 2009, through May 2011, and from April 2012, through
March 2014. For several years, he taught accounting and tax courses
to undergrad students at Florida Southern College. He received his
bachelor of science degree and his Master&#x2019;s in Business
Administration from Florida Southern College and is a licensed
Certified Public Accountant in the State of
Florida.&#xA0;</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;Due
to the small number of directors, at the present time the duties of
an Audit Committee, Nominating and Governance Committee, and
Compensation Committee are performed by the board of directors as a
whole. At such time as we have more directors on our board of
directors, these committees will be reconstituted.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Code of Ethics</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">A
copy of the company&#x2019;s code of ethics is attached to this
annual report as exhibit 14.1.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Section 16(a) Beneficial Ownership Reporting
Compliance</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Section
16(a) of the Securities Exchange Act of 1934 requires our executive
officers and directors, and persons who own more than 10% of a
registered class of the company&#x2019;s equity securities, to file
reports of ownership and changes in ownership with the Securities
and Exchange Commission (&#x201C;SEC&#x201D;). Executive officers,
directors and greater than 10% stockholders are required by SEC
regulations to furnish the company with copies of all Section 16(a)
forms they file. All of our executive officers and directors filed
the required reports; however, Kathleen Clarence-Smith and Raymond
Urbanski filed one Form 3 late and Raymond Urbanski, Anthony J.
Cataldo and Steven Weldon each filed one Form 4 late.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">43</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="executive">E</a>XECUTIVE
COMPENSATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table sets forth certain information concerning the
annual and long-term compensation for services rendered to us in
all capacities for the fiscal years ended December 31, 2018 and
2017 of all persons who served as our principal executive officers
and as our principal financial officer during the fiscal year ended
December 31, 2018. No other executive officers received total
annual compensation during the fiscal year ended December 31, 2018
in excess of $100,000. The principal executive officer and the
other named officers are collectively referred to as the
&#x201C;Named Executive Officers.&#x201D;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: inherit; font-family: inherit;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 40%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px">
<div>
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Name and Principal</font></div>
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Position</font></div>
</div>
</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="font-size: 11px"><font style="text-align: left; display:inline-block;vertical-align:bottom;width:10%;padding-bottom:2px">&#xA0;</font><font style="text-align: center; display: inline-block; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 2px;"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Year</font></div>
</font><font style="text-align: left; display:inline-block;vertical-align:bottom;width:10%;padding-bottom:2px">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="font-size: 11px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Salary</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="font-size: 11px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Bonus</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="font-size: 11px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Stock</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Awards</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($) (1)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 10%;">
<div><font style="font-size: 11px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
All Other</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Compensation</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($) (2)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="width: 10%; vertical-align: bottom;">
<div><font style="font-size: 11px"><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Total</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 40%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
J. Cataldo</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">404,151</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">404,151</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CEO
(6)</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">310,667</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">90,000</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">77,275,253</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">77,675,920</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(255, 255, 255);">
<td colspan="2" style="vertical-align: bottom; width: 50%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Steven
Weldon</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">230,000</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">230,000</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CFO
(5)</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">245,333</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">38,472,797</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">38,718,130</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 50%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Raymond
Urbanski, M.D.</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">321,154</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">7,644,490</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">7,965,644</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Former
CEO (3)</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">133,333</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">7,644,490</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">7,777,823</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(255, 255, 255);">
<td colspan="2" style="vertical-align: bottom; width: 50%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Shawn
Cross</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">233,942</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">20,000</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">253,942</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Former
CEO (4)</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">104,165</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">104,165</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="2" style="vertical-align: bottom; width: 50%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Kathleen
Clarence-Smith</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2018</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">278,846</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">278,846</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 40%;">
<div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Former
CEO (7)</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2017</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">166,667</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 10%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">166,667</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The amounts in this
column represent the aggregate grant date fair value of the
restricted stock awards and restricted stock units, determined in
accordance with Financial Accounting Standards Board (FASB)
Accounting Standards Codification (ASC) Topic 718. GT Biopharma
determines the grant date fair value of the awards by multiplying
the number of units granted by the closing market price of one
share of GT Biopharma common stock on the award grant date. These
amounts do not reflect the actual economic value that will be
realized by the named executive officer upon the vesting or the
sale of the common stock awards.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The amount in this
column represents compensation earned under Consultant Agreements
with the Company.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(3)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Dr. Urbanski was
appointed Chief Medical Officer on September 1, 2017, President of
May 9, 2018, and Chief Executive Officer on July 3, 2018. He
resigned as Chief Executive Officer on March 15, 2019.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(4)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Mr. Cross was
appointed President and Chief Operating Officer on October 15, 2017
and Chairman and Chief Executive Officer on February 14, 2018. Mr.
Cross resigned from the Company on July 2, 2018.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(5)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Mr. Weldon was
appointed Chief Financial Officer on March 20, 2019. He was
previously the Chief Financial Officer from November 3, 2014 until
October 11, 2018.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(6)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Mr. Cataldo was
appointed Chief Executive Officer on March 15, 2019. Mr. Cataldo
previously served as our Chief Executive Officer from March 2009 to
August 2011 and again in November 2014 to September 1, 2017. He was
Executive Chairman from September 1, 2017 to February 14, 2018, and
has been providing services to the Company under a Consultant
Agreement since February 14, 2018.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 36px">
<font style="font-family: Times New Roman; font-size: 13px">(7)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Dr. Clarence-Smith
was Chief Executive Officer from September 1, 2017 to February 14,
2018. Dr. Clarence-Smith served as our Vice-Chairwoman and
President of the Neurology Division from February 14, 2018 until
her resignation from the Company on October 9, 2018. Employment
Agreements</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">44</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 14px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 18, 2018, the Company entered into a Consultant Agreement
with Anthony Cataldo. The term of the Consultant Agreement shall
remain in effect until September 30, 2019. This Agreement
supersedes the Consultant Agreement dated February 14, 2018 and
will pay Mr. Cataldo $25,000 per month during the term of the
Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 19, 2018, the Company entered into an Executive Employment
Agreement with Dr. Urbanski, reflecting his current position as
Chief Executive Officer of the Company. Under the terms of this
agreement, Dr. Urbanski&#x2019;s annual salary is essentially
unchanged from his previous positions. Dr. Urbanski is also
entitled to participate in the Company&#x2019;s bonus plans. Under
the Executive Employment Agreement, the Company has agreed that
upon shareholder approval of a Stock Option Plan, it will recommend
to the Board that the Company grant Dr. Urbanski a Non-Qualified
stock option to purchase 2,971,102 shares of the Company&#x2019;s
common stock having an exercise equal to the fair market value of
the shares on the date of the Agreement. The stock option grant
would vest according to the following schedule: (i) 1,250,000 fully
vested shares upon signing of the agreement, (ii) 1,250,000 shares
on January 1, 2019, and (iii) 471,102 shares on January 1, 2020. On
March 15, 2019, Dr, Urbanski resigned his position as Chief
Executive Officer, President and Chairman of the
Board.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Option Grants</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table sets forth information as of December 31, 2018,
concerning unexercised options, unvested stock and equity incentive
plan awards for the executive officers named in the Summary
Compensation Table.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; margin: 0px auto 0px 0px; width: 100%; font-size: inherit;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 38%;">
<div style="padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="5" rowspan="1" style="vertical-align: bottom; width: 62%;">
<div><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:96%;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-size:13px;font-family:Times New Roman;color:#000000;">
<font style="font-size:11px;">Option Awards</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:2%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 38%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Name</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:11px;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-family:Times New Roman;color:#000;">Number
of Securities Underlying Unexercised Options (#)
Exercisable</font></div>
</font><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:11px;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-family:Times New Roman;color:#000;">Number
of Securities Underlying Unexercised Options (#)
Unexercisable</font></div>
</font><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:11px;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-family:Times New Roman;color:#000;">Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options (#)</font></div>
</font><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:11px;border-bottom:solid 2px #000;display:inline-block;">
<div><font style="font-weight:bold;font-family:Times New Roman;color:#000;">Option
Exercise Price ($)</font></div>
</font><font style="text-align: left; vertical-align:bottom;padding-bottom:2px;width:10%;font-size:11px;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; display:inline-block;vertical-align:bottom;width:10%;padding-bottom:2px">&#xA0;</font><font style="text-align: center; display:inline-block;vertical-align:bottom;width:80%;padding-bottom:2px">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px"><font style="font-weight: bold; color: #000; font-family: Times New Roman">Option
Expiration Date</font></font></div>
</font><font style="text-align: left; display:inline-block;vertical-align:bottom;width:10%;padding-bottom:2px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 38%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Steven
Weldon</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 38%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
Cataldo</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">358</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">750</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/1/2019</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 38%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
Cataldo</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">358</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/1/2019</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 38%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
Cataldo</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">358</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/1/2019</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Director Compensation</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Beginning
in January 2018, non-employee members of the Board of Directors are
to receive $42,500 per year, plus $15,000 annually for Chairing a
Committee and $5,000 annually as a member of a Committee. Also,
upon shareholder approval of a Stock Option Plan, Directors will be
granted 150,000 options that vest over a three-year period. Vesting
will accelerate if the Company undergoes a change of control
transaction for cash.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Name</font> <font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Fees Earned or</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Paid in Cash ($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Option Awards</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Stock Awards</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Total</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
($)</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dr.
John Bonfiglio (1)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dr.
Peter Kiener (1)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,173</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,173</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Geoffrey
Davis (1)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">26,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">26,250</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
Cataldo</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Federica
O'Brien (2)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,173</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,173</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td colspan="9" style="vertical-align: top; width: 100%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(1) Dr. Bonfiglio, Dr. Kiener and Mr. Davis resigned from the Board
on March 20, 2019</font></div>
</td>
</tr><tr>
<td colspan="9" style="vertical-align: top; width: 100%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
(1)</font> <font style="color: #000000">Ms. O'Brien resigned from
the Board on July 2, 2018</font></font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">45</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="voting">V</a>OTING SECURITIES AND PRINCIPAL
HOLDERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The following table sets forth certain information
regarding beneficial ownership of our common stock as of September
11, 2019, (a) by each person known by us to own beneficially 5% or
more of any class of our common stock, (b) by each of our named
executive officers, (c) by each of our directors and (d) by all our
current executive officers and directors as a group. As of
September 11, 2019, there were</font> <a name="_Hlk19204769"><!--anchor--></a><font style="color: #000000">66,401,060 shares of our common stock issued and
outstanding. Shares of common stock subject to stock options and
preferred stock that are currently exercisable or exercisable
within 60 days of September 11, 2019 are deemed to be outstanding
for purposes of computing the percentage ownership of that person
but are not treated as outstanding for computing the percentage
ownership of any other person. Unless indicated below, the persons
and entities named in the table have sole voting and sole
investment power with respect to all shares beneficially owned,
subject to community property laws where applicable. Except as
otherwise indicated, the address of each stockholder is c/o GT
Biopharma, Inc. at 9350 Wilshire Blvd. Suite 203, Beverly Hills, CA
90212.</font></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:76%;"><br></td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:76%;"><br></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares of</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Percent of</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:76%;"><br></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Common</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares of</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:76%;"><br></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Stock</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Outstanding</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:76%;"><br></td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Beneficially</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Common</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Name and Address of Beneficial Owner</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Owned</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font>
<font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Stock</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div>
<div>
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Security Ownership of Certain Beneficial Owners:</font></div>
</div>
</div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font>
<font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Kathleen
Clarence-Smith, M.D., Ph.D. (7)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,521,051</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11.33</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Mark
Silverman (7)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,226,108</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10.88</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">William
Heavener (1)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,674,749</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7.04</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bristol
Investment Fund, Ltd. (2)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,534,795</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">06.83</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Adam
Kasower (3)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,645,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.49</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Theorem
Group, LLC (4)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,540,130</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5.33</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Security Ownership of Management and Directors:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
J. Cataldo (5)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,734,320</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16.16</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Steven
Weldon (5)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,769,707</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10.19</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Executive
officers and directors as a group &#x2014; 2 people</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,504,027</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td colspan="1" style="width:12%;vertical-align:bottom;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">26.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">%</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">As reported on
Schedule 13G/A filed with the SEC on February 5, 2019. The address
of William Heavener is 3300 University Blvd, Suite 218, Winter
Park, FL 32792</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">As reported on
Schedule 13G/A filed with the SEC on February 12, 2019. Paul
Kessler, manager of Bristol Capital Advisors, LLC, the investment
advisor to Bristol Investment Fund, Ltd., has voting and investment
control over the securities held by Bristol Investment Fund, Ltd.
Mr. Kessler disclaims beneficial ownership of these securities
except to the extent of his pecuniary interest therein. The address
of Bristol Capital Advisors, LLC is 662 N. Sepulveda Blvd., Suite
300, Los Angeles, California 90049.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(3)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Includes 1,011,274
shares issuable upon conversion of principal on outstanding
convertible debentures and 120,088 shares available through
exercise of warrants</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(4)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">As reported on
Schedule 13G filed with the SEC on November 14, 2017. The address
of Theorem Group LLC is 315 Beverly Drive, Suite 502, Beverly
Hills, CA 90212</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 36px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">(5)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Security interest
in some of these shares has been granted to various holders of the
Company&#x2019;s senior convertible notes to secure the
Company&#x2019;s obligations under these notes in accordance with a
Stock Pledge Agreement dated August 2, 2018.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">46</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Equity Compensation Plan Information</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 60px; margin-right: 0px; text-indent: -48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following is a summary of our equity compensation plans at December
31, 2018:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 64%;">
<div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Plan Category</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0); font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of Securities</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
To be Issued Upon</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Outstanding Options,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Warrants, and Rights</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
(a)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0); font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise Price of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Outstanding Options,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Warrants, and Rights</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
(b)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: bottom;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; border-bottom: 2px solid rgb(0, 0, 0); font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of Securities</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Available for Future</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Issuance Under Equity</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Compensation Plans</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
(Excluding Securities</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Reflected in Column (a))</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
(c)</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block; padding-bottom: 2px; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; width: 10%; vertical-align: bottom; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Equity compensation plans approved
b</font><font style="color: #000000">y security holders
(1)</font></font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,113</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">$</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,320</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Equity
compensation plans not approved by security holders</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">$</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 64%;">
<div style="margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 64%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,113</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">$</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">1,320</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 12%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman; font-size: 13px;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman; font-size: 13px;">-</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div style="text-align: justify; margin-left: 60px; margin-right: 6px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">(1)
As of December 31, 2018, we had options issued and outstanding to
purchase 1,113 shares of common stock under our 2014 Stock
Incentive Plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">47</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="selling">S</a>ELLING
STOCKHOLDERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
This prospectus relates in part to our registering the resale of
41,473,822 shares of common stock of the Company by Selling
Stockholders who may acquire such shares upon the conversion of
notes. There can be no assurance that the Selling Stockholders will
sell any or all of their common stock offered by this prospectus.
We do not know if, when, or in what amounts, the selling
stockholders may offer the common stock for sale.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Selling Stockholders</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table sets forth:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the names of the
Selling Stockholders;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the number of
shares of common stock that can be acquired by each of the Selling
Stockholders through the conversion of notes and preferred stock
before the offering;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the number of
shares of common stock being registered with respect to each
Selling Stockholder;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the number of
shares of common stock owned by each of the Selling Stockholders
after the offering assuming all notes and applicable shares of
preferred stock are converted and all common shares acquired are
sold; and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the person with
voting or investment control if the stockholder is not a natural
person.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of September 11, 2019, there were 66,401,060 shares of common
stock outstanding. To the extent that any successor(s) to the named
selling stockholder(s) wish to sell under this prospectus, we will
file a prospectus supplement identifying such successors as selling
stockholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Selling Stockholders</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares Acquirable upon Conversion of Notes and Preferred
Stock</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares Being</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Registered</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares Owned After the Offering Assuming all Notes and Preferred
Stock are Converted and all Shares Sold</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:32%;">
<div style="border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px">
<div>
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Person with Voting or</font></div>
<div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Investment Control</font></div>
</div>
</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bristol
Investment Fund, Ltd.</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,625,207</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,625,207</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(1)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,745,117</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Paul
Kessler</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bristol
Capital LLC</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,375,694</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,375,694</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">(2)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Paul
Kessler</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">James
Heavener</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,317,562</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,317,562</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,892,882</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Adam
Kasower</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,901,658</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,901,658</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,091,664</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Red
Mango Enterprises Limited</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,171,350</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,171,350</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,365,180</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Chris
Parker</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Alpha
Capital Anstalt</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,850,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,850,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Nicola
Feuerstein</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Rosalinde and Arthur Gilbert Foundation</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,601,647</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,601,647</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,360,565</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Martin
H. Blank</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Hewlett
Fund LP</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,296,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,296,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Martin
Chopp</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Clearview
Bio LLC</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">825,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">825,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Tisno
Onggara</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Clearview
Ventures Inc</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">412,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">412,500</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Tisno
Onggara</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Brio
Capital Master Fund, Ltd</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">942,857</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">942,857</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Shaye
Hirsch</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jeffrey
Bronfman Revocable Living Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,347,849</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,347,849</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jeffrey
Bronfman</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Robert
H. Lipp Separate Property Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">712,130</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">712,130</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Robert
H. Lipp</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
RSZ Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,027,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,027,620</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Richard
Ziman</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diane
S. Lipp Separate Property Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">162,945</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">162,945</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diane
S. Lipp</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Lipp
Irrevocable Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300,445</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300,445</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Diane
S. Lipp</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Martin
H. Blank and Linda M. Blank Rev Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">127,286</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">127,286</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Martin
H. Blank</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Runnels Family Trust DTD 1-11-2000</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,178,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,178,571</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">G.
Tyler Runnels</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">District
2 Capital Fund LP</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,082,143</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,082,143</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Eric
J. Schlanger</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Bigger
Capital Fund, LP</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">550,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">550,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Michael
Bigger</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Michael
Breen</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Greg
Suess</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jeff
Bronfman Revocable Living Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">407,786</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">407,786</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jeffrey
Bronfman</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Contreras
Family Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">235,714</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">*</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Lipp
Revocable Trust</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">550,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">550,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:32%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Robert
H. Lipp</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
*</font><font style="color: #000000">It is unknown to the Company
whether the Selling Stockholder holds shares other than those being
registered.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(1) Of the 5,625,207 shares being registered, 3,957,584 are
issuable upon the conversion of a convertible note and 1,667,623
are issuable upon the conversion of shares of Series J-1 Preferred
stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(2) All 3,375,694 shares being registered are issuable upon the
conversion of shares of Series J-1 Preferred stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">48</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="plan">P</a>LAN OF DISTRIBUTION</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We are registering 41,473,822 shares of our common stock for
possible sale by the selling stockholders.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We will not receive any of the proceeds from the sale by the
selling stockholders of the shares of common stock. We will bear
all fees and expenses incident to our obligation to register the
shares of common stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The selling stockholders may sell all or a portion of the shares of
common stock beneficially owned by them and offered hereby from
time to time directly or through one or more underwriters,
broker-dealers or agents. If the shares of common stock are sold
through underwriters or broker-dealers, the selling stockholders
will be responsible for underwriting discounts or commissions or
agent&#x2019;s commissions. The shares of common stock may be sold
in one or more transactions at fixed prices, at prevailing market
prices at the time of the sale, at varying prices determined at the
time of sale, or at negotiated prices. These sales may be effected
in transactions, which may involve crosses or block
transactions,</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">on
any national securities exchange or quotation service on which the
securities may be listed or quoted at the time of
sale;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">in
the over-the-counter market;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">in
transactions otherwise than on these exchanges or systems or in the
over-the- counter market;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">through
the writing of options, whether such options are listed on an
options exchange or otherwise;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ordinary
brokerage transactions and transactions in which the broker-dealer
solicits purchasers;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">block
trades in which the broker-dealer will attempt to sell the shares
as agent but may position and resell a portion of the block as
principal to facilitate the transaction;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">purchases
by a broker-dealer as principal and resale by the broker-dealer for
its account;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">an
exchange distribution in accordance with the rules of the
applicable exchange;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">privately
negotiated transactions;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">short
sales;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">sales
pursuant to Rule 144;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">broker-dealers
may agree with the selling security holders to sell a specified
number of such shares at a stipulated price per share;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">a
combination of any such methods of sale; and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px">&#x25CF;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">any
other method permitted pursuant to applicable law.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
If the selling stockholders effect such transactions by selling
shares of common stock to or through underwriters, broker-dealers
or agents, such underwriters, broker-dealers or agents may receive
commissions in the form of discounts, concessions or commissions
from the selling stockholders or commissions from purchasers of the
shares of common stock for whom they may act as agent or to whom
they may sell as principal (which discounts, concessions or
commissions as to particular underwriters, broker-dealers or agents
may be in excess of those customary in the types of transactions
involved). In connection with sales of the shares of common stock
or otherwise, the selling stockholders may enter into hedging
transactions with broker-dealers, which may in turn engage in short
sales of the shares of common stock in the course of hedging in
positions they assume. The selling stockholders may also sell
shares of common stock short and deliver shares of common stock
covered by this prospectus to close out short positions and to
return borrowed shares in connection with such short sales. The
selling stockholders may also loan or pledge shares of common stock
to broker-dealers that in turn may sell such shares.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The selling stockholders may pledge or grant a security interest in
some or all of the senior convertible notes, warrants or shares of
common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may
offer and sell the shares of common stock from time to time
pursuant to this prospectus or any amendment to this prospectus
under Rule 424(b)(3) or other applicable provision of the
Securities Act of 1933, as amended, amending, if necessary, the
list of selling stockholders to include the pledgee, transferee or
other successors in interest as selling stockholders under this
prospectus. The selling stockholders also may transfer and donate
the shares of common stock in other circumstances in which case the
transferees, donees, pledgees or other successors in interest will
be the selling beneficial owners for purposes of this
prospectus.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The selling stockholders and any broker-dealer participating in the
distribution of the shares of common stock may be deemed to be
&#x201C;underwriters&#x201D; within the meaning of the Securities
Act, and any commission paid, or any discounts or concessions
allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a
particular offering of the shares of common stock is made, a
prospectus supplement, if required, will be distributed which will
set forth the aggregate amount of shares of common stock being
offered and the terms of the offering, including the name or names
of any broker-dealers or agents, any discounts, commissions and
other terms constituting compensation from the selling stockholders
and any discounts, commissions or concessions allowed or reallowed
or paid to broker-dealers.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">49</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Under the securities laws of some states, the shares of common
stock may be sold in such states only through registered or
licensed brokers or dealers. In addition, in some states the shares
of common stock may not be sold unless such shares have been
registered or qualified for sale in such state or an exemption from
registration or qualification is available and is complied
with.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
There can be no assurance that any selling stockholder will sell
any or all of the shares of common stock registered pursuant to the
registration statement, of which this prospectus forms a
part.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The selling stockholders and any other person participating in such
distribution will be subject to applicable provisions of the
Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder, including, without limitation, Regulation M
of the Exchange Act, which may limit the timing of purchases and
sales of any of the shares of common stock by the selling
stockholders and any other participating person. Regulation M may
also restrict the ability of any person engaged in the distribution
of the shares of common stock to engage in market-making activities
with respect to the shares of common stock. All of the foregoing
may affect the marketability of the shares of common stock and the
ability of any person or entity to engage in market-making
activities with respect to the shares of common stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We will pay all expenses of the registration of the shares of
common stock pursuant to the registration rights agreement,
including, without limitation, Securities and Exchange Commission
filing fees and expenses of compliance with state securities or
&#x201C;blue sky&#x201D; laws; provided, however, that a selling
stockholder will pay all underwriting discounts and selling
commissions, if any. We will indemnify the selling stockholders
against liabilities, including some liabilities under the
Securities Act, in accordance with the registration rights
agreements, or the selling stockholders will be entitled to
contribution. We may be indemnified by the selling stockholders
against civil liabilities, including liabilities under the
Securities Act, that may arise from any written information
furnished to us by the selling stockholder specifically for use in
this prospectus, in accordance with the related registration rights
agreement, or we may be entitled to contribution.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Once sold under the registration statement, of which this
prospectus forms a part, the shares of common stock will be freely
tradable in the hands of persons other than our
affiliates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">50</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="capitalstock">D</a>ESCRIPTION OF CAPITAL
STOCK</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following description of our capital stock, together with any
additional information we include in any applicable prospectus
supplement or any related free writing prospectus, summarizes the
material terms and provisions of our common stock. For the complete
terms of our common stock, please refer to our amended and restated
certificate of incorporation, the and our amended and restated
bylaws that are incorporated by reference into the registration
statement of which this prospectus is a part or may be incorporated
by reference in this prospectus or any applicable prospectus
supplement. The terms of these securities may also be affected by
Delaware General Corporation Law. The summary below and that
contained in any applicable prospectus supplement or any related
free writing prospectus are qualified in their entirety by
reference to our amended and restated certificate of incorporation
and our amended and restated bylaws.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
General</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
As of the date of this Prospectus, our authorized capital stock
consists of 750,000,000 shares of common stock, par value $0.001
per share, and 15,000,000 shares of preferred stock, par value
$0.001 per share. As of June 15, 2019, there were approximately
51.3 million shares of our common stock issued and
outstanding.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Holders of our common stock are entitled to one vote for each share
of common stock held of record for the election of directors and on
all matters submitted to a vote of stockholders. Holders of our
common stock are entitled to receive dividends ratably, if any, as
may be declared by our board of directors out of legally available
funds, subject to any preferential dividend rights of any preferred
stock then outstanding. In the event of our dissolution,
liquidation or winding up, holders of our common stock are entitled
to share ratably in our net assets legally available after the
payment of all of our debts and other liabilities, subject to the
liquidation preferences of any preferred stock then outstanding.
Holders of our common stock have no preemptive, subscription,
redemption or conversion rights. The rights, preferences and
privileges of holders of common stock are subject to, and may be
adversely affected by, the rights of the holders of shares of any
series of preferred stock that we may designate and issue in the
future. All outstanding shares of our common stock are fully paid
and nonassessable. Except as described below in
&#x201C;Anti-Takeover Provisions Under Our Charter and Bylaws and
Delaware Law,&#x201D; a majority vote of common stockholders is
generally required to take action under our amended and restated
certificate of incorporation and amended and restated
bylaws.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Anti-Takeover Provisions Under Our Charter and Bylaws and Delaware
Law</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certain provisions of Delaware law, our amended and restated
certificate of incorporation and our bylaws contain provisions that
could have the effect of delaying, deferring or discouraging
another party from acquiring control of us. These provisions, which
are summarized below, may have the effect of discouraging coercive
takeover practices and inadequate takeover bids. These provisions
are also designed, in part, to encourage persons seeking to acquire
control of us to first negotiate with our board of directors. We
believe that the benefits of increased protection of our potential
ability to negotiate with an unfriendly or unsolicited acquirer
outweigh the disadvantages of discouraging a proposal to acquire us
because negotiation of these proposals could result in an
improvement of their terms.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Amended and Restated Certificate of Incorporation</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Undesignated Preferred Stock</font><font style="color: #000000">.
Our board of directors has the ability to issue preferred stock
with voting or other rights or preferences that could impede the
success of any attempt to change control of us. These and other
provisions may have the effect of deferring hostile takeovers or
delaying changes in control or management of our
company.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Special Meetings of Stockholders</font><font style="color: #000000">. Our bylaws provide that special meetings of our
stockholders may be called only by our chairman of the board, our
president or our board of directors, thus prohibiting a stockholder
from calling a special meeting. This provision might delay the
ability of our stockholders to force consideration of a proposal or
for stockholders controlling a majority of our capital stock to
take any action, including the removal of
directors.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Board Vacancies Filled Only by Majority of
Directors</font><font style="color: #000000">. Vacancies and newly
created seats on our board may be filled only by a majority of the
directors then in office. Only our board of directors may determine
the number of directors on our board. The inability of stockholders
to determine the number of directors or to fill vacancies or newly
created seats on our board of directors makes it more difficult to
change the composition of our board of directors, but these
provisions promote a continuity of existing
management.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
No Cumulative Voting</font><font style="color: #000000">. The
Delaware General Corporation Law, or DGCL, provides that
stockholders are not entitled to the right to cumulate votes in the
election of directors unless our amended and restated certificate
of incorporation provides otherwise. Our amended and restated
certificate of incorporation and bylaws do not expressly provide
for cumulative voting.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">51</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Directors Removed Only by Special Meeting of
Stockholders</font><font style="color: #000000">. A director can be
removed only by the affirmative vote of a majority of the votes of
the issued and outstanding stock entitled to vote for the election
of directors of the corporation given at a special meeting of the
stockholders called and held for this purpose.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Amendment of Charter Provisions</font><font style="color: #000000">. In order to amend certain of the above
provisions in our amended and restated certificate of incorporation
and our bylaws, the board of directors is expressly authorized to
adopt, alter or repeal the bylaws, subject to the rights of the
stockholders entitled to vote. Stockholders can vote at any
stockholder meeting and repeal, alter, or amend the bylaws by the
affirmative vote of a majority of the stockholders entitled to vote
in such meeting.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Delaware Anti-takeover Statute</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
We are subject to Section&#xA0;203 of the DGCL. In general,
Section&#xA0;203 prohibits a publicly held Delaware corporation
from engaging in a &#x201C;business combination&#x201D; with an
&#x201C;interested stockholder&#x201D; for a period of three years
after the date of the transaction in which the person became an
interest stockholder, unless the business combination is approved
in a prescribed manner. A &#x201C;business combination&#x201D;
includes mergers, asset sales and other transactions in which the
interested stockholder receives or could receive a financial
benefit on other than a&#xA0;</font><font style="font-style: italic; color: #000000">pro rata</font><font style="color: #000000">&#xA0;basis with other stockholders. An
&#x201C;interested stockholder&#x201D; is a person who, together with
affiliates and associates, owns, or within three years did own, 15%
or more of the corporation&#x2019;s outstanding voting stock. This
provision has an anti-takeover effect with respect to transactions
not approved in advance by our board of directors, including
discouraging takeover attempts that might result in a premium over
the market price for the shares of our market price. With approval
of our stockholders, we could amend our amended and restated
certificate of incorporation in the future to avoid the
restrictions imposed by this anti-takeover law.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;The provisions of Delaware law and our amended and restated
certificate of incorporation could have the effect of discouraging
others from attempting hostile takeovers and, as a consequence,
they may also inhibit temporary fluctuations in the market price of
our common stock that often result from actual or rumored hostile
takeover attempts. These provisions may also have the effect of
preventing changes in our management. It is possible that these
provisions could make it more difficult to accomplish transactions
that stockholders may otherwise deem to be in their best
interests.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Transfer Agent and Registrar</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our transfer agent and registrar for our capital stock is
ComputerShare. The transfer agent&#x2019;s address is 350 Indiana
Street, Golden, Colorado 80401, and its telephone number is (303)
262-0600.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Listing</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our common stock is listed on the OTCQB under the symbol
&#x201C;GTBP.&#x201D; The last reported sale price of our common
stock on the OTCQB on August 30, 2019, was $0.175 per share. Our
common stock is also quoted on several European-based exchanges
including Berlin (GTBP.BE), Frankfurt (GTBP.DE), the Euronext
(GTBP.NX) and Paris (GTBP.PA).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">52</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="legal">L</a>EGAL MATTERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certain legal matters in connection with this offering will be
passed upon for us by Gary R. Henrie, Attorney at Law, Nauvoo,
Illinois. These legal matters include that shares of common stock
to be sold by the Selling Shareholders are validly issued, fully
paid and non-assessable. Mr. Henrie's address is P.O. Box 5174,
Etna, Wyoming 83118. Mr. Henrie is licensed to practice law in the
states of Nevada and Utah.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="disclosure">D</a>ISCLOSURE OF COMMISSION
POSITION ON INDEMNIFICATION FOR SECURITIES ACT
LIABILITIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers or
persons controlling the registrant pursuant to the foregoing
provisions, the registrant has been informed that in the opinion of
the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is therefore
unenforceable</font><font style="font-weight: bold; color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><a name="experts"></a></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
EXPERTS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The consolidated financial statements, and the related financial
statement schedule, incorporated in this Prospectus by reference to
our Annual Report on Form 10-K have been audited by Seligson &amp;
Giannattasio, LLP, an independent registered public accounting
firm, as stated in their report, which is incorporated herein by
reference. Such financial statements and financial statement
schedule have been so incorporated in reliance upon the report of
such firm given upon their authority as experts in accounting and
auditing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="where">W</a>HERE YOU CAN FIND MORE
INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We have filed a registration statement on Form S-1 under the
Securities Act with the Securities and Exchange Commission with
respect to the sale or resale of an aggregate of 41,473,822 shares
of common stock. This prospectus was filed as a part of that
registration statement but does not contain all of the information
contained in the registration statement and exhibits. Reference is
thus made to the omitted information. Statements made in this
prospectus are summaries of the material terms of contracts,
agreements and documents and are not necessarily complete; however,
all information we considered material has been disclosed.
Reference is made to each exhibit for a more complete description
of the matters involved and these statements are qualified in their
entirety by the reference. You may inspect the registration
statement, exhibits and schedules filed with the Securities and
Exchange Commission at the Securities and Exchange Commission's
principle office in Washington, D.C. Copies of all or any part of
the registration statement may be obtained from the Public
Reference Section of the Securities and Exchange Commission, 100 F.
Street, N.E., Washington, D.C. 20549. The Securities and Exchange
Commission also maintains a web site (http://www.sec.gov) that
contains this filed registration statement, reports, proxy
statements and information regarding us that we have filed
electronically with the Commission. For more information pertaining
to our company and the sale or resale of an aggregate of 41,473,822
shares of common stock, reference is made to the registration
statement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">53</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>

<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
GT BIOPHARMA, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL
STATEMENTS YEARS ENDED DECEMBER 31, 2018 AND 2017 AND FOR THE SIX
MONTHS ENDED JUNE 30, 2019 AND 2018</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Contents Page</font></font></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f1"><font style="font-family: Times New Roman; font-size: 13px">Report of
Independent Registered Public Accounting Firm</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-1</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f1"><font style="font-family: Times New Roman; font-size: 13px">Seligson &amp;
Giannattasio, LLP</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Consolidated
Financial Statements</font></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f2"><font style="font-family: Times New Roman; font-size: 13px">Balance Sheets as
of December 31, 2018 and 2017</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f3"><font style="font-family: Times New Roman; font-size: 13px">Statements of
Operations For Years Ended December 31, 2018 and
2017</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-3</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f4"><font style="font-family: Times New Roman; font-size: 13px">Statement of
Stockholders&#x2019; Equity For Years Ended December 31, 2018 and
2017</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-4</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f5"><font style="font-family: Times New Roman; font-size: 13px">Statements of Cash
Flows For Years Ended December 31, 2018 and 2017</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-5</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#f6"><font style="font-family: Times New Roman; font-size: 13px">Notes To
Consolidated Financial Statements</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-6</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#bs630"><font style="font-family: Times New Roman; font-size: 13px">Balance Sheets as
of June 30, 2019 and 2018</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-20</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#so630"><font style="font-family: Times New Roman; font-size: 13px">Statements of
Operations For The Six Months Ended June 30, 2019 and
2018</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-21</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#cf630"><font style="font-family: Times New Roman; font-size: 13px">Statements of Cash
Flows For The Six Months Ended June 30, 2019 and
2018</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-22</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 92%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="#n630"><font style="font-family: Times New Roman; font-size: 13px">Notes To
Consolidated Financial Statements</font></a></div>
</td>
<td style="vertical-align: top; width: 8%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">F-23</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">54</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f1">R</a>EPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 315px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">To
the Board of Directors and Stockholders of GT Biopharma,
Inc.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 10">&#xA0;</font>
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Opinion on the Financial Statements</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have audited the accompanying consolidated balance sheets of GT
Biopharma, Inc. and subsidiaries (the "Company") as of December 31,
2018 and 2017, and the related consolidated statements of
operations, stockholders&#x2019; equity and cash flows for each of
the years in the two-year period ended December 31, 2018, and the
related notes (collectively referred to as the financial
statements). In our opinion, the consolidated financial statements
present fairly, in all material respects, the consolidated
financial position of the Company and subsidiaries as of December
31, 2018 and 2017 and the consolidated results of its operations
and its consolidated cash flows for each of the years in the
two-year period ended December 31, 2018, in conformity with
accounting principles generally accepted in the United States of
America.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Basis of Opinion</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">These
financial statements are the responsibility of the Company&#x2019;s
management. Our responsibility is to express an opinion on the
Company&#x2019;s consolidated financial statements based on our
audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States)
(&#x201C;PCAOB&#x201D;) and are required to be independent with
respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due
to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting, but not
for the purpose of expressing an opinion on the effectiveness of
the Company&#x2019;s internal control over financial reporting.
Accordingly, we express no such opinion.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis
for our opinion.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
accompanying consolidated financial statements have been prepared
assuming the Company will continue as a going concern. As discussed
in Note 1 to the financial statements, the Company has incurred
significant recurring losses. The realization of a major portion of
its assets is dependent upon its ability to meet its future
financing needs and the success of its future operations. These
factors raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern. The consolidated financial
statements do not include any adjustments that might result from
this uncertainty.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">/s/</font> <font style="color: #000000">Seligson
&amp; Giannattasio, LLP</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;Seligson
&amp; Giannattasio, LLP</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
have served as the Company&#x2019;s auditor since 2008.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 144px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">White
Plains, New York</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 144px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">March
29, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-1</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f2">G</a>T Biopharma, Inc. and
Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Balance Sheets</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(in thousands, except par value and share data)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
December 31,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
December 31,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ASSETS</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Assets:</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
and cash equivalents</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">30</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">90</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Intangible
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,262</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">253,777</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deposits</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fixed
assets, net</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Other Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,309</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">253,792</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
ASSETS</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">254,368</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounts
payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,762</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,546</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accrued
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,455</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">102</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Line
of credit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Note
Payable to Related Party</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">100</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deferred
Rent</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Convertible
debentures</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">10,673</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,679</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stockholders&#x2019;
Equity:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Convertible
preferred stock - $0.001 par value; 15,000,000 shares
authorized:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
C - 96,230 and 96,230 shares issued and outstanding at December 31,
2018 and December 31, 2017, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
J &#x2013; 1,163,548 shares issued and outstanding at December 31,
2018 and December 31, 2017, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Common
stock - $0.001 par value; 750,000,000 shares authorized; and
50,650,478 and 50,117,977 shares issued and outstanding at December
31, 2018 and December 31, 2017, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">50</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Additional
paid-in capital</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">540,171</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">521,305</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
deficit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(528,685</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(269,499</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Noncontrolling
interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(169</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(169</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Stockholders&#x2019; Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,370</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">251,689</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">254,368</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these consolidated
financial statements.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<br>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f3">G</a>T Biopharma, Inc. and
Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Statements of Operations</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(in thousands except per share data)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">December
31</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2018</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size:11px;"><font style="font-weight:bold;font-family:Times New Roman;color:#000;">2017</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Operating expenses:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,067</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,068</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Selling,
general and administrative expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12,487</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">134,502</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on impairment</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">228,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">250,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">135,570</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
from operations</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(250,069</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(135,570</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Other income (expense):</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
expense</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,117</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,602</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
other income (expense)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,117</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8,602</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
before provision for income taxes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(259,186</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(144,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Provision
for income tax</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(259,186</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(144,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share &#x2013; basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(5.16</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(8.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
average common shares outstanding &#x2013; basic and
diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">50,240</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">16,769</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
accompanying notes are an integral part of these consolidated
financial statements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f4">G</a>T Biopharma, Inc. and
Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Statement of Stockholders' Equity</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
For the Years Ended December 31, 2018 and 2017</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(in thousands)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:40%;">
<div style="margin-left:0px;"><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Additional</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:20%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Preferred Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align:bottom;width:20%;">
<div><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:90%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Common Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:5%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Paid-in</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Accumulated</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-size: 11px"><font style="font-family: Times New Roman;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Amount</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;Shares</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Amount</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Capital</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">
<div><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Deficit</font></font></div>
</font><font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Balance at December 31, 2016</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">1,788</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">2</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">104</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">0</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">105,891</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">(124,649</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">)</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common stock for acquisition</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">16,928</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">17</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">253,901</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common and preferred stock for convertible notes and
interest</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">909</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">1</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">17,678</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">18</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">25,254</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common and preferred stock for warrants</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">5</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">0</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">497</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">0</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">5,819</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common for preferred stock</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">(2,042</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">)</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">(2</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">)</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">5,678</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">6</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">(4</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">)</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common and preferred stock for compensation</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">600</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">1</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">9,233</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">9</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">129,766</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Change in
accounting method for debt and warrants</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">678</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">(678</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">)</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Net
loss</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman;">(144,172</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">)</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Balance at December 31, 2017</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">1,260</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">2</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">50,118</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">50</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">521,305</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">(269,499</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%;">)</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
warrants</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">8,304</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common stock for convertible notes</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">162</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">0</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">325</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Beneficial
conversion feature on convertible notes</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">544</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Issuance of
common stock for compensation</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">370</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">1</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%;">9,693</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-family: Times New Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-family: Times New Roman; display: inline-block;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-size: 13px"><font style="color: rgb(0, 0, 0); font-family: Times New Roman;">Net
loss</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 75%; border-bottom: 2px solid rgb(0, 0, 0);">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 5%; font-family: Times New Roman;">&#xA0;</font><font style="text-align: right; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 75%; font-family: Times New Roman;">(259,186</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px;">)</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:40%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-size: 13px"><font style="font-weight: bold; color: rgb(0, 0, 0); font-family: Times New Roman;">
Balance at December 31, 2018</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">1,260</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">2</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%;">&#xA0;</font><font style="text-align: right; font-family: Times New Roman; color: rgb(0, 0, 0); border-bottom: 4px double rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%;">50,650</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">51</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">540,171</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font></font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="font-size: 13px"><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">&#xA0;</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; border-bottom: 4px double rgb(0, 0, 0);">$</font><font style="text-align: right; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 75%; border-bottom: 4px double rgb(0, 0, 0);">(528,685</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times New Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 4px; width: 10%;">)</font></font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-align: center; vertical-align:bottom;width:98%;display:inline-block;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">The
accompanying notes are an integral part of these consolidated
financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f5">G</a>T Biopharma, Inc. and
Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Statements of Cash Flows</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(In thousands)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Twelve Months Ended December 31,</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(259,186</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(144,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Adjustments
to reconcile net loss to net cash used in operating
activities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Depreciation</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on impairment of long-lived assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">228,515</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
compensation expense for options and warrants&#xA0;issued to
employees and non-employees</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">9,696</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">130,124</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Amortization
of debt discounts</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,663</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,914</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Note
Allonge</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">100</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Non-cash
interest expense</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">441</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,197</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Amortization
of loan costs</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,076</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Changes
in operating assets and liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
Expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(30</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(3</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounts
payable and accrued liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">136</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,412</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in operating activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(10,677</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(5,430</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Acquisition
of fixed assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(36</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used by investing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(36</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Proceeds
from notes payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,145</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loan
costs</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(533</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Repayment
of note payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,415</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash provided by financing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">10,197</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,991</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(516</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">557</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS - Beginning of period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">19</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS - End of period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Supplemental cash flow disclosures:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of common stock upon conversion of convertible notes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">325</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Acquisition
of intangibles through issuance of common stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">253,777</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of common stock for interest expense</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,179</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of common stock for debt</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,166</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">The
accompanying condensed notes are an integral part of these
consolidated financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
The Company</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="f6">B</a>usiness</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data,
Inc. was incorporated in the State of California. Diagnostic Data
changed its incorporation to the State of Delaware in 1972; and
changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and
Bioxytech S.A. and changed its name to OXIS International, Inc. In
July 2017, the Company changed its name to GT Biopharma,
Inc.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immuno-oncology products
based off our proprietary Natural Killer (NK) cell engager
(Tri-specific Killer Engager (TriKE) &amp; Tetra-specific Killer
Engager (TetraKE)) and bi-specific Antibody Drug Conjugate
(bispecific-ADC) technology platforms. Our TriKE and TetraKE
platforms generate proprietary moieties designed to harness and
enhance the cancer killing abilities of a patient&#x2019;s own
natural killer, or NK, cells. Once bound to an NK cell, our
moieties are designed to stimulate the NK cell and precisely direct
it to one or more specifically-targeted proteins (tumor antigens)
expressed on a specific type of cancer, ultimately resulting in the
cancer cell&#x2019;s death. TriKEs and TetraKEs are made up of
recombinant fusion proteins, can be designed to target tumor
antigens on hematologic malignancies, sarcomas or solid tumors and
do not require patient-specific customization. They are designed to
be dosed in an outpatient setting and are expected to have
reasonably low cost of goods. Our bispecific-ADC platform can
generate product candidates that are ligand-directed single-chain
fusion proteins that simultaneously target two tumor antigens. We
believe our bispecific-ADC moieties represents the next generation
of ADCs.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Also,
in connection with the acquisition of Georgetown Translational
Pharmaceuticals on September 1, 2017, we acquired a portfolio of
IPR&amp;D CNS assets consisting of innovative reformulations and/or
repurposing of existing therapies. These CNS assets address disease
states such as chronic neuropathic pain, myasthenia gravis and
motion sickness.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Basis of Consolidation and Comprehensive Income</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
accompanying consolidated financial statements include the accounts
of GT Biopharma, Inc. and its subsidiaries. All intercompany
balances and transactions have been eliminated. The Company's
financial statements are prepared using the accrual method of
accounting.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Going Concern</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">As
shown in the accompanying consolidated financial statements, the
Company has incurred an accumulated deficit of $528,685,000 through
December 31, 2018. On a consolidated basis, the Company had cash
and cash equivalents of $60,000 at December 31, 2018. The Company's
plan is to raise additional capital until such time that the
Company generates sufficient revenues to cover its cash flow needs
and/or it achieves profitability. However, the Company cannot
assure that it will accomplish this task and there are many factors
that may prevent the Company from reaching its goal of
profitability.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
current rate of cash usage raises substantial doubt about the
Company&#x2019;s ability to continue as a going concern, absent any
sources of significant cash flows. In an effort to mitigate this
near-term concern the Company intends to seek additional equity or
debt financing to obtain sufficient funds to sustain operations.
However, the Company cannot provide assurance that it will
successfully obtain equity or debt or other financing, if any,
sufficient to finance its goals or that the Company will generate
future product related revenues. The Company&#x2019;s financial
statements do not include any adjustments relating to the
recoverability and classification of recorded assets, or the
amounts and classification of liabilities that might be necessary
in the event that the Company cannot continue in
existence.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Use of Estimates</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
financial statements and notes are representations of the Company's
management, which is responsible for their integrity and
objectivity. These accounting policies conform to accounting
principles generally accepted in the United States of America and
have been consistently applied in the preparation of the financial
statements. The preparation of financial statements requires
management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenues and expenses and
disclosures of contingent assets and liabilities at the date of the
financial statements. Actual results could differ from those
estimates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Segment Information</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
segments are identified as components of an enterprise about which
separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding
resource allocation and assessing performance. To date, the Company
has viewed its operations and manages its business as one segment
operating in the United States of America.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-6</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font>&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Summary of Significant Accounting Policies</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Advertising and promotional fees</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Advertising
expenses consist primarily of costs incurred in the design,
development, and printing of Company literature and marketing
materials. The Company expenses all advertising expenditures as
incurred. There were no advertising expenses for the years ended
December 31, 2018 and 2017, respectively.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Cash and Cash Equivalents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company considers all highly liquid investments with original
maturities of three months or less to be cash
equivalents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Concentrations of Credit Risk</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company's cash and cash equivalents, marketable securities and
accounts receivable are monitored for exposure to concentrations of
credit risk. The Company maintains substantially all of its cash
balances in a limited number of financial institutions. The
balances are each insured by the Federal Deposit Insurance
Corporation up to $250,000. The Company had no balances in excess
of this limit at December 31, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Based Compensation to Employees</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company accounts for its stock-based compensation for employees in
accordance with Accounting Standards Codification
(&#x201C;ASC&#x201D;) 718. The Company recognizes in the statement of
operations the grant-date fair value of stock options and other
equity-based compensation issued to employees and non-employees
over the related vesting period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company granted no stock options during the years ended December
31, 2018 and 2017, respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Long-Lived Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Our
long-lived assets include property, plant and equipment,
capitalized costs of filing patent applications and other
indefinite lived intangible assets. We evaluate our long-lived
assets for impairment, other than indefinite lived intangible
assets, in accordance with ASC 360, whenever events or changes in
circumstances indicate that the carrying amount of such assets may
not be recoverable. Estimates of future cash flows and timing of
events for evaluating long-lived assets for impairment are based
upon management&#x2019;s judgment. If any of our intangible or
long-lived assets are considered to be impaired, the amount of
impairment to be recognized is the excess of the carrying amount of
the assets over its fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Applicable
long-lived assets are amortized or depreciated over the shorter of
their estimated useful lives, the estimated period that the assets
will generate revenue, or the statutory or contractual term in the
case of patents. Estimates of useful lives and periods of expected
revenue generation are reviewed periodically for appropriateness
and are based upon management&#x2019;s judgment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-7</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Impairment of Long-Lived Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company's long-lived assets currently consist of indefinite lived
intangible assets associated with IPR&amp;D (&#x201C;In-Process
Research &amp; Development&#x201D;) projects and related capitalized
patents acquired in the acquisition of Georgetown Translational
Pharmaceuticals, Inc. as described in Note 3 below. Intangible
assets associated with IPR&amp;D projects are not amortized until
approval by the Food and Drug Administration (FDA) is obtained in a
major market subject to certain specified conditions and management
judgment. The useful life of an amortizing asset generally is
determined by identifying the period in which substantially all of
the cash flows are expected to be generated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company evaluates indefinite lived intangible assets for impairment
at least annually and whenever impairment indicators are present in
accordance with ASC 350. When necessary, the Company records an
impairment loss for the amount by which the fair value is less than
the carrying value of these assets. The fair value of intangible
assets other than goodwill is typically determined using the
&#x201C;relief from royalty method&#x201D;, specifically the
discounted cash flow method utilizing Level 3 fair value inputs.
Some of the more significant estimates and assumptions inherent in
this approach include: the amount and timing of the projected net
cash flows, which includes the expected impact of competitive,
legal and/or regulatory forces on the projections and the impact of
technological risk associated with IPR&amp;D assets, as well as the
selection of a long-term growth rate; the discount rate, which
seeks to reflect the various risks inherent in the projected cash
flows; and the tax rate, which seeks to incorporate the geographic
diversity of the projected cash flows.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company performs impairment testing for all other long-lived assets
whenever impairment indicators are present. When necessary, the
Company calculates the undiscounted value of the projected cash
flows associated with the asset, or asset group, and compares this
estimated amount to the carrying amount. If the carrying amount is
found to be greater, we record an impairment loss for the excess of
book value over fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Income Taxes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company accounts for income taxes using the asset and liability
approach, whereby deferred income tax assets and liabilities are
recognized for the estimated future tax effects, based on current
enacted tax laws, of temporary differences between financial and
tax reporting for current and prior periods. Deferred tax assets
are reduced, if necessary, by a valuation allowance if the
corresponding future tax benefits may not be realized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Net Income (Loss) per Share</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
net income (loss) per share is computed by dividing the net loss
for the period by the weighted average number of common shares
outstanding during the period. Diluted net income (loss) per share
is computed by dividing the net loss for the period by the weighted
average number of common shares outstanding during the period, plus
the potential dilutive effect of common shares issuable upon
exercise or conversion of outstanding stock options and warrants
during the period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-8</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
computation of basic and diluted net loss per share for the years
ended December 31, 2018 and 2017 excludes the common stock
equivalents of the following potentially dilutive securities
because their inclusion would be anti-dilutive:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
December 31,</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercise
of common stock warrants</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of preferred stock into common stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,163,659</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,163,659</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Conversion
of convertible debentures into common stock</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,704,543</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercise
of common stock options</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,682,368</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,164,905</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Patents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Acquired
patents are capitalized at their acquisition cost or fair value.
The legal costs, patent registration fees and models and drawings
required for filing patent applications are capitalized if they
relate to commercially viable technologies. Commercially viable
technologies are those technologies that are projected to generate
future positive cash flows in the near term. Legal costs associated
with patent applications that are not determined to be commercially
viable are expensed as incurred. All research and development costs
incurred in developing the patentable idea are expensed as
incurred. Legal fees from the costs incurred in successful defense
to the extent of an evident increase in the value of the patents
are capitalized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Capitalized
costs for pending patents are amortized on a straight-line basis
over the remaining twenty-year legal life of each patent after the
costs have been incurred. Once each patent is issued, capitalized
costs are amortized on a straight-line basis over the shorter of
the patent's remaining statutory life, estimated economic life or
ten years.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Fixed Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fixed
assets are stated at cost. Depreciation is computed on a
straight-line basis over the estimated useful lives of the assets,
which are 3 to 10 years for machinery and equipment and the shorter
of the lease term or estimated economic life for leasehold
improvements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Fair Value</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
carrying amounts reported in the balance sheets for receivables and
current liabilities each qualify as financial instruments and are a
reasonable estimate of fair value because of the short period of
time between the origination of such instruments and their expected
realization and their current market rate of interest. The three
levels are defined as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
1 inputs to the valuation methodology are quoted prices
(unadjusted) for identical assets or liabilities in active markets.
The Company&#x2019;s Level 1 assets include cash equivalents,
primarily institutional money market funds, whose carrying value
represents fair value because of their short-term maturities of the
investments held by these funds.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 7px">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
2 inputs to the valuation methodology include quoted prices for
similar assets and liabilities in active markets, and inputs that
are observable for the asset or liability, either directly or
indirectly, for substantially the full term of the financial
instrument. The Company&#x2019;s Level 2 liabilities consist of
liabilities arising from the issuance of convertible securities and
in accordance with ASC 815-40: a warrant liability for detachable
warrants, as well as an accrued derivative liability for the
beneficial conversion feature. These liabilities are remeasured
each reporting period. Fair value is determined using the
Black-Scholes valuation model based on observable market inputs,
such as share price data and a discount rate consistent with that
of a government-issued security of a similar maturity. There were
no such liabilities at December 31, 2018.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 8px">
<div style="display: table-row">
<div style="display: table-cell; width: 36px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
3 inputs to the valuation methodology are unobservable and
significant to the fair value measurement.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-9</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Research and Development</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development costs are expensed as incurred and reported as
research and development expense. Research and development costs
totaled $9.1 million and $1.1 million for the years ended December
31, 2018 and 2017, respectively. Research and development costs for
the year ended December 31, 2018 included non-cash compensation of
$6.8 million.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Recently Issued Accounting Standards</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
February 2016, the Financial Accounting Standards Board
(&#x201C;FASB&#x201D;) issued Accounting Standard Update
(&#x201C;ASU&#x201D;) No. 2016-02, &#x201C;Leases.&#x201D; This ASU
requires all lessees to be recognized on the balance sheet as right
to use assets and lease liabilities for the rights and obligations
created by lease arrangements with terms greater than 12 months.
The amendments in this ASU are effective for fiscal years beginning
after December 15, 2018 and for interim periods therein. The
Company is in the process of assessing the impact the adoption this
ASU will have on its consolidated financial position, results of
operations and cash flows. At a minimum, total assets and total
liabilities will increase in the period the ASU is adopted. Early
adoption of this ASU is permitted. At December 31, 2018, the
Company&#x2019;s undiscounted future minimum payments outstanding
for lease obligations (including those currently included as
capital lease obligations) were approximately
$200,878.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 26px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
May 2014, the FASB issued ASU No. 2014-09, &#x201C;Revenue from
Contracts with Customers: Topic 606.&#x201D; This ASU replaces
nearly all existing U.S. GAAP guidance on revenue recognition. The
standard prescribes a five-step model for recognizing revenue, the
application of which will require significant judgment. The
amendments in this ASU are effective for fiscal years beginning
after December 15, 2017, and for interim periods therein. The
provisions of this ASU may be applied retroactively or on a
modified retrospective (cumulative effect) basis. The Company
adopted the standard using the modified retrospective approach
beginning January 1, 2018. Adoption of this ASU did not have a
significant impact on the Company&#x2019;s consolidated financial
position, results of operations and cash flows.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table; margin-left: 7px">
<div style="display: table-row">
<div style="display: table-cell; width: 23px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
3.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Intangibles</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 26px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017, the Company entered into an Agreement and Plan
of Merger whereby it acquired 100% of the issued and outstanding
capital stock of Georgetown Translational Pharmaceuticals, Inc.
(GTP). In exchange for the ownership of GTP, the Company issued a
total of 16,927,878 shares of its common stock, having a share
price of $15.00 on the date of the transaction, to the three prior
owners of GTP which represented 33% of the issued and outstanding
capital stock of the Company on a fully diluted basis. $253.8
million of the value of shares issued was allocated to intangible
assets consisting of a portfolio of three CNS development
candidates, which are classified as IPR&amp;D.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 26px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">For
the year ended December 31, 2018, the Company recorded an
intangible asset impairment charge of $228.5 million related to the
portfolio of CNS IPR&amp;D assets within Operating Expenses, which
represents the excess carrying value compared to fair value. The
impairment charge was the result of both internal and external
factors. In the 3rd quarter of 2018, the Company experienced
changes in key senior management, led by the appointment of a new
CEO with extensive experience in oncology drug development. These
changes resulted in the prioritization of immuno-oncology
development candidates relative to CNS development candidates. In
conjunction with these strategic changes, limited internal
resources have delayed the development of the CNS IPR&amp;D assets.
The limited resources, changes in senior leadership, and favorable
market conditions for immuno-oncology development candidates have
resulted in the Company choosing to focus on development of its
immuno-oncology portfolio. In light of this shift in market
strategy, the Company performed a commercial assessment and a
valuation of the CNS IPR&amp;D assets, both to assess fair value
and support potential future licensing efforts. The valuation
indicated an excess carrying value over the fair value of these
assets, resulting in the impairment charge noted
above.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 26px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
fair value of the CNS IPR&amp;D assets was determined using the
discounted cash flow method which utilized significant estimates
and assumptions surrounding the amount and timing of the projected
net cash flows, which includes the probability of
commercialization, the assumption that the assets would be
out-licensed to third-parties for continued development for upfront
licensing fees and downstream royalty payments based on net sales,
and expected impact of competitive, legal and/or regulatory forces
on the projections, as well as the selection of a long-term growth
rate; the discount rate, which seeks to reflect the various risks
inherent in the projected cash flows; and the tax rate, which seeks
to incorporate the geographic diversity of the projected cash
flows.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-10</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
4.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Debt</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Convertible Notes</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
January 22, 2018, the Company entered into a Securities Purchase
Agreement (&#x201C;SPA&#x201D;) with fourteen accredited investors
(individually, a &#x201C;Buyer&#x201D; and collectively, the
&#x201C;Buyers&#x201D;) pursuant to which the Company agreed to issue
to the Buyers senior convertible notes in an aggregate principal
amount of $7,760,510 (the &#x201C;Notes&#x201D;), which Notes shall
be convertible into the Company&#x2019;s common stock, par value
$0.001 per share (the &#x201C;Common Stock&#x201D;) at a price of
$4.58 per share, and five-year warrants to purchase the
Company&#x2019;s Common Stock representing the right to acquire an
aggregate of approximately 1,694,440 shares of Common Stock (the
&#x201C;Warrants&#x201D;).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Pursuant
to the terms of SPA the Notes were subject to an original issue
discount of 10% resulting in proceeds to the Company of $7,055,000
from the transaction.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Upon
the purchase of the Notes, the Buyers received Warrants to purchase
1,694,440 shares of Common Stock. Such Warrants are exercisable for
(5) years from the date the shares underlying the Warrants are
freely saleable. The initial Exercise Price is $4.58. According to
the terms of the warrant agreement, the Warrants are subject to
certain adjustments depending upon the price and structure of a
subsequent financing, including a qualified financing with gross
proceeds of at least $20 million, as defined in the
agreements.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
issuance of the Notes and Warrants were made in reliance on the
exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the &#x201C;Securities Act&#x201D;) for the offer
and sale of securities not involving a public offering, and
Regulation D promulgated under the Securities Act.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Contemporaneously
with the execution and delivery of the SPA, the Company and the
Buyers executed and delivered a Registration Rights Agreement (the
&#x201C;Registration Rights Agreement&#x201D;) pursuant to which the
Company has agreed to provide certain registration rights with
respect to the Registrable Securities under the 1933 Act and the
rules and regulations promulgated thereunder, and applicable state
securities laws.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Senior Convertible Debentures</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
August 2, 2018, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a
&#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company issued to
the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $5,140,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per share. The
Company used a portion of these proceeds to repay $4.4 million of
the notes issued on January 22, 2018. Additionally, the remaining
$3.3 million of the notes issued on January 22, 2018 were converted
into the Debentures at the same terms discussed above.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 7, 2018, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a
&#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $2,050,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per
share.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 24, 2018, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a
&#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $800,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per
share.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
issuance of the Senior Convertible Debentures was made in reliance
on the exemption provided by Section 4(a)(2) of the Securities Act
of 1933, as amended (the &#x201C;Securities Act&#x201D;), for the
offer and sale of securities not involving a public offering and
Regulation D promulgated under the Securities Act.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Financing Agreement</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
November 8, 2010, the Company entered into a financing arrangement
with Gemini Pharmaceuticals, Inc., a product development and
manufacturing partner of the Company, pursuant to which Gemini
Pharmaceuticals made a $250,000 strategic equity investment in the
Company and agreed to make a $750,000 purchase order line of credit
facility available to the Company. The outstanding principal of all
Advances under the Line of Credit will bear interest at the rate of
interest of prime plus 2 percent per annum. There is $31,000 due on
this credit line at December 31, 2018.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-11</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
5.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Accrued Expenses</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accrued
Expenses are comprised of the following:</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;December 31,</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
&amp; Development</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">585,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accrued
Interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">432,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Professional
Fees</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">162,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">62,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Consulting
and Advisory Services</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">161,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Board
of Directors Service Costs</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">94,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Payroll
and Benefits</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">21,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">39,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Accrued Expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">1,455,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;font-weight:bold;width:75%;font-size:13px;">101,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
6.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Related Party Transactions</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
December 21, 2018, Dr. Raymond Urbanski, Chief Executive Officer
and Chairman of the Board, provided a short-term loan of $100,000
to meet immediate capital needs. The loan matured on January 20,
2019 and carries an interest rate of 5%. The loan was repaid in
January, 2019.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
7.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Stockholders' Equity</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Split</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
July 2017, the Company approved a one for three hundred reverse
stock split.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Shares</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
July 2017, the Company amended its articles of incorporation to
change the number of authorized common shares to 750,000,000 shares
of $.001 par value stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017, the Company entered into an Agreement and Plan
of Merger whereby it acquired 100% of the issued and outstanding
capital stock of Georgetown Translational Pharmaceuticals, Inc.
(GTP). GTP is a biotechnology company focused on acquiring or
discovering and patenting late-stage, de-risked, and
close-to-market improved treatments for CNS disease (Neurology and
Pain) and shepherding the products through the FDA approval process
to the NDA. In exchange for the ownership of GTP, the Company
issued a total of 16,927,878 shares of its common stock to the
three prior owners of GTP which represents 33% of the issued and
outstanding capital stock of the Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the six months ended June 30, 2017 the Registrant has issued a
total of 390,279 shares of common stock to a total of eleven
entities or individuals in exchange for the cancellation of debt in
the total amount of $2,025,000 and interest in the total amount of
$486,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-12</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 13px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
August 2017, the Company issued a total of 17,287,625 shares of
common stock in exchange for the cancellation of debt in the total
amount of $17,141,000 and interest in the total amount of
$4,693,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
August 2017, the Company issued 496,855 shares of common stock upon
the exercise of warrants on a cashless basis.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
August 2017, the Company converted 25,000 Series H and 1,666,667
Series I shares of preferred stock into 5,327,734 shares of common
stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
December 2017, the Company converted 350,000 Series J shares of
preferred stock into 350,000 shares of common stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the quarter ended September 30, 2018, the Company issued 110,000
shares of common stock upon conversion of $220,000 of senior
convertible notes.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the quarter ended December 31, 2018, the Company issued 52,500
shares of common stock upon conversion of $105,000 of senior
convertible notes.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the quarter ended December 31, 2018, the Company issued a total of
245,000 shares of Rule 144 restricted common stock in full
settlement of outstanding legal matters, and 125,000 shares of Rule
144 restricted common stock in connection with consulting
services.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Preferred Stock</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
96,230 shares of Series C preferred stock are convertible into 111
shares of the Company's common stock at the option of the holders
at any time. The conversion ratio is based on the average closing
bid price of the common stock for the fifteen consecutive trading
days ending on the date immediately preceding the date notice of
conversion is given, but cannot be less than .20 or more than .2889
common shares for each Series C preferred share. The conversion
ratio may be adjusted under certain circumstances such as stock
splits or stock dividends. The Company has the right to
automatically convert the Series C preferred stock into common
stock if the Company lists its shares of common stock on the Nasdaq
National Market and the average closing bid price of the Company's
common stock on the Nasdaq National Market for 15 consecutive
trading days exceeds $3,000.00. Each share of Series C preferred
stock is entitled to the number of votes equal to .26 divided by
the average closing bid price of the Company's common stock during
the fifteen consecutive trading days immediately prior to the date
such shares of Series C preferred stock were purchased. In the
event of liquidation, the holders of the Series C preferred stock
shall participate on an equal basis with the holders of the common
stock (as if the Series C preferred stock had converted into common
stock) in any distribution of any of the assets or surplus funds of
the Company. The holders of Series C preferred stock are entitled
to noncumulative dividends if and when declared by the Company's
board of directors. No dividends to Series C preferred stockholders
were issued or unpaid through December 31, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
December 4, 2008, the Company entered into and closed an Agreement
(the &#x201C;Bristol Agreement&#x201D;) with Bristol Investment Fund,
Ltd. pursuant to which Bristol agreed to cancel the debt payable by
the Company to Bristol in the amount of approximately $20,000 in
consideration of the Company issuing Bristol 25,000 shares of
Series G Convertible Preferred Stock, which such shares carry a
stated value equal to $1.00 per share (the &#x201C;Series G
Stock&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Series G Stock is convertible, at any time at the option of the
holder, into common shares of the Company based on a conversion
price equal to the lesser of $2.50 or 60% of the average of the
three lowest trading prices occurring at any time during the 20
trading days preceding the conversion. The Series G Stock, as
amended, shall have voting rights on an as converted basis
multiplied by 100.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the event of any liquidation or winding up of the Company, the
holders of Series G Stock will be entitled to receive, in
preference to holders of common stock, an amount equal to the
stated value plus interest of 15% per year.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Series G Stock restricts the ability of the holder to convert the
Series G Stock and receive shares of the Company&#x2019;s common
stock such that the number of shares of the Company common stock
held by Bristol and its affiliates after such conversion does not
exceed 4.9% of the Company&#x2019;s then issued and outstanding
shares of common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 13, 2009 the Company was informed by Theorem Group, LLC
that it had purchased all of the outstanding Series G Preferred
Stock and Theorem gave notice to the Company that it intended to
exercise its ability to vote on all shareholder matters utilizing
the super voting privileges provided by the Series G
Stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Effective
February 10, 2010, the Company issued 25,000 shares of its new
Series H Convertible Preferred Stock (the &#x201C;Series H
Preferred&#x201D;) to Theorem Group, LLC, a California limited
liability company (the &#x201C;Stockholder&#x201D;), in exchange for
the 25,000 shares of Series G Stock then owned by the Stockholder.
The foregoing exchange was effected pursuant to that certain
Exchange Agreement, dated February 10, 2010, between the Company
and the Stockholder (the &#x201C;Exchange
Agreement&#x201D;).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-13</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Certificate of Designation of the Series H Preferred is based on,
and substantially similar to the form and substance of the
Certificate of Designation of the Series G Preferred. Some of the
corrections, changes and differences between the Certificate of
Designation of the Series G Preferred and the Certificate of
Designation of the Series H Preferred include the
following:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">a.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">As previously
disclosed, the holder of the Series H Preferred is entitled to vote
with the common stock, and is entitled to a number of votes equal
to (i) the number of shares of common stock it can convert into
(without any restrictions or limitations on such conversion), (ii)
multiplied by 100.</font></div>
</div>
</div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">b.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The holder of the
Series H Preferred cannot convert such preferred stock into shares
of common stock if the holder and its affiliates after such
conversion would own more than 9.9% of the Company&#x2019;s then
issued and outstanding shares of common stock.</font></div>
</div>
</div>
<div style="margin-left: 60px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">c.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The Series G
Preferred contained a limitation that the holder of the Series G
Preferred could not convert such preferred shares into more than
19.999% of the issued and outstanding shares of common stock
without the approval of the stockholders if the rules of the
principal market on which the common stock is traded would prohibit
such a conversion. Since the rules of the Company&#x2019;s principal
market did not require such a limitation, that provision has been
deleted.</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
August 2017, the Company converted 25,000 Series H stock into
5,119,401 shares of common stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 13px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
November 8, 2010, the Company sold 1,666,667 shares of the
Company&#x2019;s Series I Preferred Stock, $.001 par value, at a
price of $0.15 per share ($250,000).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
holder of the Series I Preferred Stock will be entitled to receive,
out of funds legally available, dividends in cash at the annual
rate of 8.0% of the Preference Amount ($0.15), when, as, and if
declared by the Board. No dividends or other distributions shall be
made with respect to any shares of junior stock until dividends in
the same amount per share on the Series I Preferred Stock shall
have been declared and paid or set apart during that fiscal year.
Dividends on the Series I Preferred Stock shall not be cumulative
and no right shall accrue to the Series I Preferred Stock by reason
of the fact that the Company may fail to declare or pay dividends
on the Series I Preferred Stock in the amount of the Dividend Rate
per share or in any amount in any previous fiscal year of the
Company, whether or not the earnings of the Company in that
previous fiscal year were sufficient to pay such dividends in whole
or in part.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Each
share of Series I Preferred Stock shall entitle the holder thereof
to such number of votes per share as shall equal the number of
shares of Common Stock (rounded to the nearest whole number) into
which such share of Series I Preferred Stock is then
convertible.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Upon
any liquidation of the Company, subject to the rights of any series
of Preferred Stock that may from time to time come into existence,
before any distribution or payment shall be made to the holders of
any Junior Stock, the holders of the shares of Series I Preferred
Stock then outstanding shall be entitled to receive and be paid out
of the assets of the Company legally available for distribution to
its stockholders liquidating distributions in cash or property at
its fair market value as determined by the Board in the amount of
$0.15 per share (as adjusted for any stock dividends, combinations
or splits with respect to such shares).</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Shares
of Series I Preferred Stock may, at the option of the holder
thereof, be converted at any time or from time to time into fully
paid and non-assessable shares of Common Stock. The number of
shares of Common Stock which a holder of shares of Series I
Preferred Stock shall be entitled to receive upon conversion of
such shares shall be the product obtained by multiplying the
Conversion Rate by the number of shares of Series I Preferred Stock
being converted. Initially, the Series I Preferred Stock is
convertible into 6,667 shares of common stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the event that the per-share Market Price of the Common Stock over
a period of 20 consecutive trading days is equal to at least 130%
of the initial conversion price (130% of $0.15), all outstanding
shares of Series I Preferred Stock shall be converted automatically
into the number of shares of Common Stock into which such shares of
Series I Preferred Stock are then convertible without any further
action by the holders of such shares and whether or not the
certificates representing such shares of Series I Preferred Stock
are surrendered to the Company or its transfer agent.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
August 2017, the Company converted 1,666,667 Series I shares of
preferred stock into 208,333 shares of common stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017, the Company authorized 2,000,000 shares of
Series J Preferred Stock. Shares of Series J Preferred Stock will
have the same voting rights as shares of common stock with each
share of Series J Preferred Stock entitled to one vote at a meeting
of the shareholders of the Corporation. Shares of Series J
Preferred Stock will not be entitled to receive any dividends,
unless and until specifically declared by our board of directors.
The holders of the Series J Preferred Stock will participate, on an
as-if-converted-to-common stock basis, in any dividends to the
holders of common stock. Each share of the Series J Preferred Stock
is convertible into one share of our common stock at any time at
the option of the holder.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 12px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017 the Company issued a total of 700,278 shares of
Series J Preferred Stock in exchange for the cancellation of debt
in the total amount of $840,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017 the Company issued 5,046 shares of Series J
Preferred Stock upon the exercise of warrants on a cashless
basis.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017 the Company also issued 600,000 shares of Series
J Preferred Stock to one entity as payment for $720,000 of
consulting services provided to the Company.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
December 2017, the Company converted 350,000 Series J shares of
preferred stock into 350,000 shares of common stock.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-14</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock Warrants</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant transactions for the years ended December 31, 2018 and 2017
are as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of Warrants</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average Exercise Price</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,550</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">135.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">486,351</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(501,901</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercisable
Warrants:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">December
31, 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">December
31, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Options</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company reserved 1,333 shares of its common stock at December 31,
2014 for issuance under the 2014 Stock Incentive Plan (the
&#x201C;2014 Plan&#x201D;). The 2014 Plan, approval by stockholders
in May 2015, permits the Company to grant stock options to acquire
shares of the Company's common stock, award stock bonuses of the
Company's common stock, and grant stock appreciation rights. At
December 31, 2018, 87 shares of common stock were available for
grant and options to purchase 1,246 shares of common stock are
outstanding under the 2014 Plan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table summarizes stock option transactions for the years
ended December 31, 2018 and 2017:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of Options</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average Exercise Price</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2016</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(133</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">1,020.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercisable
Options:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">December
31, 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">December
31, 2017</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,246</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,428.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-15</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
weighted-average fair value of options granted was approximately
$1,469,000 and $1,780,000 for 2018 and 2017,
respectively.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table summarizes information about all outstanding and
exercisable stock options at December 31, 2018:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; display: inline-block; vertical-align: bottom; width: 10%; padding-bottom: 2px; font-size: 11px;">&#xA0;</font><font style="text-align: center; display: inline-block; vertical-align: bottom; width: 80%; padding-bottom: 2px; font-size: 11px;">
<div style="padding-bottom: 2px;">
<div>
<div>
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
</div>
</div>
</div>
</font><font style="text-align: left; display: inline-block; vertical-align: bottom; width: 10%; padding-bottom: 2px; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:30%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font>
<font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;</font> <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;</font> <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;</font> <font style="font-family: Times New Roman;">&#xA0;</font> <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0; <font style="font-weight: bold; font-family: Times New Roman;"><font style="color:#000000;">Outstanding Options</font></font></font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:20%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font>
<font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0;</font> <font style="font-family: Times New Roman;">&#xA0;</font> <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
&#xA0; <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercisable Options</font></font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Range of Exercise</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Prices</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Options</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Remaining</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Contractual Life</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise Price</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Options</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted-Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise Price</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">750.00
to$2,225.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.49</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:10%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><font style="text-align: center; vertical-align:bottom;display:inline-block;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">8.</font>&#xA0;<font style="color: #000000">Income Taxes</font></font></div>
</font><font style="text-align: left; vertical-align:bottom;display:inline-block;">&#xA0;&#xA0;</font><br></font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Deferred Taxes</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deferred
taxes reflect the net tax effects of temporary differences between
the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes,
and operating losses and tax credit carryforwards. The significant
components of net deferred income tax assets for the Company are
(in thousands):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
December 31,</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deferred
tax assets:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Federal
net operating loss carryforward</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,306,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,949,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Intellectual
Property</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">61,787,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accrued
Interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">129,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patent
amortization</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deferred
tax asseets before valuation</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">87,227,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">15,955,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Valuation
allowance</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(87,227,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(15,955,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
deferred income tax assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-16</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10"><br></font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 11px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Generally
accepted accounting principles requires that the tax benefit of net
operating losses, temporary differences and credit carryforwards be
recorded as an asset to the extent that management assesses that
realization is &#x201C;more likely than not.&#x201D; Realization of
the future tax benefits is dependent on the Company's ability to
generate sufficient taxable income within the carryforward period.
Because of the Company's history of operating losses, management
has provided a valuation allowance equal to its net deferred tax
assets. The valuation allowance increased by approximately
$71,270,000 during the year ended December 31, 2018.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Tax Carryforward</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">At
December 31, 2018, the Company had net operating loss carryforwards
of approximately $84,354,000 to reduce United States federal
taxable income in future years. These carryforwards expire from
2019 through 2038.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company is no longer subject to U.S. and state tax examinations for
years ending before the fiscal year ended December 31, 2014.
Management does not believe there will be any material changes in
our unrecognized tax positions over the next twelve
months.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 22px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company's policy is to recognize interest and penalties accrued on
any unrecognized tax benefits as a component of income tax expense.
There was no accrued interest or penalties associated with any
unrecognized tax benefits, nor was any interest expense recognized
during the years ended December 31, 2018 and 2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="display: table; margin-left: 7px">
<div style="display: table-row">
<div style="display: table-cell; width: 47px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
9.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Commitments and Contingencies</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Leases</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
September 1, 2017, the Company entered into a three-year lease
agreement for its office in Washington, D.C. In addition to minimum
rent, certain leases require payment of real estate taxes,
insurance, common area maintenance charges and other executory
costs. The Company recognizes rent expense under such arrangements
on a straight-line basis over the effective term of each lease.
This lease was terminated as of June 30, 2018.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 1, 2018, the Company entered into a three-year lease
agreement for its office in Westlake Village, CA. In addition to
minimum rent, certain leases require payment of real estate taxes,
insurance, common area maintenance charges and other executory
costs. The Company recognizes rent expense under such arrangements
on a straight-line basis over the effective term of each
lease.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table summarizes the Company&#x2019;s future minimum lease
commitments as of December 31, 2018 (in thousands):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Year
ending December 31:</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">71,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">61,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
minimum lease payments</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">201,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 62px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Rent
expense for the years ended December 31, 2018 and 2017 was $69,000
and $9,000, respectively.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Employment Agreements</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
February 14, 2018, the Company entered into the First Amendment to
the Employment Agreement with Dr. Clarence-Smith, amending the
Employment Agreement, dated September 1, 2017, between the Company
and Dr. Clarence-Smith. Under the First Amendment, Dr.
Clarence-Smith&#x2019;s title was revised to reflect her new
position and included an annual salary of $500,000, paid in equal
monthly installments. All other terms of her original Employment
Agreement remain unchanged. In October 2018, Dr. Clarence-Smith
resigned from her position with the Company. In connection with
this resignation, the Company entered into a separation agreement
which superseded the Employment Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-17</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 13px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 18, 2018, the Company entered into a Consultant Agreement
with Anthony Cataldo. The term of the Consultant Agreement shall
remain in effect until September 30, 2019. This Agreement
supersedes the Consultant Agreement dated February 14, 2018 and
will pay Mr. Cataldo $25,000 per month during the term of the
Agreement.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 19, 2018, the Company entered into an Executive Employment
Agreement with Dr. Raymond Urbanski, reflecting his current
position as Chief Executive Officer of the Company. Under the terms
of this agreement, Dr. Urbanski&#x2019;s annual salary is
essentially unchanged from his previous positions. Dr. Urbanski is
also entitled to participate in the Company&#x2019;s bonus plans.
Under the Executive Employment Agreement, the Company has agreed
that upon shareholder approval of a Stock Option Plan, it will
recommend to the Board that the Company grant Dr. Urbanski a
Non-Qualified stock option to purchase 2,971,102 shares of the
Company&#x2019;s common stock having an exercise equal to the fair
market value of the shares on the date of the Agreement. The stock
option grant would vest according to the following schedule: (i)
1,250,000 fully vested shares upon signing of the agreement, (ii)
1,250,000 shares on January 1, 2019, and (iii) 471,102 shares on
January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his
position as Chief Executive Officer, President and Chairman of the
Board.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
10.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Change of Accounting Method</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Adoption of ASU 2017-11</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
connection with the securities purchase agreements and debt
transactions during the year ended December 31, 2017, the Company
issued warrants to purchase common stock with a five-year term.
Upon issuance of the warrants, the Company evaluated the note
agreement to determine if the agreement contained any embedded
components that would qualify the agreement as a derivative. The
Company identified certain put features embedded in the warrants
that potentially could result in a net cash settlement in the event
of a fundamental transaction, requiring the Company to classify the
warrants as a derivative liability. The Company changed its method
of accounting for the debt and warrants through the early adoption
of ASU 2017-11 on January 1, 2018 on a retrospective basis.
Accordingly, the Company recorded the warrant derivative and
conversion option derivative liabilities to additional paid in
capital upon issuance.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
following table provides a summary of the derivative liability
activity as a result of the adoption of ASU 2017-11 (in thousands,
except per share data):</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:36%;">
<div><font style="text-align: left; vertical-align: bottom; width: 3%; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Consolidated Balance Sheet</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 3%; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" style="vertical-align:bottom;width:36%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
December 31, 2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Previously Reported</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Revisions</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Revised Report</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Additional
Paid-in Capital</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">519,702,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,603,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">521,305,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
Deficit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(267,896,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,603,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(269,499,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="null"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:36%;">
<div><font style="text-align: left; vertical-align: bottom; width: 3%; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Consolidated Statement of Operations</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 3%; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" style="vertical-align:bottom;width:36%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 94%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
For the Year Ended December 31, 2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 3%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Previously Reported</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Revisions</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0); font-weight: bold;">
Revised Report</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Change
in Warrant Liability</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">925,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(925,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:64%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Earnings
per Share</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8.54</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.06</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8.60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
During 2018, the down round provisions of certain of the notes was
triggered. The Company calculated the value of the down round
feature on that date and determined there to be no additional cost
to be reported.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-18</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="margin-left: 12px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
11.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Subsequent Events</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Financing</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
February 4, 2019, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;) with the purchasers identified on the signature
pages thereto (individually, a &#x201C;Purchaser,&#x201D; and
collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224
(the &#x201C;Notes&#x201D;), consisting of gross proceeds of
$1,052,224 and settlement of existing debt of $300,000, which Notes
shall be convertible at any time after issuance into shares (the
&#x201C;Conversion Shares&#x201D;) of the Company&#x2019;s common
stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;),
at a conversion price of $0.60 per share (the &#x201C;Conversion
Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Notes accrue interest at the rate of 10% per annum and mature on
August 2, 2019. Interest on the Notes is payable in cash or, at a
Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Notes with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Contemporaneously
with the execution and delivery of the Purchase Agreement, on
February 4, 2019, the Company and certain of its wholly-owned
subsidiaries entered into a Security Agreement (the &#x201C;Security
Agreement&#x201D;) with Alpha Capital Anstalt, as collateral agent
on behalf of the Purchasers, and with the Purchasers, pursuant to
which the Purchasers have been granted a first-priority security
interest in substantially all of the assets of the Company and such
subsidiaries securing (i) an aggregate principal amount of
$1,352,224 of Notes and (ii) an aggregate principal amount of
$9,058,962 of the Company&#x2019;s 10% Senior Convertible Debentures
issued on August 2, 2018, September 7, 2018 and September 24, 2018
held by such Purchasers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Purchase Agreement contains customary representations, warranties
and covenants, including covenants, subject to certain exceptions,
that the Company, until the date on which less than 10% of the
Notes are outstanding, shall not effect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
addition, the Company entered into a registration rights agreement
(the &#x201C;Registration Rights Agreement&#x201D;) with the
Purchasers, pursuant to which the Company has agreed to file,
within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form
S-3 was filed by the Company on February 14, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
the first quarter of 2019, the Company issued 723,940 shares of
common stock upon conversion of $437,271 in principal and interest
on senior convertible notes.</font></div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-19</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><a name="bs630"></a></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
GT Biopharma, Inc. and Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
as of June 30, 2019 and December 31, 2018</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Balance Sheets</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(in Thousands, Except Par Value and Share Data)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
June 30,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2019</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
December 31,</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ASSETS</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0);">(unaudited)</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Assets:</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Cash
and cash equivalents</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">264</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">30</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">286</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">90</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Intangible
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,262</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">25,262</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deposits</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">12</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
lease right-to-use asset</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">147</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fixed
assets, net</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Other Assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,421</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,309</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
ASSETS</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,707</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounts
payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,710</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,762</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accrued
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,665</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,455</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deferred
rent</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
lease liability</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">147</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Note
payable to related party</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">100</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Line
of credit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Convertible
debentures</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">12,170</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">10,673</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Current Liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">16,731</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">16,731</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">14,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stockholders&#x2019;
Equity:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Convertible
preferred stock - $0.001 par value; 15,000,000 shares
authorized:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
C - 96,230 and 96,230 shares issued and outstanding at June 30,
2019 and December 31, 2018, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
J-1 &#x2013; 2,353,548 shares issued and outstanding at June 30,
2019 and December 31, 2018, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Common
stock - $0.001 par value; 750,000,000 shares authorized; and
52,644,882 and 50,650,478 shares issued and outstanding at June 30,
2019 and December 31, 2018, respectively</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">51</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Additional
paid-in capital</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">545,073</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">540,171</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accumulated
deficit</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(535,984</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(528,685</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Noncontrolling
interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(169</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(169</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Stockholders&#x2019; Equity</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">8,976</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,370</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,707</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">25,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">The
accompanying notes are an integral part of these consolidated
financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-20</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="so630">G</a>T BIOPHARMA, INC. AND
SUBSIDIARIES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Statements of Operations</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(Unaudited)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(In thousands, except per share data)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Three Months Ended June 30,</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Six Months Ended June 30,</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2019</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2019</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
<div><!--rule below paragraph--></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Operating expenses:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Research
and development</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">154</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,251</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">988</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Selling,
general and administrative expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,125
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,906
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,347
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,593
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,279
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,157
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,335
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">12,317
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
from operations</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,279</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(5,157</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,335</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(12,317</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Other income (expense):</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on disposal of assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">--</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
expense</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(479</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,924</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(933</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,855</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
other income (expense)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(510</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,924</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(964</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,855</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:-36px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
before provision for income taxes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(2,789</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(9,081</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,299</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(19,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Provision
for income tax</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,789</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(9,081</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(7,299</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(19,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
</tr><tr>
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss per common share &#x2013; basic and diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(.05</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(0.18</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(.14</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(0.38</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)<!--rule below paragraph--></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:52%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Weighted
average common shares outstanding &#x2013; basic and
diluted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">51,918,252
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">50,117,977
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">51,507,849
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">50,117,977
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The accompanying notes are an integral part of these consolidated
financial statements.</font></div>
<br>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-21</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="cf630">G</a>T Biopharma, Inc. and
Subsidiaries</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Consolidated Statements of Cash Flows</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
For the Six Months Ended June 30, 2019 and 2018</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
(in Thousands)</font></div>
<div style="null"><font>&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2019</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0);">(unaudited)</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">
<div><font style="font-family: Times New Roman; color: rgb(0, 0, 0);">(unaudited)</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
loss</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(7,299</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(19,172</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Adjustments
to reconcile net loss to net cash used in operating
activities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Depreciation</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Stock
compensation expense for options and warrants&#xA0;issued to
employees and non-employees</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,705</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,489</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Amortization
of debt discounts</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">331</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,855</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Non-cash
interest expense</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,140</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loss
on disposal od assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">31</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Amortization
of loan costs</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">407</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Changes
in operating assets and liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Other
assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounts
payable and accrued liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">26</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(581</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in operating activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,048</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Acquisition
of fixed assets</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used by investing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">0</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Proceeds
from notes payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,352</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,055</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Loan
costs</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(533</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Repayment
of note payable</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(100</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash provided by financing activities</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,252</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">6,522</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Minority
interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">204</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">520</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS - Beginning of period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">60</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">576</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS - End of period</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">264</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,096</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Supplemental
disclosures:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
paid</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Income
taxes paid</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td colspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Supplemental
disclosures:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of common stock upon conversion of convertible notes</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,035</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Issuance
of common stock upon conversion of accrued interest</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;"><font style="font-size:13px;font-family:Times New Roman;color:#000000;">The
accompanying condensed notes are an integral part of these
consolidated financial statements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-22</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
<a name="n630">1</a>.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
The Company and Summary of Significant Accounting
Policies</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Business</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data,
Inc. was incorporated in the State of California. Diagnostic Data
changed its incorporation to the State of Delaware in 1972. and
changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI
Pharmaceuticals merged with International BioClinical, Inc. and
Bioxytech S.A. and changed its name to OXIS International, Inc. In
July 2017, the Company changed its name to GT Biopharma,
Inc.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">We
are a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immuno-oncology products
based off our proprietary Natural Killer (NK) cell engager
(Tri-specific Killer Engager (TriKE) &amp; Tetra-specific Killer
Engager (TetraKE)) and bi-specific Antibody Drug Conjugate
(bispecific-ADC) technology platforms. Our TriKE and TetraKE
platforms generate proprietary moieties designed to harness and
enhance the cancer killing abilities of a patient&#x2019;s own
natural killer, or NK, cells. Once bound to a NK cell, our moieties
are designed to stimulate the NK cell and precisely direct it to
one or more specifically-targeted proteins (tumor antigens)
expressed on a specific type of cancer, ultimately resulting in the
cancer cell&#x2019;s death. TriKEs and TetraKEs are made up of
recombinant fusion proteins, can be designed to target tumor
antigens on hematologic malignancies, sarcomas or solid tumors and
do not require patient-specific customization. They are designed to
be dosed in an outpatient setting and are expected to have
reasonably low cost of goods. Our bispecific-ADC platform can
generate product candidates that are ligand-directed single-chain
fusion proteins that simultaneously target two tumor antigens. We
believe our bispecific-ADC moieties represents the next generation
of ADCs.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Going Concern</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s current operations have focused on business
planning, raising capital, establishing an intellectual property
portfolio, hiring, and conducting preclinical studies and clinical
trials. The Company does not have any product candidates approved
for sale and has not generated any revenue from product sales. The
Company has sustained operating losses since inception and expects
such losses to continue over the foreseeable future.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
financial statements of the Company have been prepared on a
going&#xAD;concern basis, which contemplates the realization of
assets and the satisfaction of liabilities in the normal course of
business. Accordingly, the financial statements do not include any
adjustments that might be necessary should the Company be unable to
continue in existence.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company has incurred substantial losses and negative cash flows
from operations since its inception and has an accumulated deficit
of $536 million and cash of $264 thousand as of June 30, 2019. The
Company anticipates incurring additional losses until such time, if
ever, that it can generate significant sales of its products
currently in development. Substantial additional financing will be
needed by the Company to fund its operations and to commercially
develop its product candidates. These factors raise substantial
doubt about the Company&#x2019;s ability to continue as a going
concern.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 5px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Management
is currently evaluating different strategies to obtain the required
funding for future operations. These strategies may include but are
not limited to: public offerings of equity and/or debt securities,
payments from potential strategic research and development, and
licensing and/or marketing arrangements with pharmaceutical
companies. If the Company is unable to secure adequate additional
funding, its business, operating results, financial condition and
cash flows may be materially and adversely affected.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Use of Estimates</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The financial statements and notes are representations of the
Company's management, which is responsible for their integrity and
objectivity. These accounting policies conform to accounting
principles generally accepted in the United States of America, and
have been consistently applied in the preparation of the financial
statements. The preparation of financial statements requires
management to make estimates and assumptions that affect the
reported amounts of assets, liabilities revenues and expenses and
disclosures of contingent assets and liabilities at the date of the
financial statements. Actual results could differ from those
estimates.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Basis of Consolidation and Comprehensive Income</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The accompanying consolidated financial statements include the
accounts of GT Biopharma, Inc. and its subsidiaries. All
intercompany balances and transactions have been eliminated. The
Company's financial statements are prepared using the accrual
method of accounting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Basis of Presentation</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The accompanying unaudited interim condensed consolidated financial
statements have been prepared in accordance with accounting
principles generally accepted in the U.S. (&#x201C;U.S. GAAP&#x201D;)
and the rules and regulations of the U.S. Securities and Exchange
Commission (&#x201C;SEC&#x201D;). Certain information and disclosures
required by U.S. GAAP for complete consolidated financial
statements have been condensed or omitted herein. The interim
condensed consolidated financial statements should be read in
conjunction with the audited consolidated financial statements and
notes thereto included in the Company's Form 10-K for the year
ended December 31, 2018. The unaudited interim condensed
consolidated financial information presented herein reflects all
normal adjustments that are, in the opinion of management,
necessary for a fair statement of the financial position, results
of operations and cash flows for the periods presented. The Company
is responsible for the unaudited interim consolidated financial
statements included in this report. The results of operations of
any interim period are not necessarily indicative of the results
for the full year.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-23</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Cash and Cash Equivalents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company considers all highly liquid investments with original
maturities of three months or less to be cash
equivalents.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Concentrations of Credit Risk</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company's cash and cash equivalents, marketable securities and
accounts receivable are monitored for exposure to concentrations of
credit risk. The Company maintains substantially all of its cash
balances in a limited number of financial institutions. The
balances are each insured by the Federal Deposit Insurance
Corporation up to $250,000. The Company had balances totaling
$14,000 in excess of this limit at June 30, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Stock Based Compensation to Employees</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company accounts for its stock-based compensation for employees
in accordance with Accounting Standards Codification
(&#x201C;ASC&#x201D;) 718.&#xA0;&#xA0;The Company recognizes in the
statement of operations the grant-date fair value of stock options
and other equity-based compensation issued to employees and
non-employees over the related vesting period.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company granted no stock options during the six months ended
June 30, 2019 and 2018, respectively</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Long-Lived Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our long-lived assets include property, plant and equipment,
capitalized costs of filing patent applications and other
indefinite lived intangible assets. We evaluate our long-lived
assets for impairment, other than indefinite lived intangible
assets, in accordance with ASC 360, whenever events or changes in
circumstances indicate that the carrying amount of such assets may
not be recoverable. Estimates of future cash flows and timing of
events for evaluating long-lived assets for impairment are based
upon management&#x2019;s judgment. If any of our intangible or
long-lived assets are considered to be impaired, the amount of
impairment to be recognized is the excess of the carrying amount of
the assets over its fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Applicable long-lived assets are amortized or depreciated over the
shorter of their estimated useful lives, the estimated period that
the assets will generate revenue, or the statutory or contractual
term in the case of patents. Estimates of useful lives and periods
of expected revenue generation are reviewed periodically for
appropriateness and are based upon management&#x2019;s
judgment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Impairment of Long-Lived Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company's long-lived assets currently consist of indefinite
lived intangible assets associated with IPR&amp;D
(&#x201C;In-Process Research &amp; Development&#x201D;) projects and
related capitalized patents acquired in the acquisition of
Georgetown Translational Pharmaceuticals, Inc. as described in Note
2 below. &#xA0;Intangible assets associated with IPR&amp;D projects
are not amortized until approval by the Food and Drug
Administration (FDA) is obtained in a major market subject to
certain specified conditions and management judgment. The useful
life of an amortizing asset generally is determined by identifying
the period in which substantially all of the cash flows are
expected to be generated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company evaluates indefinite lived intangible assets for
impairment at least annually and whenever impairment indicators are
present in accordance with ASC 350. When necessary, the Company
records an impairment loss for the amount by which the fair value
is less than the carrying value of these assets. The fair value of
intangible assets other than goodwill is typically determined using
the &#x201C;relief from royalty method&#x201D;, specifically the
discounted cash flow method utilizing Level 3 fair value inputs.
Some of the more significant estimates and assumptions inherent in
this approach include: the amount and timing of the projected net
cash flows, which includes the expected impact of competitive,
legal and/or regulatory forces on the projections and the impact of
technological risk associated with IPR&amp;D assets, as well as the
selection of a long-term growth rate; the discount rate, which
seeks to reflect the various risks inherent in the projected cash
flows; and the tax rate, which seeks to incorporate the geographic
diversity of the projected cash flows.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company performs impairment testing for all other long-lived
assets whenever impairment indicators are present. When necessary,
the Company calculates the undiscounted value of the projected cash
flows associated with the asset, or asset group, and compares this
estimated amount to the carrying amount. If the carrying amount is
found to be greater, we record an impairment loss for the excess of
book value over fair value.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-24</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Income Taxes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Company accounts for income taxes using the asset and liability
approach, whereby deferred income tax assets and liabilities are
recognized for the estimated future tax effects, based on current
enacted tax laws, of temporary differences between financial and
tax reporting for current and prior periods. Deferred tax assets
are reduced, if necessary, by a valuation allowance if the
corresponding future tax benefits may not be realized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Net Income (Loss) per Share</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Basic net income (loss) per share is computed by dividing the net
loss for the period by the weighted average number of common shares
outstanding during the period. Diluted net income (loss) per share
is computed by dividing the net loss for the period by the weighted
average number of common shares outstanding during the period, plus
the potential dilutive effect of common shares issuable upon
exercise or conversion of outstanding stock options and warrants
during the period. The weighted average number of potentially
dilutive common shares excluded from the calculation of net income
(loss) per share totaled in 39,416,352 and 3,390,120 as of June 30,
2019 and 2018, respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Patents</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Acquired patents are capitalized at their acquisition cost or fair
value. The legal costs, patent registration fees and models and
drawings required for filing patent applications are capitalized if
they relate to commercially viable technologies. Commercially
viable technologies are those technologies that are projected to
generate future positive cash flows in the near term. Legal costs
associated with patent applications that are not determined to be
commercially viable are expensed as incurred. All research and
development costs incurred in developing the patentable idea are
expensed as incurred. Legal fees from the costs incurred in
successful defense to the extent of an evident increase in the
value of the patents are capitalized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Capitalized cost for pending patents are amortized on a
straight-line basis over the remaining twenty year legal life of
each patent after the costs have been incurred. Once each patent is
issued, capitalized costs are amortized on a straight-line basis
over the shorter of the patent's remaining statutory life,
estimated economic life or ten years.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Fixed Assets</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Fixed assets is stated at cost. Depreciation is computed on a
straight-line basis over the estimated useful lives of the assets,
which are 3 to 10&#xA0;years for machinery and equipment and the
shorter of the lease term or estimated economic life for leasehold
improvements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Fair Value</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The carrying amounts reported in the balance sheets for receivables
and current liabilities each qualify as financial instruments and
are a reasonable estimate of fair value because of the short period
of time between the origination of such instruments and their
expected realization and their current market rate of
interest.&#xA0; The three levels are defined as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
1 inputs to the valuation methodology are quoted prices
(unadjusted) for identical assets or liabilities in active markets.
The Company&#x2019;s Level 1 assets include cash equivalents,
primarily institutional money market funds, whose carrying value
represents fair value because of their short-term maturities of the
investments held by these funds.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 24px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
2 inputs to the valuation methodology include quoted prices for
similar assets and liabilities in active markets, and inputs that
are observable for the asset or liability, either directly or
indirectly, for substantially the full term of the financial
instrument. The Company&#x2019;s Level 2 valuation amounts consist
of warrants and beneficial conversion features arising from the
issuance of convertible securities and in accordance with ASC
815-40.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="display: table; margin-left: 24px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">&#x25CF;</font>&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Level
3 inputs to the valuation methodology are unobservable and
significant to the fair value measurement.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Research and Development</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Research and development costs are expensed as incurred and
reported as research and development expense. Research and
development costs totaling $1 million and $6.7 million for the six
months ended June 30, 2019 and 2018, respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-25</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Revenue Recognition</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
License Revenue</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future
product royalty payments. Some of these arrangements are multiple
element arrangements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Non-refundable, up-front fees that are not contingent on any future
performance by us, and require no consequential continuing
involvement on our part, are recognized as revenue when the license
term commences and the licensed data, technology and/or compound is
delivered.&#xA0;&#xA0;We defer recognition of non-refundable
upfront fees if we have continuing performance obligations without
which the technology, right, product or service conveyed in
conjunction with the non-refundable fee has no utility to the
licensee that is separate and independent of our performance under
the other elements of the arrangement. In addition, if we have
continuing involvement through research and development services
that are required because our know-how and expertise related to the
technology is proprietary to us, or can only be performed by us,
then such up-front fees are deferred and recognized over the period
of continuing involvement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Payments related to substantive, performance-based milestones in a
research and development arrangement are recognized as revenue upon
the achievement of the milestones as specified in the underlying
agreements when they represent the culmination of the earnings
process. As of June 30, 2019, the Company has not generated any
licensing revenue.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Recent Accounting Pronouncements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In February 2016, the Financial Accounting Standards Board
(&#x201C;FASB&#x201D;) issued new guidance related to accounting for
leases, Accounting Standards codification Topic 842 (ASC 842). We
adopted the new guidance on January 1, 2019 using the modified
retrospective approach and the optional transition method. Under
this adoption method, comparative prior periods were not adjusted
and continue to be reported with our historical accounting policy.
The primary impact of adopting this standard was the recognition of
$173 thousand in operating lease liabilities and $165 thousand in
right of use assets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">2.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Intangibles</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On September 1, 2017, the Company entered into an Agreement and
Plan of Merger whereby it acquired 100% of the issued and
outstanding capital stock of Georgetown Translational
Pharmaceuticals, Inc. (GTP). In exchange for the ownership of GTP,
the Company issued a total of 16,927,878 shares of its common
stock, having a share price of $15.00 on the date of the
transaction, to the three prior owners of GTP which represented 33%
of the issued and outstanding capital stock of the Company on a
fully diluted basis. $253.8 million of the value of shares issued
was allocated to intangible assets consisting of a portfolio of
three CNS development candidates, which are classified as
IPR&amp;D.&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
As of September 30, 2018, the Company recorded an intangible asset
impairment charge of $228.5 million related to the portfolio of CNS
IPR&amp;D assets within Operating Expenses, which represents the
excess carrying value compared to fair value. The impairment charge
was the result of both internal and external factors. In the
3</font><font style="font-size: 70%; vertical-align: top; color: #000000">rd</font>
<font style="color: #000000">quarter of 2018, the Company
experienced changes in key senior management, led by the
appointment of a new CEO with extensive experience in oncology drug
development. These changes resulted in the prioritization of
immuno-oncology development candidates relative to CNS development
candidates. In conjunction with these strategic changes, limited
internal resources have delayed the development of the CNS
IPR&amp;D assets. The limited resources, changes in senior
leadership, and favorable market conditions for immuno-oncology
development candidates have resulted in the Company choosing to
focus on development of its immuno-oncology portfolio. In light of
this shift in market strategy, the Company performed a commercial
assessment and a valuation of the CNS IPR&amp;D assets, both to
assess fair value and support potential future licensing efforts.
The valuation indicated an excess carrying value over the fair
value of these assets, resulting in the impairment charge noted
above.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The fair value of the CNS IPR&amp;D assets was determined using the
discounted cash flow method which utilized significant estimates
and assumptions surrounding the amount and timing of the projected
net cash flows, which includes the probability of
commercialization, the assumption that the assets would be
out-licensed to third-parties for continued development for upfront
licensing fees and downstream royalty payments based on net sales,
and expected impact of competitive, legal and/or regulatory forces
on the projections, as well as the selection of a long-term growth
rate; the discount rate, which seeks to reflect the various risks
inherent in the projected cash flows; and the tax rate, which seeks
to incorporate the geographic diversity of the projected cash
flows.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-26</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
3.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Debt</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Convertible Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On January 22, 2018, the Company entered into a Securities Purchase
Agreement (&#x201C;SPA&#x201D;) with fourteen accredited investors
(individually, a &#x201C;Buyer&#x201D; and collectively, the
&#x201C;Buyers&#x201D;) pursuant to which the Company agreed to issue
to the Buyers senior convertible notes in an aggregate principal
amount of $7,760,510 (the &#x201C;Notes&#x201D;), which Notes shall
be convertible into the Company&#x2019;s common stock, par value
$0.001 per share (the &#x201C;Common Stock&#x201D;) at a price of
$4.58 per share, and five-year warrants to purchase the
Company&#x2019;s Common Stock representing the right to acquire an
aggregate of approximately 1,694,440 shares of Common Stock (the
&#x201C;Warrants&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
Pursuant to the terms of SPA the Notes were subject to an original
issue discount of 10% resulting in proceeds to the Company of
$7,055,000 from the transaction.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Upon the purchase of the Notes, the Buyers received Warrants to
purchase 1,694,440 shares of Common Stock. Such Warrants are
exercisable for (5) years from the date the shares underlying the
Warrants are freely saleable. The initial Exercise Price is
$4.58.</font> <font style="color: #000000; background-color: #FFFFFF">According to the terms
of the warrant agreement, the Warrants are subject to certain
adjustments depending upon the price and structure of a subsequent
financing, including a qualified financing with gross proceeds of
at least $20 million</font><font style="color: #000000">, as
defined in the agreements.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The issuance of the Notes and Warrants were made in reliance on the
exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the &#x201C;Securities Act&#x201D;) for the offer
and sale of securities not involving a public offering, and
Regulation D promulgated under the Securities Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Contemporaneously with the execution and delivery of the SPA, the
Company and the Buyers executed and delivered a Registration Rights
Agreement (the &#x201C;Registration Rights Agreement&#x201D;)
pursuant to which the Company has agreed to provide certain
registration rights with respect to the Registrable Securities
under the 1933 Act and the rules and regulations promulgated
thereunder, and applicable state securities laws.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Senior Convertible Debentures</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On August 2, 2018, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a
&#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company issued to
the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $5,140,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per share. The
Company used a portion of these proceeds to repay $4.4 million of
the notes issued on January 22, 2018. Additionally, the remaining
$3.3 million of the notes issued on January 22, 2018 were converted
into the Debentures at the same terms discussed above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On September 7, 2018, GT Biopharma, Inc. (the
&#x201C;Company&#x201D;) entered into a Securities Purchase Agreement
with the purchasers identified on the signature pages thereto
(individually, a &#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $2,050,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per
share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On September 24, 2018, GT Biopharma, Inc. (the
&#x201C;Company&#x201D;) entered into a Securities Purchase Agreement
with the purchasers identified on the signature pages thereto
(individually, a &#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $800,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per
share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On February 4, 2019, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;) with the purchasers identified on the signature
pages thereto (individually, a &#x201C;Purchaser,&#x201D; and
collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224
(the &#x201C;Notes&#x201D;), consisting of gross proceeds of
$1,052,224 and settlement of existing debt of $300,000, which Notes
shall be convertible at any time after issuance into shares (the
&#x201C;Conversion Shares&#x201D;) of the Company&#x2019;s common
stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;),
at a conversion price of $0.60 per share (the &#x201C;Conversion
Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Notes accrue interest at the rate of 10% per annum and mature
on August 2, 2019. Interest on the Notes is payable in cash or, at
a Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Notes with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Contemporaneously with the execution and delivery of the Purchase
Agreement, on February 4, 2019, the Company and certain of its
wholly-owned subsidiaries entered into a Security Agreement (the
&#x201C;Security Agreement&#x201D;) with Alpha Capital Anstalt, as
collateral agent on behalf of the Purchasers, and with the
Purchasers, pursuant to which the Purchasers have been granted a
first-priority security interest in substantially all of the assets
of the Company and such subsidiaries securing (i) an aggregate
principal amount of $1,352,224 of Notes and (ii) an aggregate
principal amount of $9,058,962 of the Company&#x2019;s 10% Senior
Convertible Debentures issued on August 2, 2018, September 7, 2018
and September 24, 2018 held by such Purchasers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-27</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Purchase Agreement contains customary representations,
warranties and covenants, including covenants, subject to certain
exceptions, that the Company, until the date on which less than 10%
of the Notes are outstanding, shall not effect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the Company entered into a registration rights
agreement (the &#x201C;Registration Rights Agreement&#x201D;) with
the Purchasers, pursuant to which the Company has agreed to file,
within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form
S-3 was filed by the Company on February 14, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On May 22, 2019, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;) with the purchasers identified on the signature
pages thereto (individually, a &#x201C;Purchaser,&#x201D; and
collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
Company issued to the Purchasers, on May 22, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,300,000
(the &#x201C;Notes&#x201D;), which Notes shall be convertible at any
time after issuance into shares (the &#x201C;Conversion
Shares&#x201D;) of the Company&#x2019;s common stock, par value
$0.001 per share (the &#x201C;Common Stock&#x201D;), at a conversion
price of $0.35 per share (the &#x201C;Conversion
Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Notes accrue interest at the rate of 10% per annum and mature
on November 22, 2019. Interest on the Notes is payable in cash or,
at a Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Notes with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Purchase Agreement contains customary representations,
warranties and covenants, including covenants, subject to certain
exceptions, that the Company, until the date on which less than 10%
of the Notes are outstanding, shall not effect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the Company entered into a registration rights
agreement (the &#x201C;Registration Rights Agreement&#x201D;) with
the Purchasers, pursuant to which the Company has agreed to file,
within 30 days after May 22, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form
S-1 was filed by the Company on June 21, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#xA0;</font><font style="font-style: italic; color: #000000">Financing
Agreement</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On November 8, 2010, the Company entered into a financing
arrangement with Gemini Pharmaceuticals, Inc., a product
development and manufacturing partner of the Company, pursuant to
which Gemini Pharmaceuticals made a $250,000 strategic equity
investment in the Company and agreed to make a $750,000 purchase
order line of credit facility available to the Company. The
outstanding principal of all Advances under the Line of Credit will
bear interest at the rate of interest of prime plus 2 percent per
annum. There is $31,000 due on this credit line at June 30,
2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
4.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Stockholders' Equity</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In the first six months of 2019, the Company issued 1,994,405
shares of common stock upon conversion of $1,045,453 in principal
and interest on senior convertible notes.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Preferred Stock</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On September 1, 2017, the Company designated 2,000,000 shares of
Series J Preferred Stock. Shares of Series J Preferred Stock will
have the same voting rights as shares of common stock with each
share of Series J Preferred Stock entitled to one vote at a meeting
of the shareholders of the Corporation. Shares of Series J
Preferred Stock will not be entitled to receive any dividends,
unless and until specifically declared by our board of directors.
The holders of the Series J Preferred Stock will participate, on an
as-if-converted-to-common stock basis, in any dividends to the
holders of common stock. Each share of the Series J Preferred Stock
is convertible into one share of our common stock at any time at
the option of the holder.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-28</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On the
same day, the Board issued 1,513, 548 of those shares in exchange
for the cancellation of debt.&#xA0; In the first quarter of 2019,
it was discovered that a certificate of designation with respect to
the Series J Preferred Stock had never been filed with the Office
of the Secretary of State for the State of Delaware.&#xA0; Legal
research determined that despite the fact the Company had issued
shares of Series J Preferred Stock, those shares had, in fact,
never existed.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">To
remedy the situation, on April 4, 2019, the Company filed a
certificate of designation with the Office of the Secretary State
for the State of Delaware designating a series of preferred stock
as Series J-1 Preferred Stock.&#xA0; On April 19, 2019, the Company
issued 2,353,548 of those shares.&#xA0; The issuance was in lieu of
the preferred stock that should have been issued on September 1,
2017, and in settlement for not receiving preferred stock until 20
months after the debt for which the stock was issued was cancelled.
The Company reflected an expense in general and administrative
costs in the quarter ended June 30, 2019 totaling
$1,140,000.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Shares are convertible into shares of common stock of the
Registrant at the rate of $0.60 per share. &#xA0;The issuance was
exempt from the registration requirements of Section 5 of the
Securities Act of 1933 pursuant to Section 4(2) of the same Act
since the issuance of the Shares did not involve any public
offering. &#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
350,000 of the Series J shares of preferred stock had been
previously converted into 350,000 shares of common stock in
December 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
5.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; background-color: #FFFFFF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Stock Options and Warrants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Stock Options</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table summarizes stock option transactions for the
six months ended June 30, 2019:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Options</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise Price</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
December 31, 2018</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,133</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,133</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">1,320.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding,
June 30, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercisable,
June 30, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant transactions for the six months ended June 30, 2019 are as
follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Number of</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Warrants</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Weighted Average</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Exercise Price</font></div>
</font><font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at December 31, 2018:</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercised</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Outstanding
at June 30, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Exercisable
at June 30, 2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,813,053</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.35</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-29</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
6.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Commitments and Contingencies</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Leases</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
As described in&#xA0;</font><font style="font-style: italic; color: #000000">Note 1. Nature of Operations
and Summary of Significant Accounting Policies</font><font style="color: #000000">, we adopted new lease accounting guidance
effective January 1, 2019.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We determine if a contractual arrangement is a lease at inception.
Our lease arrangements provide the Company the right to utilize
certain specified tangible assets for a period of time in exchange
for consideration. Our leases primarily relate to building office
space. Our leases currently consist solely of operating leases.
Leases with an initial term of 12 months or less are not recorded
on the balance sheet.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We recognize a lease liability and a right of use asset at the
lease commencement date based on the present value of the future
lease payments over the lease term discounted using our incremental
borrowing rate. Implicit interest rates within our lease
arrangements are rarely determinable. Right of use assets also
include, if applicable, prepaid lease payments and initial direct
costs, less incentives received.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
We recognize operating lease expense on a straight-line basis over
the term of the lease within selling general and administrative
expenses.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our leases do not contain any material residual value guarantees or
material restrictive covenants. Some of our leases include optional
renewal periods or termination provisions which we assess at
inception to determine the term of the lease, subject to
reassessment in certain circumstances.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table summarizes the Company&#x2019;s future minimum
lease commitments as of June 30, 2019:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Year
ending December 31:</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">
<div><font style="font-size:13px;font-family:Times New Roman;">&#xA0;</font></div>
</font><font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;2019</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">34,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;2020</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">71,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;2021</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">61,000
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
minimum lease payments</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">166,000
<!--rule below paragraph--></font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Rent expense for the six months ended June 30,
2019&#xA0;and&#xA0;2018&#xA0;was&#xA0;$35,000&#xA0;and&#xA0;$54,000,
respectively.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Employment Agreements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On October 18, 2018, the Company entered into a Consultant
Agreement with Anthony Cataldo. The term of the Consultant
Agreement shall remain in effect until September 30, 2019. This
Agreement supersedes the Consultant Agreement dated February 14,
2018 and will pay Mr. Cataldo $25,000 per month during the term of
the Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On October 19, 2018, the Company entered into an Executive
Employment Agreement with Dr. Urbanski, reflecting his current
position as Chief Executive Officer of the Company. Under the terms
of this agreement, Dr. Urbanski&#x2019;s annual salary is
essentially unchanged from his previous positions. Dr. Urbanski is
also entitled to participate in the Company&#x2019;s bonus plans.
Under the Executive Employment Agreement, the Company has agreed
that upon shareholder approval of a Stock Option Plan, it will
recommend to the Board that the Company grant Dr. Urbanski a
Non-Qualified stock option to purchase 2,971,102 shares of the
Company&#x2019;s common stock having an exercise equal to the fair
market value of the shares on the date of the Agreement. The stock
option grant would vest according to the following schedule: (i)
1,250,000 fully vested shares upon signing of the agreement, (ii)
1,250,000 shares on January 1, 2019, and (iii) 471,102 shares on
January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his
position as Chief Executive Officer, President and Chairman of the
Board.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On April 3, 2019, the Company entered into the Separation Agreement
with Dr. Urbanski in connection with his resignation as the
Company&#x2019;s Chief Executive Officer. Pursuant to the terms of
the Separation Agreement&#xA0;Dr. Urbanski will receive six
months&#x2019; salary of $212,500 paid in two installments and the
Company will reimburse the premiums associated with
Dr.&#xA0;Urbanski&#x2019;s continuation health coverage for six
months following his resignation. The Settlement Agreement also
contains a release by Mr.&#xA0;Ali of any claims against the
Company arising from or relating to his employment and customary
confidentiality, non-disparagement and cooperation
covenants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">F-30</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
8.</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Subsequent Events</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Debts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;On July 31, 2019, GT Biopharma, Inc. (the
&#x201C;Company&#x201D;) entered into a Securities Purchase Agreement
(the &#x201C;Purchase Agreement&#x201D;) with one purchaser, pursuant
to which the Company issued to the Purchaser, on July 31, 2019,
Secured Convertible Note in the principal amount of $25,000 (the
&#x201C;Note&#x201D;), which Note shall be convertible at any time
after issuance into shares (the &#x201C;Conversion Shares&#x201D;) of
the Company&#x2019;s common stock, par value $0.001 per share (the
&#x201C;Common Stock&#x201D;), at a conversion price of $0.20 per
share (the &#x201C;Conversion Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Note accrues interest at the rate of 10% per annum and matures
on January 31, 2020. Interest on the Note is payable in cash or, at
a Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Note contains customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Note with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Purchase Agreement contains customary representations,
warranties and covenants, including covenants, subject to certain
exceptions, that the Company, until the date on which less than 10%
of the Note is outstanding, shall not effect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the Company entered into a registration rights
agreement (the &#x201C;Registration Rights Agreement&#x201D;) with
the Purchaser, pursuant to which the Company has agreed to file,
within 30 days after July 31, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights
Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
On August 14, 2019,</font> <font style="color: #000000">the
Company&#x2019;s CEO Anthony</font> <font style="color: #000000; background-color: #FFFFFF">Cataldo received as
compensation a restricted stock award of 7,000,000 common shares
and the Company&#x2019;s CFO Steven Weldon received as compensation
a restricted stock award of 4,500,000 common shares. Also, two
Company consultants were paid as compensation a restricted stock
award of 1,000,000 common shares each.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px"><font style="font-size: 13px">F-31</font><br></font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PART II</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
INFORMATION NOT REQUIRED IN PROSPECTUS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following table sets forth the expenses expected to be incurred
in connection with the issuance and distribution of common stock
registered hereby, all of which expenses, except for the Securities
and Exchange Commission registration fee, are
estimated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Securities
and Exchange Commission registration fee</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">867.10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Miscellaneous
expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">500.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Legal</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,000.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Accounting
fees and expenses</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,000.00</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:88%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">16,367.10</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 14.&#xA0; &#xA0; &#xA0; PRINCIPAL ACCOUNTANT FEES AND
SERVICES</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Seligson &amp; Giannattasio, LLP was our independent registered
public accounting firm for the fiscal years ending December 31,
2018 and 2017. The following table shows the fees that were paid or
accrued by us for audit and other services provided by Seligson
&amp; Giannattasio, LLP for the 2018 and 2017 fiscal
years.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:76%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Fiscal</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2018</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
<td colspan="1" rowspan="1" style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
Fiscal</font></div>
<div><font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">
2017</font></div>
</font><font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Audit Fees</font><font style="font-size: 70%; vertical-align: top; color: #000000">(1)</font></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">69,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">64,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Audit-Related Fees</font><font style="font-size: 70%; vertical-align: top; color: #000000">(2)</font></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Tax Fees</font><font style="font-size: 70%; vertical-align: top; color: #000000">(3)</font></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Subtotal</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">73,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">68,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">All other Fees</font><font style="font-size: 70%; vertical-align: top; color: #000000">(4)</font></font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:76%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">73,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:12%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">68,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(1)Audit fees represent fees for professional services provided in
connection with the audit of our annual financial statements and
the review of our financial statements included in our Form 10-Q
quarterly reports and services that are normally provided in
connection with statutory or regulatory filings for the 2018 and
2017 fiscal years.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(2) Audit-related fees represent fees for assurance and related
services that are reasonably related to the performance of the
audit or review of our financial statements and not reported above
under &#x201C;Audit Fees.&#x201D;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
(3) Tax fees represent fees for professional services related to
tax compliance, tax advice and tax planning.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
All audit related services, tax services and other services
rendered by Seligson &amp; Giannattasio, LLP were pre-approved by
our Board of Directors or Audit Committee. The Audit Committee has
adopted a pre-approval policy that provides for the pre-approval of
all services performed for us by Seligson &amp; Giannattasio, LLP.
The policy authorizes the Audit Committee to delegate to one or
more of its members pre-approval authority with respect to
permitted services. Pursuant to this policy, the Board delegated
such authority to the Chairman of the Audit Committee. All
pre-approval decisions must be reported to the Audit Committee at
its next meeting. The Audit Committee has concluded that the
provision of the non-audit services listed above is compatible with
maintaining the independence Seligson &amp; Giannattasio,
LLP.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%"><font style="font-family: Times New Roman; font-size: 11px"><font style="font-family: Times New Roman; font-size: 13px">II-1</font></font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px"><br></font></div>
</div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
In January 2015, the Company agreed to issue 39,657 shares of
common stock as a price protection to a note holder that originally
converted notes at a price of $2.50 and continues to hold these
shares. These additional shares would have been issued if the
conversion shares price was $1.75. As of December 31,
2015,&#xA0;33,142&#xA0;shares of common stock have been issued and
$247,000 of interest expense was recorded for this issuance. During
January 2016 the remaining 6,515 share were issued and $20,000 of
interest expense was recorded.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
During the six months ending June 30, 2016, the Company issued
an</font> <font style="color: #000000">aggregate of 12,580,183
shares of common stock to a total of 34 persons or entities in
exchange of the cancellation of warrants on a cashless
basis.&#xA0;&#xA0;The shares issued were exempt from the
registration requirements of Section 5 of the Securities Act of
1933 (the &#x201C;Act&#x201D;) pursuant to Section
4</font><font style="color: #000000; background-color: #FFFFFF">(2)
of the Act since the shares were issued to persons or entities
closely associated with the Company and there was no public
offering of the shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
During the six months ending June 30, 2016, the Company also issued
an</font> <font style="color: #000000">aggregate of 2,022,230
shares of common stock to a total of 17 persons as payment for
consulting services provided to the Company.&#xA0;&#xA0;The average
valuation of these shares was $2.00 per share. These shares were
also exempt from the registration requirements of Section 5 of the
Act pursuant to</font> <font style="color: #000000; background-color: #FFFFFF">Section 4(2) of the Act
since the shares were also issued to persons closely associated
with the Company and there was no public offering of the
shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
During the six months ending June 30, 2016, the Company also issued
an aggregate of 4,612,341 shares of common stock to two executive
officers of the Company in fulfilment of contractual rights held by
the officers pursuant to their employment
agreements.&#xA0;&#xA0;These shares were also exempt from the
registration requirements of Section 5 of the Act pursuant to
Section 4(2) of the Act since the shares were also issued to
persons closely associated with the Company and there was no public
offering of the shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
During the six months ending June 30, 2016, the Company also issued
an</font> <font style="color: #000000">aggregate of 4,275,186
shares of common stock to a total of 17 persons as payment for the
conversion of certain note and the related accrued
interest.&#xA0;&#xA0;The conversion price of these shares was $0.40
per share. These shares were also exempt from the registration
requirements of Section 5 of the Act pursuant to</font>
<font style="color: #000000; background-color: #FFFFFF">Section
4(2) of the Act since the shares were also issued to persons
closely associated with the Company and there was no public
offering of the shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
In August 2016, the Company issued 1</font><font style="color: #000000">,115,000 shares of common stock to H.C. Wainwright
and Co., LLC as payment for investment banking services provided to
the Company.&#xA0;&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; background-color: #FFFFFF; font-family: Times New Roman; font-size: 13px">
In August 2016, the Company entered into a securities purchase
agreement with one accredited investor to sell 10% convertible
debentures up $1,000,000, with and an exercise price of $0.40, with
an initial principal balance of $250,000 and warrants to acquire up
to 2,500,000 shares of the Company&#x2019;s common stock at an
exercise price of $0.45 per share.</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
In October 2016 the Company issued an</font> <font style="color: #000000">aggregate of 453,431 shares of common stock to one
noteholder as payment for the conversion of certain accrued
interest.&#xA0;&#xA0;The conversion price of these shares was $0.40
per share. These shares were also exempt from the registration
requirements of Section 5 of the Act pursuant to</font>
<font style="color: #000000; background-color: #FFFFFF">Section
4(2) of the Act since the shares were also issued to persons
closely associated with the Company and there was no public
offering of the shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; background-color: #FFFFFF">
In October 2016 the Company issued an</font> <font style="color: #000000">aggregate of 594,530 shares of common stock to one
noteholder as payment for the conversion of a certain
note.&#xA0;&#xA0;The conversion price of these shares was $0.0841
per share based on 60% of the average of the lowest three trading
prices occurring at any time during the 20 trading days preceding
conversion These shares were also exempt from the registration
requirements of Section 5 of the Act pursuant to</font>
<font style="color: #000000; background-color: #FFFFFF">Section
4(2) of the Act since the shares were also issued to persons
closely associated with the Company and there was no public
offering of the shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
In November 2016 the Company issued an aggregate of 975,039 shares
of common stock to one noteholder as</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="color: #000000">payment for the conversion of a certain note. The
conversion price of these shares was $0.0513 per
share</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="color: #000000">based on 60% of the average of the lowest three
trading prices occurring at any time during the 20 trading
days</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="color: #000000">preceding conversion These shares were also exempt
from the registration requirements of Section 5 of
the</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="color: #000000">Act pursuant to Section 4(2) of the Act since the
shares were also issued to persons closely associated with
the</font><font style="color: #000000; font-size: 13px">&#xA0;</font><font style="color: #000000">Company and there was no public offering of the
shares.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
In January 2017, the Company entered into a securities purchase
agreement with eight accredited investors to sell 10% convertible
debentures with and an exercise price</font> <font style="color: #000000; background-color: #FFFFFF">of the lesser of (i)
$15.00 or (ii) the average of the three (3) lowest intra-day
trading prices of the Common Stock during the 20 Trading Days
immediately prior to the date on which the Notice of Conversion is
delivered to the Company,</font> <font style="color: #000000">with
an initial principal balance of $633,593 and warrants to acquire up
to 42,240 shares of the Company's common stock at an exercise price
of $15.00 per share.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
In March 2017, the Company entered into a securities purchase
agreement with two accredited investors to sell 10% convertible
debentures with and an exercise price</font> <font style="color: #000000; background-color: #FFFFFF">of the lesser of (i)
$15.00 or (ii) the average of the three (3) lowest intra-day
trading prices of the Common Stock during the 20 Trading Days
immediately prior to the date on which the Notice of Conversion is
delivered to the Company,</font> <font style="color: #000000">with
an initial principal balance of $232,313 and warrants to acquire up
to 15,487 shares of the Company's common stock at an exercise price
of $15.00 per share.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In April 2017, the Company entered into a securities purchase
agreement with two accredited investors to sell 10% convertible
debentures with and an exercise price of the lesser of (i) $15.00
or (ii) the average of the three (3) lowest intra-day trading
prices of the Common Stock during the 20 Trading Days immediately
prior to the date on which the Notice of Conversion is delivered to
the Company, with an initial principal balance of $70,000 and
warrants to acquire up to 46,666 shares of the Company's common
stock at an exercise price of $15.00 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In May 2017, the Company entered into a securities purchase
agreement with two accredited investors to sell 10% convertible
debentures with and an exercise price of the lesser of (i) $15.00
or (ii) the average of the three (3) lowest intra-day trading
prices of the Common Stock during the 20 Trading Days immediately
prior to the date on which the Notice of Conversion is delivered to
the Company, with an initial principal balance of $125,000 and
warrants to acquire up to 8,333 shares of the Company's common
stock at an exercise price of $15.00 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In May 2017, the Company entered into a securities purchase
agreement with two accredited investors to sell 10% convertible
debentures with and an exercise price of the lesser of (i) $15.00
or (ii) the average of the three (3) lowest intra-day trading
prices of the Common Stock during the 20 Trading Days immediately
prior to the date on which the Notice of Conversion is delivered to
the Company, with an initial principal balance of $125,000 and
warrants to acquire up to 8,333 shares of the Company's common
stock at an exercise price of $15.00 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In July 2017, the Company entered into a securities purchase
agreement with one accredited investors to sell 10% convertible
debentures with and an exercise price of the lesser of (i) $15.00
or (ii) the average of the three (3) lowest intra-day trading
prices of the Common Stock during the 20 Trading Days immediately
prior to the date on which the Notice of Conversion is delivered to
the Company, with an initial principal balance of $650,000 and
warrants to acquire up to 43,333 shares of the Company's common
stock at an exercise price of $15.00 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In August 2017, the Company entered into a securities purchase
agreement with three accredited investors to sell 10% convertible
debentures with and an exercise price of the lesser of (i) $15.00
or (ii) the average of the three (3) lowest intra-day trading
prices of the Common Stock during the 20 Trading Days immediately
prior to the date on which the Notice of Conversion is delivered to
the Company, with an initial principal balance of $3,890,000 and
warrants to acquire up to 259,333 shares of the Company's common
stock at an exercise price of $15.00 per share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In January 22, 2018, the Company entered into a Securities Purchase
Agreement (&#x201C;SPA&#x201D;) with the fourteen accredited
investors (individually, a &#x201C;Buyer&#x201D; and collectively,
the &#x201C;Buyers&#x201D;) pursuant to which the Company has agreed
to issue to the Buyers senior convertible notes in an aggregate
principal amount of $7,760,510 (the &#x201C;Notes&#x201D;), which
Notes shall be convertible into the Company&#x2019;s common stock,
par value $0.001 per share (the &#x201C;Common Stock&#x201D;), and
five-year warrants to purchase the Company&#x2019;s Common Stock
representing the right to acquire an aggregate of approximately
1,694,440 shares of Common Stock (the
&#x201C;Warrants&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Pursuant to the terms of SPA the Notes are subject to an original
issue discount of 10% resulting in proceeds to the Company of
$7,055,000 from the transaction. The Notes are due on July 22,
2018. The Notes are convertible, at the option of the Buyers, at
any time prior to payment in full, into shares of common stock of
the Company at a price of $4.58 per share (&#x201C;Conversion
Price&#x201D;). According to the terms of the note agreement, the
Notes are subject to certain adjustments depending upon the price
and structure of a subsequent financing, including a qualified
financing with gross proceeds of at least $20 million, as defined
in the agreements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Upon the purchase of the Notes, the Buyers received Warrants to
purchase 1,694,440 shares of Common Stock. Such Warrants are
exercisable for (5) years from the date the shares underlying the
Warrants are freely saleable. The initial Exercise Price is $4.58.
According to the terms of the warrant agreement, the Warrants are
subject to certain adjustments depending upon the price and
structure of a subsequent financing, including a qualified
financing with gross proceeds of at least $20 million, as defined
in the agreements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The issuance of the Notes and Warrants were made in reliance on the
exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the &#x201C;Securities Act&#x201D;) for the offer
and sale of securities not involving a public offering, and
Regulation D promulgated under the Securities Act.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Contemporaneously with the execution and delivery of the SPA, the
Company and the Buyers executed and delivered a Registration Rights
Agreement (the &#x201C;Registration Rights Agreement&#x201D;)
pursuant to which the Company has agreed to provide certain
registration rights with respect to the Registrable Securities
under the 1933 Act and the rules and regulations promulgated
thereunder, and applicable state securities laws. All descriptions
of the SPA, the Registration Rights Agreement, the Notes and the
Warrants contained herein are qualified in their entirety by
reference to the exhibits filed herewith.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On August 2, 2018, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a
&#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers 10% Senior Convertible Debentures in an aggregate
principal amount of $5,140,000 (the &#x201C;Debentures&#x201D;),
which Debentures shall be convertible into the Company&#x2019;s
common stock, par value $0.001 per share (the &#x201C;Common
Stock&#x201D;), at a price of $2 per share. The Company used a
portion of these proceeds to repay $4.4 million of the notes issued
on January 22, 2018. Additionally, the remaining $3.3 million of
the notes issued on January 22, 2018 were converted into the
Debentures at the same terms discussed above.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On September 7, 2018, GT Biopharma, Inc. (the
&#x201C;Company&#x201D;) entered into a Securities Purchase Agreement
with the purchasers identified on the signature pages thereto
(individually, a &#x201C;Purchaser,&#x201D; and collectively, the
&#x201C;Purchasers&#x201D;) pursuant to which the Company has issued
to the Purchasers one year 10% Senior Convertible Debentures in an
aggregate principal amount of $2,050,000 (the
&#x201C;Debentures&#x201D;), which Debentures shall be convertible
into the Company&#x2019;s common stock, par value $0.001 per share
(the &#x201C;Common Stock&#x201D;), at a price of $2 per
share.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On February 4, 2019, GT Biopharma, Inc. (the &#x201C;Company&#x201D;)
entered into a Securities Purchase Agreement (the &#x201C;Purchase
Agreement&#x201D;) with the purchasers identified on the signature
pages thereto (individually, a &#x201C;Purchaser,&#x201D; and
collectively, the &#x201C;Purchasers&#x201D;), pursuant to which the
Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224
(the &#x201C;Notes&#x201D;), consisting of gross proceeds of
$1,052,224 and settlement of existing debt of $300,000, which Notes
shall be convertible at any time after issuance into shares (the
&#x201C;Conversion Shares&#x201D;) of the Company&#x2019;s common
stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;),
at a conversion price of $0.60 per share (the &#x201C;Conversion
Price&#x201D;).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Notes accrue interest at the rate of 10% per annum and mature
on August 2, 2019. Interest on the Notes is payable in cash or, at
a Purchaser&#x2019;s option, in shares of Common Stock at the
Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary
default provisions, including provisions for potential
acceleration, and covenants, including negative covenants regarding
additional indebtedness and dividends. The Conversion Price is
subject to adjustment due to certain events, including stock
dividends and stock splits, and is subject to reduction in certain
circumstances if the Company issues Common Stock or Common Stock
equivalents at an effective price per share that is lower than the
Conversion Price then in effect. The Company may only prepay the
Notes with the prior written consent of the respective Purchasers
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Contemporaneously with the execution and delivery of the Purchase
Agreement, on February 4, 2019, the Company and certain of its
wholly-owned subsidiaries entered into a Security Agreement (the
&#x201C;Security Agreement&#x201D;) with Alpha Capital Anstalt, as
collateral agent on behalf of the Purchasers, and with the
Purchasers, pursuant to which the Purchasers have been granted a
first-priority security interest in substantially all of the assets
of the Company and such subsidiaries securing (i) an aggregate
principal amount of $1,352,224 of Notes and (ii) an aggregate
principal amount of $9,058,962 of the Company&#x2019;s 10% Senior
Convertible Debentures issued on August 2, 2018, September 7, 2018
and September 24, 2018 held by such Purchasers.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The Purchase Agreement contains customary representations,
warranties and covenants, including covenants, subject to certain
exceptions, that the Company, until the date on which less than 10%
of the Notes are outstanding, shall not affect any Variable Rate
Transaction (as defined in the Purchase Agreement) and that, for as
long as a Purchaser holds any Notes or Conversion Shares, the
Company shall amend the terms and conditions of the Purchase
Agreement and the transactions contemplated thereby with respect to
such Purchaser to give such Purchaser the benefit of any terms or
conditions under which the Company agrees to issue or sell any
Common Stock or Common Stock equivalents that are more favorable to
an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated
thereby.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In addition, the Company entered into a registration rights
agreement (the &#x201C;Registration Rights Agreement&#x201D;) with
the Purchasers, pursuant to which the Company has agreed to file,
within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to
the Company, such form of registration that is then available to
effect a registration for resale of the subject securities)
covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form
S-3 was filed by the Company on February 14, 2019.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On May 22, 2019, GT Biopharma, Inc. (the "Company") entered into a
Securities Purchase Agreement with ten purchasers (individually, a
"Purchaser," and collectively, the "Purchasers") pursuant to which
the Company has issued to the Purchasers Convertible Debentures in
an aggregate principal amount of $1,300,000 (the "Debentures"),
which Debentures are convertible into the Company's common stock
(the "Common Stock") at a price of $0.35 per share.&#xA0; The
Company and each Purchaser also entered into a Registration Rights
Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On August 20, GT Biopharma, Inc. (the "Company") entered into a
Securities Purchase Agreement with XX purchasers (individually, a
"Purchaser," and collectively, the "Purchasers") pursuant to which
the Company has issued to the Purchasers Convertible Debentures in
an aggregate principal amount of $975,000 (the "Debentures"), which
Debentures are convertible into the Company's common stock (the
"Common Stock") at a price of $0.20 per share.&#xA0; The Company
and each Purchaser also entered into a Registration Rights
Agreement.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The abovementioned equity securities were issued in reliance on the
exemption from registration provided by Section&#xA0;4(2)&#xA0;of
the Securities Act of 1933 (the "</font><font style="text-decoration: underline; color: #000000">Securities
Act</font><font style="color: #000000">") and/or Rule 506 of
Regulation D under the Securities Act, as
amended.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-4</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#xA0;</font><font style="font-weight: bold; color: #000000">ITEM
16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">(a)
Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The following exhibits are filed with this registration
statement:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px;">

<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 11%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Exhibit Number</font></div>
</td>
<td style="vertical-align: top; width: 49%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Exhibit Description</font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Form</font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Date</font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Number</font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Filed Herewith</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex2-1.htm">
2.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Agreement and Plan of Merger</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2.1</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt">
3.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Restated Certificate of Incorporation as filed in Delaware
September 10, 1996 and as thereafter amended through March 1,
2002</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-KSB</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
04/01/02</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3.A</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm">
3.2</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certificate of Amendment to Amended and Restated Certificate of
Incorporation of GT Biopharma, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
03/31/11</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3.2</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000010965710000005/exhibit31.htm">
3.3</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certificate of Designation of Preferences, Rights and Limitations
of Series H Convertible Preferred Stock of GT Biopharma, Inc.,
dated February 5, 2010</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
02/16/10</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3.1</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex34.htm">
3.4</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certificate of Designation of Preferences, Rights and Limitations
of Series I Convertible Preferred Stock of GT Biopharma, Inc.,
dated March 18, 2011.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
03/31/11</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3.4</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000119312503036323/dex3.htm">
3.5</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Bylaws, as restated effective September 7, 1994 and as amended
through April 29, 2003</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-QSB</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
08/13/03</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm">
3.6</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Certificate of Amendment to the Certificate of Incorporation of the
Registrant, effective as of July 19, 2017.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
03/15/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="gtbp_ex51.htm">5.1</a>&#xA0; <font style="color: #000000; font-family: Times New Roman; font-size: 13px"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm">
<br></a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-1.htm">
10.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
License Agreement with ID4 Pharma LLC</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
08/11/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-2.htm">
10.2</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
License Agreement with MultiCell Immunotherapeutics,
Inc.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
08/11/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-3.htm">
10.3</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
License Agreement with the University of Minnesota</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
08/11/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.3</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-4.htm">
10.4</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
License Agreement with Daniel A. Vallera, Ph.D.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
08/11/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.4</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-6.htm">
10.5</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Warrant Conversion Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.6</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-7.htm">
10.6</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Preferred Conversion Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.7</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-8.htm">
10.7</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Note Conversion Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.8</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-9.htm">
10.8</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Warrant Conversion Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.9</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495417010615/gtbp_ex10-10.htm">
10.9</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Amended Preferred Conversion Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/14/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.10</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000093979817000002/securitiespurchaseagree.htm">
10.10</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/13/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000093979817000002/debenture.htm">
10.11</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10% Senior Convertible Debenture</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/13/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000093979817000002/warrant.htm">
10.12</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Common Stock Purchase Warrant</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/13/17</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.3</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex101.htm">
10.13</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Securities Purchase Agreement by and among the Company and the
Buyers, dated January 22, 2018.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/23/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex102.htm">
10.14</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Registration Rights Agreement by and among the Company and
the Buyers, dated January 22, 2018</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/23/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex103.htm">
10.15</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Note</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/23/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.3</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418000646/gtbp_ex104.htm">
10.16</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Form of Warrant</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
01/23/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10.4</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418001758/gtbp_ex102.htm">
10.17</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
First Amendment to the Employment Agreement, dated as of February
14, 2018, between the Company and Dr. Clarence-Smith.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
02/21/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418001758/gtbp_ex103.htm">
10.18</a></font></div>
</td>
<td style="vertical-align: top; width: 49%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Consultant Agreement, dated as of February 14, 2018, between the
Company and Mr. Cataldo.</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
02/21/18</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit;padding-top: 0px; padding-bottom: 0px; margin-left: 0px; margin-right: auto; width: 100%;">
<tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418008406/gtbpex4_1.htm">
10.19</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Form
of 10% Senior Convertible Debenture</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">08/03/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418008406/gtbp_ex101.htm">
10.20</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">08/03/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418009975/gtbp_ex41.htm">
10.21</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Form
of 10% Senior Convertible Debenture</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">09/07/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418009975/gtbp_ex101.htm">
10.22</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">09/07/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418010637/gtbp_ex41.htm">
10.23</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Form
of 10% Senior Convertible Debenture</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">09/24/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418010637/gtbp_ex101.htm">
10.24</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">09/24/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418011065/gtbp_ex101.htm">
10.25</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Separation
Agreement between the Company and Dr. Clarence-Smith</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10/12/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418011231/gtbp_8k.htm">
10.26</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Resignation
of Steven Weldon</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10/16/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418009126/gtbp_ex1010.htm">
10.27</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Stock
Pledge Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">08/14/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.10</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495418012574/gtbp_ex1017.htm">
10.28</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Executive
Employment Agreement with Dr. Urbanski</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10-Q</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">11/14/18</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.17</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex41.htm">
10.29</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Secured
Convertible Note</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">02/06/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex101.htm">
10.30</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">02/06/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex102.htm">
10.31</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">02/06/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419001122/gtbp_ex103.htm">
10.32</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Registration
Rights Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">02/06/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.3</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exfourone.htm">
10.33</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Form
of Note</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">05/24/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exhibittenone.htm">
10.34</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Security
Purchase Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">05/24/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000093979819000027/exhibittentwo.htm">
10.35</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Form
of Registration Rights Agreement</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">8-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">05/24/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: rgb(0, 0, 0);"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex41.htm">
<font style="font-size: 13px; font-family: Times New Roman;">10.36</font></a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-family: Times New Roman; font-size: 13px;">Form of
Note</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-size: 13px; font-family: Times New Roman;">8-K</font><br></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;">08/23/19</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;">4.1<br></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: rgb(0, 0, 0);"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex101.htm">
<font style="font-size: 13px; font-family: Times New Roman;">10.37</font></a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-family: Times New Roman; font-size: 13px;">Security Purchase
Agreement</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-size: 13px; font-family: Times New Roman;">8-K</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-size: 13px; font-family: Times New Roman;">08/23/19</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;">10.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: rgb(0, 0, 0);"><a href="http://www.sec.gov/Archives/edgar/data/109657/000165495419009972/gtbp_ex103.htm">
<font style="font-size: 13px; font-family: Times New Roman;">10.38</font></a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-family: Times New Roman; font-size: 13px;">Form of
Registration Rights Agreement</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-size: 13px; font-family: Times New Roman;">8-K</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;"><font style="font-size: 13px; font-family: Times New Roman;">08/23/19</font></font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman;">10.2</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000151316015000022/ex141.htm">
14.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Code
of Ethics</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">03/31/15</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">14.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="http://www.sec.gov/Archives/edgar/data/109657/000151316015000022/ex211.htm">
21.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Subsidiaries
of GT Biopharma, Inc.</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">10-K</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">03/31/15</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">21.1</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><a href="gtbp_ex231.htm"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">23.1</font></a></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Opinion
of Gary R. Henrie</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">X</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">23.2</font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Consent
of Seligson &amp; Giannattasio, LLP, Independent Registered Public
Accounting Firm, relating to the Registrant</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">X</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">23.3</font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Consent
of Gary R. Henrie (included in Exhibit 5.1)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">X</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman"><a href="#poa">
24.1</a></font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Power
of Attorney (included on signature page hereto)</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">X</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 11%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">101</font></div>
</td>
<td style="vertical-align: top; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">Interactive
Data File</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="color: #000000; font-size: 13px; font-family: Times New Roman">X</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<br>
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;(b) Financial Statement Schedules</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
See the Index to Financial Statements included on page 54 for a
list of the financial statements included in this
prospectus.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-5</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 24. INDEMNIFICATION OF DIRECTORS AND OFFICERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our officers and directors are indemnified as provided by Delaware
Corporation Law and our bylaws. Under the Delaware Corporation Law,
director immunity from liability to a company or its shareholders
for monetary liabilities applies automatically unless it is
specifically limited by a company's articles of incorporation that
is not the case with our articles of incorporation. Excepted from
that immunity are:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">a willful failure
to deal fairly with the company or its shareholders in connection
with a matter in which the director has a material conflict of
interest;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">a violation of
criminal law (unless the director had reasonable cause to believe
that his or her conduct was lawful or no reasonable cause to
believe that his or her conduct was unlawful);</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(3)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">a transaction from
which the director derived an improper personal profit;
and</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(4)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">willful
misconduct.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our bylaws provide that we will indemnify our directors and
officers to the fullest extent not prohibited by Delaware law;
provided, however, that we may modify the extent of such
indemnification by individual contracts with our directors and
officers; and, provided, further, that we shall not be required to
indemnify any director or officer in connection with any proceeding
(or part thereof) initiated by such person unless:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">such
indemnification is expressly required to be made by
law;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">the proceeding was
authorized by our Board of Directors;</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(3)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">such
indemnification is provided by us, in our sole discretion, pursuant
to the powers vested us under Delaware law; or</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(4)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">such
indemnification is required to be made pursuant to the
bylaws.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our bylaws provide that we will advance all expenses incurred to
any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or
investigative, by reason of the fact that he is or was our director
or officer, or is or was serving at our request as a director or
executive officer of another company, partnership, joint venture,
trust or other enterprise, prior to the final disposition of the
proceeding, promptly following request. This advanced of expenses
is to be made upon receipt of an undertaking by or on behalf of
such person to repay said amounts should it be ultimately
determined that the person was not entitled to be indemnified under
our bylaws or otherwise.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Our bylaws also provide that no advance shall be made by us to any
officer in any action, suit or proceeding, whether civil, criminal,
administrative or investigative, if a determination is reasonably
and promptly made: (a) by the board of directors by a majority vote
of a quorum consisting of directors who were not parties to the
proceeding; or (b) if such quorum is not obtainable, or, even if
obtainable, a quorum of disinterested directors so directs, by
independent legal counsel in a written opinion, that the facts
known to the decision-making party at the time such determination
is made demonstrate clearly and convincingly that such person acted
in bad faith or in a manner that such person did not believe to be
in or not opposed to our best interests.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-6</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
ITEM 28. UNDERTAKINGS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The undersigned registrant hereby undertakes:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
1.</font><font style="color: #000000; font-size: 1px">&#xA0;</font>
<font style="color: #000000">To file, during any period in which
offers or sales are being made, a post-effective amendment to this
registration statement:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">To include any
prospectus required by Section 10(a)(3) of the Securities Act of
1933;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(2)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">To reflect in the
prospectus any facts or events arising after the effective date of
this registration statement, or most recent post-effective
amendment, which, individually or in the aggregate, represent a
fundamental change in the information set forth in this
registration statement. Notwithstanding the foregoing, any increase
or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in
the aggregate, the changes in volume and price represent no more
than a 20% change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective
registration statement; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">(3)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">To include any
material information with respect to the plan of distribution not
previously disclosed in this registration statement or any material
change to such information in the registration
statement.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2. That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities
offered herein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering
thereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3. To remove from registration by means of a post-effective
amendment any of the securities being registered hereby, which
remain unsold at the termination of the offering.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to our directors, officers
and controlling persons pursuant to the provisions above, or
otherwise, we have been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act of 1933, and is,
therefore, unenforceable.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In the event that a claim for indemnification against such
liabilities, other than the payment by us of expenses incurred or
paid by one of our directors, officers, or controlling persons in
the successful defense of any action, suit or proceeding, is
asserted by one of our directors, officers, or controlling persons
in connection with the securities being registered, we will, unless
in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification is against
public policy as expressed in the Securities Act of 1933, and we
will be governed by the final adjudication of such
issue.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-7</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Pursuant to the requirements of the Securities Act of 1933, the
registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the
City of Las Vegas, State of California, on</font> <font style="color: #000000">September 13, 2019.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-size: 13px; font-family: Times New Roman"><font style="font-weight: bold"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">GT
BIOPHARMA, INC.</font></font></font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><br></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ <font style="color: #000000; font-style: italic; font-family: Times New Roman; font-size: 13px">
Anthony J. Cataldo</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Anthony
J. Cataldo</font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Chief
Executive Officer</font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">II-8</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;&#xA0;<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
</div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
<a name="poa">P</a>OWER OF ATTORNEY</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Each person whose signature appears below hereby constitutes and
appoints Anthony J. Cataldo his true and lawful attorney-in-fact
and agent with full power of substitution and re-substitution, for
him or her and in his or her name, place, and stead, in any and all
capacities, to sign any and all (1) amendments (including
post-effective amendments) and additions to this Registration
Statement and (2) Registration Statements, and any and all
amendments thereto (including post-effective amendments), relating
to the offering contemplated pursuant to Rule 462(b) under the
Securities Act of 1933, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, and hereby grants to such
attorney-in-fact and agent full power and authority to do and
perform each and every act and thing requisite and necessary to be
done, as fully to all intents and purposes as he or she might or
could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents or his or her substitute or
substitutes may lawfully do or cause to be done by virtue
hereof.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed below by the following
persons in the capacities and on the dates indicated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline; color: #000000">
/</font><font style="font-style: italic; text-decoration: underline; color: #000000">s/
Anthony J. Cataldo</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Anthony J. Cataldo, CEO and Director</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
September 13, 2019</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline; color: #000000">
/s/ Steven Weldon</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Steven Weldon, CFO, Chief Accounting Officer and
Director</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
September 13, 2019</font></div>
&#xA0; <font style="font-family: Times New Roman; font-size: 13px;"><br></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px">II-9<br></font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>gtbp_ex51.htm
<DESCRIPTION>OPINION ON LEGALITY
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 5.1</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 16px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 16px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 16px">
Gary R. Henrie</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Attorney at Law</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Licensed in Nevada and Utah</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 50%">
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">General
Delivery</font></div>
</td>
<td style="width: 50%">
<div style="text-align: right"><font>&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Telephone:
&#xA0;307-200-9415</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Alpine,
Wyoming 83128</font></div>
</td>
<td style="width: 50%">
<div style="text-align: right"><font>&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">E-mail:
&#xA0;grhlaw@hotmail.com<br></font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
September 13, 2019</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GT Biopharma, Inc.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
9350 Wilshire Blvd. Suite 203</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Beverly Hills, CA 90212</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Re: GT Biopharma, Inc., Registration Statement on Form
S-1</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Ladies and Gentlemen:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
I have acted as securities counsel for GT Biopharma, Inc., a
Delaware corporation (the "Company"), for the purpose of issuing
this opinion letter in connection with the registration statement
on Form S-1 (the "Registration Statement") to be filed with the
Securities and Exchange Commission pursuant to the Securities Act
of 1933, as amended. The Registration Statement relates to the
offering of 41,473,822 shares of the Company&#x2019;s common stock
by selling stockholders that underlie convertible notes and Series
J-1 Preferred Stock.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
In rendering the opinion set forth below, I have reviewed: (a) the
Registration Statement; (b) the Company's Certificate of
Incorporation as restated and amended; (c) the Company's Bylaws;
and (d) such statutes, records and other documents as I have deemed
relevant. In my examination, I have assumed the genuineness of all
signatures, the authenticity of all documents submitted to me as
originals, and conformity with the originals of all documents
submitted to me as copies thereof and the truthfulness of
statements set forth in such documents. In addition, I have made
such other examinations of law and fact, as I have deemed relevant
in order to form a basis for the opinions hereinafter
expressed.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Based upon the foregoing, I am of the opinion that the 41,473,822
shares of common stock to be sold by the selling
stockholders</font> <a name="_Hlk525211171">
<!--anchor--></a><font style="color: #000000">that they will
receive upon the conversion of the notes and/or the conversion of
Series J-1 Preferred Stock and upon resolution by the board of
directors directing the issuance thereof will be legally issued,
fully paid and non-assessable and will remain legally issued, fully
paid and non-assessable in the hands of any subsequent purchaser.
This opinion is based on Delaware general corporate law, all
applicable Delaware statutory provisions and reported judicial
decisions interpreting these laws.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Very truly yours,</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<font style="text-decoration: underline">/s/ Gary R.
Henrie</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Gary R. Henrie, Esq.</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 16px">
Gary R. Henrie</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Attorney at Law</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Licensed and the States of Utah and Nevada</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 50%">
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">General
Delivery</font></div>
</td>
<td style="width: 50%">
<div style="text-align: right"><font>&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Telephone:
&#xA0;307-200-9415</font></div>
</td>
</tr><tr>
<td style="width: 50%">
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Alpine,
Wyoming 83128</font></div>
</td>
<td style="width: 50%">
<div style="text-align: right"><font>&#xA0;</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">E-mail:
&#xA0;grhlaw@hotmail.com<br></font></div>
</td>
</tr></table></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
I hereby consent to the use of my opinion in the body of the
Registration Statement and as an Exhibit to the Registration
Statement and to all references to myself under the caption Legal
Matters in the Registration Statement.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Very truly yours,</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<font style="text-decoration: underline">/s/ Gary R.
Henrie</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Gary R. Henrie, Esq.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>gtbp_ex231.htm
<DESCRIPTION>CONSENTS OF EXPERTS AND COUNSEL
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Untitled Document</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px"><font style="font-weight: bold"><font style="font-size: 13px">&#xA0; Exhibit
23.1</font></font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: auto; margin-right: auto; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px"><img src="gtbp_ex231000.jpg"></font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; display: inline-block; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gtbp_bikemediatedkilling.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_bikemediatedkilling.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &- S # 2(  A$! Q$!_\0
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M@%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU[/:;[ZQOY=:N'_Y:W2*LKLC_P"_*]?2R/N6OR]*VQW$E%%%, HHHH ****
M(WZU\O\ _!/G_DD_C'_L?->_]*FKZ@?K7R__ ,$^?^23^,?^Q\U[_P!*FH ^
MI**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:P(M,B;YV^>7_<KG]-A^TM%%LWNWR+6#<:C)JFHR7<V!+(VYO]BMG4?$EO\
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MJK_G97V3;PI;PI$B[(U7:JUY_P#"'X40_"^SNT>[&H7MP_S3^7MVI_"M>DT
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MHHH **** "BBB@ HHHH C?K7R_\ \$^?^23^,?\ L?->_P#2IJ^H'ZU\O_\
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M_O+_ .@K6[_S)FM_[B4 <UI7[[[_ ,_^_7L5K_J(O]VO'M'ZBO8;7_41?[M
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MH'ABUT_7;CS?](5G;RO-?=+Y:LQ6+>W+; -V*]/^XM #J*** "BBB@ HHHH
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M>U2VM_;7EOY]O/'-%_?C;<OZ4 7**C\Y/[XJK]NM_M7V;SX_M&S?Y6\;MO\
M>VT 7J*CWHU24 %%%% !1110 5&#E:DIA'%1(#\KO^"S2^7XJ^$[]C::BO\
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M'?/>_$ZWTRZ'VBUE5VV.V=CJNZOJ==NU"O3UQ7RC\'R#\:],!Z;)O_135];
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MW%LRK_%_?_\ ': $_P"&J=3_ .B%?%K_ ,$]K_\ )5'_  U3J?\ T0KXM?\
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M7V[^S;S=][RG_P#0:\K_ &1_^39?AM_V!K>@#V&BBB@ HHHH **** "BBB@
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M1?\ QV@#ZZHKY%_X;\G_ .B _%__ ,$$7_QVC_AOR?\ Z(#\7_\ P01?_':
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M6='TZ_2$1;X)49DB?;\OR 8JY^R/_P FR_#;_L#6] 'L-%%% !1110 4444
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MP?\ ">DVG[P+IT-Q-*YW/+-*N^65F_B9F9CGWKT;8:Y[X<_\D^\,?]@JU_\
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MFNBAC$,>U1@5/UI=M5&G&.J6I2IPB^:*LQN>O>GT45H:!1110 4444 %%%%
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MK='7^ZWE+Q724 %%%% !1110 4444 %%%% !1110 4444 >%?M)?\C;\$O\
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MO_YY+\_W:V/"OPK_ .%6:YHFOZU\5]"\*>(-$VQ16^C+]L^\W[V*X3^)=O\
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MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*;NGJBX5(U(J4=F344G2EKJ- HHHH **** "BBB@ HJ/>:-YH DHJ/>:-YH
M6GT44 %%%% !1110 4444 1L-R?-Q7YK_LDEOV=/^"A7Q:^$S#[-H/B='U33
M(/X/ES*FW_@#RI_P"OTJ?I7YQ?\ !2_2)_@O\;/@O^T!H\+^;I6H)INI[/XX
ME;>B?\"1[A: /T<I]9NCZM;:[I-EJ=G(LUK>PI<12+_$C+N4_D:TJ "BBB@
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M72Z;IZ1P[4541?E5:BLK7<M=!8VU7EN7T\/%*)];E^1X#(:;A@HV\WJR2PM
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M[]_M]W;_ ,"KE?AO^Q'#\.;[X+7,7BZ>_/PW@OX(TDT\+]O^U'K]_P#=;?\
M@5 'SM'^VU\?=/\ A[_PFNHV_A.32/#/BQ?">KQQ0R^=J<K-\\L?\,:KE:^A
M-)_:%\77WQ:_:'T R6<>F>"-'M;_ $=!!\ZRRV7FMYK_ ,7S5GWW[ \%_P#"
M;Q-X$/C.9(-;\9_\)B]]_9J9B?<O^CA/-Y^Y]^M+XD?L1R^,OB7XF\6:)\2=
M<\&1>*].BT[Q%I^G6L3K?+%%Y2,CM_JCM5>F>E 'DDW[6OQB\1>!_P!FH>'7
MT!/$GQ(6]BOFO[)C;*\3*J,JJ^Y=N=]22_MN?$+X9_!KXM3>+K71-4\<>#/$
MT7AFUOK1&ALKEY3\LKIU"JM>M^&/V(K?PY#\"8T\7W%Q_P *K>[>(G3D7^T?
M/_X'^ZV_\"JQK'[$.B>);'XMVFK:]=S0^/-<BUZ-[6W6*;2IXA\GE/O;<<XY
MPO>@#B_V4_VK/%?CWXT7WPZ\6ZSX>\9HVE+J=GXC\,VLL%NK*WSV[I)U9>NZ
MOM>O#_@?\$O&7PTU?4-1\7?%S7?B(]S$D$-M?6L5K;P*HSNVKN+/_M%J]PH
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M,P6[B9V_X"J/7JOA+7KC5IKZ*?9*(GPDJ?QK0!U=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %1NGF5)10!YE\3OV>_AU\:=/:U\9^#]-UH$ K<20;;B/_
M ')5PZ?\!85XQ:_L/ZS\/I!+\+/C7XU\(1(<IIFH7(U2Q7_9\J6OK2B@#\%_
MCU>_&?5/VX+R#3]2?Q;\3] GMK6VU#P[8&!6\N)&3]T#\N"Q5MQ[&OVP^$5_
MXPU+X<Z)<^/--M-)\7-;K_:%K9S>9&DGLPS^63]:B\%_"/PC\/=:\1:SH6CV
M]KK&O7CWVIZ@Z[KBXD9LX9S\Q4?PKG KN414I-7 1NM>=_'1L_#/6"1GB/'_
M '\2O1J\^^-D<DGPWUE(E9W,88!>I^9:\?-H_P"PU;?RL[\O_P![I?XE^9\A
M6V&&!6U9UA6KXD(_STKH+/K7X#@FKI'],56^4Z.P[5T^G#YJY>P>NHTUZ^]P
MC6A\AB[ZF=\7M#\1^)OAOJ&@>%XE_M#66BT^>X:55^RVLK[;B7YOO,L6_;7*
M6/[,]Q\*/&?@3Q=\/=3\1:Q<:9<?V;J.G:]KK72MI$J;76(ROM3RF6)U1?[M
M>SZ:]='8<-O_ (Z^VPM3E1^=8ZASRNSY,TW]EOQ_9Z9X5AMHX+-+[4=4TKQ7
M;^>I1])GU)KJ*7_:;[Z_[MPU=UXB^%?C_P /V,NJZ#X67Q#?6?Q-?Q/!I::C
M!:F>S:+:G[U_E7[_ -ROIFSV;-GR_P#?-:4+_)7M0E=:GS%2E9G(?"?QEXP\
M96.H2^,? $G@&Z@E58;>35H+_P ]"OWM\7"^E4U\(ZK_ ,-&/XJ,"_V(WA=-
M,%P9%W_:/M32[=G^ZW6N3U?]J_P]I<FHM9^%?%^N^'].EEBOO$ND:8DNGVYB
M_P!:X<RK)*J?-N:)&^XU>LV_B_1;S2--U5=5M!I^HJKV=PTRJMQN^9=NZMKH
MXVK;'RGXN^$7Q2AUOQ?X<TCPU87GA?6?&]GXN77I-25)O*^T6\LMOY7]Y?*?
MY]WW:U-!^!/BJP\">%-.GTV!+NP^)4OB6Y3SU^6R:6Z96_WMLJ?+7K7BO]H3
MPOX1\?Q^$;RWO_[3:^T[3-\42F+S;Q96AYWYVXMWW?+W6O3YME)O0N"NSY1\
M4?"7QSH_BK5O&.AZ-::QJ&F^,I=<L]&N+Q(/[1M9=/BMWV2_\LI=R/MW5R5]
M\%_'OC/Q7_PG>N:'I^CZEJGBO1M0GT.*^2?['9V:LNYY?NRR_O7^[7V->/7/
MW[UPU*O*CVL-1YGJ<YJU<IJ?\5=1?O7+ZB_#5\EBY7;;/O<%&R2.7U*N7OF0
MOD<G\:Z;4JYR][U\1C)))GW&%C=JYSEW:Q+<B=4\N7=]_P#O5]>?!_3;-_ F
ME7)MHTG: ;I5'+>]?)=S]ZOLSX769L_ >BQ-_#:(#^5;<(8>G6Q\YS@G9=5<
M_/>-,OP>&ITZE*FE.3WL=8JE$.>E3XQ4>/E/OBIZ_;8QLK'Y?UN, I]%%4M-
M$ 44450!1110 4444 %%%% !1110 4444 %%%% #*B^S1_-M15+=?EJQ10!X
M?X#_ &8/#?@7XQ>(OB;)J^M>(?%&K-+#%+J]X9TTZWEE\U[>W0_<3.!CLOXU
M[3]G3Y_E7Y_O5/10!5^R1>6$=%=%[;:\T^.GP'T/X]>&M-T?6;J\LK>QU6WU
M='LBJL\D6=BMN'W?FZ5ZK10!7CMT1=JXY^]0MLB,655#?[M6** (/LZ;M^Q=
M_P#>IZ)Y=244 %%%% !1110 4444 <YX\_Y%/4O]U?\ T):\XT7_ %L7^]7H
M_CS_ )%/4O\ =7_T):\XT'[Z?[U &G\0>?$L7^U M='X!^[,O^PM<Y\0O^1D
MB_ZX+70> _\ 72_[E ';T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 ULUSGC/31K'AO4K3!/G021?+U^88KI!4,F#&1VKFQ%)5J4J;
MZIHTIS=.:FNA\ PQM#=O&_R2(WS+6S9O\U:OQ8\/R>%_'E^A7]U,WGHW^RU8
M5F_W*_G&,)83$3I5%9IM'],86LL5A*=6.J:1U5@]=-I\U<99S5T=C<5]CA*J
MT/(Q5/1G<:;-72V$U</8W/O71V=Y7V%"JK(^)Q=!MG:V<U:<;[UV_P!^N4L[
MSY*U;:Y_VZ]VG431\G7H.Y\W?#+X[:%^S_\ #>V^'OBC1M=_X3;2#/:1:3;Z
M/<3OK+[VV2V\JH4990Z_-N^7=\^*\I_:6T.7Q#\1M+U#X@2S^$-"NO"UM%HU
MC#X:77X8KTNYN+>([/W4_P!S:WR[MOWJ^\DF1_X*E^TK]VNQ5$CS'0;9\%7V
MB:Q9_$WP3%>+JE_+:ZCX+66[U&UV7#[;6_5VN-NY=WS_ #?-]ZOON:;_ &ZJ
M/,FS:]5)KRIG55C:EAW<?>35S]_-5B\O*PK^\KR:U56/H<-0=RC?S5RNI35J
MW]Y7-7UQVKY?$U4?9X2BT9-_-7-WS<5J7\U8=XX5B3WZU\3C:BY6?986-FBI
M# ;R^MX$.]I)%B5?]ZONS1[-=/TNVMT'$<2+7R9\#O#'_"3>/H)67?!9?OV]
MF_AK[ C3;QZ5]MP9A)1H3Q$OM:+Y'Y7QKBHU,3"A%_"KOYCUR5]Z>M+2'CI7
MZ8E8_-^EAU%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#$\56,^J:!>VT"[I94PM<'X?\
M#>I^>D4MG+#M;YG?[E>KT4 >;^.M U"\UF*[@MVFA\I4;9_#6WX-TJYLQ)+<
M1M#N7:J/76T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gtbp_charts.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_charts.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &9 9 # 2(  A$! Q$!_\0
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M_"?BXV@T_P#M[2K;4_L@E\SR/-B64)OPN[;OQG:,UVU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%,^G--V]\8J'))V'8EHHHJQ!1110 444
M4 %%%% !1110 4W/I1PH]<TF:!7%[>M!J OM&,?K07+?PY_&C7J+F[%FBBB@
MH**** "BBB@ HHHH **** "O,/CSX^U;X8_##5_$FAV&EZAJ-G)%Y=OK.J1:
M;:-NE57W7$AV)\K-UZMQWKT^N6^('@'P[\3/"MYX>\3Z3;:WHEX4,]E=KN27
M:RLG_CRH?PJ)(#\MM5\3V^M^+/%?B>Y^$OPQ.L^*+2>RU&6+XNV2?)<)MN'B
M7S=L3,OWF6OT5^".GV/B;X ^%K&Z\.:+8Z5<:4ELVA65W'J6GQQ ;1$DJEDE
M3:!\V6!Y]Z^+8?!OPCU3X\V_A/2_V;_#H\%RZCJVBQ:_/=?O[V^T^WEEF2*#
M?\J[DV;V]3[5]L_LSZ_H'BCX"^!=5\+Z-%X?T*]TN*6VTF'[EGG[T2_[K;Q^
M%-:Q(>DC8?X+> IO"\/AEO!/AY_#,$OVB+26TN#[*DO]]8MFW=_M5S/[64"6
MO[*?Q>BA58XE\'ZHJJJ_*J_9)?Z5[)7D'[7?_)JOQA_[%+5?_266J++7[*__
M ";-\)?^Q4TO_P!)8J]5KRG]E7_DV3X2?]BGI?\ Z2Q5ZM0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(W2F$9II=:F_<5SRSQ9^TU\+? ?B&[T+Q#
MX[T32M8L]OVBQN[M$FBW*&&Y?3:RG\:[_0=>T[Q5HMGJ^DWD>H:9?P+/;7=N
MVY)(V&593Z$<U^;?[='[4NM_#3]IC0=/LM"T748_"K)J4#W4;,T\L]J\3K)A
MA\JJ_P M?67PH_;2^$OCO0=+1_&NB:5J[0)]HT^ZE^R>5)M!95\T+\HYQ^%?
M5X[AS%87+\/CHTVXU%>Z=_P2NM-=3*-6,I.*Z'T70<51M=0MKR$2V\\4R-]U
MXW# _B*G+J>"OZU\JTXNTM#6^ERQ14*L&XZ?C2MR,=_2I<K*XUJ2T4458!11
M10 4444 ,KG_ !AXPTSP3X=O]:U>X-GIME%YL]QY;-L7UVJ"WZ5T6*KS0)-&
MR2*K(P^96K.5[6B.-E*\E<^6O'/[?GPYT#0WG\.W,OB?46(1+.**2#/'WF>5
M.%Z\_-]*VO#/[='PLU;3[274-:DTJ[F4;K66TG=D?NNY4VL?]W->H^-OA%X/
M^(6CG3];T&UU&USN"E=C(W]Y67#*WN.:U-!\ ^'_  KIL-GI>D6MC;0J%CCC
MC!" >@KCC#$*;;E=6[=3Z>5?(_JRIQHS]K_B5OR.CCN4N;9)(\[)%W+_  FO
M$3\5_$VB?$[QY9Z[IME;^&]"\.)KNGPP3&6YG599U>25]H5-PA&U%#;>[<E5
M]VV?)]T9KBK[X=Z=J'C#5O$-R9;F34=%30I[1BIB:!997_[Z;SF6O0/ESQ7X
M$_&;QCXVNKY=3U!=9U&\T/\ MG3=&DT"XT9)7^3Y;:ZEW+/;[I$3S=NY?E;[
MKBD7XM_$O5/V?)M8M-/:[\>2>*+C1&7P]9?;4M8HM6>U=D64JK;(D;YI=@_B
M?;7HOPW^!</P]UVVU&7Q/KWB8:=I[:1I$.K/%MTVS9T9XE\J-&DW>5#\TN]O
MW2_-3U^!MK'X)G\/:=KVLZ/*=:N]>MM5L952Y@NI[N6Z?C;L9-TKH4=65EQQ
M0!YXOC[QMJ7PADU:P\57-GJGA^YNK?6_M'A-KK5/M"NIBM1902LN<2)N96;<
MFUA]XLI\1/BIX[T_X0^'OB)I>LZ396S:1;W]QI]CIDNKQ7EZR;GB>X1]L%JN
M/]?T7EG;'#==%^SRUA8VTFD^//$VC>)A=7%W?^(H'M6N-1:<(LHEB>%H.D42
MKMB79Y2[?XMT>I?LU6']AZ7HGA_Q-XB\*Z3:Z2NAW=IIT\3I?V8W?*_GH^R7
M+O\ O8MK_,?FX7: >T6-TEY:QS(R2)(NY71MRM5VLC1=)L]#TFQTRQ@2WL;*
M!+>WA3[D<:*%1?P6M>@ HHHH 3;7-^./&NB_#WPMJ?B+Q!=QZ9HNFPM/<W4O
MW41:Z,=Z\/\ VR/A;K'QF_9Q\9^%- 1)=:NX(;BTMY&PD[07$4_E-_O>5L_X
M%42!'RM\9/AC\#]:\-Z5^T!/XX^(W@SP?XIOFGEM] =DA6:Y1HKBX>+8[1>:
MJ,DK+][</6ONGX8Z3X<T/X?^'-/\(F%_"MMI]O%IC0-O1[<(OE,K_P 0VX.:
M^./&/[8OB3QU\--5\ 6'[.?Q!7QSJM@VD-IE[IFS2X&E1HM[7'_/)?O?<5?]
MI?O5]#_#"RM?V7?V7?#5MXSU'R+?PIH,2:G>(/,5&51O5 OS/\QV+M&6^7BG
MI&(FKNY[E7D'[7?_ ":K\8?^Q2U7_P!)9:S+[]JKP;IN@V^JW5EXFBN[B]EL
M(]#?0K@:DTL47GRXM]FYE6+Y]ZY7G&=W%1?M'>)-.\9_L;_$W6]%NDOM*U'P
M3J5[:747*RQ-9.ZL/^ XJAG0_LJ_\FR?"3_L4]+_ /26*O5J\J_97_Y-F^$O
M_8J:7_Z2Q5ZK0 4444 %%%% !1110 4444 %%%% !1110 G%(W2LO59I[:QN
M);>%KNYCC9HX%;9YC <+N[5X7\.?VC/%OC_XA:KX7G^%6I:.VC7,5MJ]U)K%
MG*MBTL0E7*J_[SY63[F[K6M&C.O"4X6M%7=VE^;$W;<^A.B@'O7@W[2_[0DG
MP?T[3=$\.6*^(OB)XBF-GHFC+*H9F_Y[R^D2]^Y]@&9=/]HCX_Z)\!?"JWMV
MCZEXCU!_LFB:':@M/?7+?<5%_N[BNYN/098JIX_]F?\ 9_O_  S?3?$WXC3?
MVU\4]<B#W5Q+]S2HF_Y=;=<X5%R-WO7;@\/3IT_K>)6BTBOYG_EW?R,I2YO=
M1X#!^R+\4;+QYI7B77/"WAGXCZP-2?5=8U+6M9V+J)DM6B6U$36K>5%$[?+]
M[=L7[O\ #]=ZM\#? _Q,T'39?&WP]\/RZDEJB21/;QS_ &4[3^Z278K;5W-T
M"_3FO7.U+6^+SC%8ODN^5P5E:Z\^_P"5AQI1C?S/E>]_8(\&:+J'V_X?^)/%
M7PQO",O_ ,([JTOE2_[\<I8-_%_WT:\'_:IT']I3X,^ =.ET[XGWWC+3WU".
M!9M*TAK74XSY3GY_*W%X^#NW?W8Z_2#'XT,N>#S73@<]Q&&K1JUXQJVW4DG?
MYM-BE2BU9:'Q_P#\$X_%'Q!\5?"GQ#<?$&YUJ[U--;:.!]<219?($$6-N[G;
MOW^W6OKP8QZG\J>H"]*7'YUY&.Q$<;BIXF,%#F?PK9%QBXQM<=1117(6%%%%
M !1110 @-9NI:I::)8RW=_<PV-I$NZ2>XD"(H_VF:M%JP_%7A72O&NA7FB:Y
MI\&J:3>IY5S:7";DE7T;\JF+7-:0'C_Q@_;(^&/P3TRQO-5UV/5H[R5H8TT5
MH[MT;;NRP5LJN.];'PR_::^'?Q8\)V'B+3?$5G8VMXSK%::I<16]SE963YHV
M;(^9/E^M>5_&+_@G+\+?B7I>GVVA6%OX"FMI6EEN-%M%W3_+C:V[^&MOX6_L
M#?"3X?\ A&QTK5?#.G^+M0MG=FU?5+-/M$^YV9=V/[JL%'^[7UE2GD7]GPE"
MI/ZQ?565K??^OR.=*HIVMI^)]-(RR+O6O*],_:(\!7EUK4$>L2H-'@N+JZNK
MC3KJ*VDA@D\JX:WE9-D^R3Y&\IF^;U->G0P);P)'$FQ%7:J+_#7@.G?!#X@Z
M)\/M7\":5XWLM*T1+*YMM%OK.PE6]A>67S4>:3SNB+NC_=;6;=N^4BOD^8Z#
MI%_:>\ KIMS>3WVJV+6][;V$EE?:'?07OGW"LUN@M6A$K&78X7:OS,NT<\5:
M\'_M(>"/'>O:?I.C:AJ$E]?O+%!]HT>]MX?/B#M+;M)+$JK.BHQ:%B'7;]VO
M-?!?[*NM^'O&DFO7VN:=/YFJ:5J+6]L+J5E^QQ72,K2SRRRRL_VA/G9OX/NU
MW'AWX%WNA7F@2/JUN_\ 9GC+5O$S(D3?O(KS[;MB_P!Y/M2?/_LM5 4;7]IJ
M)?#/Q+UR]\,:AIT7A&]CLX+6]D2*XOVE@MY(F96 \C<UPB8?[HY;:056UX/^
M/=]KW@GQ-KDFAZ=K4FDND4$'@W6XM8BO79?]4'V0F)U;A_-555?GW;<[8_%W
M[/;>,M(^+NFW>J0Q1>-[NVNK5OL_FFU>"TMXT\Q6XE'FV^_;TVX&:U? /PP\
M0:=X@\7^(_$NHZ7/KGB&SM;!HM$LWM[2**W64(_SNS/*WVA\M_=1%_A!H X_
MQ=^U-'X=^%7PS\4KI=C#?>.((KB.TO[R5(K5/LC7+Y>"WEE?;A$RL7\6[Y:U
M_B!\>M8\&_#NR\8VF@Z)K&@_V7_:MYJ \1+':RG:I2ULG,6Z>67+;"R1*V .
MK8%K1?A;XU\&_#OX<:1X9U[1UU7PII4>EW*ZI8&2UO=MND6Y64^;%M9-_P K
M?-]UNN5P9OV?O%6C_#G2O!VB^(M!U+2Q8W=OJ=AXCT/[5:374\K2M=1(K[EV
MM+*GE.S)M9>FWY@#H?B=\:M;^'UUIEX?"EO<>'[F6SA#7>JK!J%S-/+L\JUM
M=C>8T6Y&8,Z9R=N=IKVA.M> >.O@'XG\4>%K/P9#XHL;OPE_9-GIS2ZSIPGU
M"SE@^5[JWE4J/-E4)][[C+N7^[7OR?=H >M>??&+XL:)\$_ MUXM\2&>/1[2
M>"*YF@C\SREEE6+S&7KM7>K-BO0Z\R^/6K2:3\*]>FC\$W7Q'5T2"3PS:*C/
M>Q22(KCY_EPJLS?1:3=@6AE?%+]ICX;?"'P'9^+_ !-XILXM'OK?[18-;RK-
M)J*[%;_1U4_O?OKT^7YAGM7(?$[2;W]L3]D><:):7.@WOB6RM]1T^TU-F@E4
MQ7"7$2R.ARF_RD^9?N[Z^#O@_P##_P 5_"/XY:AXLC_96\7^(?"ABQHNEZ[+
MY]QH3[V?;;L_R>5\S?>7=_M?>W?JK\-?$E_XN\$:/K6J:#=^%]0O8!+/H]\V
M9K5B?N/_ +5-I.(NMCY+TWX ?%#0-9TSQ?I^BK>+IFIZN-,\':GKYNI;.SO+
M"*W_ ./N7<.)XO,*[FPLK;?[M<Q\9OV*[[PE^RSK>H7?Q;\>65QX;\#/#<>'
MM(UAH=$N);:R^=?LY3YHY60[A_%NK]"*\@_:[_Y-5^,/_8I:K_Z2RT#+/[*O
M_)LGPD_[%/2__26*O5J\I_95_P"39/A)_P!BGI?_ *2Q5ZM0 4444 %%%% !
M1110 4444 %%%% "''>@8[4P,,4UGP#S^.*AR25^@#6PJ8//6OCJ3XV>'?@1
M\3/VA_$6M>;,K:SI-M965HN^:\N6TV';%$G=Z]H^.'[0GAKX-V,%O>K<:UXE
MU ^5IGAO2D\V^O9/1(^NWI\QXK\UOV/_ -G_ .(D/[6>EW.N^&;I;+PWJ1EU
MEKBXBE%G+):O+!O^?YF^>+[M?=</Y52Q&#Q6*QD^11BFD].>S3T\M+7MNSEK
M3:DHI7N?<'[.OP3U_7_&EY\:?BS:0CQYJRJFE:2&++H-GC"Q*?\ GHP^][[O
M[S"OJ5451@_G3H?N_P 535\?BL1/&3YI:):)+9);)=CHC%1%HHHK H**C #+
M@# INW;T7]:6MP):3;49&1ROXYIQPJ]/PS1KU$24444QA1110 4444 )]ZDV
MTZBHY5U C[8!Q^M)C'4Y/TJ2EI<JT ****?* 44458!3=@IU% !47EIZU+10
M 4444 %><?&[PSK/BKX;ZOIN@^-9OAYJ4WENOB2*%9C9JKHSG8SJIW*K*>>-
MQ->CUYU\;O@_H_QZ^&NK>!?$-Q?0:/J9B^T/82"*;"2K*-K,K <H.Q]/I+5P
M/S2OM9^/GC[Q\W@_X)_'_P 5?%6ZM9S%J>O)ID5AHE@%[?:M[^:W^ZOS?P[J
M_3OX1^'O$7A?X<>'M(\6:[_PDWB2SLTBU#5BFW[3+_$U?,^B_P#!+_X=^&=/
M^PZ/X\^)>E62G=]EL?$8ABW_ -[8L5?4'PY\%VGPV\%Z-X:M;[4=2M]-MQ;Q
M76K7'GW,@S_'(?O-57T%]HZ^O(/VN_\ DU7XP_\ 8I:K_P"DLM>N[J\B_:[_
M .35?C#_ -BEJO\ Z2RT#+/[*O\ R;)\)/\ L4]+_P#26*O5J\I_95_Y-D^$
MG_8IZ7_Z2Q5ZM0 4444 %%%% !1110 4444 -J,R!>I_6D;"J2>,]Z^6O^"@
MVO:=X2^ [Z_=:;<ZE<65]"EM';ZG=6&QY0R[F:!U9@!CY6.*ZL#A98[$PPT=
MYM)6UU?EH3.2A'F9]0FYC"AMV :^:O''[16N^/O$UUX$^!]M:^(-<@98M2\3
M70W:1H_*9^91MGEVLW[I6_A.3\K+7R]^QEX'\4?M(>#;JV.M7WA+P7:-#8Z[
M+9:M<W&HZW<1)O"!Y69;6(^;N98EYW;?]W]#/A[\.?#GPS\*V/A[PSI,6CZ1
M9QB..V@SZ#YF8G<S?+]YOFSWKUL=@:.38F="K+GJ1>UK)>NKN_+_ (8RC.51
M<RV.$^#?[.FA_">:;Q#>W<_BOQ_?(O\ :?BK5?WEU/\ *JLD8_Y91?)\J+_X
M]6-\"[F&3]HK]H#+J2-5TO'S?]0V&O=+[38-6LY[2[A6>UN(VBDC;HRM]Y37
MEGAO]DGX0^#]>L];T;P)I5CJUI)Y]O=Q*P>)_P"^#NKSZ>.A4A6]NVY222TO
M:S3[K32Q?*]/(]EI],I]>:E8T"DI:0]*H" R;%YX)KCO'GQ4\-?#.WMY_$>I
MP:9%</LC:X)4,W''2NK9MVX$^9G^'IBOCW]MCQ9=^,K:+X;^%+2_UCQ&S1WF
MH0Z:,^3;]EDSP=Q"MM'8?@W+B:SHT^:._1=SV,FP$<QQT*%5V@]WT2ZM^A]+
M^ ?BMX9^)EO<S>'-4@U*.W94E:%B0K,,J#QWKLPWRFOF[]B;0]<\-_"EM,\0
M66J6-_;W;'R]2A$:*K$X6(C[R\?FQKZ-1/E53Z56'E*I24JFC9CFN&I8/&U*
M-"7-",K)]UW+5%%%=!YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 55NY)8[:5H$$DJJ=J],M5G^&H6X3=2;L(_..S^+7[23?MF72_P#"
MM=*?Q'_PA*&7PM_PE/\ H*6WVW_C[W_=\W?\FW^[7WM\0/&FF?#KP?JOB76'
M=-/TV!IYA$NZ1^R(B]6=F(55[LPK\Z/B7\2OB_K'QFU;7=.^+_ASX;:1-XAU
MGPE#/<:1:8TY;%7EMXKJXE3>/M"*'7+=_N]A]@_ ?3+'X_\ [*O@=_'ZKXXB
MUG3+>]OGUBV1?M$^[>6=%^7Y6 VX_NBI^P'VCR/P3^U-\3O'6D^'-)^P:)X;
M\9:SKOB.UE-Y:M<6]A;Z8N[RG595W2;F1=V[^\VVL/XU?MX?#SQ5^RSXATC6
MKF[TSQKXH\#RS#2X-,NIK=)[FR)11.J;"NYL;BWR]^E>T:3^Q#\/-!T<Z=X<
M;5O"TZ:S>ZM#JFCW"174#W*-%- C;-OE>4^P*5;;L4[BR@UL_M%>$]+\"_L7
M_$OP]HUHMEI&E^"-1LK*W3_EE&MDZHE6,Z7]E?\ Y-F^$O\ V*FE_P#I+%7J
MM>4_LJ_\FR?"3_L4]+_])8J]6H **** "BBB@ HHIE  S4=J^6?VM/".LV7]
MA^)M+\>>+-!EO]<TG1I=.TK4?*M4CGNDBE94V\-M9OFKVBVN-*^#WPX\[7O$
M%Q+I>C0-+<ZOK=SYDY4?,6E?^)N?RVUT_5_W<9Q=W+2R[D<VKOL;_B[Q9I?@
M?P_?ZYK=_#IVDV,+3W-U.VU(U7N:^#/$GP_^*7[=IM?&[VVF:+\/8II5T#PO
MXAGF1+V+:R_;I_LS;MW]U?\ V7[W<:%X?UW]N[Q9;^)?$EM=Z-\#=,G\W2-!
ME^63Q!*O_+Q<=/W&?NI_]E7V79Z?#I]I':VL:PV\*JD44:[515Z**]BC6_L)
M\U%_OWN]^5=E_>[M;$./M-SP/]D'X%Z_\ ? UUX<UBU\-PQ,\4JW.@-<L]U*
MJ*DLL_F_QML7A?EXKZ'554<'.*E_&CCI7B8JO4QE65:J[RD[M]V:12@N5;#
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MZ-Y>M6?^@^,IO%WD:3HBV-H#+8R6GV6*%96$:?O2^XEC@?-ECOKZ'HH ^?\
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M_P 81O:OY5M>Z5%*R)<?W6;Y%V_WJ_4&GTH^ZK#:UN?DMX:^%_BC0O@_\&O
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MQ%I=KJ6EWD&I6%Y&L]O=VLJRQ2QL,JRLO#+[UKUY5^RO_P FS?"7_L5-+_\
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MR\2:IXHL[*_N;BT34KII1&RV\K[EW?[4:_\ ?-?:5K;>+/V\K]KW49;OPK\
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MMRAMJ@'U9J>K66AV1NM0O8;*W1UC\ZXE55#LP51N;IEF"C/K6GO-?%?[1?Q
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MNV*TLK,Q5=S[5SQN;U->E_<J2HWZTP$>54;YJ\D_:X;=^RK\82G_ $*.J_\
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gtbp_ex231000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_ex231000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$ K<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1N!5@<CUJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP51^)H GHK.T_7])U49L-1MK@YQM209S].M+=:]I%A,T-YJ=I;RH S)+,JD
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M?IFB\^R_KY![OF=#]MM/^?J#_OX*89]/;=F6T.[[V67GZUD_\(+X7_Z UO\
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M)9)HX3)=73[8X4YVJ.@^@'4UU%M\/_$_B2Z%YK=T8 QY,[;I /91P*]*\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?K6H2*HMKN*V6)@W)*!]W';[PH W**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&C=;=X=V^=C&8U+@C"84G(!.3Z5?L= N;7P"N@/+$;D6+6WF#.S<5(SZXYH
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MNM4:,:)I8NO]#AO)O.G\K:LHW(B\'+X!/.![U%HG@:+18#$FH2S#^SS89>,
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MB/ "JK+P?<,:BT[PV;34+:]N]2N+Z6TMS;VWFJJA%.-Q.T#<QVJ,^W2@#/\
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M\8W]M)K5R-*C;2])G2.6;S\/(I1&9E7&/E#]"><4C^,K^)M3NY-*B&E:=?\
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MU.:%;4M\S1JXE5B2592.G/;'2IK+PY;6/AJ;1(I'\J9)0\F #F0L6( X'+'
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M\.V]CJEO?I-*TD&GK8*K8P45@=QXZ\?2@!WB4:BV@7?]EW4=I<"-B9W3>44
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MY)8;L;MI))*YQS0!S5M\3#/;?:0EA,+BSFN;>&WG+R0E(S(%FXXR!C(Z'BK
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MHEA([%G:VC9F8Y))4<FJ,/AFUBT*_P!,,TSG4/,:ZN6(\R1W&&;I@<8 &,
M5;BM;FU?3K>WD/V."(I+N R^% 7WSWXH ?JME+J%BUO'>S689E+RPX#[0<E0
M>V1QD<BN#2_NC#/;Z=>WAT:\U>WLK2Y>5G?81^^\N1LL5)!4-D]\'I7:^(=&
M.OZ/+IWVZ>S24C>\ 7<R]U.0>#T/M5/_ (1AYM).GWFJ32K&\<EK)'#'";9D
M.5*A% X('!&.U &9;_VM'+XBT73-0,?V1X6MKB[W3M"DB98 DY8@@D;CW&<U
MF#4KYOAIX7=KNZFN+M[=)UCD/VB[4@EU1LC#$#).1P#R*['2]$CTV.\+W$MS
M=7K[[FYD #.=H4<       53'A*U30-+TR&ZN(Y-+*M:70V^8C %<D8P<@D$
M$8.: (/ ]U<7&G:A%<R3YM[Z6*."Y?=-!'P521N<G!R#D\$<FM/Q-JDFB^&-
M3U.% \MK;/*BGH6 XS[4W3-"_LS>\=[-)<3W'GW<TBJ6N#MVX/&%  &,8QBM
M.X@BNK:6WGC62&5"DB,,AE(P0: .-UBSG\.^&FUV#4[Z:_M0DT[2SLT=R,C<
MI0_*H()QM (XJS)XON$T^^N?LD1:VUD::J[SAE+JN[Z_-T]JM1^$E\NWM;G5
M+VZTVV9&BLY2NWY3E0S ;G XX)[#-1W?@N&ZNYW_ +2O(K6:[2^>U3;M\Y2I
MSDC.#M&5SB@"?PSK&IZW]MN;JVM8+.*YFMX!&[,[^7(4W'L <=*;K6MZE:>(
MM-TFPM[5A<PS3S37#L!&L93. .I.ZM/1])BT:SDMH9'D5YY9R7QG,CER..P+
M4VXT>"YURUU5W?S+>"6!8^-K*Y4G/?\ A'YT <CI7Q&74;NS_P"/%H+\NL$,
M,Q:>$A2RF5>@!V]NF14]AXUU*.PTO4-;T^V@M=3MGFA6VD+NC+&9-K9 !W*"
M1CIC!K3M?"?V!(XX=2O9+.U1Q:63, D98$ $@9<#)P&)Q^%4/#/@I[?0]*AU
MRZGNY+2S,*6LK*4A+IM< J,MQD DG Z4 17GC35=*TX7>H:=:K]KL9KRS2*5
MCM,:>9Y<F1U*]QQD&EL=4\27'CG2X+Q[&*TGTQ[F2WB+G'S(!SW89QZ8S[5<
M?P);W%D]I>:G>W,26DEG:^9LS;1NNTX('S-M &6SQ]:U6T"+^V=/U.*YECFL
M[=K8J I$L9P<'(XY4'(Q0!KT444 %%%% !1110 4444 %%%% !7"2>)=13Q!
M-IUA;6:23:R;(R2;C\HMA(7.#RW;'3BN[K#7PMIHU;^T09OM O3>XW\>88O*
MZ>FWMZT 9%GXGU:_>#38H;5-0:]N;:6X(8Q*L.,N%SDDY48SZ\UEZUKFK:'X
MCN+J;R'N8M)AS$C,826NPFX \YVM74/X0T\Y>*6Z@N!>27B3Q28='D^^!QC:
M1Q@BF2^#-,N!,;F6\G>:T^R2223DL5W[]V>S;N01TQTH I:MXLN[#6;[3H8(
M7=39Q6I<D R3N5RQ'88SQ6/+K^K>'M7U][WR)YYKJQMK=EW^4 ZM\Y09(Q@Y
M SG%=(/!FG-]M:XN+VXFNUB$D\LWSJ8R2C*0!M()SP*:O@G3MM\TUS?3W%Y+
M%,]Q)-^\22,81D('RD?2@#,M_&&H7-TNE110M>2W8AAO&AD2%H_++L^UL'<,
M8VYZD<U=\$-?$:\-1=6N%U:4?(Q*@;5QMST'M5IO"%B\!$EU?27?VA;E;UIO
MWRN!M&#C &TE<8Q@FKNB:%;:##<QVTMQ*;FX:YE>>3>S.V,G/X4 <QXA\<76
MCW=\T:V\D%C-$DD2QR.65B@9FD VQD;^%.3QSC-.F\6:Q"^H7AALC866L)I_
ME@-YDBLR+NSG (+_ (X[5I:EX&TW5/MR375^EM?2B>>VCGVQM(-OS8QG^%3C
M...E6Y?"VFRVEU:NTVR[OEOW_><^:K*PQ[90<4 /\4ZX?#VA27Z1"63S$BC5
ML[=SL%!. 3@9R<#/%8'_  E^I1V6JR+##='3$CN7F$+PI/#SYBKOZ.H!QR0>
M.F:ZS5-,MM8T^2RNU8Q/@Y5MK*P.0RGL00"#64W@^QF@FBN[J^N_/ECDG:>;
M)E5.5C. !LSR0 ,]Z ,>S\5:WJT.B3V,%G%%K,\QA,V6,5NJ$JS 'ESC..V<
M=JH7'B6[?7M.N)_*2>P34HKB-92D,CQ*I4Y/0$8/.<9-:U]X(!U;2I-.N)[6
MT@O+B[E$<NUHFDC(Q&,8"ECDKTY-79/ VC2V\4,HN'"1W",S2_-*9_\ 6,Q[
ML3SGM0!SD_Q!U"VAU)1%;W$L.EG4+=S!+"K$.$*8?DKDCYN/I6K<>*-4TN?4
M[:_2P>:WL8;V)U9HXQO=D*-G)."N01R>F,U:F\!:;=27$MY>:C=S3VALGEFG
M!;RBP; P !R.N.YJ]J?A73M5N+F>X:=9)[:.W+1R;2HC<NC+Z,&.<T <3JOB
MW5K^UO\ 3[>Y6"XMI["5+D6\D1DCEF"D%&((Y'XC(P*W;OQ5JEO::GJJP6S:
M?IEW]EEB.1+-M*J[@YPN"W"\YQU%7&\":;+)>S3W=_-<WB1++/),-X\I]\97
MC (/M4TO@W3IKB1WGO#!-*L]Q:B7$4\BX^9EQU) )P0#@<4 9$?BG6EM+K59
MHK/^SK?5FLF1%;>(1+Y?F$YZ@D<8Z"NBT#59M8BO;IDC6U6[DAM63/[Q$.TL
M?JP;\!5/4]!^S^%M4TW38%G:_>9G%Q-M56F)+-G!X!.0!6KHVF1:+HEEID)+
M1VL*Q!CU; Y)]R>?QH Y5_%6M01:KJ<L-E_9FGZF;,QKN\V2/<JE\YP""W3'
M..U,NO'%S;:W%#MMY+9M533F2.*1MH9MH<RXV;L]4&<="<U9TSP3B^U2?4KB
M=X;G5'O4M$FS"X^4H67'4$9QG&0*N3>!]-GEC+W-\8(KX:A%;>=^[28/YF0,
M9QNR<$]S0!E6_B[5FT234[DV$,<FH264"['8JJR,N_"Y+L0OW0/QQ3=.\:ZC
MJ4J:7%% FHMJ,EH)I8G1/+2(2F0H>02#C;GKWK>/A'3QIT%G%+=0_9[M[R&:
M.3$D<CEBQ!QC'SL,$=#65>>"UL83)I2W%Q=2WWVR6:6\\N97*;"R/M(Y  *D
M8()Z4 5+7Q9XANKRUT[R=/CNI-5NK&20!BBI$FX.!G))]/>G2^.+R#6((2MM
M);MJ2V$BQQR$(&;:',N-F[/\ SCIG-7O#/@Q=,A@N;Z65[V.]N+T#SO,VM*-
MI#-@;N.^!S5B3P-ITDL1:[O_ "(;P7L-MY_[J.7=NR!C.,D\$GJ: ,VP\4:T
M;/2]0U*&R6SU&[>S$<&[?'RX1\DX.=O([9ZU4\%ZWJ]OIWA>VOO(E@U,31K@
ML9$*!G#%CPV0I!';CK6IX9\%C3;*S.HW%Q--;S2SI!YVZ&-W9L,HQUPQZ],F
MM6T\+Z?9QZ.D1FQI)<VVY\_?5E.[UX8T 0>*/$,FBRZ9:PA%EOYF3SI$9UB5
M5+,=J\L>, >_)K"O/'UWI?AXZY>62O9VEV]K=[%9&DS@1R1AL?*25!!Z9/I7
M7:MHUOJXMVEDF@GMI/,@N('VR1G&#@\\$$@@BJ"^#M+(MEN#<7:P/)*5N)-X
MED<8+N.YP2!V&>!0!FKJ_BF;58]-2/2XYDTM+V=FW,OFL[@1K@_=^7[WXXJI
M;>.;Z]DGO8X((M,M=&CU292"TK%A)F-3G'\'6IU\!E-?CDBU"^AT^'2EL(VC
MN<2D"1FVMD'("D 'KQ6[;^%]*MI;AH[?]U/91V+P$YC\E-V%Q]'.: .<L_&F
MK2Q?)8QW]Q-82744-M%*GERJ 1$S,,-D-P1CD'CI3X_%^H/HEU<VQMK^XADB
M#QQ6\J2VZ,?G9X3\Q"]1CK@UM6GA*TM>M[J,VVW-M 9+DY@0XSL(QSP.3D\"
MA/"ENIGE;4=2>\F5$^UF<"550DJH( &,DYR#G)H P+GQ=*+73[I'T^^8O= 2
MQ*Z[?+A+C*GE6XP5-'_";:IIUA#>:I;VDBW.CMJ2);[EV,NP;"3U!\P<]L'K
M6TW@G3)%S-+=RRM)++),\OS2-)'Y9)XQPO P.U/O/"MF]G$L47G26NG/80Q3
MR$(Z,%X<CG^!>1TH ATS5M:'BI-(U1;)DDT_[8)+<,"&WA2O)Z#/7O[4GBGQ
M!?:+>6L<:1V]G)$[/?30/+&CC&U&V<J#R=QXXJKX9\-:A9^(7U?4'F!6Q%G'
M'-=_:&QN#9SM4 #&.F3U-;^J:,-3D1QJ%]:%4*,+:4*'4^H((^AZT 8<OBNZ
M2/Q"\:6LBZ;ID-Y"\;%DD9TD8\]UR@P?>L:'6=<LI_$^MQ"V>RM5@N7AE9BS
M@0*SJG9,#D=<FNCNO VE7$+01RWEM ]F+&6.WFVK+$,X#<'D;FY'K2/X&TQ[
MFZD-Q?"*\$2W-N)OW4RQJ% (QTP.<$9H J1^*[Q_$OV&<VUC \RI;I<Q.#<Q
ME00Z2?=W9.-G7BLG1?$6JV7A^W^U7T,T]WJ5Y&)7B>1U5)7X6-<L_3V"CJ:Z
MRX\,6UW?+//>7SP+,DXM#-^Y#K@J0,9 ! .,XS5;_A"[%&1[>]O[=XKB:>)H
MI@#'YIS(HR#\I)S@YP: ,32O&6LZ[<Z;9VD-G!-.EX+AY4<A&@D5,A<@\Y'!
MZ9Z\55M_$>J:KJ>EZB9(XK:31+N>:SP2C.CJI.<C\..!GUKJ-'\&Z7H=U!<6
MAN#)#Y^WS)=V?.97<GU.5'ZTD7@O3+>*SCADND%K!-;+B3[\<IRRMQSS@CZ4
M <W>>.;RPT1+BVBM0;?2XKUK=8I)2^4+%25XB4 <%B2?3BMSPQ>->^)/$4N]
MS$QM'C4MD*&@5N/SHG\ Z7-:RVHN;^*VGM4M;B&*?"S(B[5W<9SC@X(S6OI6
MA6FCS7,ML9"UPL2OO;/^K0(N/P H Y+QIJ^KWNA>*X=*\B*'3(?*=G+"21C&
M'8J1]W:K#'7)STJY?>)]4MK;6;^V@MFL-%8)*DA/F3X17D((X7 88X.3Z5HZ
MUX*TW7&OO.GO;=+^-8[N.VFV+-MZ%N.N.,C&0,'-/O/!^FWMS<R/)=)%=E#=
MVT<N(K@J  7&.X !P1D 9H S+KQ?>0Z3K%XD$)-GJ45I$&!^9',8R??#FL_2
M=7UC2(+^]N#!-II\03VVQBQE"/<&,,#TX8CY<=!UKH+_ ,%Z=J%S<R27%['%
M<RQSRV\4VV-I(]NUL8Z_*N><'%);^"M-M[V2<7%[)%)?-J#6LDV8O/9MV[&,
M\'D#.,C- $7@2;4;C2[]]1O!<N-1N41@I&U5D(QR3QQQZ5FZOXXNM.U.41K;
MR6\%_%:21)'(QVNRJ7:4#8K M]WD\<XS75Z7H]OI'VH6TDQCN9VG,;ME49CE
MMO' )YK(O/ VFWK3B2YOEMYKH7K6R38C$P8-NQC/WAG&<4 86AZOK&DV,EY<
MF";3I==GM0I+&4(]PR*^>G#$#;CIWK1M?%>IR0:9JLMO;?V;J-\+2.%2?-C#
M,RHY/0Y(Y&. >IJ_:>"M.M+OSA<7LD7VU[\6TLV8A.S%MP&,\$Y S@'FI+?P
M?IUO>0S++=-;P3FX@LVES!%(<G<JXSU)(&< DT 9=CXKU"_TKPW-Y4$<VKO*
MDAP2(]J.00,^JBKW@":^N? ^FSZA="YN9$+&7:03\QQG).34EKX,TZTO;2X2
M>]9;.:2:V@>;,<1<$, ,=/F/4G%:6C:1!H>G+86LDSVZ,QC$K;B@)SM!QT':
M@#SC2[S7Y[S0/]/CFN)=6U*/=*&VJB[QR,_-C' X[5L+XZO)?L=D5MK>\DDN
MDFN#%))&/(D\O*JO/S'GD\<]:Z&T\):?97\-W%)<DP7,US%&TF41I0=X QT.
M2<4S_A#M/0(UM<7EK<)//,MQ#* X\YMSKR""I/.".,"@"YX<U:36]$AOIK=K
M>5BR/&00,JQ&1D X.,C(Z&N8G\<W,&L6\96WDM9=3%@Z1QR'8"2JMYN-A;(Y
M49QG&<UV6FZ?!I>GQ65MO,<8X,CEF8DY))/4DDFL)_ NFO)#NNK\P07GVV"V
M\_\ =12[B^0,9QDG@D]30!@^%]6UC3/#^C-?F":SO;N6U7EC*A+2%&))P<[<
M$=ABLJW\13E8=2-O$5FTK3C]ERWE(7NW0D#/7'\J[;3O!.FZ:]MLN+V:&UDD
MEMX)YMT<4C[LL!CK\S >F33$\!:.EK%;@W.R.""W7][SMAE,J=NNXG/M0!C:
M/KFK:<\\NH7,5U9R>()[.1RI4P(<B/!R>-P _P"!"NI\-ZI/K6C)J,T:1I/(
M[0*N?]5N(0GW(&?QK)U[PF;G0]5TRP#.FKS^9-YTV%MRQ!:1 !G.1G&>O<5T
M]I;165G!:P+MA@C6-%]% P/T% ')Q^*-4:"RU5X+8:;>WWV-(AGS44N460GH
M<D#*XX!ZT[X>1W3:7J%W?7"W%S-J-RK2!2#A)64#DG@8X]!6A%X/TZ&]CF$M
MT;>*X-U%9F7]Q'*<G<%QGJ20,X!/2M+2=*MM&M'MK7?Y;S23G>V3N=R[?ADF
M@#FHDBUO4=?NM3CN;J*PN?LMO9Q,?D 126"@C+,6SD]L8K.U*&PO_AOK%RLU
MW<W.FP7444]UE)X64$A2<\E>!GOBNLO/#MO<7\E];W5W8W,RA9GM9 OFX&!N
M!!!('0]:%\,Z<GAZ[T55E%M>+()W,A,DAD'SL6/\1SUH ET+3[6PTN'[+"(_
M-C1WP2=QVCGFO.[Z*YGC\9W$6E75U<07LJPWD-UL>WQ%&1M&0?E)+8'7I7JD
M,2P01PIG;&H49] ,5@2^#[:234-FHZC##J$IEN88I@JL2H4XXR 0H'!H Q(_
M%<_]HSPV$,%S+.EA';W,F5\SSE8[W'H I.!]*EN?%&NPZHNB1PV,E^M]% \[
M!A&87B9]^W.0PVD;<GZ\UL3>#=)F>Y<+-$TRP!3%)M,)ASY93T(S69J?@CSI
M=/>UNKEIEU%;R[NY)L3-MC95P<8XR!C&,9H S+[6M9O=?T>Q0V\=_9ZM+:3N
MI;RG7[/O#[>OW6'RYZ]ZNKXRO6L(4E^RPW1OKBSDD6.27=Y1QN2)?F.>,Y(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ@)D\]ZZ3PWK%UJL-]%?010WEC=-;2B%BR,0 0RYYY##K1_PBVG^5Y>9MO\
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M;H8@ZD,H7'(P3C/3I2VG@>QM8FM_MVI2V@MWMH+:2X)C@1Q@A1WP.!NS@=*
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MRFB\]8V:-GG*MG"@'('<5J+?:K:>)#%J]W?1075Y+!:R0>4]LZD-Y:' WI(
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M34+FUB>^N86E_=&>2-80ZAL JK G&<=NE=Q-H>EW$=Q'+8PNMS*)I<K]Z0
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MT\2PILAGT>-<D[4MW R3DG[WK6W;B<6\8N61IMOSF,$*3[ T 2T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<#JB+!KFL7>B>)+:RNSM^W:?
MJ$(:*5@G!&<, 5P,J2/QKOJK7&GV5W+'+<VEO-)']QI(PQ7Z$CB@#S"[U2]N
MYH/M-O%IULFC0W%O;G4&LD@<[MS+M4[]N%P#T&..::+Z_&I&>:XQ?2MHHG:(
ML@<L9-PYP<'T('TKU.XL[6[\O[3;0S>6VY/,C#;3ZC/0TYK:!W+M!&S$@EB@
M))'3\NU 'EUI>*UQX7NY-7NO[9NM5D2^MS=-T"RY5H\X 7"@<#MUIMMJ%[I,
M-VD-X^H:C-87+PZA9WS7"2L@W;I(#_JV'0;>">*[>W\(VT6KQZC/>7%V\,AE
MB698\JQ! )8*&? 8@;B<5M0V-I;32306L$4LIS(\<85G^I'6@#RW7+Q;'3[Q
M-!U>ZFMY="GN+J4732&.4;?+DW$G8QRW QTZ<5U&B1MIOCB;38KJYDMY-)AN
MG6>9I"9?,92_S$XR ,@8'M741Z?90QRQQ6=NB3',JK$H#GU(QS^-3"*,2^:(
MU$FW;OV\X],^E 'D?C*Z \0ZEK,P7[)I\L%K>:4)-LVH1IB1'7/7#OP!U ;)
MKO-3N+K7OAY=7&G!?M5YI[-$L3[OF9/N@]_2MQ[.UDN4N9+:%[B,825D!91[
M'J*E1$C0(BJJCH%& * //]:U^VA\(V#Z6-)N;54A5=.N$8RLX90JJH.58'U'
M45GR:E<3W]UI\UY(4FUN[3;->-#$$2.,A6<?,,%LA5(SSZ5Z4MA9I=F[6T@%
MRPP9A&-Y_P"!=:);"SGC:.:T@D1G\PJ\8(+?WL'O[T >5>&;FX\07/AVSO=1
MNI+=9=5A=8;EU$Z1N@3)SN( /!)S[U8T 2Z]?Z9:7^HWTD":7=$JETZ&0I<[
M%+%2"2!WKU!+6WC<.D$2L"2"J $9Z_G@?E0EM!$P:."-" 5!5 , G)'Y\T >
M2_VO=:IH.EFZU B1=#6Z>6>]:!=_S .H3#2/\O.3@<<$FLV98M9T/4M2O3(]
M]=>%[.=CY[@R-EPQV@@'H,\8'XU[0VG63^3NL[=O(_U68E/E_P"[QQ^%.^PV
MF5/V6#*(47]V/E4]0/8^E 'D_BK43:V6KRV&H>2FEV<)M9)-0<%&V9'E(I_>
M9R,LY89&.@-:US?/;^)%U*XN_ML<EQ;A8K;4&CFM=P4>68/NR*2<GO@GTKO_
M .S+#*'[#;9C3RT/E+\J?W1QP/:G?8+,W*7)M(/M$8VI+Y8W*/0'J!0!YIH]
MVNH7D5KKFJW$=@#?O&QNFB$DBW3+RX()VKT7.,=N*[/P9?W5[X4TZ74)2]W)
M&QS)P\B!R%<CW7:<^]:\NGV4T(AEL[>2(-O"/$"H;KG&.O/6@V41U!+TC]ZD
M1B7@< D$^_84 <TUY:VGQ2NC<W,,.[1H<>9(%S^^E]:9IFHV,/C[Q$\M[;(L
MEM9E"TJ@,,2<CGD5TUUI>GWSJ]Y86MPZC ::%7('IR*CDT329MGFZ792;%"+
MNMT.U1T XX% ')V/]L3>-?%!T>YT](RUJ6:XC>0Y,(P5VL!C%=3H&CQZ#H=K
MID4K2K I'F,,%B223CMR3Q5Z*"&#/DPQQY !V*!D 8'Y"I* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q9_%.E6VEZGJ,LLBV^
MF3-#<_NSN#KC@#J<[AC'7- &U16)?>*])T^TMKF:9S%<VSW492,MF)5#%O;A
ME_.M5[A4MO/5))%P"%1<L<^U $U%5;34K2_FNHK:82/:2^3,!_ ^ <?D15KK
M0 45SG_";:7]GENC#?BSAE>*2Z^RMY2%6*L2?[H(/-:UAJMIJ378MG+?9)VM
MY<KC#@ G'J.1S0!=HJ)I@L\<6R0[P3O"_*N/4]JEH **,YZ5EZ[XATWPW:V]
MUJD_D03W"6ROM) =LXSZ#CK0!J453;4[5=8CTHLWVJ2!KA5V\%%95)S]6%6\
MCU% "T451N=7M+35;/3IW9)[P.8"5.URHR5W=-V.<>@- %ZBJ5GJMK?WM[:V
MS,[V4@BF;:=H<C.T'H2 1G'3-7<CUH **I:?JEKJ:W#6SDBWN'MI-RXPZ'##
M\ZNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7GVI6<C?$)=(\IFL]2EAU*7Y?DQ"I5@?<L(3^%>@UBWGB6TM;NYMT
MMKRZ>T4-<M;0[Q"",C/J<<X7)H \X>SNI= \4VTR2?\ $FT^72X6VD%MSE\K
M_P  \H?A5C7[ :2VIVNFQ2PP2:'!(RQEOFD$X&X_[6.]>HP7EK=6D%S%*C0W
M"AHF/&\$9'6I6DB5@K.@8G !(R?:@#R:^M/LL^NQP01Q"3Q%')?!E8![4QY4
MOMYV&3J1[YXS78>!U98M4\N6-K$W7^CI"KB)/E&\1EN67=D\<9)Q6];ZK8W>
MI7MA#,K7-GL$Z?W=PR/TJVLL1C5E=-AX!!&* .!\.Z#>ZQX6O+&XU)H=.N;R
M[26!+<!RAG?(WD]QWQT-94H,<MY;21QQVTGB*?=+<[O(0"$;=ZC&[)Z D#->
MIK-$VT+(AWC*X8?-]*I:9JUEK$#R6S9"RO&5<8.48J3CTR.M 'CL$EY)I4T0
M>=HH(M<CA*Q/$-FQ2F$))4<_*,UT3:/;V4HL[>:YT^WN_#A-S<1!G;>&4!R!
MRS $^Y!->F[XR[(&4NHRRYY%"21R$['5B.NTYQ0!QG@V[M[-]1A:*PB@3R6^
MVV3N+>5FRH7:WW7&!D G[P[U9\>6<6H0:#:7$ GMY=7B25"N05*2 YK1;6-$
MU/5KK0!.LMQ:1K<7$:?=0!N Q'?(SBETWQ1I^J7D-M$MQ$\\1GMC/$4$\8(!
M9/S'7!P0<4 >?&+7M/\ $&H:*D=Q)=Z=X?NDTZ\ R9XVDC\OG_GHH!4^I />
MF0V#W-I<#27B4PZ8)WCM%EP\T;J\?F%NDF588ZX)S7K-W=06-I-=W+[(84+N
MV,X4<GI61;>*],D%QYZ7%B8;;[8PNHO+W0]W'L.XZC(R* .$TV2^U3Q+:JT-
MTMMK\L>K/YF0(8X2<)[9VPG'^T:[?QQ9+>>$=0D!=+FSB:[M98_OQS1@LK+^
M(Q[@D59T_P 1V-]+-$RS6DL,0G9+M/+/E'.'';;P?IWQ4$7C'1;C09]:BN&D
ML8IVMPZH29'#;<(.K9/ ]: ,&_T^.P\'>'[=EG;3GNHI-489+2*ZLS-)CD@R
M%2W^%8DUA!?ZI:V<$4K^'F\01_9T!81LHMG,@7UCW_@3G%>DZ;JUOJ9GB2.6
M&>W(6:"=-KID9&1T(([@D=?2KV    ..E 'E/AVWN;'QA)-J"EM&.L7D-C'&
MI5;><MPS_P![<-RJ>@^IKU>DP/2EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O/\ 78]/CUW4+FVU35=!U;"EC'&7
MAO,+\K;"&5_[O&#Q7H%% 'E&IG49;U;CQ%%#"9M&B6-);6255F);S1&$(VR9
MV>_3!X-0LE@FH:O:ZY'<W.J'1+2.%FB<NTA5^@7.V0MM[Y]Z]=JK#IUK!J5U
MJ$<9%S<HB2MN/S!,[>/;<: /*KRPOX1KL<D++J,R:;)=ND3$RPJJ"X.5P6&0
M<@')YJ5[(7]PGE8FTV;6+$-';6TD4&Y0^\J"2>FT-T' ]Z]:HH \M_LE+6XN
MY[>S>.6+Q5;K"RJV4B)CW!?1/F?...35?3(+4K%%IEK/'X@'B"21W:-P1'YQ
MWL6(QY93C'3D=Z]:HH \F\.PW7VW1XI9-FKPW$KWP6UD\Y@0^\2R%MI4DK@\
M]L"NN^'&G0Z?X#T@);F*:2V5IBX(=F_VL\Y^M=710!RD5JEG\1+B2WL]L1TC
M<1''@.YF)//0L:S[:\AU3QSIFIZ<+MV:WECO8;J-@+-,# &1A&+#! SG'M7=
MTA *D'N,<4 4[C5;.#1Y=4:0O9QQ&4M&I8E1UP!R3[5Y]=!O%>DZUJ(D+ZG/
M8&.UT^,',4 8.5.0 9&(&?3@>]>DV]O%:V\<$*[8XQM49S4M '&6$MKXF\6_
M;((6FTV/2_L\_G0E5=W<'RR&') '([9K+%BO_"(:RTD=Q ;;79;F%H8-YC*S
M J^SC<@[@=LXKT>B@#CO"2W=[XBUO6)9Q/;SQV\$4J0F)'*!MVU6R< MC)ZG
M-=C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gtbp_pic.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_pic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #( AP# 2(  A$! Q$!_\0
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M_@% $/\ PK1?^>:UP/QX\ +8?"C6Y_*^[+:_^E45?5W]E15YC^TMIL2?!'Q
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M/]NOQU#XO\67LWPM.IZGHL%A>2_Z/93Q6JWD17^[N5&5?]ZM;_@G!\;/B/\
M$GXE?$Z7XA>)+Z^T\Z58:W8V-Y+F&Q@NFEE7;_=_=;* /17_ ."6/P=D3:TF
MMNO^U<1?_&JZ6Q_8O\&_#7P3JB6&I:WJ4T*/<0OJ=TDK+M151/N?=5$5:\ ^
M$G[5_CV__:0T3QYK.N-+\$?B)KU_X7T'37=?*L7@V):S_P"SYK(__C]?H9XF
M3SO#^H)_>@;^5 'PYKWA'3_#&AZAJ^I_Z-I]A ]Q=3)$[[8E^^^Q?FK%^',G
MA/XN:#+K/A'4H=7TV*=H&E6)TVR_W=CIN_CKZ4N?#UM>6LMM<Q^=:7$312PO
M_&K?(]? G[$]O+\"?VL/B5\$-3;997K/=:8\W\?E?/%_WW __CM 'J_C/Q%X
M%\ >+-'\,:]J\=GK^K;/L-EY#RM+O?:GW4^3YJ[K_A6*_P#/):^<?@;8+^TQ
M^W_XR\>M_I/AKP2GV?3VV_)N3]Q;[?\ @?FRU]_?V/%0!X?_ ,*T7_GFM>>?
M!;P.MSXR^,$7E_\ 'OXF2+_R2MZ^L_['BKQ_X#V"O\0/CJO]WQ@G_IOMZ #_
M (5VG_/.O*O$_P 4?!W@_P"-6E?##5[;4K;7=4\K['=O GV1_-^Y\V_^^FS[
MGWJ^NO[-6OB3_@J#\,;E/ _A7XGZ,6CU7PKJ*12S)]Y(I7WQ/_P"55_[[H ]
M6^(-EI'PR\&:QXIUO?#I6EP?:)]B_._\&Q/]JLSX/ZEI'QI\#6GBS0[&]L]*
MNI98H/[1B1';:^QW^5W^7?7B7[;GQH_X6_\  OX/^&O#.V35/B/+;WLUNOWE
MV[%V-_V\-_Y"K[B^&_PSL?AIX \/^$]/1?L^C6,5KO3^)E3YW_X&^]Z //?^
M%<Q?\\J[_P#9?T-=!^*7Q @5=F[3-+?_ ,?NJZ;^S5H^#D*P_&GQPJ_] 72?
M_1M[0![G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $>,_0
M4O7KTI:RM6UJVT:#S;J0 'Y53/S.W]U5_B-<M>M3P\'5K2Y8Q*6IJ]O>HF8=
M]OXFN&O_ !1J>H-MML:=#[[7F;_V5?\ QZLN2P\]=UR)+H=A<2M+_P"A5^3Y
MEXD8'"SE'!4I5^7K';[SICA[_'+E/3]V[HU9>L>)-(\/QHVJ:I9:8LGW6NYT
MBW?]]5XYXX\4S> ?#<E[IR-_:]Q/'::98)+LBN+J5MD4;+]W;N^]C^%6:O,_
MA1XPT*'QQ=Z9\2=!L=9\8W4[V]UXDNE\]7DW?ZI%E_U$'\*HGR_WOXFKW>'>
M,\'GL+N+IOLS#$4_JUN;J?6]CJ5KJENES97,5W X^66WD5T;_@0KF/B%\5O#
M_P -K6)]8NBDT_\ JK:,;Y7^BUPU]X=T[X4?%SPC<>&K2'2M/\53SZ7J.DV*
M>7!+*D#W$5TL2?*KIY+(S8^99?FSL2OG+XP:Q=>,_BSK;%@ZQ7+VL7^RL?R_
MY_WJ]KB+-WE.%]I2CS2EHCZ;AO)HYSBO9U)<L8J\CWG3_C?J?Q,\1+IOAG7M
M$\,0LRJAU*RENKV;Y<_*F](U_B_B?I7977@WX@V<<ESI_P 1'N[Y1NCM-3TF
MV-DS<X5O*1)57W#U\<7GA'4=-B2YB#?+\]?4'[.?QBE\<::^@ZS-YFMV:;EE
M?[US%_>_WEZ&O#X?XFGCJGU;&QY9]/,]GB#AF&!I?6\!/GI_:[H]&^''C4>.
MO#QN9K-M.U2QN9;#4]/E?>;6ZBX==W\:_=96_B1T;O7722K&N68*O^U7S]-\
M1AX'^*'Q.M;:-9[JZGTZ>.)_NQ.UJJ.[?\!2+Y:XC6_$.H>(KIY]2O);Q_\
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MO[WS&9^H^\QKU!NE &3JVJ0Z/8R7+_/M^557[S-_"HKA"]QJ%ZUU=MYER_\
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M9<JW\/S?*_\ X\O_ (_7Z'Q-2E4P.'Q$OLM7^9^D\%UN6K4H_:G!_?N>Q_\
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MPS_X B@#\BO^%T)_S]4__A="?\_5?KA_PPU^S_\ ]$D\,_\ @#3O^&&_V?\
M_HDOAG_P!% 'Y%/\;(HUW-<[$_VVKJ/%7PY^(/PQ^'^E_$O4=$O4\-^,&>]:
M58&WV#?=B\]/X?-B5'5WK]6=#_8Y^"/AO4[?4M,^%GAFVOH&WQ3?V>CE&]?F
MKV*2WCN(WBDC5XV7:R,ORM0!_/S_ ,+U@_Y_HO\ OJC_ (7K!_S_ $7_ 'U7
M[X?\(/X=_P"A?TK_ , XO_B:/^$'\._]"_I7_@'%_P#$T ?@?_PO6#_G^B_[
MZH_X7K!_S_1?]]5^^'_"#^'?^A?TK_P#B_\ B:/^$'\._P#0OZ5_X!Q?_$T
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M^[_#\SK0!^GE%?D3XZ_X*-?'CQ)X@GN_#']D^$M$W?Z-ITFG+=RA/X?-E?\
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M8EM+B^T^UNY[.3SK:6X@5WA?^\FX?*WN* /S^_:DO_"_A#XW_%OQK9?'>_\
M 7Q(T;PO;/:^'Y].BBBNDC3?#"CSHWVI))?O)%_$_/W:T?C;\5O#7C7X'R:3
MXF\3:9\'_B[KW@2WU'6;Z\T>)'U2S:W??I\4LO\ ?=ON(S.E?<6M^!?#OB2\
MM+[6?#^EZO>V>3;7-[9Q32P_[C,OR_A3O$'@CP[XN:V;7=!TS6VM6W6[:A9Q
MSF%O]G<IVT ?$EO\1OA_=?L[?#CP_J&H:?\  +QUJW@4+I6O:IIB7"VFG+A)
M;6*ZG_YZJH?;OW[7W?>KVG_@GOJBZO\ LB?#]HM!/AV&&UD@@M]SLDR+*_\
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M[MR;FYZI_>6OTLA\)Z+:WEA<Q:+81W-C!]GM)4M$5[:/^Y&V/D7_ &5J+4/
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MV-F]Q,]SJ3:0LS!5C^U(F]HMS/\ >V_^A+7977A72+^6\>>PAE>Z.9V=/O\
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MSM_X\S&BB@#IZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gtbp_s1000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_s1000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '> G8# 2(  A$! Q$!_\0
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MP F(.Z@#M001D<@T5'!"MO;QPIDJBA1DY.!4E !1110 4444 %%%% !1110
M4444 <[XV\02^&/"]UJD,8DDB'"MTKSNT^)_BBPTRSUO6M)B.D7)'[Z+JN:Z
MWXN1O+\/K]8T9CCHHR:\MN/$T6O_  QTWPAIEG=3ZD0B,#&0%Y]: /8[WQ_X
M<TZVMI[N_6,7"!T7&3@U93QIH#M9*NHQ,;WB#'\=>*>*9+W2IK30[NS@M_+L
M@@G> NTA] :S[#2+V3X6'5D5UO-*O3)'N7!"\4 ?0\.OZ9<:Q-I,5TK7L0R\
M0ZK7#_$7XBZAX4NHK:QT]G!8!YY/NC/I6=\%K6XU)-2\4WV3<WL@49'8"L_X
MZ:[:/:6VD1I*]TDHD?;&2,#WH ]*UCQ1%HOA :S<XWF%65/[S$=*Y[X9^.M0
M\8F_%];I"T#?*JCD ^M<OK,.L^/=(T6X\.QI)962+YD<X*[G Z$5%\'(]:B\
M4:PMQ D<&\B;*D88=@: .R\5>-[O0?'&D:-'$AM[Q=TC'J*U)?B-X5AF$3ZM
M"'+%<$]#[UP/Q*AF?XK>'GCBD=1"<X4D5QLNCQ3?#[Q/>-8'[6NH'9(8SN S
MVH ]XT_QQX=U756TVSU.*6Z SM!ZBH3\0O#*ZK_9IU.,7._9C' /IFO&+JR_
ML?7/"%UIM@PE:S#2B-#\YQW-8'B"_GU(3?Z/';74=[Q;Q6Q##GJ30!]':UXU
MT#P](L6HZA'%(PR%ZG'K4/\ PGWAS^QAJW]I1BT+;0W<GV%>">+;JX_X2:2-
MD4^98QHYD3?M&WDCT-3>(=/@AT7PO<Z;<E]*C5A-,D>X+)GG(H ^A]$\0Z7X
MAMFGTR[2=%.&V]5/O6I7D?P=T^SCN]3N[/4)+@2$;@8BBY]J]<H **** "BB
MB@ HHHH **** "BBB@ HHHH *X7XF>,;[PAIME+80I+/<S^4JO7=5Y)\==PT
MC1Y1&[K'=AVV+D@>M $VF_$?7-+UBRL/%>F+!'?$"">/ID]!77ZAX^\-:9J/
MV&[U...XS@CL/QKRO6=7_P"%BZKX<T_2+.X9;)T>>:1"H&,=*YOQQ?W%U<ZS
M926T5M+$X1$6WR\@'?=0!]"P>*='N-5;38KV-KH1^9M'=?6IM,U[3M9^T#3[
ME9S;OLDV]CZ5X#K,5[X>T#P_XMM8W\U[<VTRMU)Q@9KUGX7:+_9'@R&>:+;<
MW9,\I[G/2@#E_%GC_P 9^&[UKZ;28H])6?RQN.68>M:/C/XF7^BZ#8WNGZ8S
MM<Q+(SL/E3-<1XO\90>)O'"Z?J@N(=#L)?F1(B3*PK;^*GB72+CP/:Z=8QS$
MS*K0J(C\JCL: /6= OI-3T"QOI1B2>%78>Y%<=:?$&5O'VIZ/>+'%864)D:7
MOQ6E\-M>M-9\(64=N) ]M$L<@=".0*\KU*";_A/?%Y$,A5K)\':>3QTH ]:7
MXD>$FF$0UB#=MW D\5=TOQEH.M)</8:A%*ML,RG.-HKY]NM#A&@>$W^PMYDT
M^)&V')&>]=%91-H7Q"\1"QTW,"V!;R!&=C-@4 >LZ?X^\-:GJ8T^UU.-[ECA
M5Z9^E1ZG\1?"VCWCVMYJD:3(<,N"<&OG<WUU?ZIH]Y'$L<RS'?';P%/+/H33
M)9X[S4+NVU!E2R>\#23&/<R\]-WI0!]'WOCSPYIT%M-=:E&B7*[H^Y(^E;>G
MZE::K9I=V4ZS0/\ ==3Q7S7XFLTM?&2R3W30Z7); 6T_E;UVXXQ7LGPHLH;'
MPB([>[DN8VE9@[IMZ^U '=4444 %%%% !1110 4444 %%%% !4<+EU)/8XJ2
MH+7_ %;?[QH GHHHH **** "BBB@ HHHH **** "C ]*** "BBB@ HHHH **
M*J:AJ=EI4 FOKF."(G 9S@9H MT5@_\ ":^&_P#H,6O_ 'W33XX\,@X.LVN?
M]^@+'045SX\<>&"NX:U:8_WZ</&GAPKN&KVQ4=P] &]17.GQWX7!P=:M0?=Z
M&\=^%T&6UJT _P!^@#?DB2:,I(@=#U!&0:BAL+.V;=#;11GU5 *Q!X]\*MTU
MRS_[^4#QYX68@+K=H2>P>@#;GL;6Z='GMXY&3[I=0<5F>(?#Z:UH%QI<,@M5
MGX9D7M4(\<^&22!K%J2.N&J1?&7AU_NZO;'/^W0!:\/:+!X>T.UTRW.8X$V[
ML<GWJU/86=R^^>VBD;IED!-9#>./#*$JVLVH(_VZ;_PG?A? _P")W9\]/WE
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M=VT'K7NX@CTG3%@@A52>GM7AOAG6+K1D\ZU;>#P=PZUU6M^*;J:U2;[0T<Y
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MSCG->B?#5-NBSC_IL:\7*JO/4:/I>(J_/02.V'3D8I:**^C/B@HHHH ****
M"JU_9IJ%A/9R$A)D*,1U -6:* .8M/!&GV?@UO#,<LOV1E*EB?FYK.O?AEIE
MWHFDZ8+NYC33'\R&12-V?>NXKBOBAK.H:#X2-YIT_DS"51N]C0!KV/AV>WF+
M76K75["1@PS %33-7\&:/JMHD(MDM7CD$D<L"!65O6H-%\8Z;=C[!)<EM0MK
M19[@;>@(SFGQ>/?#TVCR:HMZ/LR2>5DKR6] .] %2S^'.CV\&H+<-+=S7XQ-
M-,?F/I3M#^'VFZ-J'VUIIKN41^4GGD'8OH*T]#\6:5X@FEALIG\Z(9>*1"K
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M* !BG1FXJZ.G%^[4.;T3X9Z?977GWLOGD'Y%[?C783Z5:);A+>V1<<#"U==
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M--*2^([R7PF+*QAU&S/G+U=2.E>@Z7XVT5]/5?M 1XU 9".<^E97A:9;KP\
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M-SX?OXKF]8R&Z$KH\NT$$9QF@#WY/#'AV1 Z:59,IZ$1@BG?\(IH'_0(M/\
MOV*Q/ACJ,6H>#H/)BDC$3%#O.<GZUV= &.?"F@8Q_9-I_P!^Q7,^)HT@ET^*
M)0L:LP50, "N^K@/%YQ<V)_Z:-7+C5>C(Y\5+EIME#>=W![UI^%+N_2:6.&V
M#VYE^9CVK!\SY\>]=7X'.;*X/_34]Z\3*86JLX\/4O-6.NHHHKZ4]0**** "
MBBB@ HHHH **** "BBB@ HHHH **** ,[6M&M==TYK*\4M$Q!X/<5S@^%_AQ
M9;N589%>Y #D-V%=>]S!&^QYHU8=F< TTWMJ.MS#_P!_!0!R=S\.-,N=:M]5
M-S=+/  (\/P *[)1A0,YP,5#]MM?^?F'_OX*47EJ>ES#_P!]B@":BH/MMK_S
M\P_]_!1]NM/^?J#_ +^"@">N0U/X;^']6GFFNH79YIA,Q#=Q73_;K3_GZ@_[
M^"E^VVAZ74)_[:"@#C=2^%GA_4A,&\^,RN';8^.0.*Z;0M%AT'35L8)I944Y
M#2MDU<^V6O\ S\P_]_!2"^M.US#_ -_!0%F6**@^W6G_ #]0_P#?P4?;;3_G
MZA_[^"@">D8;@0>A&*A^VVG_ #]0?]_!1]MM#TNH?^_@H Y(_##PZUW;W+0N
M9(9C,#NZL?6DO/AIH]U;R6Z27,,<DADD6-\!B>M==]LMCTN83_VT%'VVTSC[
M5#G_ *Z"@"MHNC6>@Z7#IUBA2WB&%4FM"H/MEKWN8?\ OX*3[=:8YNH!_P!M
M!0!8HJ#[=:?\_4'_ '\%.^TP?\]H_P#OL4 9NO>';'Q%!!#?*S)#)YBA3WK!
M@^%_AN"(QI ^TSB<Y;^(?TKL/M$/_/:/_OL4OGP]I8_^^A0!S:_#_P .IKUO
MK$-BD5S /E\O@9]<>M=14?VB#_GM'_WT*3[3!_SVC_[Z% $M%1?:8/\ GM'_
M -]"E2XAD8JDJ,1U"L#0 ]E#J5/0C!KD)/AKX>F^S^9;LP@G:=1GJQZYKK]P
M]11D4 <?<_#?1YM.^Q1R7$$7FM(1&^,D]170Z-HUGH6F0V%C'LAB&!ZGW-7\
MCUHW+ZB@!:*** "JM]IUKJ4(ANX5E16# ,.XJU2'CI0!D#PMHJ^=MTZ ><P=
M\+U(Z5!%X,T"'4QJ,>G1"Z!R'[YK>!I:  <#%%%% !69=Z!IE]-++<VD4KRI
MY<A9?O+Z5ITE &+/X2T*Y@,,FFP;"@CP%_A]*ET;PWI6@"0:9:) )#\P6M7-
M'TH 6BBB@ ZC%8[^%M%D8,VGPDB3S02O\7K6Q10!A7?@[0;R$Q3Z=$RE]Y&.
M]:ME8VVGVJ6UI"L4*#Y548 J?\:6@ HHHH HW6CV%[/YUS:QR2;#'N9<G:>U
M0VOA_2K-X7MK&&-X5*H57& >U:?-+0!1M](L;6^FO8;:-+B88D=5Y-7J** "
MBBB@#(G\,:-=&4SV$,AE<2.67.6'>HKSPAH5]$\<^G1,KD,PQW'2MRB@"K8:
M?:Z9:):V<*0PH,!5&*M444 %>?>-"!+8_P#71J]!/2O//')^>P[?.U88E7I,
MXL>_W+,'?\U=!X&GU!8YDCME: RG+D\US.[FNS^'I_XE<_/_ "U->3EL;39Y
MN E>JD=GFEJO=^;]GD\A@KXX)[5R$>OZCY,S"16%N"S,?XL'I7NGO';T5S.A
M:Q>:C<QR2@"&53A?[N*Z:@84444 %%%% !1110 4444 %%%% !1110!\\?%B
M>:/QU.J2R*HC7 5L=J\]NYY]ZYN)0,_WS7??%D_\5[/_ -<D_E7G.H!C)&?X
M0V32;-Z4;Q<WL$5U=--,/M$WWL#YS79Z9I<HA427,I:4 C+GBN0T>T:]U(QI
MG#25ZC9Z<6."QRF%%-&+=V>=:ZEQINI_9S<S$-SG>:R;JZNA!Q<S<C^^:]%^
M(^C0KIT-Z@_>(,,?6O-9#OL58?W<4GHS6"3BUU($N[L*!]IF.1W<U:T^[NC%
M<$W,V0./WAJC_".V!5C3LPV]Q(W.X<9I-]B84W)FU!<W!BA03S,[#IO-;SZ5
M?M8HR2RF0#)&XUF>%;-]0U*W"KG SBO2!:2"XW)PH^4BA*Y4ZEG[IY'=W%S%
M<^5)/,LB]MYJE<7-TL+_ .DS9SC[YKI_'FD-INJ+<?PS#((KE+D&6U8+]X')
MHM8J-JD7W%:^NA"F;B;@?\]#3;:\NOL\A^TS=>N\U%)D1K_NTZTV+:NS#(SP
M*+F48.3Y3<TR[NMO,\IR/[YKIK30;V:V-P\\H)&0-YK-\#:.^MZL%_@&,BO7
MM7T V-JL475E&#Z4<KW-75C'W8H\6ULWEFXA::56VD_?-8%S>7(TZ-EN9LEN
MN\UU'C0M#J$:N<E4P3ZUR=Z +*/'W2<BB]A2BIQYHEJ&_NDMS(+B4LN#RYK0
MLO%NK2*-UP>.,Y/2L+<19MCN*73QF'..E.YE!W9U%MXIU5Y2/M#' ]36Y!JV
ML/;-B8\C/4UC>$?#=QK=^5B4[%.6->CZGHR:; +=8AO"BIU.E0IQ^)GGUSXC
MU:&*9&F8,JYZFLJZ\6:PEO"PN6YZ\FKGB552:0)P63D5S%^I2W@4^E-,RJ1M
MK$UCXOU@#<+EN!ZFNG\$^.YM!FGO+GS)GE (!;(%>=D_NFSV%:%N#]EP.I6F
MR(]CVBW^-"W#D_965B>M6I?C%]E_Y=B<\UXWI%G+<W/E1@DGT[5TU_X<FBL]
MTC;G Z5)V0A"WO;G:/\ &E'=!]E?DT0?&6*21Q]E<8;%>/D$RQ#(R"<BEL?]
M?-Z[Z:,9^[L?5/@?Q&/$VD/=A"H20H,UJ>(I9(?#NH2Q.R2) Q5E/(.*XGX+
M?\BE/_U\&NS\3_\ (KZE_P!>[?RJCFW/F*\\9^)D5=FMW8.<??I#XT\2K(Q.
MN79V@<;ZQ+T[(N>[<5"_-PX(Z@5.YT*U%<SUN=99>*/%5TQ*:M=[?7?4.I^*
M/%ME@G6;P*?]NM'2--GM]+CW*5>09&12>*--G;0DG*_ZLY8XI\K2"-92?+(P
M3XY\4&#*Z[>9S_?JHOCOQ9L_Y#MYG/\ ?K+)5HPR]SS5,@@]>*+F<H<KL=/8
M>.O%4MQ(KZ[>' X^>K\/C3Q-]G7?K5T6+8X>N4T]0C/D8;:>/:KNE*TC0*1U
MDI:LNZIKS.SM]=\6S6CS+JEWQT7?S61<^,O%,:$'6KQ&5N07KN-&C^TW"VZ
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M ]ZSI+1G=C-7&_8[&.)(_D!]JN*@0<#)%59)%5F.,LO-6XVWH&QC(SBK>C.
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M."*ADU"+RSMY)%2!\V_%VXSXC^S\ @\BN))QIS #D5TGQ61QXXD=CD,,BN<
MSLA/W6%9RCS221W8'1-L]%^#=S"FJA)W";_N[N]?1 .#GHO;WKYGL4M;71TD
M@;R[N%N"*]5\&>/!J,45C=C;=J,*S'[]>G7P<HPYHGF1JJ<G%[IGH4D0^\.H
MKG_%6K0:-I;W[PI(ZC$>Y<G-;D$^Z'=+M7GN:X?XB:KIJZ/+:.Z/,QRB*<_-
M7+0AS32>QJI65WH<?!\0[V\,EO?)'Y+ C<H^[7F]ZQE\12 G*L<@^M=1;:;!
M9V0O-2+;6X6,?Q5@:M#;PZFMQ:AA&V/E/.*UQ/L)3Y*;U._+HU)476<?<[GI
M/@=-MY;@CJ:]AWH,,PX'>O&?!5S#+=0)&_S@ XKU=CYD(Y/(VFN>49124E8X
M9-<S=]#E=?\ B$D-Y)9:7#YTZ<&3^$5S]CXSU"/48X]4$1CF/#J>!63JVG+X
M?UF[LKB1E@N0724#UJIIUC#JE_:V<9+6MNVZ>8\ "NI0]]1BM+&*:?7WNQ%\
M3I"=0MR,%67(-<%I6!/)W^:NS\?3PZA>[-/5I(8!M#@9!KD=)MGDNRBJ=Y[5
MRSP\N8]?#3M2D^B/6O!,8$\84=1G%>I01#[XR#[UXMX9UJ30M5CCOXR$;@,1
MTKV6"YCEME=) RL,@U=2BZ=CS='*R=RMJS!H@%['FN<U*5_LKXX&.#72:D(E
M@,KG"*/FYZ"O+]6U6;6;EX+.<06,0VNY_B-*G%23OLB92<%?<X!<_P#"91$]
M[E?YU[9XP^_IW^\U>-R6/V+Q39'S!)').A1\YSS7LWB]29=.'3YFHC&#E[CN
M<69J2P[YE8P^=U;W@>SN9(YIH[DK$)3E,=:Q]O/2NH\!#&G7 _Z;&M:M/E5S
MPLIUKG7=!2U!=QO+;.B2F(D??'45Q+76HQ)/LU"4I; NKD??QV-<Q]8=[17(
M^'-0O+VYBN9YV83J<Q]EQ774 %%%% !1110!1UB^ET[2IKJ&V:XE1?EB7JQK
MS;P/XQU_4O&.O0ZZOV>*UA$B6V/N#ZUZO7ENAZ7=2_%?Q8\MO*EM<VXC60CA
MCCL: *.D^(M9\5WDU[;^)+;3C'=&*&R<C$BCU]ZTO',OB71K&ZUA_$"6T$:*
M(((DQO;N#7!S>'+G3M)O- 32I_[9>]W6]TB$C:3G.[M7;^(-;=O#TWAS5]!O
M)KI;4+'+Y>]7DQC(/UH O27'B76_"6GZI_:<>DIY'F7#;<L3CC%6_AAK^IZ]
MH<\FI'S?*F,<5QC_ %J^M8VAZM?>$O!VEZ5KVDW5WYL3>8R+OV#L"*M_"JPU
M&W75KF:&2VT^XN"]K;R#!1?IVH ](HHHH \-\77)M_B]N/W?+2NIUIM\438]
M#FN(^)T5R/B#+-#&QPB8(%;UUJT46CV4ERP60C!!-2MSHE[U-/L=?I6V6U1S
M]X5JW*#[,S.< #-<IIFL01I&O #8Q6[J=R&T]@'"@K5(Y]T<5JESONV"<CVK
MS+QA/YEQ$AZ#)-=[<R+&'9G' )S7E>OWWVNZD*] <"IGV-:$;RN5O#U[%::X
ML\I^4\?2O0;^Y_M6&&*SMI&&X$/CI7DT6?.7'7/:OI#X<WMG<Z1%;/%'YR#D
MD#-;T:E.F[R6HZ\/;*ZZ'5^&I'&F6UK,S%HUPQ/6N@<;%&SDC@UB01/!>.ZC
M*]2!Z59M-<L;])&AD7"DAN>]3\3;,[70FO2F.R=P>HYKS:ZD7[-)(PYP37=Z
M]<QR6#!2,8ZYKRWQ'JMO;6+1JP$A7 %0VD@@KRL</#.#K:OGJYQ7MOA\7;>'
M+U+!@ERR@H?>OGDW16>.3(R6->\_#?5(K^U\H2@2A>>?2IIRY3KQ7O)270ZW
MPY'J']D)_:1S=\ACZUT<95(59R!@=3Q56VY'+?,&ZUD^+-)O]9MHHK*]-N ?
MGV]ZTLI2.+1LX[XE>)[NVO8["QN-B%,N5/->3:Q;S7&F27,HD<'^)SUKUS1?
M"4EWKDC:C$7BMQL&_G<?6N4^*]Y:6*II5K&B$')517:ZU.C#EZFD87E8\K _
M=1QH,L"./>O<_ T+$0R2\$*,9KQ31'5=4M]Z@@G)![U[?H%R-RX^5>,8KS5N
M=&+ES6:/0OM<7F%3U%-MKG[1=$+G8O>J%I$;BXWJ-P'!K9\I+:3;&F-PS5G&
M4;\A+C@UQ7CNY3^SQIR1AYIP3D]JZO4Y<*3T.:Y;QOID=SH<=Z9/+N(AP0<<
M5M1<5+WB91;MRGA(A>SN51CMV2UZ]X%(.HI(W4UY(&%Q>D2,3E\YKT+PE<2Z
M;XAMD=LI*.!6E/#J:E-'9BY645Y'M\=TO.2  *B6X2<N!AAVQ6(Y>Y>1%) (
M.,5<T.QDMHV$A)P#C-<QRE._(!*@8QWKSGQ[<6KVC6V09?O<<XKM_%5W+!92
M&W7+J#SBO+5GCFT^X6>)WN9<G)&<5UX>A&I%MF=2?);3<])^"6?^$/N!G_EY
M.*[?Q&YB\-Z@P&66!C^E<;\&;?[/X5N$W9S<$UV7B5MGAO4&QTA8FN62496-
M7!WY6>'6%SILDBWS.8YMF&3WJ?PL8KG6[@&1AYGW%]:R)[6"ZL8[VUP,\.O;
M-=%X*TR)+G[;."KQM\H)Q7H4Z=&%%N&[(G3K*KS3E<[_ $O1F%C,F\J <D5Y
MSXHU W&JG3;,Y"G'%>DZMK"6.B3R!P%Q@'U/I7B]M>!=9^U3<!V))J,+1<HN
M36Q-=\D&QFNZ9!;Z?(%G+W"8W<],UA^$M4%AXH@)( ! _6NA\3"QBLY[F&YW
MM.  F>AKSB-W6[4K][=P1UKSJDZE1^^MCT,-.E&DO9O<^O)KL3Z;&RD;74'K
M5K1W&[;GMS7E/A?6+E?#:27LQ0HV%5SR171Z?K,L6HQ2(^Z%NI[4TSEG'EE8
M[C5KCRPB8X/4U1/EI$TC.!Q1>ZS8SQJH8,^,GVKSKQAX\L;>R>VM[A6GY&%-
M/8E/4\R^(]XFI^,G\G#*G (KG)B([B)P#P15A"TDTD\K!G<]35.\ZX)QWJ$[
M2N=::A!'=_8U:SM[B+F)\!C[UN:S:2VMG:W5L"A1>J\&N4\'Z@;E&TQP768?
M(PYVFM[4KO4(+?[#<QE=OW6/>O9PE:56R;V/)S'#U%B(SI[$^FC5=5)=]0N%
MB4\X<\UIQZ-;_:A+)))-(/\ GH<US>G:O-8<+RIZBM,^)R4/[K (QD#O6F(H
M3<N6%DCR,5];E)Q6QH:SIG]H^6WG"((-NSM6)+:Z:=0MK2%RRQ#=,W7-1BWU
M*ZCENB72%0268X%<UIVM_8M>,P4.B\$-WKR98"&'FW&5Y'U6!KXGZJJ-5^ZE
ML=UJ2#2GMM4TXF, C';(KU;PSJ:^(=&\QCL;'.*\2OM2N=44$)B(=%4<5Z1\
M+;@_V;<0J<LCYQ78Z;>'7.[LX</&4$U([1]$M;^,B]A250, LN37FOCQX-,E
MBTO3 D"2'$GE]2/2O1-<U.YL;.66#:ZB(D\XP:^?[J[FN;J2>5RTC,22QS5X
M*G*?O-Z(N;:@^5FI>O=:>Z6MLH6(J/X<[JR5>73[EY"H6<^W2K,FMWEC;H)1
MP?NEEJGIA_MAYFDN427.=S]Z\G&X>M3YI*5[GT^3XR@Z*I5X62Z]SH-*N_[7
M1[.[19'"Y1^]&F>(]0T+4#ME:54.TQL>,5<TVSL],MWE\Y9)MOWAVKE9G\RZ
MDD/\3'!KKR>G5DFJVQ\[F.(PT\=)X1>Z=;KWCB[U1%M[<>6CKAL=ZRM8AEL[
M"TACR%=-SX'>L>$?Z1&>.&KM[C4H;2S07)1@5R 5S71FF%G*FH4%ZG+3S2&$
MQD)U(\R70Y#3[=II8G*G$,R')]R*]?\ %G^OTTGU->57FOB\U2RM[>%8T:=,
MX&,\BO4/&;[7TUA_>.:X\)AY4I1A+<O/L6L51=>,>5/H4L@FK_A2POKF"ZDM
MM0:%3*1M"UA?:""/K77^ &W:;<''_+4UZ.,IN,$SY3)JBG7LC<.FW4ND26DM
MXYF88\T=165:^$7AMO)>^=U.0V>XKJ12UY1]@8NFZ FFW7F1RDQ*,)'Z5M44
M4 %%%% !1110 4F!DG R:6B@!-HSG S1M!Z@'TXI:* &[<_> /X4H&!@#%+1
M0 4444 >"_$[5[JS\<RQQA=JHC#(]JX;4-3N=2V>>WRJ<@#M75_%@@>/;C./
M]4G\JXG')!J6:TI):,Z_PSJ%Q>RB,G_5"G^)O&4XB^Q6[G@X8@]*J>#7%O\
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M( 0!C-0]2Z2Y/>9'K7EB\S:IE2?E KL/!6HQ^%UEU&]E*!E^2,]S7-Z4BMJ
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M2/F,CP_LZS;.Y%+2"EKPCZ\**** "BBB@ HHHH **** "BBB@ HHHH ****
M.$\3?#*R\2ZR^I37LT4CJ%*H!CBL?_A2.E9S_:-SQ["O4F8*I9C@#J:SX->T
MRYMYYX;V)HK?_6L&X7ZT <CIWPLL=-M9X(KZ8K,,-N45DO\  [2W8G^T[D9/
MH*[V7Q3HD%C'>2:C L$APC;NIK4AFCN(4FB8,CC*L.XH+4Y+8\M'P,TK&#JE
MU^0JM+\ =(EZZK=_D*]?HH(>NYY#:? +1[2ZCG75+IBC9 (&*V]4^$NF:K<I
M-/>3C8N%  KT.J4VK6%O?QV,UU&ES*,I&6P30!Y\?@QIA_YB-Q^0K0TCX7V>
MD22/#?3,SKM.0*ZNX\1:3:W$T$U_"LL";Y$W<J/>F:3XETC7'=--OHKAH_O*
MIY%*Q7M&<#-\$]-N)GD?4KD%B2< 5'_PHO2L_P#(3NOR%>L44["<G+<\E'P)
MTQ6+)JUVI/H!4'_#/^D[]W]K7>>_ KV&DS2L"=G<X+PY\+=/\.F4PWDTID7:
M2PK'G^!NE3W$LQU.Y#2,6. .]>D/K%A'J2Z>UU&+MAD19YJ%O$6D))<QM?P!
M[89F&[[GUI@VV><GX#Z201_:EU^0J)O@%I3 !M7O#CU KU+3-7L-9MOM&GW*
M3Q9QN4]#5V@.9VL>36WP(T>"=9&U&YDQV8"M*7X16#+MBU">+_<4"O1Z* 3:
MV/+O^%*Z:<L=3N68C[Q S6Q:?#+3K?3OL;W4LJ]F8#(KM9YXK:%YIG"1H,LQ
MZ 50'B#2CIIU$7T/V0'!EW<9H$<.?@YIW;4K@?@*ICX':<MXMRFKW:NISP!S
M7H$GB;1HI[>%]0A$EPH:)=W4'I6N"",CH:!IM'E5Y\#]+O+CSGU2Z#$<\"I[
M#X+Z58*X34+EB_4G%>G44+029P6D_"^TTIY#'J5RX<YVD# JY<?#^TN$8?;9
MU9AC(%='%J]A-?RV,=U&;F(9>/=R*B3Q#I$D5Q*M_ 8[<[96WC"FG=@<#_PI
M:P6?SH]7NT8]2*5O@S:LQ;^W+X$^]=Y<^(M)M-/BOY[Z%+:7_5R%N&^E:$$\
M5S DT+J\;C*LIR"*3U&I-&'X3\+IX5TQ[*.ZEN0SER\IYK3U>R?4='N[.-@K
M31,@)[9J[10(\+7X(ZNO34;<?@:W-$^%FI:9;SQR7ENS2 @$ \5ZQ6)XD\4Z
M;X5M(KG4I"D<K[%('>@%H>3S?!/6)'9AJ%L"Q)Y!ID'P0UJ.97.IVQ /3::]
M2OO&^C:?J.GV4MP#+? -%CI@]*+/QKINH>('TBU$LCH2&E5?D!';-&@VWW/,
MM5^"FK7Z+LO[57'?!K(;]G_7#C_B:6O!]#7T110(\6L_@YJMNL(:_MR4()P#
M6MK_ ,,=2U::W>.]@41)M.0>:]3KG_\ A,=('BAO#[3XOE7=@]*+ >8M\%]8
M)S_:%K_WR:@;X(ZPV?\ B96PS[&N_F^)^@QO>K&99VM'VN(EW?6M?PMXNT_Q
M9:RSV <+$VUMXQS18'KN>3?\*.UC_H)6O_?)JE+\ ]<=]PU2T_[Y-?0M% 'S
MN/@!K@(/]IVGY&NC\,?![4]%U>*[GO[=U0=%!S7L;N(XV<]%&37,6/C_ $+4
M++4+J&YPE@3YX(Y&*+@KGG_B3X/:OK.N7%]%J%NL<IX5@<BLO_A1.M<?\3.U
M./8UZ/+\4O#L6BVNI^:[I<L52-1\W'4GVKJ].U&VU6PAO;1]\,R[E:@ISD^I
MX/+\ ]:>3<-2M .^0:6+X"ZY$V1JEK_WR:^@J*"3P,? O6<_\A*U_(U+'\$-
M90$?VE;<^QKU?5/&.DZ/KEKI-Y-Y=Q<_</:JES\0M M=7N]-EN@)K5-\A'(^
ME)JY4)NGL<7_ ,*R\0_V.NF?VE;B#N,&LJX^"6L30,@U"VR>F0:]2\-^,-/\
M3B46;,DD1^:-Q@X]:Z*ERHTG7E-6/G^U^!7B"TDW1ZO; 'J,&M2T^#6L0+(7
MU&V,C'A@#Q7ME(>!FJ,3PAO@?K1D+?VC:X/L:V_#GPIU31KYIY;VW=2N. :[
MBQ\=:'J%YJ%K'<;9; %I@X[#KBJ8^)?AUM$;51<'R!+Y.,<EJ5BG-M69PNH?
M!O5[N^FN%U"W D;(!!XJK_PI+6<?\A&U_(UZ5JWQ T31A:?:97)N5#@(,E%/
M<UTUO/'<V\<\3!HY%#*P[@T[!&3CL>*6?P5U:WU&WN'O[8K'(KD 'L:W/B9E
M(=-!;.)"#7JE>4?%9MD&GD?\]6KJP?\ &1SXB//!IG$^=V!%>@_#+3UN=-DN
M_.D!64C:#Q7F'F\^N37K/PE8?\(Y,,\^<>,UZ>8/]T>?@Z*C*YZ$**04M>$C
MU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:ADZ?<@#)\IOY5\T0:;X
MAL?M&GVEK.MOK+.)."0,5]/\=Z9Y,88?NUXZ<=* /EX:=JVG1V1:WF$,*MY2
M21%U9L],5]'>&)+B;PUI\EW$(IVA!= ,8/TK3:")@ T2$ Y *CBG]!Z4 +11
M10 5X?\ %+3M2F\;Q:CIT$QDLK<2JZ ]1VKV\GBFE$;EE4DC!R*!'@?@W3;N
MX\52ZKK]G,Z7]H\LH9#C&.A_*NT^%/A];5M4ULVOV8WDQ6.+;C"#I7I&R/IL
M7@8Z=J<JJB[5 4#L!0,6BBB@ I#2TAH \*\=Z?JD?CV^UZQAE+Z?$KJ #ANQ
MKEUTW5 NKW%W97#37\ D<A3A<G-?3;(C;LHK9&#D=::T43 AHT((P?E'(I"/
M+_@M%<6MAJ$4L#[6D#"?!"OQV!KU6HXHHX4V1HJ*.RC I],8M%%% '/^-TDD
M\':FD2,[F$X51R:^?'T/Q ND_P#".+#<&Q:,7APIX]17U"WS#'!^M)Y:<?(N
M<8Z4 ?-6J:!=JVE_8Y))[F6.$%&1MT0![&OI"QC>*Q@CD)++&H)/KBGB&$/N
M$488# .T9Q4M !112$XH ^>/$]KK>E^-M4US38)]WF^2=@.&#<4_2M&.E^$?
M$D&J03[V4%3M/S2'FOH)HHVSE%.3DY'6D:&)U*O&K ]05!S0,^=)IEN-'\/O
M=VMS+I]M;M"\?EDA9.QQ7L'PUM;NT\&6L=V'4DDQJW4*3Q74?9;<1^7Y$>SK
MMVC%3 !0   !V% A:*** "N ^*'AN[\366GVEO#YBB;,A_NC'6N_I#TH ^>;
M#P%XH>]M[F\MW9[>?R8B6^[&.A]JU_"/AKQ-I?C4*D<\,"SO)<.S?NW!Z8]Z
M]NZB@  ?C0(=1110,*\.\<>$O$5SXPU+6=(M6\U0ODN/XN,$5[C24 >(>'_"
M6M^%QK<L>G&:2>U7:6&=TA^]^5>E^!?#_P#PCWABWMY$ N9/WDQQ@[CVKI:2
M@!:*** (+Q&DLIT7[S1L!]<5\^-\//$T=RJ6]LT<-^[+=@'C Z9KZ*I.M 7/
MG74O!'B!=%TZV.E.(X6< P8W#GC/M7M/@>RO-.\(6%K?1K'<1IAD7M70\8HH
M 6BBB@#R3XD>#]5U_P 2K=V5N6\BWW1/G^,=!7,Z?\/M51_MFL6$]PUS;,\_
MEGYT?L*^@.:0DT >8?"WPSJ6F:CJ6IWJ2I'<*J1+-]_ ]:]0'2BEH *1ONGZ
M4M% 'SYJ7P_\2G5;B^LH&C^UW3138/6(GK5BZ\*:KI/@&^TB/17N9WNP8BH'
M '>O>J/RH \"U+0_$4SFX31)9/M]DEMAN?)(ZFO:O#EA)IGAVQLIF)DBA56S
MZXK3X^E+0 5Y)\6SBTT__KJU>M5Y#\7FQ9:?_P!=6KJP?\9$SUB><>8>N:]3
M^$^F"?1I+KSY%Q,?E!XKR?=QUYYKV;X.\^%93_TW:O3S!?N3GH1U/1!TI:!T
MHKPD=04444 %%%% !115>]O(["QGNYL^7"A=L=<"@"Q17-6OC73;OPBWB1%E
M%DH)(*_-Q5-_B1I":=I-\8YS%J<OE0\<@^] '8T4@.1FLK7_ !%8^'K-;B[8
MDR.$CC7EG;T% &M17(VGQ!TJ>UOIYX;FT^QC,B3QE3^%/T/Q]IFMZFNG+%/;
MW$B>9$LRXWKZB@#JZ*** ."^(?Q G\%/;"*Q6Y\Y2?F;&,5PX^/=]LB9M&A&
M_MYAJ;X\C]_IC>B-Q7C#/YGV4=^<CTI7U->6*C<]QTWXRZIJ4K"/1H0BGEO,
M-6M4^+6I:?;^>-)A9!U_>&N!\,Z;+;Z8\Q&/-;Y>*VSH1U&PFMI9,94E?K39
MDK7U+"_'N^8$_P!C0\?]-#4/_#0=]]H$7]AP\C_GH:\KEMVL[V>U899"15".
M/_B8J/13FIOJ;S@E#G1Z])^T1?(<?V%#UQ_K#5M/CSJ#R1C^Q8 &&<^8:\-9
M?,FVC^]S6B3B[@4-\H7I3N*,$H<TCVI/CE>LRK_8\)).,"0U:7XQ:M(KLFAQ
M;5&22YKA/"'A6;5'6X8?*IRH]:Z?4K,6*F'8/0@"@Q35P?X^7\;,&T6'COYA
MJO+^T+?1N@&B0G=T_>&O,-5VIJLR*,*2>GK6/=+MN(E]*+FTH)QYUL>UR?M
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M*\I'2O8O@_<PQ^%YEDD56\]N":]7,/X)ST7J>E$A5RQP!U)J)KJ!0A,J@/\
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M).K(64*?F.>M8OBC3&?2WC89 %>KZC-%'$H" \<\5QWB'RGL'9.6(Z4 ?/\
ML,4CIZ-7J?B\;O!7AO/]VO,]10KJ<N?7I7M.H^%-2\3^"-"&FF,-"@+;SBM\
M/44)J3''?4\SV?-^!XKU+X1Z9:SZ+)=.A\Q9VP<^]<Z?A?XHR0!;>QWUZ3X
M\-77AC0S:7;JTK.7.T\<UVXO$PG3Y8E22Z'5BEHHKRT0%%%% !1110 4444
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M) W<YK+,Q@12XR .:!J,5R-D:-[DT 0^(X8Y=)F;8@9E/(7DU\TW,'V?7)T
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MA6-9 WI7IK%5MC@BM3@,BZE#RL!\HKQ7XJP&/482#\I%>UR!'W,2,5YC\3K
M3V*3J/N4 =#\$O\ D4+C_KY/\J[?Q-_R+&I?]>[_ ,JXCX)?\B?.?^GD_P J
M[?Q-_P BSJ7&?]';^5 'RWI4)GU.-!R,\YKV32K+%C$F.@KR[P;;"XUP \A>
MM>V0H(5 4< 4 5-4EU:'35?24#R@X(;FMB*.]FT.$WJ[;HCY\5)I#9!ZCYNI
MJ_?EO*D9...IK2^E@/"O'C^4)T9B2!R:\WC &G.H'!YKT7QXH<W.:\Z7)M6
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M3'4XK.>Z._"?!,ZSP\L]I!$S']V[Y KW7PQJ226<1/4<8]:\A$2I;6UN@ P
M2:]'\,64K6HDWX48-7U. [*^B#N<\C&:YJZLEDCDR..W%=#ARA8G..*J7000
MY'7O3 ^?/%]F+/6G."%8\5[QX>OY;?PCH\-JH:>:(!=W2O'?B-M^W*0!NSS7
MLOANQ:[\':3+"X2>.$;210!ICQ!%9XAU E9E'SLHX%-G\6Z9 8QN=VD'RA5R
M<54N?#%Q?EEN;@%9>7(ZYJ*T\&M!J<5RUP&2%2J#'K0!>3Q;8DS,VX1H0%..
MI-;EM.MS;I,H(5QD US)\*-';3PQR*WG/NR1]WZ5T.G6GV&PAMMY<QK@L>]
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M6I-:DPI24N5G:?:9IM*GMH[W<W.&S7G^E6LT>IRN[[N2"?6I'-U%D(955NN
M:=IQD%PQ97P!_=-)VD^8=22O[,R;R0)J$F1E6)!KI_A]?7^GZE)';H6C8_-Z
M 5RE\&:ZD.QSS_=-=1X*U.33VE:2(NI&/NFI6Y4&IQY9;GIM]X_BTC58;=P-
MLBC)STIFJ^.8)+F+RSN P20>@KSK5-M_>/,83R>#@UT?A.QM+JQODN82<1G!
M*FK,5%-V*_B'QRUW=I':'*KU.<US!UJ]2X,@DX)Z55DM5M[B81(VW<<<&F.K
MG'RM_P!\FDMS6<E"/*BNMG<ZKJN4."[=<=*])\,W8\(+,+V]0K(F0OO7G-I?
MW&GWN](V..VTU%?7]S?73S3HY4CA<'BE+?0FG*ZY#VOPC\2A>![2?@ASY9S6
MU>>()$F#M)MC/4G@5X3HJ/#J-HR*_,B]C7HOQ.F>#3;.* ,@8#. :JY$H.,K
M%+QAX]5IOLULVXJ<-(/2N5\4WDMQ;VSQY^SLHRWO7/.CJ2[HY/;Y375Z0@U'
MPY-;S(2R<@E3Q2N;1_=Q\SG]/TV]U D1@1HI^\U=?H.LP^%6?S'-Q*1T7I6/
M?SO;6<5O;&08&&PIK+"/P"KG(YRII,FE4W@^I[?IWB0ZG81SPEP3U4=JT=3^
M($&AZ>6F;<RC[N<9KC_A[&\6C7LS9 125!'M7$ZG))J5S*\ZN5+\ @XJHF4E
MRNS/6U\<W&I:$)K)5:249QG[M>$^(I+C^T[F6X&9G8YR>E=7H6H'29&18FPX
MXX.!7(>(+A[O5IY!&^,XSM-3;4VBE"-^IDVQ9I%)YYKU'1+R.;2PH;)C7%>9
MP1R>8JHCY)X^4UUUHDFC619MQDF'W<'%#5F%)\R:9ZWX'ODC@FRXX.:Z4ZK%
M<EPK=L5XAX.U>^BNIK>-6=G!(# BM:^U_4],MFAF3;.^<;5)XJEJ86L['I$M
M[;RSK KJ6'7::Y7QQXG6TM39V\@:0C:0.U<9X=U^33M4>YNUEE$O!8@_*:EU
M30+F_O+B^M9&D63Y\,#2DM36C%.5WT/4?@L"?"MR[=3<&NU\4#/A?4A_T[M_
M*N-^#4<D7A>YCE7:XN6S7?ZA9IJ&GW%G(Q5)D*$CJ,TT1*5W<^0HPT;94D-G
M@BNQ\/>,IK>2&VN 6(."<UZ-_P *3T3_ )_KOKTR*%^">BJX;[==Y!R.14V+
M<U*-F9*ZR8G-S(S(@&?:N=UOQ;::C:29EP-V  :]5O/AQIMYI_V1KFX5=N-P
M(S7-_P#"B="Z?VA>8!XY%4G8SC9,\4U>YM+BU=T9C(H !-<_EG:'D]17T4_P
M&T%Q@ZA>?F*8/@'H 92-0O?E.>HI6UN7.=U9'F$2[((^/2NAC\[3/"$TJE1]
MH.T"O1?^%1:1L5?MMU\HQU%7;KX;:9=Z7'9/<SA(^A&,TQ0J..A\^$@,".&7
MG(J&]EFG(>20MCH":]T/P8T4_P#+]=?I3'^">B.I!OKO\Q2:-'."^%'S_P D
MDU$\AA>.1>J'=7T"/@;H0&!?WGYBHY/@/H,@P=0O?S%,QD[NY\\SZC-=7)D>
M1@#T&>E:NBWTVFW221R'86YYKVO_ (9_T#_H(7GZ5,OP)T1$VC4+O'OBI:-H
M3BX\LSE_$NH-8>&[>_MW;=/C)S7D]S++/<&8NQ=NIS7TYJ'POTO4=%M],EN[
M@10?=88S6&WP(T)H]OV^\^N13L1#V:/G@Y9@N20.M64Z@^E>]#X!Z""#_:-[
MQ[BI1\"="'_+_>?F*+:"J2YF>#I I8L37?\ A^>RA\-3E)$CN0I^IKO5^!^A
MJ,?;[S\Q4J?!;1D&!?W?/N*2B4YIQLSS3P:KSZQ<#>0-A:LN^D+:C*S,3\QK
MW#2/A;I6CW3SPW=R[,NWYL53F^#VD33-(;VZRQR>E-HB%D]3PS5!NTZ4URR,
MX4C<=O7%?3,_P9T6>W,)O;L ]3D5FC]G_0!_S$;WGW%"5ASFY,\0L;4I$MY.
MWR C:OK6YI.KW)UQ-K$1O\H%>OM\$-$:U2W^WWFU>AR*?:?!71K2YBF6^NF,
M;9&<4K&G/%QLSSWQ'K$FGP"TAD^:0?,?2N7TW6;O2)Y)XR&:08);O7NFI?"+
M2-2NC<27ERK'L,8JF?@EHK'+7UV?RIV)@X11Y%!XAT]MQNM/0R$Y+#UKV_3H
M(-3T[08V+B!XRVU6Q60WP,T(Y/V^[S^%;L]FVEVVFV-FS.T"E$;N<4)$3=V;
M"^&]'D<JA<L."!(:!X7THN4'FEAU'F&LJ:]BMK",6LFR=CB:3KM/>LU-9OC=
M2[K@I'QMEQ]ZF2=2?"FEJ,E91COYAJ.+P[HTY(B=G*GG;*346BW-YJ>BW3WK
M^7N)"'T'K6)8WAM+S[''.J1;LM<*/O>U '0S>&M'A"F3S%#' )D/6H-0T"RT
M^T:ZMO,$B$%3O)[US/B#6[V6]5(B6B23*@=2?I5FQU+5+RWN1>N@CXPH.<4
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M\"^([KQ'JFKZ;;%9C,H@8'&Y3UI;+PAK/AK0]=MVT9K[[5$$C/!^8]37N5%
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+X(MXP?[HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gtbp_s1001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_s1001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E 94# 2(  A$! Q$!_\0
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MBN*^+/\ R(DO_7U;_P#HP5VL7^I3_=% #Z*** "BBB@ HHHH **** "BBB@
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MK"TFF2^0;_*0G#CC''J*G^"?AW57O+V]DC5=*N(GMIPS?,6';'4$5[ZP4C+
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M2U#4K2T2.^OP/M$HSE\#BM2BO!-3*T!;N#3H[2ZM# 8%"AMX8/[C'2M6BB@
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M/&;_ 'ZZ6@ HHHH **** "BBB@ HHHH **** "BBB@#A_BS_ ,B)+_U]6_\
MZ,%=K%_J4_W17$_%IA_P@LH+ '[5;G!/_305VT)!@0@@C:.0<T /HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,ORC.L\(.#
M)"4S]1BO./ >O6G@_P +7/AC5Q+!JMG/*D-N4):X#'Y2GKFO3;7_ (^3_N"K
M9BC9P[1J6'0D<T >2?"62VM;#6-!U2%K+6[NYDDFMG4AF1@<$=B #5GP1JL7
MP[M;KPOXDWV<%M<.]E>.I,4T;'(&1W'I7J?EIOW[%W?WL<T/&D@PZ*W^\,T
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MHHH **** "N#\"_\CAXU_P"OV+_T$UWE<'X%_P"1P\:_]?L7_H)H [RBBB@
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M;UK_ +\5WU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?44 <#_PL^/\
MZ%O6O^_%'_"SX_\ H6]:_P"_%=]10!P/_"SX_P#H6]:_[\4?\+/C_P"A;UK_
M +\5WU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?44 <#_PL^/\ Z%O6
MO^_%'_"SX_\ H6]:_P"_%=]10!P/_"SX_P#H6]:_[\4?\+/C_P"A;UK_ +\5
MWU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?4=J /%/ 'CV/3--U*/\
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MJD@VKGV!YH ZQ9XGE>))4:1/O*&!*_45)7*>"Q&]M<ZM(V)M7N7G16ZA%^4
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M " !7/4PT)SYV)QN?/7BK4FU;Q-?W9#!6E*JK?P@<8_2O2/@YI&RUO-6=?\
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M)"A/3%>DPHLLCQN,J\>TCV(KB=&\-^*_"MI>:'I2V%QI<LSO;3S2,KP*_4$
M<X[4 8?PQN=6U/\ X2K6[^:22:",643$\.8U/S?7@5N_!%4;X<P7)8/<7%Q-
M).^.2^XYS]*F\!>%]>\'?:-&G-K>Z5)*TRW18B4ENH*_6C3_  UXA\&:C>CP
MZ+6]TB\F,_V6YD*-;N>NT@<@T =MJ7_(*O/^N#_^@FN&^"?_ "3.S_Z^)_\
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MX/Y5-4-I_P ></\ N#^534 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX/Y5-4-I_P ></\ N#^534 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0>E%!Z4 <'\*_\ D$:Q_P!A6?\ I7>5P?PK_P"01K'_
M &%9_P"E=Y0 4444 %%%% !1110 4444 %%%% !1110!1M?^/D_[@J]5&U_X
M^3_N"KU !1110 4444 %%%% !1110 5R>M>'+R\U*2Y@9&63'!.,5UE% ',:
M9X>N;?3[R*9U#SKM4#M64OA/4MP!\L#/7-=Y10 R%/*@CC)SM4"GT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 <'
M\*_^01K'_85G_I7>5P?PK_Y!&L?]A6?^E=Y0 4444 %%%% !1110 4444 %%
M%% !1110!1M?^/D_[@J]5&U_X^3_ +@J]0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !0>E%!Z4 <'\*_^01K'_85G_I7>5P?PK_Y!&L?]A6?^E=Y0 4444 %%
M%% !1110 4444 %%%% !1110!1M?^/D_[@J]5&U_X^3_ +@J]0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\7W/ANPTF:[NK>W6X=@V!M/_ .NM_1[Z^OH9'OM/>R=6PJLV=P]: -*BBB@
MJ*ZN%M;2:X<$K$A<@>PS4M4=9_Y E]_U[O\ ^@FDW9%TXJ4TGU9Y#=?&#6#<
MR&VMK=(<G:&&3BKWA[XK:E>:W;6E];0M#.XCS&,%23UKRMOOM]:T_#?_ ",V
MF_\ 7RG\Z\.&)J\R]X_4J^1Y>J$K4EHGZ['T_1117NGY48>AZ//8ZCJU]=NK
MS7EP63:?NQ@#:O\ .MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gtbp_s12019000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_s12019000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '> G8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBH;JXC
MM+66XE.(XT+,?84 345X+HGQ:U^?QG"+TQ#1+BY:&,[,=^.:]Y!! (Z&@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K@OB[KO]C>![A(V/GW9$,8'4YZUWM<]XC\':9XI
MFLWU(2L+5_,C56P,^] 'S_JMKXBB\!6%JWA6:"*Q?[0+S=G/N17O?@OQ#!K?
M@_3M1::-=\85MS8^8<5MW6GP7FFR6$RYMY(_+9?:N5B^&6@0:*FDQ-=+:I+Y
MP F(.Z@#M001D<@T5'!"MO;QPIDJBA1DY.!4E !1110 4444 %%%% !1110
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ML<GWJU/86=R^^>VBD;IED!-9#>./#*$JVLVH(_VZ;_PG?A? _P")W9\]/WE
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M=VT'K7NX@CTG3%@@A52>GM7AOAG6+K1D\ZU;>#P=PZUU6M^*;J:U2;[0T<Y
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MSCG->B?#5-NBSC_IL:\7*JO/4:/I>(J_/02.V'3D8I:**^C/B@HHHH ****
M"JU_9IJ%A/9R$A)D*,1U -6:* .8M/!&GV?@UO#,<LOV1E*EB?FYK.O?AEIE
MWHFDZ8+NYC33'\R&12-V?>NXKBOBAK.H:#X2-YIT_DS"51N]C0!KV/AV>WF+
M76K75["1@PS %33-7\&:/JMHD(MDM7CD$D<L"!65O6H-%\8Z;=C[!)<EM0MK
M19[@;>@(SFGQ>/?#TVCR:HMZ/LR2>5DKR6] .] %2S^'.CV\&H+<-+=S7XQ-
M-,?F/I3M#^'VFZ-J'VUIIKN41^4GGD'8OH*T]#\6:5X@FEALIG\Z(9>*1"K
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M* !BG1FXJZ.G%^[4.;T3X9Z?977GWLOGD'Y%[?C783Z5:);A+>V1<<#"U==
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M--*2^([R7PF+*QAU&S/G+U=2.E>@Z7XVT5]/5?M 1XU 9".<^E97A:9;KP\
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M-SX?OXKF]8R&Z$KH\NT$$9QF@#WY/#'AV1 Z:59,IZ$1@BG?\(IH'_0(M/\
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MDI:LNZIKS.SM]=\6S6CS+JEWQT7?S61<^,O%,:$'6KQ&5N07KN-&C^TW"VZ
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M ]ZSI+1G=C-7&_8[&.)(_D!]JN*@0<#)%59)%5F.,LO-6XVWH&QC(SBK>C.
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M."*ADU"+RSMY)%2!\V_%VXSXC^S\ @\BN))QIS #D5TGQ61QXXD=CD,,BN<
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M]4G\JXG')!J6:TI):,Z_PSJ%Q>RB,G_5"G^)O&4XB^Q6[G@X8@]*J>#7%O\
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M( 0!C-0]2Z2Y/>9'K7EB\S:IE2?E KL/!6HQ^%UEU&]E*!E^2,]S7-Z4BMJ
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M2/F,CP_LZS;.Y%+2"EKPCZ\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MJO+^T+?1N@&B0G=T_>&O,-5VIJLR*,*2>GK6/=+MN(E]*+FTH)QYUL>UR?M
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M*\I'2O8O@_<PQ^%YEDD56\]N":]7,/X)ST7J>E$A5RQP!U)J)KJ!0A,J@/\
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M).K(64*?F.>M8OBC3&?2WC89 %>KZC-%'$H" \<\5QWB'RGL'9.6(Z4 ?/\
ML,4CIZ-7J?B\;O!7AO/]VO,]10KJ<N?7I7M.H^%-2\3^"-"&FF,-"@+;SBM\
M/44)J3''?4\SV?-^!XKU+X1Z9:SZ+)=.A\Q9VP<^]<Z?A?XHR0!;>QWUZ3X
M\-77AC0S:7;JTK.7.T\<UVXO$PG3Y8E22Z'5BEHHKRT0%%%% !1110 4444
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M) W<YK+,Q@12XR .:!J,5R-D:-[DT 0^(X8Y=)F;8@9E/(7DU\TW,'V?7)T
M(!SUKZ0U.X+64J/'GC&:^?=?C$?B!F4YR#4U&W&QTX/^.CE[N,MJ 5>26Z5]
M$^"M$G32[.<Q\87BO#=.LOMOB.VC(P-X)KZQT6%8=-ME51@(.E$=8D8A6JR)
M9K-5(D6,'(Y%4618[@2/'A3QFM]@&!7UJC?6Q>'=GE15&)Y_\2--2Z\/2M$<
MX&:^<HDV3>61]UL5].^(6\S1[B-US\N,U\XZG ;;6&(&%9L 5,MC7#:5$9E[
M_P ?)&!BO=?@Q:^79SMT+UX=.F[4-IY.17O_ ,*&V(8]O1:(?"7BOXK/5T!1
M%7K@4R:W21@6 )'M4N-BL>OM3/.)8 "J1SF?K4/F6JJ.@KYE^)B,-=7.<"OJ
M#4T+6C<U\V_%6 KJ <=NM)CC\2.-D_X]5%2^&1+'X@@91QY@Y%02_P#'FA[\
M5UO@S2A/<VK,O._-13ZG=C]XGOLVI(='6  _-$ P_"F^%-(AL;)RD07<VZG6
MVC&78S'Y0!716T2Q0A$& .M:\VEC@$%LLR9=0:YSQL+6#PK?QH@+F(XKHV+O
M;L$.".E>>^.;UX]*N-XV[8R#[U(=3YS5,6D[$8R]):N8[U!CT[5(#YEG(V."
MYQ5G3;9I[L?+D 5G3W9WXR*48>A[AX!F\RU(C!R<9KTFUB4'S&B  'I7GWPU
MA6-9 WI7IK%5MC@BM3@,BZE#RL!\HKQ7XJP&/482#\I%>UR!'W,2,5YC\3K
M3V*3J/N4 =#\$O\ D4+C_KY/\J[?Q-_R+&I?]>[_ ,JXCX)?\B?.?^GD_P J
M[?Q-_P BSJ7&?]';^5 'RWI4)GU.-!R,\YKV32K+%C$F.@KR[P;;"XUP \A>
MM>V0H(5 4< 4 5-4EU:'35?24#R@X(;FMB*.]FT.$WJ[;HCY\5)I#9!ZCYNI
MJ_?EO*D9...IK2^E@/"O'C^4)T9B2!R:\WC &G.H'!YKT7QXH<W.:\Z7)M6
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M3'4XK.>Z._"?!,ZSP\L]I!$S']V[Y KW7PQJ226<1/4<8]:\A$2I;6UN@ P
M2:]'\,64K6HDWX48-7U. [*^B#N<\C&:YJZLEDCDR..W%=#ARA8G..*J7000
MY'7O3 ^?/%]F+/6G."%8\5[QX>OY;?PCH\-JH:>:(!=W2O'?B-M^W*0!NSS7
MLOANQ:[\':3+"X2>.$;210!ICQ!%9XAU E9E'SLHX%-G\6Z9 8QN=VD'RA5R
M<54N?#%Q?EEN;@%9>7(ZYJ*T\&M!J<5RUP&2%2J#'K0!>3Q;8DS,VX1H0%..
MI-;EM.MS;I,H(5QD US)\*-';3PQR*WG/NR1]WZ5T.G6GV&PAMMY<QK@L>]
M%JBBB@ HHHH ***YCQOJ^K:3H;-HUD;BZ?(![1C^\: -37]$MO$.CS:9=EA#
M+]XJ>:P]8^'6BZUX=LM%NA+Y%GCRF!^88KC_  ?XUU6+X:ZQK6J3FXNK>9D4
MGH#VJ[X1O=3U.?3K\>+(I994+SZ>XZ_[M '7#P9IPUW3M7#RB?3X/(A&>-OO
M36\$Z:?%Z^)4>6.]"[6"'"L/<=Z\^N?&'BJ3XHZ98W*-8Z=,[!(,\R*.,FI/
M%?BN_A^(DUE)>W]KI-I"#*UK'G!/<T >Q,H92K $'@@BFQQ1PH$C144=%48K
M@[Q+S4O#UKJ.F>)GATQ(R[SLN9'XXYK.\(ZAXF\4^#;H1ZF+>6.<I%>NF2T8
MZGZT >H45YAX%US59O'&IZ-)J+:E8V\0;SW&"'[BO3Z /+OB;;0W'B31?M#A
M$56.2?>MC3=B0_NR"N.,54^)-O!<7-F)H@1Y; 2;L;*YWP9J;O#-9R2;EB;"
M-G.:UC%.%T0Y.]CNI@9(57&3FIK.UVY7;\QJK;3-(X4X&W]:VXY5C4%L9]:R
MMJ58S==A2+1IY-N&5:^:=3F,^O2%CTS7T[KZEM!N2><J:^5FDWZ]=;OX6(J*
MEU$Z\#_'B6-)N%MO$]JS-\A<9KZPT:XAN-.B:$Y 45\:74K0W\3)]X-7UA\/
MQ)_PB]N\F=[H",TX;&-;^([G4%SYH&/E]:60X!&,Y%5W\P.KD\&I(IEFW[>J
M\51F<SXBA3^S+D;>2*^?O&%B(5AF4896YKZ)\08%M(&ZFO'O&.E"XTQG#8"G
M)J9;&M"[J1MW/+5^?5D7')(-?07PSA9;EWV_+M KP&V&-<A Z@XKZ7^'=N8K
M)W(Y(%$'I8O%:56CN0PSL I=@&, 56FF$<P^8 D\T[[0CR *V2#DBJ.<BU+(
M@8_PXYKP#XE6XD,Q(Y'(KWW4I@L&X_=KQ?QM:_;4F90<E>*3V''<\C;'V*+<
M.20*]4\"6F+BV)&!D5Y>+61WBAQG#\UZ[X'NHFO8H-NTQXR354:4G!R.S'N[
MC8]M@B41+CTI9 50X'%-M95:(;3G I)I3M^7GVI(XB!Y&5B$'45YE\2)-FB7
M1D/)6O3+BYAL;.2ZN2$B09)->&_$GQ/9:OI4RV1)4<'=WJE!M-C6YY3%_P @
MPGU>NP\,68:%79>37&PJPT\,3QNXKT[PS:XTF&0\Y%84[W9VXS7D/2O ,*JL
MQ9:[!UW J#@$]*Y3P3A(923P3UKJO,0,23G%:HX=QC11QHP8\ <UYK\0+J/^
MSY8\C&#BN]N[HL' '![=Z\I^(\4T5D&((#M0!UWP2&/"%Q_U\FNV\3G'AC4C
M_P!.[_RKBO@F,>$)Q_T\'^5=IXH_Y%?4^<?Z.W\J /!?AS"LM_<,!DX_K7K4
M1+ ^F,&O(_!.I#1(9;G[(]QO)!V]J]2TW4H-0MDN(3\C]1Z'TK1TI)7$G=V-
M>SPAP.E/OI#]F9LU!:'==$8.S%.U1E@M&'8YJ+]!GBGC>1C]H)[\5PEFA>78
M!D' -=SXS#&UF9AU:N'L;@6]W%(V"!(/TJ&W%HZ\&O?/1?!I:R\26Z,"@ P1
M[5[CICHZG<.#7$6\%C<V%MJ$4""4H,N*[71WC-LN>M=->M[2QR/=FH1"D>\J
M,=J='+& !NY]*IZDR+;'G: *QK>X9FRA+?C6*6@KGBGQJU#'B!K8-UYQ7GV/
M^):<#KBNK^+\BS>,>/O!1Q[US<,89!%VXS]:QGN=^#7NRN>V?"FV\BPBDQ\Q
M45ZH'(G5<YSS7"?#^*.+3(>1CRQ78I.SW0"<X[UK'8XGHV9FK>$Y]2\3VVJK
M>/''$.8PW!_"EU.":T?<G*D]:Z@C*KDX]:YW6KAW8Q ?*O>JO<FYY7\2%>73
M97_V:\C'%@J^IKUKQM(\EA=+(. AQ7DI&+!A_$.16-3='=@T[/T/8/@A>AHV
MMB<D.3BO=CTKYH^"4FW7YOG^4#I7O]UJ3.ICC(!/0UH<)HJX8MAOF':LB^:5
MU?*G;FDTZVO"6DWDYZYJUJ[+;V.2?F- SS#QSH7V[0+I@NYE7=TKP^W)#6ZD
M8*OBOIN_>$^&+J27&=AS]*^:)PGVMC'_ ,]3S^-0X\TTCLPMW2FT>A68\P1O
MD'"@5ZKX7YL=H'6O'+-7M9;<>;O\P#(KUKPE.=FU>179B*"I6MU.&+3U1O&9
MDWQMG&:SKEG*,QS@&M"X>1[DKMXK.O+R*SCD><?(@R<]ZY[.]BCQWXAAEOH^
M#AN>:]X\#?\ (F:9_P!<17BOB2\M_%8=8(3#+&?W9/>O;O!T30^$]/B8898@
M#52@X[AJ;M%%%0 4444 %%%% !1110 54U1'DTJZ1!EVB8 #OQ5NB@#QGPMX
M5U.\^&>N:3-:O;W$UP[1K(,;N:S-+T#4[O7/#<5EI4UG+IP*W<S)M# 'U[U[
MQ2]Z /+_ !AI>H7/Q6\.7D%K+);0H1(ZKPO/K6GXIU^6$ZGIA\.7,K30E(KB
M./<LI/'/'%=[10!Y7X:>^\$>$--TO4=%N+U)%9Y3$-XC)Z#&*@\(?V[X9T[5
M]6;2)YK6ZNM\-DO#(A[[>U>MT4 >5^'[+4-5^)<FO6EA-IVF^0%E25-A=OI7
MJ?:EHI <3XSTFTUG4[.VN99(R4;&T]:S+/P]9:#,$M=S!N2S5:\>ZE#8ZOI@
M>0(YR5)[U3_MF"XNHDED!)':K]I+EY0<>INV\:B031@D9^;-7=3P;=7B<*?2
MJ&G7MK+(8UDP?[I[U5NYY8KUN?W?Z4DK,'Y''>([[Q)=:PUK \HM< 84?*?K
M7E7B*U^P^(YA'U<C/UKWVXNHX;>1Y6&W:3P:\&U*=-2\32N#E%S@U56I=<IU
M8=\OOLR/*5]?MHY/NF0$CUKZJT"=;;2H/*'RA ,5\IWDI2Z\U>9(WR:]^\#>
M)(M4TB-5DW%5 85C%D8A>]S'HL,QN YSVQCTJQ9PF)&)&"36-92LMWE#E36O
M+?PPNJNX!/O5G/<PO%N!:;E:O+_$LW_$H9/[PKT/Q3>H80N]3D\5Y/XH>2]C
MEBLP7*#'6ID=.&5I<QPFFQ+)JL,@Q\K8/YU],^"Y NG9&!\HKY9MI9K'4Q&^
M 5;)Y[U]$_#W4EN],<I(/E7D5,-&:8JU1>T1V6U[B8N1D!NE68K219]Q("M2
M6:LB%GP0W-6'N8XSC=T%:G&9GB+Y;/ ;&VO-;IEE65GP0 >M=CXIOREJZHV7
M/Z5Y?K5]]CTV1FDP["I9I1C>:.+@"R>(FA+A4WG%>E^'=)2QO4N Y9CUQ7D,
M,K)?K/NYW9->T>%+J*_@C*R#< ,U5.M*,7 WQ/[Q<ZZ'J6FJ^Q1V*YJ[Y 5#
MUS5&PN8UC7<XZ8K24@J64Y!I(Y+HXKQ6EQJFC75E"^)-W"^M>6^+_#5KI7A4
MR$G[24&X$\ U[;]B7S)9SZYKPOXHZ^L]Z=-B?Y48^8*IU6H\J+@KM'FZ?ZE8
M5_A&37H7AO5)8(8+:3&TIQ7F]O(3=J3P&.*]1TW3K:WM(9\[W*@CVK7"NFHO
MFW.S%R4XIKH>A^%;D1V\BA<DMQ71B4D^XKG_  2(Y+9V8<YZ5T:J$G=W& .@
MKG>]SST1-M$FZ0]:\\\?:WIVI12:;;QN[1YRX[&N[O+D.<D9!XQ7G^J^#KE+
MJ6[CG589#N?/I750C3:]\-;V1U/P64IX2G5OO"Y.3^%=EXH/_%+ZE_U[M_*N
M4^$XB30[Y822@NB 3WKJ_%''A?4S_P!.[?RKGFTG[I:5I),\&\-+=7&F?9[>
MV$K,Q <'I]:[WP[HTNF6BVTQ_>D[F'I7G_@OQ(EI,D$@$8SP1WKUM)HKB6*X
M20$,O-:NLW"PZE/DFV:MA$1PPQQR:Q/$<K1@A6PM:L5RO3>*YWQ',NSEQM]Z
MQCN9O8\U\0Q.=*N?M#AL\K7G+132^7'!&S,#R%'/M7<>+-0"H8=V6;G ]*QK
M758M$L8YHXDDN)#P>XI5-6==/W(-G?\ A34;Q-%^SW<31K"!G?Q7?:7KD<3V
M\?\ "_>O&'U*^NK<2R2$;P"RJ:U]-_M2ZL#<6UP5\GALGC%73@G+5DU(IVDC
MV[5KZV>V\H.!(1D+GDUDR7,-AICW3D+L4D\UX_:^(;U=14O<-(['86)S@>U6
MO'NL7PT^*UAEVQR## 'FG423LF8<M]$</XBOEU[Q//>ALQ@X'X5GB5HE,G?=
M1;VX@R.I(RQHDC9T\I.K\+6+1U<_)9(]N^'NJ>=IRHK9(3&*]$TV1D8D\<]Z
M\,\&7%UH4D27<D<<9&<YKU'3O%EC?,R03(Y7N#33,*\;2NCO&G5HMXY85SVI
MR"0[0.IY-4HM=)E=,@*/>N?O/&MC'JIM&D7=C)YX%4S+1G&_$F_6U_T4'YG.
M*\T&"V",9&*[/Q9JNFZK<22%]TBD[6[5Q?.?;.:S>IVTY>R2.F^&-]'I?BLQ
MS-M63@>]?0%V=T*R1GJ1S7RT)S:74,\9/FJ=P(]>U>W>$?%ZZQH9BF;;<Q+S
MD=:J.QSU8\LF^C/6;#*62L_'&<USVOWZ/$2'SDXQ6/%XU%YI[012#S -IQ7(
MW7B2"&X6&=W/S<XJKF2U+/C;7([/P_+;)(!(X QFO$%F\RZ9"<;N/Q%>A>([
MO0[R<W$DTQ3JP-<EJ-MIC6ZW6GL1@\YJ+W9VTI.E&W<[+1+*)K&*XD.Z3;7H
MW@Z0#..H->1^'=<2%1#.P 8@"O2/#6H10SN21M(R.:UE5<_B.:M'EG[NQZ))
M*@W2 9.*YZ^2.Z+1RJ&63[RGTI%UJ.5)""0!_%5'3]6L+K4&C%P&DC&2/:DG
MU(2N['-^(K#3?"UC+=VP.^3@!NU>J^$)?.\+6,N<[XP:\"^(/B%-6U'[+;M^
MYC.&'K7O'@MUC\':;O95_=#J:3FY/4Z*KCR)(Z&BH_/A_P">J?\ ?0I?.B_Y
MZI_WT*#G'T4SSXO^>J?]]"D\^+_GJG_?0H DHJ/SXO\ GJG_ 'T*42QDX$B'
MZ-0 ^BBB@ HHHH **** "BBB@ HHHH **** /&/C>/\ 3-*()!"L<BO,[/5+
MNUNXIS.6V<<UZ;\;]WVO2RH8X5N@KR;8_P#=;D?W34:W-X)3CRK<]2TO4'^R
M?;R0%QN+#M5*?QE_:M\;&-_+AVG=*3WJC;NZ>!9@ P)/H>:X@K*I;:&&>N%-
M6I-:DPI24N5G:?:9IM*GMH[W<W.&S7G^E6LT>IRN[[N2"?6I'-U%D(955NN
M:=IQD%PQ97P!_=-)VD^8=22O[,R;R0)J$F1E6)!KI_A]?7^GZE)';H6C8_-Z
M 5RE\&:ZD.QSS_=-=1X*U.33VE:2(NI&/NFI6Y4&IQY9;GIM]X_BTC58;=P-
MLBC)STIFJ^.8)+F+RSN P20>@KSK5-M_>/,83R>#@UT?A.QM+JQODN82<1G!
M*FK,5%-V*_B'QRUW=I':'*KU.<US!UJ]2X,@DX)Z55DM5M[B81(VW<<<&F.K
MG'RM_P!\FDMS6<E"/*BNMG<ZKJN4."[=<=*])\,W8\(+,+V]0K(F0OO7G-I?
MW&GWN](V..VTU%?7]S?73S3HY4CA<'BE+?0FG*ZY#VOPC\2A>![2?@ASY9S6
MU>>()$F#M)MC/4G@5X3HJ/#J-HR*_,B]C7HOQ.F>#3;.* ,@8#. :JY$H.,K
M%+QAX]5IOLULVXJ<-(/2N5\4WDMQ;VSQY^SLHRWO7/.CJ2[HY/;Y375Z0@U'
MPY-;S(2R<@E3Q2N;1_=Q\SG]/TV]U D1@1HI^\U=?H.LP^%6?S'-Q*1T7I6/
M?SO;6<5O;&08&&PIK+"/P"KG(YRII,FE4W@^I[?IWB0ZG81SPEP3U4=JT=3^
M($&AZ>6F;<RC[N<9KC_A[&\6C7LS9 125!'M7$ZG))J5S*\ZN5+\ @XJHF4E
MRNS/6U\<W&I:$)K)5:249QG[M>$^(I+C^T[F6X&9G8YR>E=7H6H'29&18FPX
MXX.!7(>(+A[O5IY!&^,XSM-3;4VBE"-^IDVQ9I%)YYKU'1+R.;2PH;)C7%>9
MP1R>8JHCY)X^4UUUHDFC619MQDF'W<'%#5F%)\R:9ZWX'ODC@FRXX.:Z4ZK%
M<EPK=L5XAX.U>^BNIK>-6=G!(# BM:^U_4],MFAF3;.^<;5)XJEJ86L['I$M
M[;RSK KJ6'7::Y7QQXG6TM39V\@:0C:0.U<9X=U^33M4>YNUEE$O!8@_*:EU
M30+F_O+B^M9&D63Y\,#2DM36C%.5WT/4?@L"?"MR[=3<&NU\4#/A?4A_T[M_
M*N-^#4<D7A>YCE7:XN6S7?ZA9IJ&GW%G(Q5)D*$CJ,TT1*5W<^0HPT;94D-G
M@BNQ\/>,IK>2&VN 6(."<UZ-_P *3T3_ )_KOKTR*%^">BJX;[==Y!R.14V+
M<U*-F9*ZR8G-S(S(@&?:N=UOQ;::C:29EP-V  :]5O/AQIMYI_V1KFX5=N-P
M(S7-_P#"B="Z?VA>8!XY%4G8SC9,\4U>YM+BU=T9C(H !-<_EG:'D]17T4_P
M&T%Q@ZA>?F*8/@'H 92-0O?E.>HI6UN7.=U9'F$2[((^/2NAC\[3/"$TJE1]
MH.T"O1?^%1:1L5?MMU\HQU%7;KX;:9=Z7'9/<SA(^A&,TQ0J..A\^$@,".&7
MG(J&]EFG(>20MCH":]T/P8T4_P#+]=?I3'^">B.I!OKO\Q2:-'."^%'S_P D
MDU$\AA>.1>J'=7T"/@;H0&!?WGYBHY/@/H,@P=0O?S%,QD[NY\\SZC-=7)D>
M1@#T&>E:NBWTVFW221R'86YYKVO_ (9_T#_H(7GZ5,OP)T1$VC4+O'OBI:-H
M3BX\LSE_$NH-8>&[>_MW;=/C)S7D]S++/<&8NQ=NIS7TYJ'POTO4=%M],EN[
M@10?=88S6&WP(T)H]OV^\^N13L1#V:/G@Y9@N20.M64Z@^E>]#X!Z""#_:-[
MQ[BI1\"="'_+_>?F*+:"J2YF>#I I8L37?\ A^>RA\-3E)$CN0I^IKO5^!^A
MJ,?;[S\Q4J?!;1D&!?W?/N*2B4YIQLSS3P:KSZQ<#>0-A:LN^D+:C*S,3\QK
MW#2/A;I6CW3SPW=R[,NWYL53F^#VD33-(;VZRQR>E-HB%D]3PS5!NTZ4URR,
MX4C<=O7%?3,_P9T6>W,)O;L ]3D5FC]G_0!_S$;WGW%"5ASFY,\0L;4I$MY.
MWR C:OK6YI.KW)UQ-K$1O\H%>OM\$-$:U2W^WWFU>AR*?:?!71K2YBF6^NF,
M;9&<4K&G/%QLSSWQ'K$FGP"TAD^:0?,?2N7TW6;O2)Y)XR&:08);O7NFI?"+
M2-2NC<27ERK'L,8JF?@EHK'+7UV?RIV)@X11Y%!XAT]MQNM/0R$Y+#UKV_3H
M(-3T[08V+B!XRVU6Q60WP,T(Y/V^[S^%;L]FVEVVFV-FS.T"E$;N<4)$3=V;
M"^&]'D<JA<L."!(:!X7THN4'FEAU'F&LJ:]BMK",6LFR=CB:3KM/>LU-9OC=
M2[K@I'QMEQ]ZF2=2?"FEJ,E91COYAJ.+P[HTY(B=G*GG;*346BW-YJ>BW3WK
M^7N)"'T'K6)8WAM+S[''.J1;LM<*/O>U '0S>&M'A"F3S%#' )D/6H-0T"RT
M^T:ZMO,$B$%3O)[US/B#6[V6]5(B6B23*@=2?I5FQU+5+RWN1>N@CXPH.<4
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M\"^([KQ'JFKZ;;%9C,H@8'&Y3UI;+PAK/AK0]=MVT9K[[5$$C/!^8]37N5%
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+X(MXP?[HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gtbp_s12019001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 gtbp_s12019001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E 94# 2(  A$! Q$!_\0
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MBN*^+/\ R(DO_7U;_P#HP5VL7^I3_=% #Z*** "BBB@ HHHH **** "BBB@
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MK"TFF2^0;_*0G#CC''J*G^"?AW57O+V]DC5=*N(GMIPS?,6';'4$5[ZP4C+
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M2U#4K2T2.^OP/M$HSE\#BM2BO!-3*T!;N#3H[2ZM# 8%"AMX8/[C'2M6BB@
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M/&;_ 'ZZ6@ HHHH **** "BBB@ HHHH **** "BBB@#A_BS_ ,B)+_U]6_\
MZ,%=K%_J4_W17$_%IA_P@LH+ '[5;G!/_305VT)!@0@@C:.0<T /HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,ORC.L\(.#
M)"4S]1BO./ >O6G@_P +7/AC5Q+!JMG/*D-N4):X#'Y2GKFO3;7_ (^3_N"K
M9BC9P[1J6'0D<T >2?"62VM;#6-!U2%K+6[NYDDFMG4AF1@<$=B #5GP1JL7
MP[M;KPOXDWV<%M<.]E>.I,4T;'(&1W'I7J?EIOW[%W?WL<T/&D@PZ*W^\,T
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MHHH **** "N#\"_\CAXU_P"OV+_T$UWE<'X%_P"1P\:_]?L7_H)H [RBBB@
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M;UK_ +\5WU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?44 <#_PL^/\
MZ%O6O^_%'_"SX_\ H6]:_P"_%=]10!P/_"SX_P#H6]:_[\4?\+/C_P"A;UK_
M +\5WU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?44 <#_PL^/\ Z%O6
MO^_%'_"SX_\ H6]:_P"_%=]10!P/_"SX_P#H6]:_[\4?\+/C_P"A;UK_ +\5
MWU% ' _\+/C_ .A;UK_OQ1_PL^/_ *%O6O\ OQ7?4=J /%/ 'CV/3--U*/\
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MJD@VKGV!YH ZQ9XGE>))4:1/O*&!*_45)7*>"Q&]M<ZM(V)M7N7G16ZA%^4
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M " !7/4PT)SYV)QN?/7BK4FU;Q-?W9#!6E*JK?P@<8_2O2/@YI&RUO-6=?\
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M)"A/3%>DPHLLCQN,J\>TCV(KB=&\-^*_"MI>:'I2V%QI<LSO;3S2,KP*_4$
M<X[4 8?PQN=6U/\ X2K6[^:22:",643$\.8U/S?7@5N_!%4;X<P7)8/<7%Q-
M).^.2^XYS]*F\!>%]>\'?:-&G-K>Z5)*TRW18B4ENH*_6C3_  UXA\&:C>CP
MZ+6]TB\F,_V6YD*-;N>NT@<@T =MJ7_(*O/^N#_^@FN&^"?_ "3.S_Z^)_\
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MX/Y5-4-I_P ></\ N#^534 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX/Y5-4-I_P ></\ N#^534 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !0>E%!Z4 <'\*_^01K'_85G_I7>5P?PK_Y!&L?]A6?^E=Y0 4444 %%
M%% !1110 4444 %%%% !1110!1M?^/D_[@J]5&U_X^3_ +@J]0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\7W/ANPTF:[NK>W6X=@V!M/_ .NM_1[Z^OH9'OM/>R=6PJLV=P]: -*BBB@
MJ*ZN%M;2:X<$K$A<@>PS4M4=9_Y E]_U[O\ ^@FDW9%TXJ4TGU9Y#=?&#6#<
MR&VMK=(<G:&&3BKWA[XK:E>:W;6E];0M#.XCS&,%23UKRMOOM]:T_#?_ ",V
MF_\ 7RG\Z\.&)J\R]X_4J^1Y>J$K4EHGZ['T_1117NGY48>AZ//8ZCJU]=NK
MS7EP63:?NQ@#:O\ .MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>gtbp-20190630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:GTBP="http://gtbiopharma.com/20190630">
    <link:schemaRef xlink:href="gtbp-20190630.xsd" xlink:type="simple" />
    <xbrli:context id="From2019-01-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesJPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesJPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ExerciseOfCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ConversionOfConvertibleDebenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ConversionOfConvertibleDebenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ExerciseOfCommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ExerciseOfCommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ExerciseOfCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ConversionOfPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ConversionOfConvertibleDebenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ConversionOfConvertibleDebenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ExerciseOfCommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:ExerciseOfCommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForChangeInAccountingPrincipleAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2019-01-01to2019-06-30">GT Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-01-01to2019-06-30">0000109657</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2019-01-01to2019-06-30">S-1</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-01-01to2019-06-30">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2019-01-01to2019-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-01-01to2019-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2019-01-01to2019-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2019-01-01to2019-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">750000000</us-gaap:CommonStockSharesAuthorized>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-01-01to2019-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness contextRef="From2019-01-01to2019-06-30">true</dei:EntitySmallBusiness>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">90000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">286000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">576000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">30000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">22000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">60000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">264000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">19000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-06-30" unitRef="USD" decimals="-3">1096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">576000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Assets contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">25399000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">25707000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">254368000</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">25309000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">25421000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">253792000</us-gaap:AssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">35000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">147000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">12000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">12000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">9000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">25262000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">25262000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">253777000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">1455000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">2665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">102000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">1762000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">1710000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">2546000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">14029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">16731000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">2679000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">10673000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">12170000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LineOfCredit contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">31000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">31000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">31000</us-gaap:LineOfCredit>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">100000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">147000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">8000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">8000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:Liabilities contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">14029000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">16731000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">2679000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-06-30_us-gaap_SeriesCPreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-06-30_custom_SeriesJPreferredStockMember" unitRef="USD" decimals="-3">2000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-12-31_custom_SeriesJPreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31_custom_SeriesJPreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">51000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">53000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">50000</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">25399000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">25707000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">254368000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">11370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">8976000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">251689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_PreferredStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_PreferredStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_CommonStockMember" unitRef="USD" decimals="-3">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">105891000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">521305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-124649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-269499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_PreferredStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_CommonStockMember" unitRef="USD" decimals="-3">51000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">540171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-528685000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">-169000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">-169000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">-169000</us-gaap:MinorityInterest>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">-528685000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">-535984000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">-269499000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="-3">-267896000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="-3">-1603000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">540171000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">545073000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">521305000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-12-31_us-gaap_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="-3">519702000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-12-31_us-gaap_RestatementAdjustmentMember" unitRef="USD" decimals="-3">1603000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-06-30_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-06-30_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">2353548</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-12-31_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">2353548</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">1163548</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-06-30_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-06-30_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">2353548</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-12-31_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">2353548</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31_us-gaap_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31_custom_SeriesJPreferredStockMember" unitRef="Shares" decimals="INF">1163548</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">50650478</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">52644882</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">50117977</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">50650478</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">52644882</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">50117977</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityShellCompany contextRef="From2019-01-01to2019-06-30">false</dei:EntityShellCompany>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-6335000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-12317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-250069000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-2279000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">-5157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-135570000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">6335000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">12317000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">250069000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">2279000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">5157000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">135570000</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">5347000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">5593000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">12487000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">2125000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">1906000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">134502000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">988000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">6724000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">9067000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">154000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">3251000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">1068000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-964000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-6855000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-9117000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-510000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">-3924000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-8602000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">933000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">6855000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">9117000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">479000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">3924000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">8602000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-31000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-31000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-7299000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-19172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-259186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-2789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">-9081000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-144172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-144172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_RetainedEarningsMember" unitRef="USD" decimals="-3">-259186000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-7299000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-19172000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-259186000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">-2789000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">-9081000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-144172000</GTBP:IncomeLossFromContinuingOperationsBeforeIncomeTaxes>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="USDPShares" decimals="INF">-.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-01-01to2018-06-30" unitRef="USDPShares" decimals="INF">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">-5.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="USDPShares" decimals="INF">-.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-04-01to2018-06-30" unitRef="USDPShares" decimals="INF">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">-8.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31_srt_ScenarioPreviouslyReportedMember" unitRef="USDPShares" decimals="INF">-8.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31_srt_RestatementAdjustmentMember" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-06-30" unitRef="Shares" decimals="INF">51507849</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-01-01to2018-06-30" unitRef="Shares" decimals="INF">50117977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">50240</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-04-01to2019-06-30" unitRef="Shares" decimals="INF">51918252</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-04-01to2018-06-30" unitRef="Shares" decimals="INF">50117977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">16769</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1140000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">441000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">2197000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">331000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">6855000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">8663000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">4914000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">3705000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">6489000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">9696000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">130124000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">10000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">7000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">2000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">407000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">1076000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-2048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-6000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-10677000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-5430000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">26000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-581000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">136000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">1412000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">-8000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">3000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">7000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-36000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">36000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">2252000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">6522000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">10197000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">5991000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">4415000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfLoanCosts contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsOfLoanCosts contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">533000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsOfLoanCosts contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">533000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsOfLoanCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">2352000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">7055000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">15145000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">5991000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">204000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">520000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-516000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">557000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:InterestPaidNet contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
    <GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">10000</GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest>
    <GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest>
    <GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest>
    <GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">5179000</GTBP:IssuanceOfCommonStockUponConversionOfAccruedInterest>
    <GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">1035000</GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes>
    <GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes>
    <GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">325000</GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes>
    <GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockUponConversionOfConvertibleNotes>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding&#13;capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). In exchange for the ownership of GTP, the Company issued&#13;a total of 16,927,878 shares of its common stock, having a share price of $15.00 on the date of the transaction, to the three&#13;prior owners of GTP which represented 33% of the issued and outstanding capital stock of the Company on a fully diluted basis.&#13;$253.8 million of the value of shares issued was allocated to intangible assets consisting of a portfolio of three CNS development&#13;candidates, which are classified as IPR&amp;#38;D.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As&#13;of September 30, 2018, the Company recorded an intangible asset impairment charge of $228.5 million related to the portfolio of&#13;CNS IPR&amp;#38;D assets within Operating Expenses, which represents the excess carrying value compared to fair value. The impairment&#13;charge was the result of both internal and external factors. In the 3rd quarter of 2018, the Company experienced changes in key&#13;senior management, led by the appointment of a new CEO with extensive experience in oncology drug development. These changes resulted&#13;in the prioritization of immuno-oncology development candidates relative to CNS development candidates. In conjunction with these&#13;strategic changes, limited internal resources have delayed the development of the CNS IPR&amp;#38;D assets. The limited resources,&#13;changes in senior leadership, and favorable market conditions for immuno-oncology development candidates have resulted in the&#13;Company choosing to focus on development of its immuno-oncology portfolio. In light of this shift in market strategy, the Company&#13;performed a commercial assessment and a valuation of the CNS IPR&amp;#38;D assets, both to assess fair value and support potential&#13;future licensing efforts. The valuation indicated an excess carrying value over the fair value of these assets, resulting in the&#13;impairment charge noted above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;fair value of the CNS IPR&amp;#38;D assets was determined using the discounted cash flow method which utilized significant estimates&#13;and assumptions surrounding the amount and timing of the projected net cash flows, which includes the probability of commercialization,&#13;the assumption that the assets would be out-licensed to third-parties for continued development for upfront licensing fees and&#13;downstream royalty payments based on net sales, and expected impact of competitive, legal and/or regulatory forces on the projections,&#13;as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the&#13;projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding&#13;capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). In exchange for the ownership of GTP, the Company issued&#13;a total of 16,927,878 shares of its common stock, having a share price of $15.00 on the date of the transaction, to the three&#13;prior owners of GTP which represented 33% of the issued and outstanding capital stock of the Company on a fully diluted basis.&#13;$253.8 million of the value of shares issued was allocated to intangible assets consisting of a portfolio of three CNS development&#13;candidates, which are classified as IPR&amp;#38;D.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;For&#13;the year ended December 31, 2018, the Company recorded an intangible asset impairment charge of $228.5 million related to the&#13;portfolio of CNS IPR&amp;#38;D assets within Operating Expenses, which represents the excess carrying value compared to fair value.&#13;The impairment charge was the result of both internal and external factors. In the 3rd quarter of 2018, the Company experienced&#13;changes in key senior management, led by the appointment of a new CEO with extensive experience in oncology drug development.&#13;These changes resulted in the prioritization of immuno-oncology development candidates relative to CNS development candidates.&#13;In conjunction with these strategic changes, limited internal resources have delayed the development of the CNS IPR&amp;#38;D assets.&#13;The limited resources, changes in senior leadership, and favorable market conditions for immuno-oncology development candidates&#13;have resulted in the Company choosing to focus on development of its immuno-oncology portfolio. In light of this shift in market&#13;strategy, the Company performed a commercial assessment and a valuation of the CNS IPR&amp;#38;D assets, both to assess fair value&#13;and support potential future licensing efforts. The valuation indicated an excess carrying value over the fair value of these&#13;assets, resulting in the impairment charge noted above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;fair value of the CNS IPR&amp;#38;D assets was determined using the discounted cash flow method which utilized significant estimates&#13;and assumptions surrounding the amount and timing of the projected net cash flows, which includes the probability of commercialization,&#13;the assumption that the assets would be out-licensed to third-parties for continued development for upfront licensing fees and&#13;downstream royalty payments based on net sales, and expected impact of competitive, legal and/or regulatory forces on the projections,&#13;as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the&#13;projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Convertible&#13;Notes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;January 22, 2018, the Company entered into a Securities Purchase Agreement (&amp;#8220;SPA&amp;#8221;) with fourteen accredited investors&#13;(individually, a &amp;#8220;Buyer&amp;#8221; and collectively, the &amp;#8220;Buyers&amp;#8221;) pursuant to which the Company agreed to issue&#13;to the Buyers senior convertible notes in an aggregate principal amount of $7,760,510 (the &amp;#8220;Notes&amp;#8221;), which Notes shall&#13;be convertible into the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;) at a price of&#13;$4.58 per share, and five-year warrants to purchase the Company&amp;#8217;s Common Stock representing the right to acquire an aggregate&#13;of approximately 1,694,440 shares of Common Stock (the &amp;#8220;Warrants&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;Pursuant&#13;to the terms of SPA the Notes were subject to an original issue discount of 10% resulting in proceeds to the Company of $7,055,000&#13;from the transaction.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Upon&#13;the purchase of the Notes, the Buyers received Warrants to purchase 1,694,440 shares of Common Stock. Such Warrants are exercisable&#13;for (5) years from the date the shares underlying the Warrants are freely saleable. The initial Exercise Price is $4.58. &lt;font style="background-color: white"&gt;According&#13;to the terms of the warrant agreement, the Warrants are subject to certain adjustments depending upon the price and structure&#13;of a subsequent financing, including a qualified financing with gross proceeds of at least $20 million&lt;/font&gt;, as defined in the&#13;agreements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;issuance of the Notes and Warrants were made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of&#13;1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) for the offer and sale of securities not involving a public offering, and&#13;Regulation D promulgated under the Securities Act.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Contemporaneously&#13;with the execution and delivery of the SPA, the Company and the Buyers executed and delivered a Registration Rights Agreement&#13;(the &amp;#8220;Registration Rights Agreement&amp;#8221;) pursuant to which the Company has agreed to provide certain registration rights&#13;with respect to the Registrable Securities under the 1933 Act and the rules and regulations promulgated thereunder, and applicable&#13;state securities laws.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Senior&#13;Convertible Debentures&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;August 2, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal amount&#13;of $5,140,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock, par&#13;value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share. The Company used a portion of these proceeds&#13;to repay $4.4 million of the notes issued on January 22, 2018. Additionally, the remaining $3.3 million of the notes issued on&#13;January 22, 2018 were converted into the Debentures at the same terms discussed above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 7, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal&#13;amount of $2,050,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock,&#13;par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 24, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal&#13;amount of $800,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock,&#13;par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;February 4, 2019, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with the purchasers identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and&#13;collectively, the &amp;#8220;Purchasers&amp;#8221;), pursuant to which the Company issued to the Purchasers, on February 4, 2019, Secured&#13;Convertible Notes in an aggregate principal amount of $1,352,224 (the &amp;#8220;Notes&amp;#8221;), consisting of gross proceeds of $1,052,224&#13;and settlement of existing debt of $300,000, which Notes shall be convertible at any time after issuance into shares (the &amp;#8220;Conversion&#13;Shares&amp;#8221;) of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a conversion&#13;price of $0.60 per share (the &amp;#8220;Conversion Price&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Notes accrue interest at the rate of 10% per annum and mature on August 2, 2019. Interest on the Notes is payable in cash or,&#13;at a Purchaser&amp;#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,&#13;interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,&#13;and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to&#13;adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances&#13;if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion&#13;Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Contemporaneously&#13;with the execution and delivery of the Purchase Agreement, on February 4, 2019, the Company and certain of its wholly-owned subsidiaries&#13;entered into a Security Agreement (the &amp;#8220;Security Agreement&amp;#8221;) with Alpha Capital Anstalt, as collateral agent on behalf&#13;of the Purchasers, and with the Purchasers, pursuant to which the Purchasers have been granted a first-priority security interest&#13;in substantially all of the assets of the Company and such subsidiaries securing (i) an aggregate principal amount of $1,352,224&#13;of Notes and (ii) an aggregate principal amount of $9,058,962 of the Company&amp;#8217;s 10% Senior Convertible Debentures issued&#13;on August 2, 2018, September 7, 2018 and September 24, 2018 held by such Purchasers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,&#13;that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction&#13;(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company&#13;shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such&#13;Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common&#13;Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser&#13;under the Purchase Agreement and the transactions contemplated thereby.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company entered into a registration rights agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;) with the&#13;Purchasers, pursuant to which the Company has agreed to file, within 14 days after February 4, 2019, one or more registration&#13;statements on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available&#13;to effect a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain&#13;penalties set forth in the Registration Rights Agreement. The Form S-3 was filed by the Company on February 14, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;May 22, 2019, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with the purchasers identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and&#13;collectively, the &amp;#8220;Purchasers&amp;#8221;), pursuant to which the Company issued to the Purchasers, on May 22, 2019, Secured&#13;Convertible Notes in an aggregate principal amount of $1,300,000 (the &amp;#8220;Notes&amp;#8221;), which Notes shall be convertible at&#13;any time after issuance into shares (the &amp;#8220;Conversion Shares&amp;#8221;) of the Company&amp;#8217;s common stock, par value $0.001&#13;per share (the &amp;#8220;Common Stock&amp;#8221;), at a conversion price of $0.35 per share (the &amp;#8220;Conversion Price&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Notes accrue interest at the rate of 10% per annum and mature on November 22, 2019. Interest on the Notes is payable in cash or,&#13;at a Purchaser&amp;#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,&#13;interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,&#13;and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to&#13;adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances&#13;if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion&#13;Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,&#13;that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction&#13;(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company&#13;shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such&#13;Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common&#13;Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser&#13;under the Purchase Agreement and the transactions contemplated thereby.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company entered into a registration rights agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;) with the&#13;Purchasers, pursuant to which the Company has agreed to file, within 30 days after May 22, 2019, one or more registration statements&#13;on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available to effect&#13;a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain penalties&#13;set forth in the Registration Rights Agreement. The Form S-1 was filed by the Company on June 21, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;i&gt;Financing&#13;Agreement&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and&#13;manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in&#13;the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal&#13;of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum. There is&#13;$31,000 due on this credit line at June 30, 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Convertible&#13;Notes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;January 22, 2018, the Company entered into a Securities Purchase Agreement (&amp;#8220;SPA&amp;#8221;) with fourteen accredited investors&#13;(individually, a &amp;#8220;Buyer&amp;#8221; and collectively, the &amp;#8220;Buyers&amp;#8221;) pursuant to which the Company agreed to issue&#13;to the Buyers senior convertible notes in an aggregate principal amount of $7,760,510 (the &amp;#8220;Notes&amp;#8221;), which Notes shall&#13;be convertible into the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;) at a price of&#13;$4.58 per share, and five-year warrants to purchase the Company&amp;#8217;s Common Stock representing the right to acquire an aggregate&#13;of approximately 1,694,440 shares of Common Stock (the &amp;#8220;Warrants&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Pursuant&#13;to the terms of SPA the Notes were subject to an original issue discount of 10% resulting in proceeds to the Company of $7,055,000&#13;from the transaction.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Upon&#13;the purchase of the Notes, the Buyers received Warrants to purchase 1,694,440 shares of Common Stock. Such Warrants are exercisable&#13;for (5) years from the date the shares underlying the Warrants are freely saleable. The initial Exercise Price is $4.58. According&#13;to the terms of the warrant agreement, the Warrants are subject to certain adjustments depending upon the price and structure&#13;of a subsequent financing, including a qualified financing with gross proceeds of at least $20 million, as defined in the agreements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;issuance of the Notes and Warrants were made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of&#13;1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) for the offer and sale of securities not involving a public offering, and&#13;Regulation D promulgated under the Securities Act.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Contemporaneously&#13;with the execution and delivery of the SPA, the Company and the Buyers executed and delivered a Registration Rights Agreement&#13;(the &amp;#8220;Registration Rights Agreement&amp;#8221;) pursuant to which the Company has agreed to provide certain registration rights&#13;with respect to the Registrable Securities under the 1933 Act and the rules and regulations promulgated thereunder, and applicable&#13;state securities laws.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Senior&#13;Convertible Debentures&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;August 2, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal amount&#13;of $5,140,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock, par&#13;value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share. The Company used a portion of these proceeds&#13;to repay $4.4 million of the notes issued on January 22, 2018. Additionally, the remaining $3.3 million of the notes issued on&#13;January 22, 2018 were converted into the Debentures at the same terms discussed above.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 7, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal&#13;amount of $2,050,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock,&#13;par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 24, 2018, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement with the purchasers&#13;identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and collectively, the &amp;#8220;Purchasers&amp;#8221;)&#13;pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal&#13;amount of $800,000 (the &amp;#8220;Debentures&amp;#8221;), which Debentures shall be convertible into the Company&amp;#8217;s common stock,&#13;par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a price of $2 per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;issuance of the Senior Convertible Debentures was made in reliance on the exemption provided by Section 4(a)(2) of the Securities&#13;Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), for the offer and sale of securities not involving a public offering&#13;and Regulation D promulgated under the Securities Act.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Financing&#13;Agreement&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and&#13;manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in&#13;the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal&#13;of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum. There is&#13;$31,000 due on this credit line at December 31, 2018.&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;the first six months of 2019, the Company issued 1,994,405 shares of common stock upon conversion of $1,045,453 in principal and&#13;interest on senior convertible notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Preferred&#13;Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company designated 2,000,000 shares of Series J Preferred Stock. Shares of Series J Preferred Stock will&#13;have the same voting rights as shares of common stock with each share of Series J Preferred Stock entitled to one vote at a meeting&#13;of the shareholders of the Corporation. Shares of Series J Preferred Stock will not be entitled to receive any dividends, unless&#13;and until specifically declared by our board of directors. The holders of the Series J Preferred Stock will participate, on an&#13;as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Each share of the Series J Preferred Stock&#13;is convertible into one share of our common stock at any time at the option of the holder.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;the same day, the Board issued 1,513, 548 of those shares in exchange for the cancellation of debt.&amp;#160; In the first quarter&#13;of 2019, it was discovered that a certificate of designation with respect to the Series J Preferred Stock had never been filed&#13;with the Office of the Secretary of State for the State of Delaware.&amp;#160; Legal research determined that despite the fact the&#13;Company had issued shares of Series J Preferred Stock, those shares had, in fact, never existed.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;To&#13;remedy the situation, on April 4, 2019, the Company filed a certificate of designation with the Office of the Secretary State&#13;for the State of Delaware designating a series of preferred stock as Series J-1 Preferred Stock.&amp;#160; On April 19, 2019, the&#13;Company issued 2,353,548 of those shares.&amp;#160; The issuance was in lieu of the preferred stock that should have been issued on&#13;September 1, 2017, and in settlement for not receiving preferred stock until 20 months after the debt for which the stock was&#13;issued was cancelled. The Company reflected an expense in general and administrative costs in the quarter ended June 30, 2019&#13;totaling $1,140,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Shares are convertible into shares of common stock of the Registrant at the rate of $0.60 per share. &amp;#160;The issuance was exempt&#13;from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the same Act since the&#13;issuance of the Shares did not involve any public offering. &amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;350,000&#13;of the Series J shares of preferred stock had been previously converted into 350,000 shares of common stock in December 2017.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&#13;Split&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the Company approved a one for three hundred reverse stock split.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Shares&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;July 2017, the Company amended its articles of incorporation to change the number of authorized common shares to 750,000,000 shares&#13;of $.001 par value stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding&#13;capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). GTP is a biotechnology company focused on acquiring or&#13;discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS disease (Neurology and Pain)&#13;and shepherding the products through the FDA approval process to the NDA. In exchange for the ownership of GTP, the Company issued&#13;a total of 16,927,878 shares of its common stock to the three prior owners of GTP which represents 33% of the issued and outstanding&#13;capital stock of the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the six months ended June 30, 2017 the Registrant has issued a total of 390,279 shares of common stock to a total of eleven entities&#13;or individuals in exchange for the cancellation of debt in the total amount of $2,025,000 and interest in the total amount of&#13;$486,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;August 2017, the Company issued a total of 17,287,625 shares of common stock in exchange for the cancellation of debt in the total&#13;amount of $17,141,000 and interest in the total amount of $4,693,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;August 2017, the Company issued 496,855 shares of common stock upon the exercise of warrants on a cashless basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;August 2017, the Company converted 25,000 Series H and 1,666,667 Series I shares of preferred stock into 5,327,734 shares of common&#13;stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;December 2017, the Company converted 350,000 Series J shares of preferred stock into 350,000 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the quarter ended September 30, 2018, the Company issued 110,000 shares of common stock upon conversion of $220,000 of senior&#13;convertible notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the quarter ended December 31, 2018, the Company issued 52,500 shares of common stock upon conversion of $105,000 of senior convertible&#13;notes.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;the quarter ended December 31, 2018, the Company issued a total of 245,000 shares of Rule 144 restricted common stock in full&#13;settlement of outstanding legal matters, and 125,000 shares of Rule 144 restricted common stock in connection with consulting&#13;services.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Preferred&#13;Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;96,230 shares of Series C preferred stock are convertible into 111 shares of the Company's common stock at the option of the holders&#13;at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading&#13;days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than&#13;.2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as&#13;stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock&#13;if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's&#13;common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $3,000.00. Each share of Series C preferred&#13;stock is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during&#13;the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In&#13;the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of&#13;the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets&#13;or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared&#13;by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through December 31,&#13;2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;December 4, 2008, the Company entered into and closed an Agreement (the &amp;#8220;Bristol Agreement&amp;#8221;) with Bristol Investment&#13;Fund, Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately&#13;$20,000 in consideration of the Company issuing Bristol 25,000 shares of Series G Convertible Preferred Stock, which such shares&#13;carry a stated value equal to $1.00 per share (the &amp;#8220;Series G Stock&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Series G Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion&#13;price equal to the lesser of $2.50 or 60% of the average of the three lowest trading prices occurring at any time during the 20&#13;trading days preceding the conversion. The Series G Stock, as amended, shall have voting rights on an as converted basis multiplied&#13;by 100.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;the event of any liquidation or winding up of the Company, the holders of Series G Stock will be entitled to receive, in preference&#13;to holders of common stock, an amount equal to the stated value plus interest of 15% per year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Series G Stock restricts the ability of the holder to convert the Series G Stock and receive shares of the Company&amp;#8217;s common&#13;stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does&#13;not exceed 4.9% of the Company&amp;#8217;s then issued and outstanding shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;October 13, 2009 the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred&#13;Stock and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing&#13;the super voting privileges provided by the Series G Stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Effective&#13;February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the &amp;#8220;Series H Preferred&amp;#8221;)&#13;to Theorem Group, LLC, a California limited liability company (the &amp;#8220;Stockholder&amp;#8221;), in exchange for the 25,000 shares&#13;of Series G Stock then owned by the Stockholder. The foregoing exchange was effected pursuant to that certain Exchange Agreement,&#13;dated February 10, 2010, between the Company and the Stockholder (the &amp;#8220;Exchange Agreement&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Certificate of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate&#13;of Designation of the Series G Preferred. Some of the corrections, changes and differences between the Certificate of Designation&#13;of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As&#13;    previously disclosed, the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a&#13;    number of votes equal to (i) the number of shares of common stock it can convert into (without any restrictions or limitations&#13;    on such conversion), (ii) multiplied by 100.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;    holder of the Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates&#13;    after such conversion would own more than 9.9% of the Company&amp;#8217;s then issued and outstanding shares of common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;    Series G Preferred contained a limitation that the holder of the Series G Preferred could not convert such preferred shares&#13;    into more than 19.999% of the issued and outstanding shares of common stock without the approval of the stockholders if the&#13;    rules of the principal market on which the common stock is traded would prohibit such a conversion. Since the rules of the&#13;    Company&amp;#8217;s principal market did not require such a limitation, that provision has been deleted.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;August 2017, the Company converted 25,000 Series H stock into 5,119,401 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;November 8, 2010, the Company sold 1,666,667 shares of the Company&amp;#8217;s Series I Preferred Stock, $.001 par value, at a price&#13;of $0.15 per share ($250,000).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;holder of the Series I Preferred Stock will be entitled to receive, out of funds legally available, dividends in cash at the annual&#13;rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board. No dividends or other distributions shall&#13;be made with respect to any shares of junior stock until dividends in the same amount per share on the Series I Preferred Stock&#13;shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I Preferred Stock shall not be&#13;cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the Company may fail to declare&#13;or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in any amount in any previous&#13;fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year were sufficient to pay such&#13;dividends in whole or in part.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Each&#13;share of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number&#13;of shares of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Upon&#13;any liquidation of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence,&#13;before any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred&#13;Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution&#13;to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount&#13;of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Shares&#13;of Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully&#13;paid and non-assessable shares of Common Stock. The number of shares of Common Stock which a holder of shares of Series I Preferred&#13;Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the Conversion&#13;Rate by the number of shares of Series I Preferred Stock being converted. Initially, the Series I Preferred Stock is convertible&#13;into 6,667 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;the event that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least&#13;130% of the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall be converted automatically&#13;into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible without any&#13;further action by the holders of such shares and whether or not the certificates representing such shares of Series I Preferred&#13;Stock are surrendered to the Company or its transfer agent.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;August 2017, the Company converted 1,666,667 Series I shares of preferred stock into 208,333 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company authorized 2,000,000 shares of Series J Preferred Stock. Shares of Series J Preferred Stock will&#13;have the same voting rights as shares of common stock with each share of Series J Preferred Stock entitled to one vote at a meeting&#13;of the shareholders of the Corporation. Shares of Series J Preferred Stock will not be entitled to receive any dividends, unless&#13;and until specifically declared by our board of directors. The holders of the Series J Preferred Stock will participate, on an&#13;as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Each share of the Series J Preferred Stock&#13;is convertible into one share of our common stock at any time at the option of the holder.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017 the Company issued a total of 700,278 shares of Series J Preferred Stock in exchange for the cancellation of&#13;debt in the total amount of $840,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017 the Company issued 5,046 shares of Series J Preferred Stock upon the exercise of warrants on a cashless basis.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017 the Company also issued 600,000 shares of Series J Preferred Stock to one entity as payment for $720,000 of&#13;consulting services provided to the Company.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;December 2017, the Company converted 350,000 Series J shares of preferred stock into 350,000 shares of common stock.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Stock Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrant&#13;transactions for the years ended December 31, 2018 and 2017 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;    Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,550&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;135.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;486,351&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(501,901&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    Warrants:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&#13;Options&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company reserved 1,333 shares of its common stock at December 31, 2014 for issuance under the 2014 Stock Incentive Plan (the &amp;#8220;2014&#13;Plan&amp;#8221;). The 2014 Plan, approval by stockholders in May 2015, permits the Company to grant stock options to acquire shares&#13;of the Company's common stock, award stock bonuses of the Company's common stock, and grant stock appreciation rights. At December&#13;31, 2018, 87 shares of common stock were available for grant and options to purchase 1,246 shares of common stock are outstanding&#13;under the 2014 Plan.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes stock option transactions for the years ended December 31, 2018 and 2017:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;    Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,020.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    Options:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,428.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;weighted-average fair value of options granted was approximately $1,469,000 and $1,770,000 for 2018 and 2017, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes information about all outstanding and exercisable stock options at December 31, 2018:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&#13;    Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&#13;    Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &lt;b&gt;Range of Exercise Prices&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &lt;b&gt;Number of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Remaining&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&#13;        Life&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;        of Options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    $750.00 to $2,225.00&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 3%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&#13;Options&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes stock option transactions for the six months ended June 30, 2019:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Stock Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Warrant&#13;transactions for the six months ended June 30, 2019 are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at December 31, 2018:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As&#13;described in&amp;#160;&lt;i&gt;Note 1. Nature of Operations and Summary of Significant Accounting Policies&lt;/i&gt;, we adopted new lease accounting&#13;guidance effective January 1, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;determine if a contractual arrangement is a lease at inception. Our lease arrangements provide the Company the right to utilize&#13;certain specified tangible assets for a period of time in exchange for consideration. Our leases primarily relate to building&#13;office space. Our leases currently consist solely of operating leases. Leases with an initial term of 12 months or less are not&#13;recorded on the balance sheet.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;recognize a lease liability and a right of use asset at the lease commencement date based on the present value of the future lease&#13;payments over the lease term discounted using our incremental borrowing rate. Implicit interest rates within our lease arrangements&#13;are rarely determinable. Right of use assets also include, if applicable, prepaid lease payments and initial direct costs, less&#13;incentives received.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;recognize operating lease expense on a straight-line basis over the term of the lease within selling general and administrative&#13;expenses.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Our&#13;leases do not contain any material residual value guarantees or material restrictive covenants. Some of our leases include optional&#13;renewal periods or termination provisions which we assess at inception to determine the term of the lease, subject to reassessment&#13;in certain circumstances.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the Company&amp;#8217;s future minimum lease commitments as of June 30, 2019:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Year&#13;    ending December 31:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 88%; text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;34,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,000&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;166,000&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Rent&#13;expense for the six months ended June 30, 2019&amp;#160;and&amp;#160;2018&amp;#160;was&amp;#160;$35,000&amp;#160;and&amp;#160;$54,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Employment&#13;Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;October 18, 2018, the Company entered into a Consultant Agreement with Anthony Cataldo. The term of the Consultant Agreement shall&#13;remain in effect until September 30, 2019. This Agreement supersedes the Consultant Agreement dated February 14, 2018 and will&#13;pay Mr. Cataldo $25,000 per month during the term of the Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;October 19, 2018, the Company entered into an Executive Employment Agreement with Dr. Urbanski, reflecting his current position&#13;as Chief Executive Officer of the Company. Under the terms of this agreement, Dr. Urbanski&amp;#8217;s annual salary is essentially&#13;unchanged from his previous positions. Dr. Urbanski is also entitled to participate in the Company&amp;#8217;s bonus plans. Under&#13;the Executive Employment Agreement, the Company has agreed that upon shareholder approval of a Stock Option Plan, it will recommend&#13;to the Board that the Company grant Dr. Urbanski a Non-Qualified stock option to purchase 2,971,102 shares of the Company&amp;#8217;s&#13;common stock having an exercise equal to the fair market value of the shares on the date of the Agreement. The stock option grant&#13;would vest according to the following schedule: (i) 1,250,000 fully vested shares upon signing of the agreement, (ii) 1,250,000&#13;shares on January 1, 2019, and (iii) 471,102 shares on January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his position&#13;as Chief Executive Officer, President and Chairman of the Board.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;April 3, 2019, the Company entered into the Separation Agreement with Dr. Urbanski in connection with his resignation as the Company&amp;#8217;s&#13;Chief Executive Officer. Pursuant to the terms of the Separation Agreement&amp;#160;Dr. Urbanski will receive six months&amp;#8217; salary&#13;of $212,500 paid in two installments and the Company will reimburse the premiums associated with Dr.&amp;#160;Urbanski&amp;#8217;s continuation&#13;health coverage for six months following his resignation. The Settlement Agreement also contains a release by Mr.&amp;#160;Ali of&#13;any claims against the Company arising from or relating to his employment and customary confidentiality, non-disparagement and&#13;cooperation covenants.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;September 1, 2017, the Company entered into a three-year lease agreement for its office in Washington, D.C. In addition to minimum&#13;rent, certain leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs.&#13;The Company recognizes rent expense under such arrangements on a straight-line basis over the effective term of each lease. This&#13;lease was terminated as of June 30, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;October 1, 2018, the Company entered into a three-year lease agreement for its office in Westlake Village, CA. In addition to&#13;minimum rent, certain leases require payment of real estate taxes, insurance, common area maintenance charges and other executory&#13;costs. The Company recognizes rent expense under such arrangements on a straight-line basis over the effective term of each lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table summarizes the Company&amp;#8217;s future minimum lease commitments as of December 31, 2018 (in thousands):&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Year&#13;    ending December 31:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 88%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;201,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Rent&#13;expense for the years ended December 31, 2018 and 2017 was $69,000 and $9,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Employment&#13;Agreements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 18, 2018, the Company entered into&#13;a Consultant Agreement with Anthony Cataldo. The term of the Consultant Agreement shall remain in effect until September 30, 2019.&#13;This Agreement supersedes the Consultant Agreement dated February 14, 2018 and will pay Mr. Cataldo $25,000 per month during the&#13;term of the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 19, 2018, the Company entered into&#13;an Executive Employment Agreement with Dr. Urbanski, reflecting his current position as Chief Executive Officer of the Company.&#13;Under the terms of this agreement, Dr. Urbanski&amp;#8217;s annual salary is essentially unchanged from his previous positions. Dr.&#13;Urbanski is also entitled to participate in the Company&amp;#8217;s bonus plans. Under the Executive Employment Agreement, the Company&#13;has agreed that upon shareholder approval of a Stock Option Plan, it will recommend to the Board that the Company grant Dr. Urbanski&#13;a Non-Qualified stock option to purchase 2,971,102 shares of the Company&amp;#8217;s common stock having an exercise equal to the fair&#13;market value of the shares on the date of the Agreement. The stock option grant would vest according to the following schedule:&#13;(i) 1,250,000 fully vested shares upon signing of the agreement, (ii) 1,250,000 shares on January 1, 2019, and (iii) 471,102 shares&#13;on January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his position as Chief Executive Officer, President and Chairman of&#13;the Board.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Debts&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;On&#13;July 31, 2019, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with one purchaser, pursuant to which the Company issued to the Purchaser, on July 31, 2019, Secured Convertible&#13;Note in the principal amount of $25,000 (the &amp;#8220;Note&amp;#8221;), which Note shall be convertible at any time after issuance into&#13;shares (the &amp;#8220;Conversion Shares&amp;#8221;) of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common&#13;Stock&amp;#8221;), at a conversion price of $0.20 per share (the &amp;#8220;Conversion Price&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Note accrues interest at the rate of 10% per annum and matures on January 31, 2020. Interest on the Note is payable in cash or,&#13;at a Purchaser&amp;#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,&#13;interest accrues at 18% per annum. The Note contains customary default provisions, including provisions for potential acceleration,&#13;and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to&#13;adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances&#13;if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion&#13;Price then in effect. The Company may only prepay the Note with the prior written consent of the respective Purchasers thereof.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,&#13;that the Company, until the date on which less than 10% of the Note is outstanding, shall not effect any Variable Rate Transaction&#13;(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company&#13;shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such&#13;Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common&#13;Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser&#13;under the Purchase Agreement and the transactions contemplated thereby.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company entered into a registration rights agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;) with the&#13;Purchaser, pursuant to which the Company has agreed to file, within 30 days after July 31, 2019, one or more registration statements&#13;on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available to effect&#13;a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain penalties&#13;set forth in the Registration Rights Agreement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common&#13;Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif; background-color: white"&gt;On&#13;August 14, 2019,&lt;/font&gt; &lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;the Company&amp;#8217;s CEO Anthony&#13;&lt;font style="background-color: white"&gt;Cataldo received as compensation a restricted stock award of 7,000,000 common shares and&#13;the Company&amp;#8217;s CFO Steven Weldon received as compensation a restricted stock award of 4,500,000 common shares. Also, two&#13;Company consultants were paid as compensation a restricted stock award of 1,000,000 common shares each.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Financing&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;February 4, 2019, GT Biopharma, Inc. (the &amp;#8220;Company&amp;#8221;) entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with the purchasers identified on the signature pages thereto (individually, a &amp;#8220;Purchaser,&amp;#8221; and&#13;collectively, the &amp;#8220;Purchasers&amp;#8221;), pursuant to which the Company issued to the Purchasers, on February 4, 2019, Secured&#13;Convertible Notes in an aggregate principal amount of $1,352,224 (the &amp;#8220;Notes&amp;#8221;), consisting of gross proceeds of $1,052,224&#13;and settlement of existing debt of $300,000, which Notes shall be convertible at any time after issuance into shares (the &amp;#8220;Conversion&#13;Shares&amp;#8221;) of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), at a conversion&#13;price of $0.60 per share (the &amp;#8220;Conversion Price&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Notes accrue interest at the rate of 10% per annum and mature on August 2, 2019. Interest on the Notes is payable in cash or,&#13;at a Purchaser&amp;#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,&#13;interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,&#13;and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to&#13;adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances&#13;if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion&#13;Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Contemporaneously&#13;with the execution and delivery of the Purchase Agreement, on February 4, 2019, the Company and certain of its wholly-owned subsidiaries&#13;entered into a Security Agreement (the &amp;#8220;Security Agreement&amp;#8221;) with Alpha Capital Anstalt, as collateral agent on behalf&#13;of the Purchasers, and with the Purchasers, pursuant to which the Purchasers have been granted a first-priority security interest&#13;in substantially all of the assets of the Company and such subsidiaries securing (i) an aggregate principal amount of $1,352,224&#13;of Notes and (ii) an aggregate principal amount of $9,058,962 of the Company&amp;#8217;s 10% Senior Convertible Debentures issued&#13;on August 2, 2018, September 7, 2018 and September 24, 2018 held by such Purchasers.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,&#13;that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction&#13;(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company&#13;shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such&#13;Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common&#13;Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser&#13;under the Purchase Agreement and the transactions contemplated thereby.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;addition, the Company entered into a registration rights agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;) with the&#13;Purchasers, pursuant to which the Company has agreed to file, within 14 days after February 4, 2019, one or more registration&#13;statements on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available&#13;to effect a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain&#13;penalties set forth in the Registration Rights Agreement. The Form S-3 was filed by the Company on February 14, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Common&#13;Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;the first quarter of 2019, the Company issued 723,940 shares of common stock upon conversion of $437,271 in principal and interest&#13;on senior convertible notes.&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;The Company&amp;#8217;s current&#13;operations have focused on business planning, raising capital, establishing an intellectual property portfolio, hiring, and conducting&#13;preclinical studies and clinical trials. The Company does not have any product candidates approved for sale and has not generated&#13;any revenue from product sales. The Company has sustained operating losses since inception and expects such losses to continue&#13;over the foreseeable future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;The financial statements of&#13;the Company have been prepared on a goingconcern basis, which contemplates the realization of assets and the satisfaction of liabilities&#13;in the normal course of business. Accordingly, the financial statements do not include any adjustments that might be necessary&#13;should the Company be unable to continue in existence.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;The Company has incurred substantial&#13;losses and negative cash flows from operations since its inception and has an accumulated deficit of $536 million and cash of $264&#13;thousand as of June 30, 2019. The Company anticipates incurring additional losses until such time, if ever, that it can generate&#13;significant sales of its products currently in development. Substantial additional financing will be needed by the Company to fund&#13;its operations and to commercially develop its product candidates. These factors raise substantial doubt about the Company&amp;#8217;s&#13;ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;Management is currently evaluating&#13;different strategies to obtain the required funding for future operations. These strategies may include but are not limited to:&#13;public offerings of equity and/or debt securities, payments from potential strategic research and development, and licensing and/or&#13;marketing arrangements with pharmaceutical companies. If the Company is unable to secure adequate additional funding, its business,&#13;operating results, financial condition and cash flows may be materially and adversely affected.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The financial statements and notes are&#13;representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies&#13;conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the&#13;preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions&#13;that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities&#13;at the date of the financial statements. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial&#13;statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany balances and transactions have been&#13;eliminated. The Company's financial statements are prepared using the accrual method of accounting.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited interim condensed&#13;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&amp;#8220;U.S.&#13;GAAP&amp;#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;). Certain information&#13;and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The&#13;interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements&#13;and notes thereto included in the Company's Form 10-K for the year ended December 31, 2018. The unaudited interim condensed consolidated&#13;financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a&#13;fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible&#13;for the unaudited interim consolidated financial statements included in this report. The results of operations of any interim period&#13;are not necessarily indicative of the results for the full year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid&#13;investments with original maturities of three months or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid&#13;investments with original maturities of three months or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's cash and cash equivalents,&#13;marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains&#13;substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal&#13;Deposit Insurance Corporation up to $250,000. The Company had balances totaling $14,000 in excess of this limit at June 30, 2019.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's cash and cash equivalents,&#13;marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains&#13;substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal&#13;Deposit Insurance Corporation up to $250,000. The Company had no balances in excess of this limit at December 31, 2018.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for its stock-based&#13;compensation for employees in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 718.&amp;#160;&amp;#160;The Company&#13;recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued&#13;to employees and non-employees over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company granted no stock options&#13;during the six months ended June 30, 2019 and 2018, respectively&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for its stock-based&#13;compensation for employees in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 718. The Company recognizes&#13;in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees&#13;and non-employees over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company granted no stock options&#13;during the years ended December 31, 2018 and 2017, respectively.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <GTBP:LongLivedAssetsPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our long-lived assets include property,&#13;plant and equipment, capitalized costs of filing patent applications and other indefinite lived intangible assets. We evaluate&#13;our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance with ASC 360, whenever events&#13;or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Estimates of future cash flows&#13;and timing of events for evaluating long-lived assets for impairment are based upon management&amp;#8217;s judgment. If any of our&#13;intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying&#13;amount of the assets over its fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Applicable long-lived assets are amortized&#13;or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or&#13;the statutory or contractual term in the case of patents. Estimates of useful lives and periods of expected revenue generation&#13;are reviewed periodically for appropriateness and are based upon management&amp;#8217;s judgment.&lt;/p&gt;</GTBP:LongLivedAssetsPolicyTextBlock>
    <GTBP:LongLivedAssetsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our long-lived assets include property,&#13;plant and equipment, capitalized costs of filing patent applications and other indefinite lived intangible assets. We evaluate&#13;our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance with ASC 360, whenever events&#13;or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Estimates of future cash flows&#13;and timing of events for evaluating long-lived assets for impairment are based upon management&amp;#8217;s judgment. If any of our&#13;intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying&#13;amount of the assets over its fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Applicable long-lived assets are amortized&#13;or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or&#13;the statutory or contractual term in the case of patents. Estimates of useful lives and periods of expected revenue generation&#13;are reviewed periodically for appropriateness and are based upon management&amp;#8217;s judgment.&lt;/p&gt;</GTBP:LongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's long-lived assets currently&#13;consist of indefinite lived intangible assets associated with IPR&amp;#38;D (&amp;#8220;In-Process Research &amp;#38; Development&amp;#8221;) projects&#13;and related capitalized patents acquired in the acquisition of Georgetown Translational Pharmaceuticals, Inc. as described in Note&#13;2 below. &amp;#160;Intangible assets associated with IPR&amp;#38;D projects are not amortized until approval by the Food and Drug Administration&#13;(FDA) is obtained in a major market subject to certain specified conditions and management judgment. The useful life of an amortizing&#13;asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates indefinite lived&#13;intangible assets for impairment at least annually and whenever impairment indicators are present in accordance with ASC 350. When&#13;necessary, the Company records an impairment loss for the amount by which the fair value is less than the carrying value of these&#13;assets. The fair value of intangible assets other than goodwill is typically determined using the &amp;#8220;relief from royalty method&amp;#8221;,&#13;specifically the discounted cash flow method utilizing Level 3 fair value inputs. Some of the more significant estimates and assumptions&#13;inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of&#13;competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&amp;#38;D assets,&#13;as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the&#13;projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company performs impairment testing&#13;for all other long-lived assets whenever impairment indicators are present. When necessary, the Company calculates the undiscounted&#13;value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying&#13;amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's long-lived assets currently&#13;consist of indefinite lived intangible assets associated with IPR&amp;#38;D (&amp;#8220;In-Process Research &amp;#38; Development&amp;#8221;) projects&#13;and related capitalized patents acquired in the acquisition of Georgetown Translational Pharmaceuticals, Inc. as described in Note&#13;3 below. Intangible assets associated with IPR&amp;#38;D projects are not amortized until approval by the Food and Drug Administration&#13;(FDA) is obtained in a major market subject to certain specified conditions and management judgment. The useful life of an amortizing&#13;asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates indefinite lived&#13;intangible assets for impairment at least annually and whenever impairment indicators are present in accordance with ASC 350. When&#13;necessary, the Company records an impairment loss for the amount by which the fair value is less than the carrying value of these&#13;assets. The fair value of intangible assets other than goodwill is typically determined using the &amp;#8220;relief from royalty method&amp;#8221;,&#13;specifically the discounted cash flow method utilizing Level 3 fair value inputs. Some of the more significant estimates and assumptions&#13;inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of&#13;competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&amp;#38;D assets,&#13;as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the&#13;projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company performs impairment testing&#13;for all other long-lived assets whenever impairment indicators are present. When necessary, the Company calculates the undiscounted&#13;value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying&#13;amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes&#13;using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future&#13;tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior&#13;periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not&#13;be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes&#13;using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future&#13;tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior&#13;periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not&#13;be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income (loss) per share is&#13;computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.&#13;Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common&#13;shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion&#13;of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares&#13;excluded from the calculation of net income (loss) per share totaled in 39,416,352 and 3,390,120 as of June 30, 2019 and 2018,&#13;respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net income (loss) per share is&#13;computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.&#13;Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common&#13;shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion&#13;of outstanding stock options and warrants during the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The computation of basic and diluted&#13;net loss per share for the years ended December 31, 2018 and 2017 excludes the common stock equivalents of the following potentially&#13;dilutive securities because their inclusion would be anti-dilutive:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise of common stock warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion of preferred stock into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion of convertible debentures into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,704,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise of common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,682,368&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,164,905&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Acquired patents are capitalized at their&#13;acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications&#13;are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that&#13;are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are&#13;not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the&#13;patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident&#13;increase in the value of the patents are capitalized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Capitalized cost for pending patents&#13;are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred.&#13;Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining&#13;statutory life, estimated economic life or ten years.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Acquired patents are capitalized at their&#13;acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications&#13;are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that&#13;are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are&#13;not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the&#13;patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident&#13;increase in the value of the patents are capitalized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Capitalized costs for pending patents&#13;are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after the costs have been incurred.&#13;Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining&#13;statutory life, estimated economic life or ten years.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets is stated at cost. Depreciation&#13;is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10&amp;#160;years for machinery&#13;and equipment and the shorter of the lease term or estimated economic life for leasehold improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets are stated at cost. Depreciation&#13;is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment&#13;and the shorter of the lease term or estimated economic life for leasehold improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts reported in the&#13;balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair&#13;value because of the short period of time between the origination of such instruments and their expected realization and their&#13;current market rate of interest.&amp;#160; The three levels are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&amp;#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company&amp;#8217;s Level 2 valuation amounts consist of warrants and beneficial conversion features arising from the issuance of convertible securities and in accordance with ASC 815-40.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amounts reported in the&#13;balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair&#13;value because of the short period of time between the origination of such instruments and their expected realization and their&#13;current market rate of interest. The three levels are defined as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&amp;#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 43px; padding-left: 5.25pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company&amp;#8217;s Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. There were no such liabilities at December 31, 2018.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed&#13;as incurred and reported as research and development expense. Research and development costs totaling $1 million and $6.7 million&#13;for the six months ended June 30, 2019 and 2018, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development costs are expensed&#13;as incurred and reported as research and development expense. Research and development costs totaled $9.1 million and $1.1 million&#13;for the years ended December 31, 2018 and 2017, respectively. Research and development costs for the year ended December 31, 2018&#13;included non-cash compensation of $6.8 million.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;License Revenue&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;License arrangements may consist of non-refundable&#13;upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones&#13;and future product royalty payments. Some of these arrangements are multiple element arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Non-refundable, up-front fees that are&#13;not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized&#13;as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&amp;#160;&amp;#160;We defer&#13;recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product&#13;or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent&#13;of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research&#13;and development services that are required because our know-how and expertise related to the technology is proprietary to us, or&#13;can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payments related to substantive, performance-based&#13;milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified&#13;in the underlying agreements when they represent the culmination of the earnings process. As of June 30, 2019, the Company has&#13;not generated any licensing revenue.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the Financial Accounting&#13;Standards Board (&amp;#8220;FASB&amp;#8221;) issued new guidance related to accounting for leases, Accounting Standards codification Topic&#13;842 (ASC 842). We adopted the new guidance on January 1, 2019 using the modified retrospective approach and the optional transition&#13;method. Under this adoption method, comparative prior periods were not adjusted and continue to be reported with our historical&#13;accounting policy. The primary impact of adopting this standard was the recognition of $173 thousand in operating lease liabilities&#13;and $165 thousand in right of use assets.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the Financial Accounting&#13;Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02, &amp;#8220;Leases.&amp;#8221; This&#13;ASU requires all lessees to be recognized on the balance sheet as right to use assets and lease liabilities for the rights and&#13;obligations created by lease arrangements with terms greater than 12 months. The amendments in this ASU are effective for fiscal&#13;years beginning after December 15, 2018 and for interim periods therein. The Company is in the process of assessing the impact&#13;the adoption this ASU will have on its consolidated financial position, results of operations and cash flows. At a minimum, total&#13;assets and total liabilities will increase in the period the ASU is adopted. Early adoption of this ASU is permitted. At December&#13;31, 2018, the Company&amp;#8217;s undiscounted future minimum payments outstanding for lease obligations (including those currently&#13;included as capital lease obligations) were approximately $200,878.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued ASU No.&#13;2014-09, &amp;#8220;Revenue from Contracts with Customers: Topic 606.&amp;#8221; This ASU replaces nearly all existing U.S. GAAP guidance&#13;on revenue recognition. The standard prescribes a five-step model for recognizing revenue, the application of which will require&#13;significant judgment. The amendments in this ASU are effective for fiscal years beginning after December 15, 2017, and for interim&#13;periods therein. The provisions of this ASU may be applied retroactively or on a modified retrospective (cumulative effect) basis.&#13;The Company adopted the standard using the modified retrospective approach beginning January 1, 2018. Adoption of this ASU did&#13;not have a significant impact on the Company&amp;#8217;s consolidated financial position, results of operations and cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-01-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable,&#13;    June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;    Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(133&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,020.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    Options:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,428.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2019-01-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at December 31, 2018:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding&#13;    at June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    at June 30, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;    of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;    Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 76%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,550&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;135.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;486,351&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(501,901&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding,&#13;    December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercisable&#13;    Warrants:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December&#13;    31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2019-01-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Year&#13;    ending December 31:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 88%; text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;34,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,000&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;166,000&#13;    &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Year&#13;    ending December 31:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 88%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;201,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-06-30" unitRef="Shares" decimals="INF">39416352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-06-30" unitRef="Shares" decimals="INF">3390120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">8682368</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">1164905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_ExerciseOfCommonStockWarrantsMember" unitRef="Shares" decimals="INF">1813053</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember" unitRef="Shares" decimals="INF">1163659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_ConversionOfConvertibleDebenturesMember" unitRef="Shares" decimals="INF">5704543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_ExerciseOfCommonStockOptionsMember" unitRef="Shares" decimals="INF">1113</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_ExerciseOfCommonStockWarrantsMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_ConversionOfPreferredStockIntoCommonStockMember" unitRef="Shares" decimals="INF">1163659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_ConversionOfConvertibleDebenturesMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_ExerciseOfCommonStockOptionsMember" unitRef="Shares" decimals="INF">1246</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">1113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1813053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1813053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">15550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">-133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-501901</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">1113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">1246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">135.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">15.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1020.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">15.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1320.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1428.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">1813053</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1813053</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">0</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1813053</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">486531</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.35</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">2.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2017-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">69000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">34000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">71000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">71000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">61000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">61000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">201000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2019-06-30" unitRef="USD" decimals="-3">166000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">35000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">54000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">69000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">9000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:NonoperatingGainsLosses contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">-228515000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses contextRef="From2018-04-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:NonoperatingGainsLosses>
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_PreferredStockMember" unitRef="Shares" decimals="INF">1788</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_PreferredStockMember" unitRef="Shares" decimals="INF">1260</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_CommonStockMember" unitRef="Shares" decimals="INF">104</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_CommonStockMember" unitRef="Shares" decimals="INF">50118</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_PreferredStockMember" unitRef="Shares" decimals="INF">1260</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_CommonStockMember" unitRef="Shares" decimals="INF">50650</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16928</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">17000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">253901000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">909</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17678</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_CommonStockMember" unitRef="Shares" decimals="INF">162</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">18000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">25254000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">325000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-2042</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="-3">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">600</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9233</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-01-01to2018-12-31_CommonStockMember" unitRef="Shares" decimals="INF">370</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">129766000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-12-31_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-01-01to2018-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">9693000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:ChangeInAccountingMethodForDebtAndWarrants contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">678000</GTBP:ChangeInAccountingMethodForDebtAndWarrants>
    <GTBP:ChangeInAccountingMethodForDebtAndWarrants contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-678000</GTBP:ChangeInAccountingMethodForDebtAndWarrants>
    <GTBP:IssuanceOfWarrants contextRef="From2018-01-01to2018-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">8304000</GTBP:IssuanceOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2018-01-01to2018-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <GTBP:NoteAllonges contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</GTBP:NoteAllonges>
    <GTBP:NoteAllonges contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</GTBP:NoteAllonges>
    <GTBP:NoteAllonges contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</GTBP:NoteAllonges>
    <GTBP:NoteAllonges contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">100000</GTBP:NoteAllonges>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">30000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">8000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock>
    <GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock>
    <GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock>
    <GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">253777000</GTBP:AcquisitionOfIntangiblesThroughIssuanceOfCommonStock>
    <GTBP:IssuanceOfCommonStockForDebt contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockForDebt>
    <GTBP:IssuanceOfCommonStockForDebt contextRef="From2018-01-01to2018-06-30" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockForDebt>
    <GTBP:IssuanceOfCommonStockForDebt contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="-3">0</GTBP:IssuanceOfCommonStockForDebt>
    <GTBP:IssuanceOfCommonStockForDebt contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">19166000</GTBP:IssuanceOfCommonStockForDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-01-01to2019-06-30">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;1965, the corporate predecessor of GT Biopharma, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic&#13;Data changed its incorporation to the State of Delaware in 1972. and changed its name to DDI Pharmaceuticals, Inc. in 1985. In&#13;1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,&#13;Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products&#13;based off our proprietary Natural Killer (NK) cell engager (Tri-specific Killer Engager (TriKE) &amp;#38; Tetra-specific Killer Engager&#13;(TetraKE)) and bi-specific Antibody Drug Conjugate (bispecific-ADC) technology platforms. Our TriKE and TetraKE platforms generate&#13;proprietary moieties designed to harness and enhance the cancer killing abilities of a patient&amp;#8217;s own natural killer, or&#13;NK, cells. Once bound to a NK cell, our moieties are designed to stimulate the NK cell and precisely direct it to one or more&#13;specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell&amp;#8217;s&#13;death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target tumor antigens on hematologic&#13;malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in an&#13;outpatient setting and are expected to have reasonably low cost of goods. Our bispecific-ADC platform can generate product candidates&#13;that are ligand-directed single-chain fusion proteins that simultaneously target two tumor antigens. We believe our bispecific-ADC&#13;moieties represents the next generation of ADCs.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Going&#13;Concern&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company&amp;#8217;s current operations have focused on business planning, raising capital, establishing an intellectual property portfolio,&#13;hiring, and conducting preclinical studies and clinical trials. The Company does not have any product candidates approved for&#13;sale and has not generated any revenue from product sales. The Company has sustained operating losses since inception and expects&#13;such losses to continue over the foreseeable future.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;financial statements of the Company have been prepared on a goingconcern basis, which contemplates the realization of assets and&#13;the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments&#13;that might be necessary should the Company be unable to continue in existence.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company has incurred substantial losses and negative cash flows from operations since its inception and has an accumulated deficit&#13;of $536 million and cash of $264 thousand as of June 30, 2019. The Company anticipates incurring additional losses until such&#13;time, if ever, that it can generate significant sales of its products currently in development. Substantial additional financing&#13;will be needed by the Company to fund its operations and to commercially develop its product candidates. These factors raise substantial&#13;doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Management&#13;is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include&#13;but are not limited to: public offerings of equity and/or debt securities, payments from potential strategic research and development,&#13;and licensing and/or marketing arrangements with pharmaceutical companies. If the Company is unable to secure adequate additional&#13;funding, its business, operating results, financial condition and cash flows may be materially and adversely affected.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Use&#13;of Estimates&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.&#13;These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently&#13;applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates&#13;and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets&#13;and liabilities at the date of the financial statements. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Basis&#13;of Consolidation and Comprehensive Income&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany&#13;balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Basis&#13;of Presentation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles&#13;generally accepted in the U.S. (&amp;#8220;U.S. GAAP&amp;#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission&#13;(&amp;#8220;SEC&amp;#8221;). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements&#13;have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with&#13;the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December&#13;31, 2018. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments&#13;that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash&#13;flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included&#13;in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Cash&#13;and Cash Equivalents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Concentrations&#13;of Credit Risk&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations&#13;of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The&#13;balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company had balances totaling $14,000&#13;in excess of this limit at June 30, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&#13;Based Compensation to Employees&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;)&#13;718.&amp;#160;&amp;#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based&#13;compensation issued to employees and non-employees over the related vesting period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company granted no stock options during the six months ended June 30, 2019 and 2018, respectively&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Long-Lived&#13;Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Our&#13;long-lived assets include property, plant and equipment, capitalized costs of filing patent applications and other indefinite&#13;lived intangible assets. We evaluate our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance&#13;with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&#13;Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&amp;#8217;s&#13;judgment. If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized&#13;is the excess of the carrying amount of the assets over its fair value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Applicable&#13;long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the&#13;assets will generate revenue, or the statutory or contractual term in the case of patents. Estimates of useful lives and periods&#13;of expected revenue generation are reviewed periodically for appropriateness and are based upon management&amp;#8217;s judgment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Impairment&#13;of Long-Lived Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company's long-lived assets currently consist of indefinite lived intangible assets associated with IPR&amp;#38;D (&amp;#8220;In-Process&#13;Research &amp;#38; Development&amp;#8221;) projects and related capitalized patents acquired in the acquisition of Georgetown Translational&#13;Pharmaceuticals, Inc. as described in Note 2 below. &amp;#160;Intangible assets associated with IPR&amp;#38;D projects are not amortized&#13;until approval by the Food and Drug Administration (FDA) is obtained in a major market subject to certain specified conditions&#13;and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially&#13;all of the cash flows are expected to be generated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company evaluates indefinite lived intangible assets for impairment at least annually and whenever impairment indicators are present&#13;in accordance with ASC 350. When necessary, the Company records an impairment loss for the amount by which the fair value is less&#13;than the carrying value of these assets. The fair value of intangible assets other than goodwill is typically determined using&#13;the &amp;#8220;relief from royalty method&amp;#8221;, specifically the discounted cash flow method utilizing Level 3 fair value inputs.&#13;Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected&#13;net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact&#13;of technological risk associated with IPR&amp;#38;D assets, as well as the selection of a long-term growth rate; the discount rate,&#13;which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the&#13;geographic diversity of the projected cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company performs impairment testing for all other long-lived assets whenever impairment indicators are present. When necessary,&#13;the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares&#13;this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for&#13;the excess of book value over fair value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Income&#13;Taxes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are&#13;recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial&#13;and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the&#13;corresponding future tax benefits may not be realized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Net&#13;Income (Loss) per Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares&#13;outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the&#13;weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable&#13;upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially&#13;dilutive common shares excluded from the calculation of net income (loss) per share totaled in 39,416,352 and 3,390,120 as of&#13;June 30, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Acquired&#13;patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings&#13;required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable&#13;technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated&#13;with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development&#13;costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense&#13;to the extent of an evident increase in the value of the patents are capitalized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Capitalized&#13;cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after&#13;the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter&#13;of the patent's remaining statutory life, estimated economic life or ten years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fixed&#13;Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which&#13;are 3 to 10&amp;#160;years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold&#13;improvements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fair&#13;Value&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments&#13;and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and&#13;their expected realization and their current market rate of interest.&amp;#160; The three levels are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&#13;    The Company&amp;#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value&#13;    represents fair value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs&#13;    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial&#13;    instrument. The Company&amp;#8217;s Level 2 valuation amounts consist of warrants and beneficial conversion features arising from&#13;    the issuance of convertible securities and in accordance with ASC 815-40.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Research&#13;and Development&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research&#13;and development costs are expensed as incurred and reported as research and development expense. Research and development costs&#13;totaling $1 million and $6.7 million for the six months ended June 30, 2019 and 2018, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Revenue&#13;Recognition&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;License&#13;Revenue&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;License&#13;arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,&#13;and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element&#13;arrangements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Non-refundable,&#13;up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on&#13;our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&amp;#160;&amp;#160;We&#13;defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,&#13;product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent&#13;of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research&#13;and development services that are required because our know-how and expertise related to the technology is proprietary to us,&#13;or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Payments&#13;related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon&#13;the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings&#13;process. As of June 30, 2019, the Company has not generated any licensing revenue.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent&#13;Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued new guidance related to accounting for leases,&#13;Accounting Standards codification Topic 842 (ASC 842). We adopted the new guidance on January 1, 2019 using the modified retrospective&#13;approach and the optional transition method. Under this adoption method, comparative prior periods were not adjusted and continue&#13;to be reported with our historical accounting policy. The primary impact of adopting this standard was the recognition of $173&#13;thousand in operating lease liabilities and $165 thousand in right of use assets.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Advertising&#13;and promotional fees&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Advertising&#13;expenses consist primarily of costs incurred in the design, development, and printing of Company literature and marketing materials.&#13;The Company expenses all advertising expenditures as incurred. There were no advertising expenses for the years ended December&#13;31, 2018 and 2017, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Cash&#13;and Cash Equivalents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Concentrations&#13;of Credit Risk&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations&#13;of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The&#13;balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company had no balances in excess of&#13;this limit at December 31, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock&#13;Based Compensation to Employees&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;)&#13;718. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation&#13;issued to employees and non-employees over the related vesting period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company granted no stock options during the years ended December 31, 2018 and 2017, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Long-Lived&#13;Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Our&#13;long-lived assets include property, plant and equipment, capitalized costs of filing patent applications and other indefinite&#13;lived intangible assets. We evaluate our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance&#13;with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&#13;Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&amp;#8217;s&#13;judgment. If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized&#13;is the excess of the carrying amount of the assets over its fair value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Applicable&#13;long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the&#13;assets will generate revenue, or the statutory or contractual term in the case of patents. Estimates of useful lives and periods&#13;of expected revenue generation are reviewed periodically for appropriateness and are based upon management&amp;#8217;s judgment.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Impairment&#13;of Long-Lived Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company's long-lived assets currently consist of indefinite lived intangible assets associated with IPR&amp;#38;D (&amp;#8220;In-Process&#13;Research &amp;#38; Development&amp;#8221;) projects and related capitalized patents acquired in the acquisition of Georgetown Translational&#13;Pharmaceuticals, Inc. as described in Note 3 below. Intangible assets associated with IPR&amp;#38;D projects are not amortized until&#13;approval by the Food and Drug Administration (FDA) is obtained in a major market subject to certain specified conditions and management&#13;judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all&#13;of the cash flows are expected to be generated.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company evaluates indefinite lived intangible assets for impairment at least annually and whenever impairment indicators are present&#13;in accordance with ASC 350. When necessary, the Company records an impairment loss for the amount by which the fair value is less&#13;than the carrying value of these assets. The fair value of intangible assets other than goodwill is typically determined using&#13;the &amp;#8220;relief from royalty method&amp;#8221;, specifically the discounted cash flow method utilizing Level 3 fair value inputs.&#13;Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected&#13;net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact&#13;of technological risk associated with IPR&amp;#38;D assets, as well as the selection of a long-term growth rate; the discount rate,&#13;which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the&#13;geographic diversity of the projected cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company performs impairment testing for all other long-lived assets whenever impairment indicators are present. When necessary,&#13;the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares&#13;this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for&#13;the excess of book value over fair value.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Income&#13;Taxes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are&#13;recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial&#13;and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the&#13;corresponding future tax benefits may not be realized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Net&#13;Income (Loss) per Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares&#13;outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the&#13;weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable&#13;upon exercise or conversion of outstanding stock options and warrants during the period.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;computation of basic and diluted net loss per share for the years ended December 31, 2018 and 2017 excludes the common stock equivalents&#13;of the following potentially dilutive securities because their inclusion would be anti-dilutive:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 75%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    of common stock warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion&#13;    of preferred stock into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion&#13;    of convertible debentures into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,704,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise&#13;    of common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,682,368&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,164,905&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Acquired&#13;patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings&#13;required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable&#13;technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated&#13;with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development&#13;costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense&#13;to the extent of an evident increase in the value of the patents are capitalized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Capitalized&#13;costs for pending patents are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after&#13;the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter&#13;of the patent's remaining statutory life, estimated economic life or ten years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fixed&#13;Assets&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Fixed&#13;assets are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which&#13;are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fair&#13;Value&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments&#13;and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and&#13;their expected realization and their current market rate of interest. The three levels are defined as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&#13;    The Company&amp;#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value&#13;    represents fair value because of their short-term maturities of the investments held by these funds.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 43px; padding-left: 5.25pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs&#13;    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial&#13;    instrument. The Company&amp;#8217;s Level 2 liabilities consist of liabilities arising from the issuance of convertible securities&#13;    and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability&#13;    for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using&#13;    the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent&#13;    with that of a government-issued security of a similar maturity. There were no such liabilities at December 31, 2018.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level&#13;    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Research&#13;and Development&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research&#13;and development costs are expensed as incurred and reported as research and development expense. Research and development costs&#13;totaled $9.1 million and $1.1 million for the years ended December 31, 2018 and 2017, respectively. Research and development costs&#13;for the year ended December 31, 2018 included non-cash compensation of $6.8 million.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Standards&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standard Update (&amp;#8220;ASU&amp;#8221;)&#13;No. 2016-02, &amp;#8220;Leases.&amp;#8221; This ASU requires all lessees to be recognized on the balance sheet as right to use assets&#13;and lease liabilities for the rights and obligations created by lease arrangements with terms greater than 12 months. The amendments&#13;in this ASU are effective for fiscal years beginning after December 15, 2018 and for interim periods therein. The Company is in&#13;the process of assessing the impact the adoption this ASU will have on its consolidated financial position, results of operations&#13;and cash flows. At a minimum, total assets and total liabilities will increase in the period the ASU is adopted. Early adoption&#13;of this ASU is permitted. At December 31, 2018, the Company&amp;#8217;s undiscounted future minimum payments outstanding for lease&#13;obligations (including those currently included as capital lease obligations) were approximately $200,878.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers: Topic 606.&amp;#8221; This ASU replaces nearly&#13;all existing U.S. GAAP guidance on revenue recognition. The standard prescribes a five-step model for recognizing revenue, the&#13;application of which will require significant judgment. The amendments in this ASU are effective for fiscal years beginning after&#13;December 15, 2017, and for interim periods therein. The provisions of this ASU may be applied retroactively or on a modified retrospective&#13;(cumulative effect) basis. The Company adopted the standard using the modified retrospective approach beginning January 1, 2018.&#13;Adoption of this ASU did not have a significant impact on the Company&amp;#8217;s consolidated financial position, results of operations&#13;and cash flows.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;1965, the corporate predecessor of GT Biopharma, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic&#13;Data changed its incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In&#13;1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,&#13;Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;We&#13;are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products&#13;based off our proprietary Natural Killer (NK) cell engager (Tri-specific Killer Engager (TriKE) &amp;#38; Tetra-specific Killer Engager&#13;(TetraKE)) and bi-specific Antibody Drug Conjugate (bispecific-ADC) technology platforms. Our TriKE and TetraKE platforms generate&#13;proprietary moieties designed to harness and enhance the cancer killing abilities of a patient&amp;#8217;s own natural killer, or&#13;NK, cells. Once bound to an NK cell, our moieties are designed to stimulate the NK cell and precisely direct it to one or more&#13;specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell&amp;#8217;s&#13;death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target tumor antigens on hematologic&#13;malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in an&#13;outpatient setting and are expected to have reasonably low cost of goods. Our bispecific-ADC platform can generate product candidates&#13;that are ligand-directed single-chain fusion proteins that simultaneously target two tumor antigens. We believe our bispecific-ADC&#13;moieties represents the next generation of ADCs.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Also,&#13;in connection with the acquisition of Georgetown Translational Pharmaceuticals on September 1, 2017, we acquired a portfolio of&#13;IPR&amp;#38;D CNS assets consisting of innovative reformulations and/or repurposing of existing therapies. These CNS assets address&#13;disease states such as chronic neuropathic pain, myasthenia gravis and motion sickness.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Basis&#13;of Consolidation and Comprehensive Income&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;accompanying consolidated financial statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany&#13;balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Going&#13;Concern&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;As&#13;shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $528,685,000 through&#13;December 31, 2018. On a consolidated basis, the Company had cash and cash equivalents of $60,000 at December 31, 2018. The Company's&#13;plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs&#13;and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors&#13;that may prevent the Company from reaching its goal of profitability.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;current rate of cash usage raises substantial doubt about the Company&amp;#8217;s ability to continue as a going concern, absent any&#13;sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity&#13;or debt financing to obtain sufficient funds to sustain operations. However, the Company cannot provide assurance that it will&#13;successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate&#13;future product related revenues. The Company&amp;#8217;s financial statements do not include any adjustments relating to the recoverability&#13;and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that&#13;the Company cannot continue in existence.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Use&#13;of Estimates&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.&#13;These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently&#13;applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates&#13;and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosures of contingent assets&#13;and liabilities at the date of the financial statements. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Segment&#13;Information&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Operating&#13;segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation&#13;by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the&#13;Company has viewed its operations and manages its business as one segment operating in the United States of America.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;Expenses are comprised of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;December&#13;    31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 75%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research&#13;    &amp;#38; Development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;585,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    Interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;432,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Professional&#13;    Fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;162,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;62,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consulting&#13;    and Advisory Services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;161,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Board&#13;    of Directors Service Costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;94,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Payroll&#13;    and Benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;21,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;39,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accrued&#13;    Expenses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1,455,000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;101,000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;On&#13;December 21, 2018, Dr. Raymond Urbanski, Chief Executive Officer and Chairman of the Board, provided a short-term loan of $100,000&#13;to meet immediate capital needs. The loan matured on January 20, 2019 and carries an interest rate of 5%. The loan was repaid&#13;in January, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Deferred&#13;Taxes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial&#13;reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant&#13;components of net deferred income tax assets for the Company are (in thousands):&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;    tax assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 75%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Federal&#13;    net operating loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,306,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,949,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Intellectual&#13;    Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,787,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    Interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;129,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Patent&#13;    amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;    tax asseets before valuation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;87,227,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,955,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Valuation&#13;    allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(87,227,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(15,955,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    deferred income tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Generally&#13;accepted accounting principles requires that the tax benefit of net operating losses, temporary differences and credit carryforwards&#13;be recorded as an asset to the extent that management assesses that realization is &amp;#8220;more likely than not.&amp;#8221; Realization&#13;of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward&#13;period. Because of the Company's history of operating losses, management has provided a valuation allowance equal to its net deferred&#13;tax assets. The valuation allowance increased by approximately $71,270,000 during the year ended December 31, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Tax&#13;Carryforward&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;At&#13;December 31, 2018, the Company had net operating loss carryforwards of approximately $84,354,000 to reduce United States federal&#13;taxable income in future years. These carryforwards expire from 2019 through 2038.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company is no longer subject to U.S. and state tax examinations for years ending before the fiscal year ended December 31, 2014.&#13;Management does not believe there will be any material changes in our unrecognized tax positions over the next twelve months.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax&#13;expense. There was no accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense&#13;recognized during the years ended December 31, 2018 and 2017.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Adoption&#13;of ASU 2017-11&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;connection with the securities purchase agreements and debt transactions during the year ended December 31, 2017, the Company&#13;issued warrants to purchase common stock with a five-year term. Upon issuance of the warrants, the Company evaluated the note&#13;agreement to determine if the agreement contained any embedded components that would qualify the agreement as a derivative. The&#13;Company identified certain put features embedded in the warrants that potentially could result in a net cash settlement in the&#13;event of a fundamental transaction, requiring the Company to classify the warrants as a derivative liability. The Company changed&#13;its method of accounting for the debt and warrants through the early adoption of ASU 2017-11 on January 1, 2018 on a retrospective&#13;basis. Accordingly, the Company recorded the warrant derivative and conversion option derivative liabilities to additional paid&#13;in capital upon issuance.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table provides a summary of the derivative liability activity as a result of the adoption of ASU 2017-11 (in thousands,&#13;except per share data):&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Consolidated&#13;    Balance Sheet&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Previously&#13;    Reported&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revisions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revised&#13;    Report&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 62%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Additional&#13;    Paid-in Capital&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;519,702,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,603,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;521,305,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    Deficit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(267,896,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,603,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(269,499,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Consolidated&#13;    Statement of Operations&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For&#13;    the Year Ended December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Previously&#13;    Reported&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revisions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revised&#13;    Report&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 62%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Change&#13;    in Warrant Liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;925,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(925,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Earnings&#13;    per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(8.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(8.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;During&#13;2018, the down round provisions of certain of the notes was triggered. The Company calculated the value of the down round feature&#13;on that date and determined there to be no additional cost to be reported.&lt;/font&gt;&lt;/p&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advertising expenses consist primarily&#13;of costs incurred in the design, development, and printing of Company literature and marketing materials. The Company expenses&#13;all advertising expenditures as incurred. There were no advertising expenses for the years ended December 31, 2018 and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 78%; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise of common stock warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,813,053&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion of preferred stock into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,163,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Conversion of convertible debentures into common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,704,543&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Exercise of common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,246&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;8,682,368&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,164,905&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;December&#13;    31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 75%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Research&#13;    &amp;#38; Development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;585,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    Interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;432,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Professional&#13;    Fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;162,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;62,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consulting&#13;    and Advisory Services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;161,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Board&#13;    of Directors Service Costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;94,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Payroll&#13;    and Benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;21,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;39,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accrued&#13;    Expenses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1,455,000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;101,000&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding&#13;    Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable&#13;    Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &lt;b&gt;Range of Exercise Prices&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    &lt;b&gt;Number of Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Remaining&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Contractual&#13;        Life&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number&#13;        of Options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted-Average&#13;        Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&#13;    $750.00 to $2,225.00&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.49&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 3%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,320.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#13;    31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;    tax assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 75%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Federal&#13;    net operating loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;25,306,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,949,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Intellectual&#13;    Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;61,787,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Accrued&#13;    Interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;129,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Patent&#13;    amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Deferred&#13;    tax asseets before valuation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;87,227,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;15,955,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Valuation&#13;    allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(87,227,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(15,955,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Net&#13;    deferred income tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <GTBP:ResearchDevelopment contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">585000</GTBP:ResearchDevelopment>
    <GTBP:ResearchDevelopment contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</GTBP:ResearchDevelopment>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">432000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">162000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">62000</us-gaap:AccruedProfessionalFeesCurrent>
    <GTBP:ConsultingAndAdvisoryServices contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">161000</GTBP:ConsultingAndAdvisoryServices>
    <GTBP:ConsultingAndAdvisoryServices contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</GTBP:ConsultingAndAdvisoryServices>
    <GTBP:BoardOfDirectorsServiceCosts contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">94000</GTBP:BoardOfDirectorsServiceCosts>
    <GTBP:BoardOfDirectorsServiceCosts contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</GTBP:BoardOfDirectorsServiceCosts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">21000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">39000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <GTBP:ExercisePriceRange contextRef="From2018-01-01to2018-12-31"> $750.00 to $2,225.00 </GTBP:ExercisePriceRange>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-01to2018-12-31">P5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">25306000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">15949000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">61787000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">129000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">5000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">-6000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">87227000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">15943000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">87227000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">15943000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-12-31" unitRef="USD" decimals="-3">84354000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2018-01-01to2018-12-31">These carryforwards expire from 2019 through 2038</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="-3">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="From2017-01-01to2017-12-31_srt_ScenarioPreviouslyReportedMember" unitRef="USD" decimals="-3">925000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings contextRef="From2017-01-01to2017-12-31_srt_RestatementAdjustmentMember" unitRef="USD" decimals="-3">-925000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>gtbp-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9qAps7xRiXgOn8uPZXtMSaOPObOdyJZyOZkxtW10HXkqryUl49azHiN8g1UmMRsG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:GTBP="http://gtbiopharma.com/20190630" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20190630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gtbiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" id="StatementOfStockholdersDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statement of Stockholders' Deficit</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note1-Company" id="Note1-Company">
	  <link:definition>00000007 - Disclosure - Note 1 - The Company</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" id="Note2-CompanyAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note3-Intangibles" id="Note3-Intangibles">
	  <link:definition>00000009 - Disclosure - Note 3 - Intangibles</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note4-Debt" id="Note4-Debt">
	  <link:definition>00000010 - Disclosure - Note 4 - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note5-AccruedExpenses" id="Note5-AccruedExpenses">
	  <link:definition>00000011 - Disclosure - Note 5 - Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" id="Note6-RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - Note 6 - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note7-StockholdersEquity" id="Note7-StockholdersEquity">
	  <link:definition>00000013 - Disclosure - Note 7 - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" id="Note8-StockOptionsAndWarrants">
	  <link:definition>00000014 - Disclosure - Note 8 - Stock Options and Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxes" id="Note9-IncomeTaxes">
	  <link:definition>00000015 - Disclosure - Note 9 - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" id="Note10-CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - Note 10 - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" id="Note11-ChangeOfAccountingMethod">
	  <link:definition>00000017 - Disclosure - Note 11 - Change of Accounting Method</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note12-SubsequentEvents" id="Note12-SubsequentEvents">
	  <link:definition>00000018 - Disclosure - Note 12 - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" id="Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd">
	  <link:definition>00000020 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" id="Note5-AccruedExpensesTables">
	  <link:definition>00000021 - Disclosure - Note 5 - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" id="Note8-StockOptionsAndWarrantsTables">
	  <link:definition>00000022 - Disclosure - Note 8 - Stock Options and Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" id="Note9-IncomeTaxesTables">
	  <link:definition>00000023 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" id="Note10-CommitmentsAndContingenciesTables">
	  <link:definition>00000024 - Disclosure - Note 10 - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" id="Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000025 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000026 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" id="Note4-DebtDetailsNarrative">
	  <link:definition>00000027 - Disclosure - Note 4 - Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" id="Note5-AccruedExpensesDetails">
	  <link:definition>00000028 - Disclosure - Note 5 - Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" id="Note8-StockOptionsAndWarrantsDetails">
	  <link:definition>00000029 - Disclosure - Note 8 - Stock Options and Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" id="Note8-StockOptionsAndWarrantsDetails1">
	  <link:definition>00000030 - Disclosure - Note 8 - Stock Options and Warrants (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" id="Note8-StockOptionsAndWarrantsDetails2">
	  <link:definition>00000031 - Disclosure - Note 8 - Stock Options and Warrants (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" id="Note9-IncomeTaxesDetails">
	  <link:definition>00000032 - Disclosure - Note 9 - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" id="Note9-IncomeTaxesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Note 9 - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" id="Note10-CommitmentsAndContingenciesDetails">
	  <link:definition>00000034 - Disclosure - Note 10 - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" id="Note10-CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" id="Note11-ChangeOnAccountingMethodDetails">
	  <link:definition>00000036 - Disclosure - Note 11 - Change on Accounting Method (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <element id="GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest" name="IssuanceOfCommonStockUponConversionOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes" name="IssuanceOfCommonStockUponConversionOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LongLivedAssetsPolicyTextBlock" name="LongLivedAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ChangeInAccountingMethodForDebtAndWarrants" name="ChangeInAccountingMethodForDebtAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfWarrants" name="IssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_NoteAllonges" name="NoteAllonges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" name="AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfCommonStockForDebt" name="IssuanceOfCommonStockForDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ResearchDevelopment" name="ResearchDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConsultingAndAdvisoryServices" name="ConsultingAndAdvisoryServices" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_BoardOfDirectorsServiceCosts" name="BoardOfDirectorsServiceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExercisePriceRange" name="ExercisePriceRange" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note1Member" name="Note1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note2Member" name="Note2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note3Member" name="Note3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note4Member" name="Note4Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note5Member" name="Note5Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note6Member" name="Note6Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note7Member" name="Note7Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note8Member" name="Note8Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note9Member" name="Note9Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note10Member" name="Note10Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note11Member" name="Note11Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note12Member" name="Note12Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note13Member" name="Note13Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note14Member" name="Note14Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note15Member" name="Note15Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note16Member" name="Note16Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note17Member" name="Note17Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note18Member" name="Note18Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note19Member" name="Note19Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note20Member" name="Note20Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note21Member" name="Note21Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesIPreferredStockMember" name="SeriesIPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesJPreferredStockMember" name="SeriesJPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExerciseOfCommonStockWarrantsMember" name="ExerciseOfCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConversionOfPreferredStockIntoCommonStockMember" name="ConversionOfPreferredStockIntoCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExerciseOfCommonStockOptionsMember" name="ExerciseOfCommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConversionOfConvertibleDebenturesMember" name="ConversionOfConvertibleDebenturesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LicenseRevenues" name="LicenseRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" name="ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note6ChangeInPriorYearFinancialsAbstract" name="Note6ChangeInPriorYearFinancialsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" name="Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" name="Note1CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DebtDetailsNarrativeAbstract" name="DebtDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockOptionsAndWarrantsDetailsAbstract" name="StockOptionsAndWarrantsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncomeTaxesDetailsAbstract" name="IncomeTaxesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncomeTaxesDetailsNarrativeAbstract" name="IncomeTaxesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Note6ChangeOnAccountingMethodDetailsAbstract" name="Note6ChangeOnAccountingMethodDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>gtbp-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:href="gtbp-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:href="gtbp-20190630.xsd#StatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note1-Company" xlink:href="gtbp-20190630.xsd#Note1-Company" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note3-Intangibles" xlink:href="gtbp-20190630.xsd#Note3-Intangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-Debt" xlink:href="gtbp-20190630.xsd#Note4-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:href="gtbp-20190630.xsd#Note6-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:href="gtbp-20190630.xsd#Note7-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:href="gtbp-20190630.xsd#Note11-ChangeOfAccountingMethod" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:href="gtbp-20190630.xsd#Note12-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note4-DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:href="gtbp-20190630.xsd#Note11-ChangeOnAccountingMethodDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="loc_us-gaapNonoperatingGainsLosses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapNonoperatingGainsLosses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="loc_GTBPIncomeLossFromContinuingOperationsBeforeIncomeTaxes" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_GTBPIncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders' Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="loc_us-gaapNonoperatingGainsLosses" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNonoperatingGainsLosses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_NoteAllonges" xlink:label="loc_GTBPNoteAllonges" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPNoteAllonges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaapPaymentsOfLoanCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfLoanCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaapProceedsFromMinorityShareholders" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapProceedsFromMinorityShareholders" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note1-Company" xlink:title="00000007 - Disclosure - Note 1 - The Company" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note3-Intangibles" xlink:title="00000009 - Disclosure - Note 3 - Intangibles" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-Debt" xlink:title="00000010 - Disclosure - Note 4 - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:title="00000011 - Disclosure - Note 5 - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Note 6 - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:title="00000013 - Disclosure - Note 7 - Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:title="00000014 - Disclosure - Note 8 - Stock Options and Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:title="00000015 - Disclosure - Note 9 - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Note 10 - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:title="00000017 - Disclosure - Note 11 - Change of Accounting Method" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:title="00000018 - Disclosure - Note 12 - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:title="00000020 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:title="00000021 - Disclosure - Note 5 - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:title="00000022 - Disclosure - Note 8 - Stock Options and Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:title="00000023 - Disclosure - Note 9 - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - Note 10 - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:title="00000027 - Disclosure - Note 4 - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:title="00000028 - Disclosure - Note 5 - Accrued Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:title="00000029 - Disclosure - Note 8 - Stock Options and Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:title="00000030 - Disclosure - Note 8 - Stock Options and Warrants (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:title="00000031 - Disclosure - Note 8 - Stock Options and Warrants (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:title="00000032 - Disclosure - Note 9 - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:title="00000033 - Disclosure - Note 9 - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:title="00000034 - Disclosure - Note 10 - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:title="00000036 - Disclosure - Note 11 - Change on Accounting Method (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>gtbp-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:href="gtbp-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:href="gtbp-20190630.xsd#StatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note1-Company" xlink:href="gtbp-20190630.xsd#Note1-Company" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note3-Intangibles" xlink:href="gtbp-20190630.xsd#Note3-Intangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-Debt" xlink:href="gtbp-20190630.xsd#Note4-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:href="gtbp-20190630.xsd#Note6-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:href="gtbp-20190630.xsd#Note7-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:href="gtbp-20190630.xsd#Note11-ChangeOfAccountingMethod" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:href="gtbp-20190630.xsd#Note12-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note4-DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:href="gtbp-20190630.xsd#Note11-ChangeOnAccountingMethodDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapAssetsCurrentAbstract_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapPrepaidExpenseCurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapAssetsCurrent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapAssetsNoncurrent_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_100" xlink:to="loc_us-gaapAssets_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapAccountsPayableCurrent_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapDeferredRentCreditCurrent_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapLineOfCredit_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapConvertibleDebtCurrent_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrent_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapLiabilities_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquityAbstract_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockValue_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockValue_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapAdditionalPaidInCapital_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapMinorityInterest_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_100" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockSharesIssued_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockSharesOutstanding_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders' Deficit">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfWarrants" xlink:label="loc_GTBPIssuanceOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIssuanceOfWarrants_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ChangeInAccountingMethodForDebtAndWarrants" xlink:label="loc_GTBPChangeInAccountingMethodForDebtAndWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPChangeInAccountingMethodForDebtAndWarrants_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note1-Company" xlink:title="00000007 - Disclosure - Note 1 - The Company" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note3-Intangibles" xlink:title="00000009 - Disclosure - Note 3 - Intangibles" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-Debt" xlink:title="00000010 - Disclosure - Note 4 - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:title="00000011 - Disclosure - Note 5 - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Note 6 - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:title="00000013 - Disclosure - Note 7 - Stockholders' Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:title="00000014 - Disclosure - Note 8 - Stock Options and Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:title="00000015 - Disclosure - Note 9 - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Note 10 - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:title="00000017 - Disclosure - Note 11 - Change of Accounting Method" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:title="00000018 - Disclosure - Note 12 - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:title="00000020 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:title="00000021 - Disclosure - Note 5 - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:title="00000022 - Disclosure - Note 8 - Stock Options and Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:title="00000023 - Disclosure - Note 9 - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - Note 10 - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockWarrantsMember" xlink:label="loc_GTBPExerciseOfCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPExerciseOfCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_GTBPConversionOfPreferredStockIntoCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPConversionOfPreferredStockIntoCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfConvertibleDebenturesMember" xlink:label="loc_GTBPConversionOfConvertibleDebenturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPConversionOfConvertibleDebenturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockOptionsMember" xlink:label="loc_GTBPExerciseOfCommonStockOptionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPExerciseOfCommonStockOptionsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:title="00000027 - Disclosure - Note 4 - Debt (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:title="00000028 - Disclosure - Note 5 - Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:title="00000029 - Disclosure - Note 8 - Stock Options and Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:to="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_80" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:title="00000030 - Disclosure - Note 8 - Stock Options and Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:title="00000031 - Disclosure - Note 8 - Stock Options and Warrants (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:title="00000032 - Disclosure - Note 9 - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:title="00000033 - Disclosure - Note 9 - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:title="00000034 - Disclosure - Note 10 - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:title="00000036 - Disclosure - Note 11 - Change on Accounting Method (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaapChangeInAccountingPrincipleMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="loc_us-gaapChangeInAccountingPrincipleMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaapChangeInAccountingPrincipleMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="loc_us-gaapChangeInAccountingPrincipleMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapChangeInAccountingPrincipleMember" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapChangeInAccountingPrincipleMember" xlink:to="loc_srtRestatementAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_70" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>gtbp-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="GTBP_SeriesJPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesJPreferredStockMember" xlink:to="GTBP_SeriesJPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesJPreferredStockMember_lbl" xml:lang="en-US">Series J</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockWarrantsMember" xlink:label="GTBP_ExerciseOfCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExerciseOfCommonStockWarrantsMember" xlink:to="GTBP_ExerciseOfCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExerciseOfCommonStockWarrantsMember_lbl" xml:lang="en-US">Exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="GTBP_ConversionOfPreferredStockIntoCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConversionOfPreferredStockIntoCommonStockMember" xlink:to="GTBP_ConversionOfPreferredStockIntoCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConversionOfPreferredStockIntoCommonStockMember_lbl" xml:lang="en-US">Conversion of preferred stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfConvertibleDebenturesMember" xlink:label="GTBP_ConversionOfConvertibleDebenturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConversionOfConvertibleDebenturesMember" xlink:to="GTBP_ConversionOfConvertibleDebenturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConversionOfConvertibleDebenturesMember_lbl" xml:lang="en-US">Conversion of convertible debentures into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockOptionsMember" xlink:label="GTBP_ExerciseOfCommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExerciseOfCommonStockOptionsMember" xlink:to="GTBP_ExerciseOfCommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExerciseOfCommonStockOptionsMember_lbl" xml:lang="en-US">Exercise of common stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_lbl" xml:lang="en-US">Adjustments for Change in Accounting Principle [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Revisions</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_DocumentAndEntityInformationAbstract" xlink:label="GTBP_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DocumentAndEntityInformationAbstract" xlink:to="GTBP_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-to-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Note payable to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible debentures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.001 par value; 750,000,000 shares authorized; and 52,644,882 and 50,650,478 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_LicenseRevenues" xlink:label="GTBP_LicenseRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseRevenues" xlink:to="GTBP_LicenseRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LicenseRevenues_lbl" xml:lang="en-US">License revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of License Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="us-gaap_NonoperatingGainsLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US">Loss on impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" xlink:label="GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" xlink:to="GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes_lbl" xml:lang="en-US">Loss before minority interest and provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: Loss attributable to the noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:to="GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning Balance, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfWarrants" xlink:label="GTBP_IssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrants" xlink:to="GTBP_IssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisition, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for acquisition, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common and preferred stock for convertible notes and interest Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common and preferred stock for convertible notes and interest, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock for preferred stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock for preferred stock, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for compensation, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature on convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ChangeInAccountingMethodForDebtAndWarrants" xlink:label="GTBP_ChangeInAccountingMethodForDebtAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ChangeInAccountingMethodForDebtAndWarrants" xlink:to="GTBP_ChangeInAccountingMethodForDebtAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ChangeInAccountingMethodForDebtAndWarrants_lbl" xml:lang="en-US">Change in accounting method for debt and warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending Balance, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="us-gaap_NonoperatingGainsLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_NonoperatingGainsLosses_2_lbl" xml:lang="en-US">Loss on impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation expense for options and warrants issued to employees and non-employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_NoteAllonges" xlink:label="GTBP_NoteAllonges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_NoteAllonges" xlink:to="GTBP_NoteAllonges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_NoteAllonges_lbl" xml:lang="en-US">Note Allonges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_2_lbl" xml:lang="en-US">Loss on disposal of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of loan costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Acquisition of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="us-gaap_PaymentsOfLoanCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl" xml:lang="en-US">Loan costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="us-gaap_ProceedsFromMinorityShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMinorityShareholders" xlink:to="us-gaap_ProceedsFromMinorityShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMinorityShareholders_lbl" xml:lang="en-US">Minority Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-Cash Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes" xlink:label="GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes" xlink:to="GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes_lbl" xml:lang="en-US">Issuance of common stock upon conversion of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest" xlink:label="GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest" xlink:to="GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest_lbl" xml:lang="en-US">Issuance of common stock upon conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" xlink:label="GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" xlink:to="GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock_lbl" xml:lang="en-US">Acquisition of intangibles through issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockForDebt" xlink:label="GTBP_IssuanceOfCommonStockForDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfCommonStockForDebt" xlink:to="GTBP_IssuanceOfCommonStockForDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfCommonStockForDebt_lbl" xml:lang="en-US">Issuance of common stock for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">The Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">The Company and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_3_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note6ChangeInPriorYearFinancialsAbstract" xlink:label="GTBP_Note6ChangeInPriorYearFinancialsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_Note6ChangeInPriorYearFinancialsAbstract" xlink:to="GTBP_Note6ChangeInPriorYearFinancialsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_Note6ChangeInPriorYearFinancialsAbstract_lbl" xml:lang="en-US">Note 11 - Change Of Accounting Method</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock_lbl" xml:lang="en-US">Change of Accounting Method</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation and Comprehensive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising and Promotional Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Stock Based Compensation to Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_LongLivedAssetsPolicyTextBlock" xlink:label="GTBP_LongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LongLivedAssetsPolicyTextBlock" xlink:to="GTBP_LongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" xlink:label="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" xlink:to="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract_lbl" xml:lang="en-US">Note 2 - Company And Summary Of Significant Accounting Policies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of the stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of the warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Summary of outstanding and exercisable stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Components of net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum lease commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Cash and cash equivalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Diluted shares excluded from calcuation of EPS</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_DebtDetailsNarrativeAbstract" xlink:label="GTBP_DebtDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DebtDetailsNarrativeAbstract" xlink:to="GTBP_DebtDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DebtDetailsNarrativeAbstract_lbl" xml:lang="en-US">Note 4 - Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ResearchDevelopment" xlink:label="GTBP_ResearchDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ResearchDevelopment" xlink:to="GTBP_ResearchDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ResearchDevelopment_lbl" xml:lang="en-US">Research &amp; Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConsultingAndAdvisoryServices" xlink:label="GTBP_ConsultingAndAdvisoryServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConsultingAndAdvisoryServices" xlink:to="GTBP_ConsultingAndAdvisoryServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConsultingAndAdvisoryServices_lbl" xml:lang="en-US">Consulting and Advisory Services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_BoardOfDirectorsServiceCosts" xlink:label="GTBP_BoardOfDirectorsServiceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_BoardOfDirectorsServiceCosts" xlink:to="GTBP_BoardOfDirectorsServiceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_BoardOfDirectorsServiceCosts_lbl" xml:lang="en-US">Board of Directors Service Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of December 31, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding as of June 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable as of June 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding as of December 31, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding as of June 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable as of June 30, 2019</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Exercisable as of June 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercisable as of June 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_StockOptionsAndWarrantsDetailsAbstract" xlink:label="GTBP_StockOptionsAndWarrantsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockOptionsAndWarrantsDetailsAbstract" xlink:to="GTBP_StockOptionsAndWarrantsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockOptionsAndWarrantsDetailsAbstract_lbl" xml:lang="en-US">Stock Options And Warrants Details</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExercisePriceRange" xlink:label="GTBP_ExercisePriceRange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExercisePriceRange" xlink:to="GTBP_ExercisePriceRange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExercisePriceRange_lbl" xml:lang="en-US">Exercise price range</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeTaxesDetailsAbstract" xlink:label="GTBP_IncomeTaxesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncomeTaxesDetailsAbstract" xlink:to="GTBP_IncomeTaxesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncomeTaxesDetailsAbstract_lbl" xml:lang="en-US">Note 9 - Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Federal net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Patent amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets before valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeTaxesDetailsNarrativeAbstract" xlink:label="GTBP_IncomeTaxesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncomeTaxesDetailsNarrativeAbstract" xlink:to="GTBP_IncomeTaxesDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_IncomeTaxesDetailsNarrativeAbstract_lbl" xml:lang="en-US">Note 9 - Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Net operating loss carryforward, expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xml:lang="en-US">Change in Warrant Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="us-gaap_NonoperatingGainsLosses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingGainsLosses_3_lbl" xml:lang="en-US">Nonoperating Gains (Losses)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfLoanCosts_2_lbl" xml:lang="en-US">Payments of Loan Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>gtbp-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.26a -->
    <!-- Field: Doc-Info; Name: Source; Value: 192761 GTBP 06302019 S1.xfr; Date: 2019%2D09%2D13T16:39:26Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:href="gtbp-20190630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20190630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20190630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20190630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:href="gtbp-20190630.xsd#StatementOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20190630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note1-Company" xlink:href="gtbp-20190630.xsd#Note1-Company" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note3-Intangibles" xlink:href="gtbp-20190630.xsd#Note3-Intangibles" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-Debt" xlink:href="gtbp-20190630.xsd#Note4-Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:href="gtbp-20190630.xsd#Note6-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:href="gtbp-20190630.xsd#Note7-StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:href="gtbp-20190630.xsd#Note11-ChangeOfAccountingMethod" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:href="gtbp-20190630.xsd#Note12-SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note4-DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:href="gtbp-20190630.xsd#Note5-AccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:href="gtbp-20190630.xsd#Note8-StockOptionsAndWarrantsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note9-IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20190630.xsd#Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:href="gtbp-20190630.xsd#Note11-ChangeOnAccountingMethodDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_DocumentAndEntityInformationAbstract" xlink:label="loc_GTBPDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetIncludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_SeriesJPreferredStockMember" xlink:label="loc_GTBPSeriesJPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesJPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_LicenseRevenues" xlink:label="loc_GTBPLicenseRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_GTBPLicenseRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="loc_us-gaapNonoperatingGainsLosses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNonoperatingGainsLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ParentPortionIncomeLossBeforeProvisionForIncomeTaxes" xlink:label="loc_GTBPParentPortionIncomeLossBeforeProvisionForIncomeTaxes" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_GTBPParentPortionIncomeLossBeforeProvisionForIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:label="loc_GTBPIncomeLossFromContinuingOperationsBeforeIncomeTaxes" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_GTBPIncomeLossFromContinuingOperationsBeforeIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementOfStockholdersDeficit" xlink:title="00000005 - Statement - Consolidated Statement of Stockholders' Deficit">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfWarrants" xlink:label="loc_GTBPIssuanceOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ChangeInAccountingMethodForDebtAndWarrants" xlink:label="loc_GTBPChangeInAccountingMethodForDebtAndWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPChangeInAccountingMethodForDebtAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="loc_us-gaapNonoperatingGainsLosses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNonoperatingGainsLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_NoteAllonges" xlink:label="loc_GTBPNoteAllonges" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPNoteAllonges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfLoanCosts" xlink:label="loc_us-gaapPaymentsOfLoanCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfLoanCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaapProceedsFromMinorityShareholders" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromMinorityShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes" xlink:label="loc_GTBPIssuanceOfCommonStockUponConversionOfConvertibleNotes" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_GTBPIssuanceOfCommonStockUponConversionOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest" xlink:label="loc_GTBPIssuanceOfCommonStockUponConversionOfAccruedInterest" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_GTBPIssuanceOfCommonStockUponConversionOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock" xlink:label="loc_GTBPAcquisitionOfIntangiblesThroughIssuanceOfCommonStock" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_GTBPAcquisitionOfIntangiblesThroughIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IssuanceOfCommonStockForDebt" xlink:label="loc_GTBPIssuanceOfCommonStockForDebt" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_GTBPIssuanceOfCommonStockForDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note1-Company" xlink:title="00000007 - Disclosure - Note 1 - The Company">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note3-Intangibles" xlink:title="00000009 - Disclosure - Note 3 - Intangibles">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-Debt" xlink:title="00000010 - Disclosure - Note 4 - Debt">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpenses" xlink:title="00000011 - Disclosure - Note 5 - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note6-RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Note 6 - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note7-StockholdersEquity" xlink:title="00000013 - Disclosure - Note 7 - Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants" xlink:title="00000014 - Disclosure - Note 8 - Stock Options and Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxes" xlink:title="00000015 - Disclosure - Note 9 - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Note 10 - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod" xlink:title="00000017 - Disclosure - Note 11 - Change of Accounting Method">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note6ChangeInPriorYearFinancialsAbstract" xlink:label="loc_GTBPNote6ChangeInPriorYearFinancialsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPNote6ChangeInPriorYearFinancialsAbstract" xlink:to="loc_us-gaapAccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note12-SubsequentEvents" xlink:title="00000018 - Disclosure - Note 12 - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_LongLivedAssetsPolicyTextBlock" xlink:label="loc_GTBPLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd" xlink:title="00000020 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" xlink:label="loc_GTBPNote1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPNote1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesTables" xlink:title="00000021 - Disclosure - Note 5 - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables" xlink:title="00000022 - Disclosure - Note 8 - Stock Options and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesTables" xlink:title="00000023 - Disclosure - Note 9 - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - Note 10 - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_GTBPNote1CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPNote1CompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockWarrantsMember" xlink:label="loc_GTBPExerciseOfCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPExerciseOfCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfPreferredStockIntoCommonStockMember" xlink:label="loc_GTBPConversionOfPreferredStockIntoCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPConversionOfPreferredStockIntoCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConversionOfConvertibleDebenturesMember" xlink:label="loc_GTBPConversionOfConvertibleDebenturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPConversionOfConvertibleDebenturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExerciseOfCommonStockOptionsMember" xlink:label="loc_GTBPExerciseOfCommonStockOptionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPExerciseOfCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note4-DebtDetailsNarrative" xlink:title="00000027 - Disclosure - Note 4 - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_DebtDetailsNarrativeAbstract" xlink:label="loc_GTBPDebtDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDebtDetailsNarrativeAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note5-AccruedExpensesDetails" xlink:title="00000028 - Disclosure - Note 5 - Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ResearchDevelopment" xlink:label="loc_GTBPResearchDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPResearchDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ConsultingAndAdvisoryServices" xlink:label="loc_GTBPConsultingAndAdvisoryServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPConsultingAndAdvisoryServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_BoardOfDirectorsServiceCosts" xlink:label="loc_GTBPBoardOfDirectorsServiceCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPBoardOfDirectorsServiceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails" xlink:title="00000029 - Disclosure - Note 8 - Stock Options and Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1" xlink:title="00000030 - Disclosure - Note 8 - Stock Options and Warrants (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2" xlink:title="00000031 - Disclosure - Note 8 - Stock Options and Warrants (Details 2)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_StockOptionsAndWarrantsDetailsAbstract" xlink:label="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_ExercisePriceRange" xlink:label="loc_GTBPExercisePriceRange" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_GTBPExercisePriceRange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPStockOptionsAndWarrantsDetailsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetails" xlink:title="00000032 - Disclosure - Note 9 - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeTaxesDetailsAbstract" xlink:label="loc_GTBPIncomeTaxesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPIncomeTaxesDetailsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative" xlink:title="00000033 - Disclosure - Note 9 - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_IncomeTaxesDetailsNarrativeAbstract" xlink:label="loc_GTBPIncomeTaxesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails" xlink:title="00000034 - Disclosure - Note 10 - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000035 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails" xlink:title="00000036 - Disclosure - Note 11 - Change on Accounting Method (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20190630.xsd#GTBP_Note6ChangeOnAccountingMethodDetailsAbstract" xlink:label="loc_GTBPNote6ChangeOnAccountingMethodDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPNote6ChangeOnAccountingMethodDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaapChangeInAccountingPrincipleMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="loc_us-gaapChangeInAccountingPrincipleMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapChangeInAccountingPrincipleMember" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapChangeInAccountingPrincipleMember" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6633696224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IncomeTaxesDetailsNarrativeAbstract', window );"><strong>Income Taxes Details Narrative Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 84,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss carryforward, expiration</a></td>
<td class="text">These carryforwards expire from 2019 through 2038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncomeTaxesDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncomeTaxesDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772353664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock Options and Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options and Warrants</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Stock
Options</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
following table summarizes stock option transactions for the six months ended June 30, 2019:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,133</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(1,133</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable,
    June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Stock Warrants</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Warrant
transactions for the six months ended June 30, 2019 are as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    at December 31, 2018:</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    at June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    at June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6762182912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Convertible
Notes</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
January 22, 2018, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) with fourteen accredited investors
(individually, a &#8220;Buyer&#8221; and collectively, the &#8220;Buyers&#8221;) pursuant to which the Company agreed to issue
to the Buyers senior convertible notes in an aggregate principal amount of $7,760,510 (the &#8220;Notes&#8221;), which Notes shall
be convertible into the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) at a price of
$4.58 per share, and five-year warrants to purchase the Company&#8217;s Common Stock representing the right to acquire an aggregate
of approximately 1,694,440 shares of Common Stock (the &#8220;Warrants&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">Pursuant
to the terms of SPA the Notes were subject to an original issue discount of 10% resulting in proceeds to the Company of $7,055,000
from the transaction.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Upon
the purchase of the Notes, the Buyers received Warrants to purchase 1,694,440 shares of Common Stock. Such Warrants are exercisable
for (5) years from the date the shares underlying the Warrants are freely saleable. The initial Exercise Price is $4.58. <font style="background-color: white">According
to the terms of the warrant agreement, the Warrants are subject to certain adjustments depending upon the price and structure
of a subsequent financing, including a qualified financing with gross proceeds of at least $20 million</font>, as defined in the
agreements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
issuance of the Notes and Warrants were made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;) for the offer and sale of securities not involving a public offering, and
Regulation D promulgated under the Securities Act.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Contemporaneously
with the execution and delivery of the SPA, the Company and the Buyers executed and delivered a Registration Rights Agreement
(the &#8220;Registration Rights Agreement&#8221;) pursuant to which the Company has agreed to provide certain registration rights
with respect to the Registrable Securities under the 1933 Act and the rules and regulations promulgated thereunder, and applicable
state securities laws.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Senior
Convertible Debentures</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
August 2, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal amount
of $5,140,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock, par
value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share. The Company used a portion of these proceeds
to repay $4.4 million of the notes issued on January 22, 2018. Additionally, the remaining $3.3 million of the notes issued on
January 22, 2018 were converted into the Debentures at the same terms discussed above.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 7, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal
amount of $2,050,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 24, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal
amount of $800,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
February 4, 2019, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with the purchasers identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and
collectively, the &#8220;Purchasers&#8221;), pursuant to which the Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224 (the &#8220;Notes&#8221;), consisting of gross proceeds of $1,052,224
and settlement of existing debt of $300,000, which Notes shall be convertible at any time after issuance into shares (the &#8220;Conversion
Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a conversion
price of $0.60 per share (the &#8220;Conversion Price&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Notes accrue interest at the rate of 10% per annum and mature on August 2, 2019. Interest on the Notes is payable in cash or,
at a Purchaser&#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,
and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to
adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances
if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion
Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Contemporaneously
with the execution and delivery of the Purchase Agreement, on February 4, 2019, the Company and certain of its wholly-owned subsidiaries
entered into a Security Agreement (the &#8220;Security Agreement&#8221;) with Alpha Capital Anstalt, as collateral agent on behalf
of the Purchasers, and with the Purchasers, pursuant to which the Purchasers have been granted a first-priority security interest
in substantially all of the assets of the Company and such subsidiaries securing (i) an aggregate principal amount of $1,352,224
of Notes and (ii) an aggregate principal amount of $9,058,962 of the Company&#8217;s 10% Senior Convertible Debentures issued
on August 2, 2018, September 7, 2018 and September 24, 2018 held by such Purchasers.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,
that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction
(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company
shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such
Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common
Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated thereby.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the
Purchasers, pursuant to which the Company has agreed to file, within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available
to effect a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form S-3 was filed by the Company on February 14, 2019.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
May 22, 2019, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with the purchasers identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and
collectively, the &#8220;Purchasers&#8221;), pursuant to which the Company issued to the Purchasers, on May 22, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,300,000 (the &#8220;Notes&#8221;), which Notes shall be convertible at
any time after issuance into shares (the &#8220;Conversion Shares&#8221;) of the Company&#8217;s common stock, par value $0.001
per share (the &#8220;Common Stock&#8221;), at a conversion price of $0.35 per share (the &#8220;Conversion Price&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Notes accrue interest at the rate of 10% per annum and mature on November 22, 2019. Interest on the Notes is payable in cash or,
at a Purchaser&#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,
and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to
adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances
if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion
Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,
that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction
(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company
shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such
Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common
Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated thereby.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the
Purchasers, pursuant to which the Company has agreed to file, within 30 days after May 22, 2019, one or more registration statements
on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available to effect
a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain penalties
set forth in the Registration Rights Agreement. The Form S-1 was filed by the Company on June 21, 2019.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;<i>Financing
Agreement</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and
manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in
the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal
of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum. There is
$31,000 due on this credit line at June 30, 2019.</font></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Convertible
Notes</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
January 22, 2018, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) with fourteen accredited investors
(individually, a &#8220;Buyer&#8221; and collectively, the &#8220;Buyers&#8221;) pursuant to which the Company agreed to issue
to the Buyers senior convertible notes in an aggregate principal amount of $7,760,510 (the &#8220;Notes&#8221;), which Notes shall
be convertible into the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) at a price of
$4.58 per share, and five-year warrants to purchase the Company&#8217;s Common Stock representing the right to acquire an aggregate
of approximately 1,694,440 shares of Common Stock (the &#8220;Warrants&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Pursuant
to the terms of SPA the Notes were subject to an original issue discount of 10% resulting in proceeds to the Company of $7,055,000
from the transaction.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Upon
the purchase of the Notes, the Buyers received Warrants to purchase 1,694,440 shares of Common Stock. Such Warrants are exercisable
for (5) years from the date the shares underlying the Warrants are freely saleable. The initial Exercise Price is $4.58. According
to the terms of the warrant agreement, the Warrants are subject to certain adjustments depending upon the price and structure
of a subsequent financing, including a qualified financing with gross proceeds of at least $20 million, as defined in the agreements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
issuance of the Notes and Warrants were made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;) for the offer and sale of securities not involving a public offering, and
Regulation D promulgated under the Securities Act.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Contemporaneously
with the execution and delivery of the SPA, the Company and the Buyers executed and delivered a Registration Rights Agreement
(the &#8220;Registration Rights Agreement&#8221;) pursuant to which the Company has agreed to provide certain registration rights
with respect to the Registrable Securities under the 1933 Act and the rules and regulations promulgated thereunder, and applicable
state securities laws.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Senior
Convertible Debentures</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
August 2, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal amount
of $5,140,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock, par
value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share. The Company used a portion of these proceeds
to repay $4.4 million of the notes issued on January 22, 2018. Additionally, the remaining $3.3 million of the notes issued on
January 22, 2018 were converted into the Debentures at the same terms discussed above.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 7, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal
amount of $2,050,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 24, 2018, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement with the purchasers
identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and collectively, the &#8220;Purchasers&#8221;)
pursuant to which the Company has issued to the Purchasers one year 10% Senior Convertible Debentures in an aggregate principal
amount of $800,000 (the &#8220;Debentures&#8221;), which Debentures shall be convertible into the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;Common Stock&#8221;), at a price of $2 per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
issuance of the Senior Convertible Debentures was made in reliance on the exemption provided by Section 4(a)(2) of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), for the offer and sale of securities not involving a public offering
and Regulation D promulgated under the Securities Act.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Financing
Agreement</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and
manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in
the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal
of all Advances under the Line of Credit will bear interest at the rate of interest of prime plus 2 percent per annum. There is
$31,000 due on this credit line at December 31, 2018.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752887552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b>Debts</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;On
July 31, 2019, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with one purchaser, pursuant to which the Company issued to the Purchaser, on July 31, 2019, Secured Convertible
Note in the principal amount of $25,000 (the &#8220;Note&#8221;), which Note shall be convertible at any time after issuance into
shares (the &#8220;Conversion Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common
Stock&#8221;), at a conversion price of $0.20 per share (the &#8220;Conversion Price&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Note accrues interest at the rate of 10% per annum and matures on January 31, 2020. Interest on the Note is payable in cash or,
at a Purchaser&#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Note contains customary default provisions, including provisions for potential acceleration,
and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to
adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances
if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion
Price then in effect. The Company may only prepay the Note with the prior written consent of the respective Purchasers thereof.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,
that the Company, until the date on which less than 10% of the Note is outstanding, shall not effect any Variable Rate Transaction
(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company
shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such
Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common
Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated thereby.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the
Purchaser, pursuant to which the Company has agreed to file, within 30 days after July 31, 2019, one or more registration statements
on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available to effect
a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain penalties
set forth in the Registration Rights Agreement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b>Common
Stock</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">On
August 14, 2019,</font> <font style="font: 8pt Times New Roman, Times, Serif">the Company&#8217;s CEO Anthony
<font style="background-color: white">Cataldo received as compensation a restricted stock award of 7,000,000 common shares and
the Company&#8217;s CFO Steven Weldon received as compensation a restricted stock award of 4,500,000 common shares. Also, two
Company consultants were paid as compensation a restricted stock award of 1,000,000 common shares each.</font></font></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Financing</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
February 4, 2019, GT Biopharma, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with the purchasers identified on the signature pages thereto (individually, a &#8220;Purchaser,&#8221; and
collectively, the &#8220;Purchasers&#8221;), pursuant to which the Company issued to the Purchasers, on February 4, 2019, Secured
Convertible Notes in an aggregate principal amount of $1,352,224 (the &#8220;Notes&#8221;), consisting of gross proceeds of $1,052,224
and settlement of existing debt of $300,000, which Notes shall be convertible at any time after issuance into shares (the &#8220;Conversion
Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), at a conversion
price of $0.60 per share (the &#8220;Conversion Price&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Notes accrue interest at the rate of 10% per annum and mature on August 2, 2019. Interest on the Notes is payable in cash or,
at a Purchaser&#8217;s option, in shares of Common Stock at the Conversion Price. Upon the occurrence of an event of default,
interest accrues at 18% per annum. The Notes contain customary default provisions, including provisions for potential acceleration,
and covenants, including negative covenants regarding additional indebtedness and dividends. The Conversion Price is subject to
adjustment due to certain events, including stock dividends and stock splits, and is subject to reduction in certain circumstances
if the Company issues Common Stock or Common Stock equivalents at an effective price per share that is lower than the Conversion
Price then in effect. The Company may only prepay the Notes with the prior written consent of the respective Purchasers thereof.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Contemporaneously
with the execution and delivery of the Purchase Agreement, on February 4, 2019, the Company and certain of its wholly-owned subsidiaries
entered into a Security Agreement (the &#8220;Security Agreement&#8221;) with Alpha Capital Anstalt, as collateral agent on behalf
of the Purchasers, and with the Purchasers, pursuant to which the Purchasers have been granted a first-priority security interest
in substantially all of the assets of the Company and such subsidiaries securing (i) an aggregate principal amount of $1,352,224
of Notes and (ii) an aggregate principal amount of $9,058,962 of the Company&#8217;s 10% Senior Convertible Debentures issued
on August 2, 2018, September 7, 2018 and September 24, 2018 held by such Purchasers.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Purchase Agreement contains customary representations, warranties and covenants, including covenants, subject to certain exceptions,
that the Company, until the date on which less than 10% of the Notes are outstanding, shall not effect any Variable Rate Transaction
(as defined in the Purchase Agreement) and that, for as long as a Purchaser holds any Notes or Conversion Shares, the Company
shall amend the terms and conditions of the Purchase Agreement and the transactions contemplated thereby with respect to such
Purchaser to give such Purchaser the benefit of any terms or conditions under which the Company agrees to issue or sell any Common
Stock or Common Stock equivalents that are more favorable to an investor than the terms and conditions granted to such Purchaser
under the Purchase Agreement and the transactions contemplated thereby.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
addition, the Company entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the
Purchasers, pursuant to which the Company has agreed to file, within 14 days after February 4, 2019, one or more registration
statements on Form S-3 (or, if Form S-3 is not then available to the Company, such form of registration that is then available
to effect a registration for resale of the subject securities) covering the resale of all Conversion Shares, subject to certain
penalties set forth in the Registration Rights Agreement. The Form S-3 was filed by the Company on February 14, 2019.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Stock</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
the first quarter of 2019, the Company issued 723,940 shares of common stock upon conversion of $437,271 in principal and interest
on senior convertible notes.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769780176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2016</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Amount at Dec. 31, 2016</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 105,891<span></span>
</td>
<td class="num">$ (124,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">253,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common and preferred stock for convertible notes and interest Shares</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">17,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common and preferred stock for convertible notes and interest, Amount</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">25,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for preferred stock, Shares</a></td>
<td class="num">(2,042)<span></span>
</td>
<td class="nump">5,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for preferred stock, Amount</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for compensation, Shares</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">9,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for compensation, Amount</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">129,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ChangeInAccountingMethodForDebtAndWarrants', window );">Change in accounting method for debt and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678<span></span>
</td>
<td class="num">(678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,172)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2017</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">50,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Amount at Dec. 31, 2017</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">521,305<span></span>
</td>
<td class="num">(269,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IssuanceOfWarrants', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common and preferred stock for convertible notes and interest Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common and preferred stock for convertible notes and interest, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for compensation, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for compensation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature on convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259,186)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">50,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Amount at Dec. 31, 2018</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 540,171<span></span>
</td>
<td class="num">$ (528,685)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ChangeInAccountingMethodForDebtAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ChangeInAccountingMethodForDebtAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769032352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT Biopharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6608371200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Intangibles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding
capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). In exchange for the ownership of GTP, the Company issued
a total of 16,927,878 shares of its common stock, having a share price of $15.00 on the date of the transaction, to the three
prior owners of GTP which represented 33% of the issued and outstanding capital stock of the Company on a fully diluted basis.
$253.8 million of the value of shares issued was allocated to intangible assets consisting of a portfolio of three CNS development
candidates, which are classified as IPR&#38;D.&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As
of September 30, 2018, the Company recorded an intangible asset impairment charge of $228.5 million related to the portfolio of
CNS IPR&#38;D assets within Operating Expenses, which represents the excess carrying value compared to fair value. The impairment
charge was the result of both internal and external factors. In the 3rd quarter of 2018, the Company experienced changes in key
senior management, led by the appointment of a new CEO with extensive experience in oncology drug development. These changes resulted
in the prioritization of immuno-oncology development candidates relative to CNS development candidates. In conjunction with these
strategic changes, limited internal resources have delayed the development of the CNS IPR&#38;D assets. The limited resources,
changes in senior leadership, and favorable market conditions for immuno-oncology development candidates have resulted in the
Company choosing to focus on development of its immuno-oncology portfolio. In light of this shift in market strategy, the Company
performed a commercial assessment and a valuation of the CNS IPR&#38;D assets, both to assess fair value and support potential
future licensing efforts. The valuation indicated an excess carrying value over the fair value of these assets, resulting in the
impairment charge noted above.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
fair value of the CNS IPR&#38;D assets was determined using the discounted cash flow method which utilized significant estimates
and assumptions surrounding the amount and timing of the projected net cash flows, which includes the probability of commercialization,
the assumption that the assets would be out-licensed to third-parties for continued development for upfront licensing fees and
downstream royalty payments based on net sales, and expected impact of competitive, legal and/or regulatory forces on the projections,
as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the
projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</font></p><span></span>
</td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding
capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). In exchange for the ownership of GTP, the Company issued
a total of 16,927,878 shares of its common stock, having a share price of $15.00 on the date of the transaction, to the three
prior owners of GTP which represented 33% of the issued and outstanding capital stock of the Company on a fully diluted basis.
$253.8 million of the value of shares issued was allocated to intangible assets consisting of a portfolio of three CNS development
candidates, which are classified as IPR&#38;D.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For
the year ended December 31, 2018, the Company recorded an intangible asset impairment charge of $228.5 million related to the
portfolio of CNS IPR&#38;D assets within Operating Expenses, which represents the excess carrying value compared to fair value.
The impairment charge was the result of both internal and external factors. In the 3rd quarter of 2018, the Company experienced
changes in key senior management, led by the appointment of a new CEO with extensive experience in oncology drug development.
These changes resulted in the prioritization of immuno-oncology development candidates relative to CNS development candidates.
In conjunction with these strategic changes, limited internal resources have delayed the development of the CNS IPR&#38;D assets.
The limited resources, changes in senior leadership, and favorable market conditions for immuno-oncology development candidates
have resulted in the Company choosing to focus on development of its immuno-oncology portfolio. In light of this shift in market
strategy, the Company performed a commercial assessment and a valuation of the CNS IPR&#38;D assets, both to assess fair value
and support potential future licensing efforts. The valuation indicated an excess carrying value over the fair value of these
assets, resulting in the impairment charge noted above.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
fair value of the CNS IPR&#38;D assets was determined using the discounted cash flow method which utilized significant estimates
and assumptions surrounding the amount and timing of the projected net cash flows, which includes the probability of commercialization,
the assumption that the assets would be out-licensed to third-parties for continued development for upfront licensing fees and
downstream royalty payments based on net sales, and expected impact of competitive, legal and/or regulatory forces on the projections,
as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the
projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6765825536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (535,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (535,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (528,685)<span></span>
</td>
<td class="num">$ (269,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Diluted shares excluded from calcuation of EPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,416,352<span></span>
</td>
<td class="nump">3,390,120<span></span>
</td>
<td class="nump">8,682,368<span></span>
</td>
<td class="nump">1,164,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 3,251<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 6,724<span></span>
</td>
<td class="nump">$ 9,067<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6633039408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock Options and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the stock option activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,133</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(1,133</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable,
    June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
    Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2016</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(133</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,020.00</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    Options:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,428.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the warrant activity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    at December 31, 2018:</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding
    at June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    at June 30, 2019</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.35</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
    Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2016</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,550</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">135.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">486,351</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(501,901</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    Warrants:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of outstanding and exercisable stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Outstanding
    Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Exercisable
    Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    <b>Range of Exercise Prices</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    <b>Number of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Remaining</b></font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Contractual
        Life</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Exercise Price</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
        of Options</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Exercise Price</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 1%; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    $750.00 to $2,225.00&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.49</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 3%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !6!+4\?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ %8$M3R?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*FP';7;F'QM?!+L6?MU%]P502P,$%     @ %8$M3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MXM[:SKCFXL^NH8,I=I>+RNR[_FWBWC?C0>UXT=G3= @=74["5_\#4$L#!!0
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MI"1+-IL]4UQH6F0Q=S)%AKV30L/)$-LKQ<V?(T@<<KJEU\2+:%H7$JS(.M[
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MI06?5$PIG+Z-8].Z<1A7XGBB^0GA1 AGPC[X+R&:"-&*0,;*G-6O5-,LD6)
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M'"[71H!TN:IJI5:*KFK[[, "UMF8VB9<_[YK0RB7TA?L769F9^UU.AC[XAH
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M?-@^X-Z.@S8&WG33&V+S0\[_ %!+ P04    "  5@2U/$R82V[L!  #4 P
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MCLYTHB8[TS1MTB:3;;K]S>CU(PMB <?MVQ?0M=8E_3/ Y9S#.0[<=!3R134
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M8KQ%%I6:2U"6:X4,- 6^3T_G+. CX">'T:[.*%1RU?HY&%_J B<A(1!0N:#
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MM!DP;@R<A-!@C"1WQD-M/@SC@<%)V^W*[*4?C_Z@13=,?C1^?LJ_4$L#!!0
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MYY))^/%7D]IG36G8?O]B7ZK@13#O:4T7+/^3K?EN:D>VM::;])#S5W;Z1G5
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M6.73V^1J<#'8N*SW_^^;JWB\U-$8H/W]:;UX('&3ST,.KW>8KGLO^2%W"!B
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MV4Z6'5)0D :Q#WUURR2_Y( 2,FC3']*SAVX*?C0!@OMW()UB=^S"D-+@"G1
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MY=%^=K _/M#!#;F^(#;M1N>3"47RD9L;/K:7*'[=TPIOP*"NVP2Y;,$:>?@
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M$7(9*1=G1MO7P$/)0@F T%V98="0H!?H>KW24AF^">:J>N'NUD"XIY@[1-(
MG6?.!1T!8'_ _BAHZ0R20QK23)A >EN3SCRE*L(4Y<QF!(\#J52/F^9E(]4[
M808)%J<?;&X/B7EL=)_F:VJ[(-TZ"SS$-VU+CKGFM%P,'\3(=(P[,>BV%J4)
MD4.I4NH"^>8(1-AGH$M>J@XWDN\\0IA:XG"QAX44$IFA ($%-C+IXMF1 [YG
MJOBJ65%MJ$YTUD9:SSU21 MT+6VU6[,KE.526L])DG=H!-?*P?!)41/3OJFU
M&$I%\AX%9BIFV?)L(H%@9#;)K%1(N:]ZVXV6>4M\F3=!Z[CL%09XP@6&0TZ%
M2BH3$WL]WQPJ/^+'<,S@HM9)?5!CTMAZN1>\OMB<J6>&"8Z83)?K8?$A@T2Y
ME$JQK*^Q,,XW5@(H.^43TRC45B2-QLL&I3*8F:^!)%*J5#=:;2C#Z,2L8+,J
M^B%QP5*98+D$8S,5DA8]MU5C-MM!W6\YOVZ>A-A3O1F(=W5^B[<;3H_K5_9A
M-J(*8:A02Q_":BI)FD.Q;5 %RV@!/6ZY3/IN6DL8^A<7+*Y/?:=UB@46[F$U
M78]W+D<R20F<$6?]?;/A8M9YD+>X?H^LMT9X]T60;P;M!W.K'P4@D#T0E5=:
M/:Q8$KU"7)JY?N#:=?=(BT4I23;DF^*LAJ=>;BPCMR]:/?[AOKNX^. U>)4D
MN5EF1JW);]:+F(K1&,9YBJ_YGL14_ZLA+4VGN7IU&=Q-EV)\,R6D7?MB><8*
MD@9-AFN4&E@@#><<B[<S_#S4J3_C$FWS0,> N1=2/;US/#L,+P(M11!G,ZDC
M\+=UV<J&40QX=$ 7&(@ZA^5Z^;,+B$Y*^FAX^.<H>71+(<7;?!LV1JMS876V
MS+?P,P\YS4]L$C9QDEK1T00 ;5-=?G4'RB*3>,O]O([ UDQ'M3<:&S$?TTQ-
MODH]J0SURE3NM-*_ $AK-?E]Q&)YS'V=?M4+M$<P(SXV&ABY#L_7OV:Q9^H<
MO%:G8J%"J"#9?89]H9",!Z\2C:A+QIPZ[M393>0B(XA*>$#,JF4ETM?KO"/K
M]!?]MH-XSJ@%Y'PA.D>\L5D9C4VP8$:)=&E7^D3RI<Y_/17@H0@C$AG)WZSR
MJ IV+<U?%^3(DMU>*1PDD1>C1_IJCWDM.0(]NWM:@G8[$[N3>4>M:9$IXS]>
M!>OR%KN0K_W'M^T6].N%]J=T;'8VHGE5%S=%2;V,5TJC"5GJ/&]7Z>,D"+HO
MQM#=01TR794K@Z^77*SW8]'\N&7AV'1#]]N>)!7]@G/[8W;BI0F.9Z)7V.X.
MPFE5B[T(3HC+4;*^UUJAE!.N885M/V[![B77Z\^CCBJX5B^,4"Z<*F>AJYPE
ME""5K=9!WS."3)US80.JR1"T9ZU'_3(G@@92DI1L2$ROKV1]Q\T#CJ4Y4VP/
MF85IJ)\38NW>B,O8BG^K"=G>M(&D74.]<]3/I_>KG1X0'+O*3>?59>C]C1R^
MI9J7ES80#Z;GW/@N>8_HBS\QK5E"=O=#JJ+IHM ^.CD=LD\B-9;Q*W2$4@'D
MRVK&#0VM7'AQY>7"Y%3%%/5&FH(CVO7:R@2&>>(S\JD=DI(5=TEI]1T)Q4[(
ME,(;C&,7Q=V-7AR_S4P:H(9?O$&8*ZYR"CQ)X5*MVT)7/7YPWM%ZG$E[WK&H
M8<Q=_J&.U-20<;_%D2;V2-VO<*1?)2]TZDA5Y<WA6PKIO2 +0_L%JNB++RTD
M[I?,$*J:JY,G=>@F8B\R DH$+_$44=5IEM>(,A(GN:.^!5I8M@UMC#B;8S59
M3!G^S )R7-48B\?ZQ'E7]2Z3<!,@6M02MD1CD__\\0G27ER]NDPF)Q3V"4HP
M'BF'L&'_=U.K/ H^4ZE:PL3P[%J--@COJ,@1KQOMB])>$[$:*Z!1J5YO-R0X
MLBDX*".$="NT7I"4RPOCZ^<-SX\"B7@2(SFY18,NY;V'?UO/;MBT_X85BXKJ
MV3H#P:KO-'!DE33YOL#^>.9\QCZA  ZS(LVD]07,V2D>,;0 4A?&L*%3>%2^
M03==]D%RX8L:;UBM--7 \"0TB$L#-]3T]3*#GJ[>9S:GJ@$-C4$Y*$N$71(*
M$YY)+6Z/#S(G>4)\+P<Q$P+:<AXWDC,N>\8^9U]FG*H(^=X.;&+FZ]6T<,:N
MB=4BK3$\%R=E/O..4%D(F5 H".)SD=_[Q4OW5M*JT<L*"A9.J1&B3T"C3@.<
M</2P+*10R38*%4N4W8/T_A>G>B2BUZ/7OU.R\,V'C_^:+>^^>>G9T9OR\ -&
MD#>8*"^N#WH%Z+%7/SW# ABA;9VOJ3(!2R'ER+0U8>@/CW]+21@T?^95?9.O
M,%F=HKO8? 9H\"'RF31J&L6@KU;U>S?&W@O5/452[[QMW8!W*/GK(>Y$VZ>1
MQ-BJXN[N+^OU37)AZFYC--KKEQ<'E,NGC=))DEYF?ZM\<=2>J+I0Y=[$/+'V
M[BWW@4"194IQ?JY1VK)N(A94[3T8-*GCBD_QO_;U3WSK=KFY1>D[>V^(V31&
M(A+S]78Q-?.A!RT+@_"SIH.@KHN@;<(MO=*EKI8XI3R?,F\*/T(GJ)BO&RF]
MTLONCD&W^ &&<=Z6UE>&A+S;9A)JC**V#:')&)WG8[2,V(7JB(][C/BC+=#0
MY,ZVB(G%MBYX#+._ 40DVHJ<X^'.-Y[V!QT,]W*U:VQ-,F?/2%T]9(O5@]CR
MY3ZG+FIB3;:G4,C?'[XZ +A9 T[R%DE#,HFV7]ZM;7%X'(SBSJS;?;,;JBAO
MV96L%D&ZAZQ6DICVPIY!+"002O.]SF>A( _AK7<=\BC*= 6/\:BG2$M9V@<5
M%] 4:_W?<*#4'R@<C:S[%5M?IZ$*F$P9//FW>1@0^-GTMJP6U0WY?E%'WT*5
M1%C#"L#W%'')ZVSR1>XC53)F"\0G;^KJ'@-$8:QOHF.CGW3/39[_*.UA0D^U
MSUE-]>=P17A#+=C1*:E@#"#\)L159E_Z)\ >,:S3LZ?K)J] ^K^#ES + B/2
M5@_=DPI3Q 0$R!,:U9M(?F)%@ZS.1*#H8G09Y>ZD@NE!LH$>^!HKC1BYP\5P
M4<&5ONUT3MJ+1R@'27<..,/UG8:1+>\R;A-&%015PA)LEW#+EG#HHPC:<GB!
M)&M=>BI=YV@)3K'% E.Y;40NR*/75?6CDB8$J!$ZGZ67GRZ]3)ZEEV?IY5EZ
M>99>GJ679^GE67KY[R&]M#P"OO-AWC@3%L7-U4P0VX._[V13I0RN+2UD6_%O
M"1NFO&70;\9#DJVDSK1"3D/W-JUZG9<9<S=X:Y$A[:@>:Y<<_'MT1_!^^![(
M%$HD0TOL055+HU6L6:W;L_NB?6!?T!G%8AODQ&:G_?U0!0NJFF-+.$BXIXVL
MF).YV2V+:]T,E7RE7:SWWP)>'"2^6&-?N-J4J*V<S_["?\#IT 4UQ &VP%((
M97,K"N!W$>*)3")2U[UT#D\RZ?L17*IQ00^3"6GK^XHWQ;TL%FME"IN7F?QB
MRW2[+#--[A9KIC,AGGJ&*\<('$GSZNR<RD>@J$"655^-VR<B4;XYV>3#U%VO
MEJ]:VP4>T>0M.[15??UJHS5B:5:.4I+8TMS356%JV\Z%H@U8I)Z<IT>C$\Q1
MID5/TLGY,!V-AWV9$,&+Z;;YO/H#CYZ1^I\!J1DR'@FOZ= Y/I0@ZSR$ D"?
MV$!#,+\1VFS2#&VJK\8=^AK*YDXY#RP3^'(M[;E7$K0/DU 4[+W&B:(6=ZA?
MOH@:69OF]:\\8%LYD!YRH_1L-$F'QY/DT%U&.9%P681Q\2>4YAL-,DI')Y/T
MY/@\_*LUADV5G)DB )VACM/3X5%Z?(3+V+AH/7J8;33!LOU')^XL/3D;IY.3
M,UK#47H^/.X$R7U@6T4G@E%-%]Z60?[58.-@;UU1.VO4H&J_520F$:ZQ+B$M
M4,7;'2?L:NS'LIKE"TD J+-[RL<)V3\X]$:7N6LOD84"VZHW2I'ZS+4!@HZ"
M<?*7C[R1<(F3JFG]C.Y+QX*UBL*V%[V((AQ1&R?-:;I@J);_-D"K(T3WA0IH
M_*]#4XZMRLP1AST[4CL&A21'09H7U'>C/W>I)\Y4GFH/%UX=EQV:Y=F6>7B/
M=.R!+7:&;]93E/W0ZH.",/;P$3T@_[(2IRB5&B+CCJ-.P>CT%9C&.DH_(@^T
M/(J/S.#Z0=*52+YRD0M\AYY+W'F'X'(/ SPDTK<*=ZT&+ IWTP.EU/L A1!3
M[V'FWJ.D:S\JM&1(7WC)4U<<N^]EBM\W82<N.-UQ!ZG1+$#K**LE\ _>&B)R
MR4RB&QK]3%B>"<L_)V%I?A'*<OA,6;2"Y9>-@3'\3"/V&@Z')%J#6T([A 0T
MH6AMU8;'=]<?Y13'7*FM$"$W04P;#46&GI./9'H+ ]</+HH9#,4&8OAQISMN
MEU9O!-6\DC:)6)X(+5U8_&'9FW(0 0>7^-\3.G%$I?O5H(,LYZ]XX?LL?BV[
MHZ8@>9^?D[!S6&:NKIX0JR\Y5&(?L\8\NHS:HRAK6C'T]3JD0M-MI);U%2=_
MZYXI,!([D3&U4JU)"^(@V%3IQ=^P)J=:]/ %R6U1_9!B,MMSLP9FHN5"S0S_
MV.GVQ!6H12ZU>(PT-*24F052?<9!K<Z5:7_;YH7[U_]]?G)Z_HUX7D;B;E'*
M'>R"[*I!#OI 8_U]75&D(=8=;)+]=<G9<_GL@ VTY!E$#X4ZG.KH+,B=1MR5
MMQ!;ZGT0GZZJ%1?<2><(N5LV'P*3B*HR?U P89(^W0R4"%I>-)_S;F,X6P>,
MJ7UXQ.PK:><G(2<+N4Q:-&[%12%PYD$+V..=@*U[C@'.[8J7Q2*K-]FN.R"6
MVI8RIQ8#JZ[11)69K'TQHYL3>P#V49!C9 :RW113YLD(KW]Q+;?8VTOV!\SF
MLTTH^Z[<MI,?6\NT4 ,3J!":;Y4SL4=K904U"OA.8E%C93HMTSO-V@U:Z4 ;
M'+]GH^/#HV'[2"<[WY]U:0!/I1:-.],V<F=$7 (M@FWT!K0^T\QGFOE,,Y]I
MI@>1W9&AEK%C\Q>@AB^  &B?P." G5-RPPH("0$LM*@T00E<N:K&/*?>;GX*
MY:TT7BO*=!VX0CUG3,Z")U5M]Z^C:)O>T)=O%]GTQ\.K*0BW,*Q!.[2!!)>O
MP0RY0(P[J2;@B-6?*SQC0T$FGG&@A:E.HW[^3-I5WJ :4"(.'$IBF*_U2\\5
MP>6F/;1SQ+E&G(507XKF?P>V]M%:-DS,X-;WNA80:]9PM@@;1QIJ29UFLR5%
MOAXDC\QDLIBC6FM[)X-3_<'79OBJC,GM,/K-]YYC/_=!:_.C\(-[FJ^K78O@
MD27L4DS$^?(6F#U)+#'*M80K!*=UI@ON@3?G+GWDF)"^0CIOJ0X9OL*OZM]1
M$3(,F3"4&1=3Y]2)%NMWK.^ +!,-Y4_1\I:RYZ]ANCAE*YU4O:4^Y$@L<BH2
M(_8F-8IYT^<#,S,-U))H*";ZM=3=@XUC%>!2<DS5%"K5[C383VNU15%Y[3U2
MSOQZL<*B/DDNS2[L&P-J*![VG2;KNT/>.=D:(U.IJ55%F/7@UV:V ;+#6EBV
MV*&1Y%$A>VI:*7P#2^LA9$#VJ!:?)86WQ"1#ZN>>ML)^7.9K:E$8&-M$Y&R(
M4Y/9-E1^NC5'A"0^-6>@T7^(=A1,10R'2N*C??.'G,.3-(/<QS-$D$H40PA.
MQ1Q#L,@&:387'>_UHK@1 S3R$ZQ &&)-+8(01J5ZX([J3->?D5<1OWW(-Q<+
M:BT1EB:54#F^DPL;&MB$M@8-5U#+1<*8Y8BZ:(_BS,]H*Z'*M.1-+WRY4I;#
M H)A '<22DGW@\GB@#985FKHVH1&8&$DP5#L2:5>6.^/975_>%O=^P)L6)0E
M9&8+& Q.%%10$F0"$)-J@A.B<04Z"_9<QZ8-UQ[1.>YBS3F?)?/S^-Z(VI(;
M2N\CV+P1,6A<_< 8)!^T(*-9MQ=7,9K5'(LDY@?JP?'J&]F*.:5VC)VY;&MM
MA(+FROQS5%+)3(5"E0:^:VX^H<F"->+0OEUOKRG(SU;\]6)I=$PRLDI386[B
M0Q5FNR%!<6@G8+N+ZOXF7 5(ZU+*MGJ8"E8/B8HRPV'"OZ>\[$X"JREA#:LX
MX56\]FI"&,B%@@??5MC!2I,S7E]<?>MS+T2.+//[Y&9=L&1OSKS5FYQ,O(!]
MO645IK:LPJ?JKIBZLZ-QLD\ZPM'X@ @<M=_.I1F]G;1JMRT_-P+XDH8F[=XT
M,0_AW$IY.6A#F[G3W7<LI0Z2[X5X8!BX]@#G9ZG$RF;:?X6\2IR\+*+S*E%U
M76)KI41KW(E9BA@!%8!95A66GERX=HW+!RT=65!U[A#<S:NB';-'A>#*':=O
M_37QHLKH=)+XXKW8"B54BR:3?53*D82QD^/H R+WDKFMA0]VBF?[A7"P!ZF2
M[^^HC$8HTO&]_^I=-:#9#X?C5),3WA)^#K3SV"< I,,F[[X&)T9Y8T*%-%2(
M<_^%X$36,B))!"@BS'ED/&C#V8NAVI&@G#G+?J<4-4TTG+_M%J?EO@L27IUP
MLXZQ* N,.-3F0NNU,:[@%DG<]TV$V '?(/ZQO'V=WQ14:UW\EUXZ'AT;R9O#
MJVTI-ZGI)_4&;=$YW]RZTN!N!$WC[RPC-E47\/?-KY9R3H@=8Y$3,>SV%*=[
M6LD\H-/8N@"SJ9;K9<J*B;.EQO&'Z,0X^:7ECO8E%'):K%(,E-%>937F#^F&
MM.*1O':'MH,5O7@15&NG&DA_#T:;!J""K6PA%$:VL8F>$D>RW7YH'L-A#R&]
MSRL^V*A(FA=U!CA@6D<T]0L9;V&C>^/A,#T[/2-QZB\9W?<CN>]PA?W5A>W#
M?<1@P*/#X7D:FF^8NO>74E9",/V2&N3D=?."F45R,CR);F["-_=ND:'4A6$7
MDD?F.^:%"IO*1K!S@DH0AF R\GJ2BJ2,\OX:ZI[T.3\$RGXGYARQCA-1,)Q;
MBHB$< [R09 <33@D)"8J9QZGVSWQXB:[7=S3M'US7>_--?W<+-)*N6DM@DS\
M-1.MFXJ.4NIA/_O=EW+S(?;V@-W5 V=IA67Y_@AVY^T! +%\ #AYT7<-9\7,
MA=X-D0U*>6W9>P]_)A+TB_3G^$2>FH-D__NKE\E>ITN'GT/'OS#COW]\?!Z^
M$\K:%XL?;,([R0K/L<);8H7IV([AV"[$_OU*"W?J@7?*Y06<:7_SI.-P\7&H
M=<UUDK23X[-CJLIXZ&1"YSMD'DW&\@ATEGE.I9.!WV)!UF1TPL_X/PA]O#N4
M: :H>3$#6H3A25>J5(].1C(6"8JH_;\D9PDFV,E;@-UHZSL_TEFSA[I:+&C$
M;S4A:<SC3,YI7EVS!^PH/3KF#8V&_&;OH9S!H4@G99,"\(,BYP['P]0N8 ?[
MEHI5N_)=_SF]H^P(A(+._X,D4+@+2:#PV$CM']U[T[W-=>VJ@(232;('_YV,
ML7&K^T[*P!T:Q-:_[LBJL<_?'(1OHCEBF_4AC.T'(H->WPMM8#]U\X>R>?>4
MS9_PC7S*UO'?6\<\??J8^PK,80\P>P^,:(F,;R#K!"HA$<-M^JK]0ECVT?AL
MT(/\+016A]Y7XJZ_+T] 7M?GDWIAV,%>,AQ,CB. OZ[J>5[T@[\U=(R4G5$M
MF!]]^ZG8W ''UZ+S<7I\# 1L<FPQ[^@,<]E&\-3@"^+=,1"Z\^$(<4\>[8SD
M^(J.'W8_CB<PU^9QI.X;@Z"MP.G'ZNBS+E8?=DF+166K/+%9UL\;<_"=#M1B
ME!*HGNOI/E)7 9@^/MW&O?.I;QOIVT<?E'P9BO&YMQAJ^0CR)$^GGGNGQT@M
MN.)O.AXCE@@E&0Z.S@W7D%_-#[W<$ZF])/Q^PBSMC?P2Q=6J5!,^)LAMSL_^
M*?*-ID6[,-P+IY60<=JXU1K'NH!*=8^JRO@XG0Q/6&8X3L^/6+)X8QK2H?S#
M#>E BCD].XU$#R\NC<;G7G!94<0MQWRS-LE""4W372[:+ZYS[.!FW.\PSWA\
MZM?%8HW[JSYW(9M[W[P*.D1X.SEP[_*5VY(4WW>SZ(Q'0U8WEL4JQ&)=JJ,N
MTEHZ-W-ZF\_6W!RR9>]@J\0T#-O^]C]!3G7BW#3TY84C"CTAT1#^/1XFIR/]
M]RAAX=)](GM0/)>WL !2GQ#X=T*T[>LX.?_Z=8RWR:4_58]\F:^R8@&*Y*$D
MQW;2B6RJYV9E[X^/*G ]=?B?HL-M_WQ7]6WG5??3_Y\5YLD[A R"%:&/>OS^
MW@%@75'"Z&R5[\P/F#7P?']C.X96=%]G$,GLEFSH.'V>4N>]/>O5AZM>$!S!
MBE]BT[:?LIDMVJY!R]W&VEQ5K)L?QY,I&>X8.8SJVM=+Y(]!=4UZ5==."0MR
M=&S67[L)PZ3%)E:+_2J=U !Q+_G#AONMGQHAIEN6VTA+Q)@[@MSCGT22\X9K
MR'%BC[^N\DO2KSWTMQ1XWW^C19KM)*6H!K&)8G0>/.5(DM'V0_$?;#D5>><G
M+6.\?1GQ$!=V"!EA(SWED$9R9NW$/I->F;.S.2\HJX4MZE&?]P.J76DB)/C9
MPM:8MM3^]%BC\L8GU,#[T:'S:/^I7=[C>S%:R),GVO+M!@G\R22VIY30B\ZU
M81$Z>42$[@8QF&;.*COW%U)(K)"\PQ([8G+[F[]VJQWUU2O:60]Y!-Z64>[.
MZ\_DB+J ,U-T9D@NKAO"[[X-/>%X'GD=L0_T_4V=!#550-YN^&WQ 9)TK*%6
MX^&DPTEVUBV>C,]]G 4%])[?1IUMD=^X7V#_J3OX&E'JHPG/[9]_]'\'LA]R
MKR$PJ2.U2WTAQRYB#S]]^)$Y>>#+5(MU"#C$$7$+;D!B)GA9"727-D8S"N(8
MH )HI:+@ UOACU&KP)9?!> Z)BP =&$ T$DYE0I!T+4W6%;K0J8[$1+ZQ<4E
M=@!02P,$%     @ %8$M3R/H0#P] @  @ H   T   !X;"]S='EL97,N>&UL
MU5;;:MPP$/T5H9220(GMW69+&MO0!@*%-@2R#WT+6GML"W1Q97GKS==7%U]V
MM_2V3<OFQ9HYHSES=,&CN-$;!O<5@$8=9Z))<*5U_38(FJP"3IIS68,PD4(J
M3K1Q51DTM0*2-S:)LV 6AHN $RIP&HN6WW#=H$RV0B=X/D+(YU_+'!+\</KR
M2ROUU0ODQY-7)R?AP]G5/G[J F<8>8X/>8*CQ6L<_#[I>1C^F-@&]\@O_I#\
M9]Q[U M+'?0;E,:%%+O[9 %3FW! :\(2?$T872EJLPK"*=MX>&:!3#*ID#8'
M9+1%%FD>?3CRGCV[GH=3(96K[2OX[ZJ?OA<8/"N0,C8*G&$/I'%-M 8E;HSC
M)COPNQ#J[>6F-@I+13;1[ )/"6XP1592Y:#&,A$>H#1F4%@YBI:5';6L QO4
M6G)CY)244A"G8<CH#4.; 6/W]F)_+G:XNP+Y.?9(0HRLBL$TJ^[-Z=1")WF;
MS7-OTX8'\:*:KJ5^WYKE".?;NP-W"@K:.;\K1@&&G=0UV[QCM!0<_&)^63 Z
ML& :DZ$.JJ2BCX;/7I7, * P6H/2--M&OBI2+Z'3PW7JBD,USYZAYJ?>YQ($
M*,*V19N[?\R[_)\5VQ;PUYK=;V5?\1.*G+\Y?HVVW3T#D8OC%SF__,<:@[[K
M;+6VG<8VHFC54J:IZ-56-,_!Z[$OBP3?VD<-VVDO4W\S])JLS'-PA]_DYE"0
MEND[NT073/!D?[3"H\4X:SE2)'BR/T%.6W[I"DYOSO0;4$L#!!0    ( !6!
M+4]&3KT2A@,  +X8   /    >&PO=V]R:V)O;VLN>&ULQ9E;;]HP%(#_BI67
M=0\;) %Z4:FT =LJ32TJJ'N<3&*(5<=FMD,OOW['9JQF6X[V@GFBL1W[RRGG
M?':X?%3Z8:'4 WFJA33#I+)V?='IF*)B-37OU9I)Z%DJ75,+EWK5,6O-:&DJ
MQFPM.EFW.^C4E,ODZG(WUU1WP@ME66&YDM#H&NXY>S2O_>Z24!BP87.Z&";=
MA-#&JD]<6*;'U++/6C5K+E?#)$W(DFMC9VYM/[+FDM?\A97^RE3J\8O2_$5)
M2\6LT$H(?Y?K\#?!"N9WRSW3EA=[ RU=W%%@'2:#+DRXX88ON.#V>9CXOP5+
MX"DZP6/X..P^MT&\T/\31K5<\H*-5='43-IM'#43;G5I*KXV"9&T9L-D-X10
M69*)M$!#KN5V*ACKG@66OBZWSV4A8J^P1%]PZ-#79>K #P<Y@FLE> FKE^0C
M%506C/B0FP P0P"SHP&2DRD-(',$,H\(.7,0[@9#U)+<KID.('L(9.\8D(YQ
M9E7Q$$#V$<C^T2(YHJ8*( <(Y."PD#=0&4E*WI%YQ<A(U6LJGP.R4X3L- )9
MMD_FZ\^LJ6L:?A'/$,BS") Y0%Y#N9<KMWA8;,X1LO,(9#T@&[.%#0MT%ZO0
MW0A0?8#Z4!2Z@;28/,%L9B]F*:J0 SO$ PX \,[U N"4:G#=7%-I8(,08F(B
M20]L$H]Y"IB^W%5*E$R;-V3RHP$SAY"82-(#F\1#GNT@P1Y^A$_A;U2'"9QB
M*DD/[!*/>>Y3N% U(W/ZM/]]Q!22'M@AV_+<!3JH@#6W6X.X$()=+ \Q,8FD
M42SB-#*JH PRYSA(<=4 HUR1$!,S2AI#*:ESRJQ9&/:C<9N&R<;%-$3$?)+&
M$$J;];YG(28FES2&75HQ\W"_C?DF.Y9OR D<PT2(B5DGBV&=MDJY]T_/T.-+
M#.O\62FWD63F;4B):2>+H9VVDKD?3$P[60SMM&90+\3$!)3%$% K9C_$Q 24
MQ1#0;K=+3L;,4BX,N8%]!@S>A)B8@+(8 OIW/7+((28FH2R&A%KKT5YUQR24
MQ9!0*V:80CDFH3R&A%HQPQ3*,0GE,23T=W7_E4IA><\Q">7'D= NXT-,]"W:
M42T4IE".62B/8:%6S+T4PBR41SD&A><+V7*^R#$+Y=Y"G=W[\I(MN63E#2QA
MH+V@HIAJXCZV!_Q>W^VQEXT0(VB[E5\5]6^XW1R[GPZN?@)02P,$%     @
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M77(U_&[-"&X?+I5]?,8P]>[^D=*AWV+-<'VX.L/4WPAS=0*]_0%02P,$%
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M%_CL"U!+ 0(4 Q0    ( !6!+4\?(\\#P    !,"   +              "
M 0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !6!+4\GZ(<.@@   +$    0
M              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M%8$M3R]B.('O    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ %8$M3YE<G",0!@  G"<  !,
M ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  5@2U/;&1Q
MI#H"  "T!P  &               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ %8$M3U ZM%U;!   %1<  !@
M ( !: L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !6!
M+4]FY>0&O0(  -L+   8              "  ?D/  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  5@2U/T-QE93X$  "V%   &
M        @ 'L$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ %8$M3T^WH1JV P  DQ   !@              ( !8!<  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !6!+4]<U>+3@04  "D?   8
M              "  4P;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  5@2U/RKW)9;0!  #4 P  &               @ $#(0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ %8$M3P>LF87/ 0
M;00  !@              ( ![2(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( !6!+4\-A*RAT $  &T$   8              "  ?(D
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  5@2U/!0=J
M2L\!  !M!   &0              @ 'X)@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( !6!+4^3D2E\N0$  -0#   9
M  "  ?XH  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M%8$M3S&?<*ZX 0  U ,  !D              ( ![BH  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  5@2U/M2B[>LX!  !L!   &0
M            @ '=+   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( !6!+4^,8 H\N $  -(#   9              "  >(N  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ %8$M3X^D6T^X 0
MU ,  !D              ( !T3   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  5@2U/D)LT0] !  !M!   &0              @ '
M,@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !6!+4]!
MW!7,N0$  -0#   9              "  <<T  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ %8$M3S]CR*+0 0  ;00  !D
M     ( !MS8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M"  5@2U/KGP/B.4"  #>#   &0              @ &^.   >&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !6!+4^\BCABM0$  -0#   9
M              "  =H[  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L!
M A0#%     @ %8$M3Q,F$MN[ 0  U ,  !D              ( !QCT  'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  5@2U/J.K3-.X!
M  !;!0  &0              @ &X/P  >&PO=V]R:W-H965T<R]S:&5E=#(R
M+GAM;%!+ 0(4 Q0    ( !6!+4_'",0>N0$  -0#   9              "
M =U!  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %8$M
M3QHHF5_1 0  ;00  !D              ( !S4,  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  5@2U/GWM<0H0"  ":"   &0
M        @ '510  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( !6!+4_-]>A-TP(   X*   9              "  9!(  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ %8$M3S8,ZW>_ 0  1 0
M !D              ( !FDL  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  5@2U/5S;0<$$"  !T!P  &0              @ &030
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !6!+4^AWD%B
M-0,  #4/   9              "  0A0  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ %8$M3Z]&\I@] P  ^ X  !D
M ( !=%,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  5
M@2U/>@:!X2<"  "*!@  &0              @ 'H5@  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !6!+4^ZEIU$,P(   P'   9
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M970S-BYX;6Q02P$"% ,4    "  5@2U/K%(*0\5R  !^"@( %
M    @ %N90  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  5@2U/
M(^A /#T"  " "@  #0              @ %EV   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( !6!+4]&3KT2A@,  +X8   /              "  <W:  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  5@2U/[)9%4(T!  "1%@  &@
M            @ & W@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  5@2U/7 T#FIP!   *%P  $P              @ %%X   6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     +0 M "T,   2X@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6754903568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Debt (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_DebtDetailsNarrativeAbstract', window );"><strong>Note 4 - Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DebtDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DebtDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632812400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of net deferred income tax assets</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>December
    31,</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
    tax assets:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 75%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Federal
    net operating loss carryforward</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">25,306,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,949,000</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Intellectual
    Property</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">61,787,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    Interest</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">129,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Patent
    amortization</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
    tax asseets before valuation</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">87,227,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,955,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Valuation
    allowance</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(87,227,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(15,955,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Net
    deferred income tax assets</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>62</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>14</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statement of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Note 1 - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note1-Company</Role>
      <ShortName>Note 1 - The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Note 2 - The Company and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Note 3 - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note3-Intangibles</Role>
      <ShortName>Note 3 - Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Note 4 - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note4-Debt</Role>
      <ShortName>Note 4 - Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Note 5 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note5-AccruedExpenses</Role>
      <ShortName>Note 5 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Note 6 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note6-RelatedPartyTransactions</Role>
      <ShortName>Note 6 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Note 7 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note7-StockholdersEquity</Role>
      <ShortName>Note 7 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Note 8 - Stock Options and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants</Role>
      <ShortName>Note 8 - Stock Options and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note9-IncomeTaxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Note 10 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies</Role>
      <ShortName>Note 10 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Note 11 - Change of Accounting Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note11-ChangeOfAccountingMethod</Role>
      <ShortName>Note 11 - Change of Accounting Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Note 12 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note12-SubsequentEvents</Role>
      <ShortName>Note 12 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Note 2 - The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd</Role>
      <ShortName>Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Note 5 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note5-AccruedExpensesTables</Role>
      <ShortName>Note 5 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note5-AccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Note 8 - Stock Options and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables</Role>
      <ShortName>Note 8 - Stock Options and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrants</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note9-IncomeTaxesTables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note9-IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Note 10 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables</Role>
      <ShortName>Note 10 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note10-CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Note 2 - The Company and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Note 2 - The Company and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note2-CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsd</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Note 4 - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note4-DebtDetailsNarrative</Role>
      <ShortName>Note 4 - Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note4-Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Note 5 - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note5-AccruedExpensesDetails</Role>
      <ShortName>Note 5 - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note5-AccruedExpensesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Note 8 - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails</Role>
      <ShortName>Note 8 - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Note 8 - Stock Options and Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails1</Role>
      <ShortName>Note 8 - Stock Options and Warrants (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Note 8 - Stock Options and Warrants (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsDetails2</Role>
      <ShortName>Note 8 - Stock Options and Warrants (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note8-StockOptionsAndWarrantsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Note 9 - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note9-IncomeTaxesDetails</Role>
      <ShortName>Note 9 - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note9-IncomeTaxesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Note 9 - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note9-IncomeTaxesDetailsNarrative</Role>
      <ShortName>Note 9 - Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note9-IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Note 10 - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetails</Role>
      <ShortName>Note 10 - Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Note 10 - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Note 10 - Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/Note10-CommitmentsAndContingenciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gtbp-20190630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Note 11 - Change on Accounting Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Note11-ChangeOnAccountingMethodDetails</Role>
      <ShortName>Note 11 - Change on Accounting Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gtbp-20190630.xml</File>
    <File>gtbp-20190630.xsd</File>
    <File>gtbp-20190630_cal.xml</File>
    <File>gtbp-20190630_def.xml</File>
    <File>gtbp-20190630_lab.xml</File>
    <File>gtbp-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6761375440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 25,306<span></span>
</td>
<td class="nump">$ 15,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Intellectual Property</a></td>
<td class="nump">61,787<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Accrued Interest</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Patent amortization</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation</a></td>
<td class="nump">87,227<span></span>
</td>
<td class="nump">15,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(87,227)<span></span>
</td>
<td class="num">(15,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6761170976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Change on Accounting Method (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="nump">$ 545,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,171<span></span>
</td>
<td class="nump">$ 521,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">$ (535,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (535,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (528,685)<span></span>
</td>
<td class="num">(269,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Earnings Per Share</a></td>
<td class="num">$ (.05)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (.14)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="num">$ (8.60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Earnings Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.54)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_RestatementAdjustmentMember', window );">Revisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Earnings Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6760614176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify">The Company&#8217;s current
operations have focused on business planning, raising capital, establishing an intellectual property portfolio, hiring, and conducting
preclinical studies and clinical trials. The Company does not have any product candidates approved for sale and has not generated
any revenue from product sales. The Company has sustained operating losses since inception and expects such losses to continue
over the foreseeable future.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify">The financial statements of
the Company have been prepared on a goingconcern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. Accordingly, the financial statements do not include any adjustments that might be necessary
should the Company be unable to continue in existence.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify">The Company has incurred substantial
losses and negative cash flows from operations since its inception and has an accumulated deficit of $536 million and cash of $264
thousand as of June 30, 2019. The Company anticipates incurring additional losses until such time, if ever, that it can generate
significant sales of its products currently in development. Substantial additional financing will be needed by the Company to fund
its operations and to commercially develop its product candidates. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify">Management is currently evaluating
different strategies to obtain the required funding for future operations. These strategies may include but are not limited to:
public offerings of equity and/or debt securities, payments from potential strategic research and development, and licensing and/or
marketing arrangements with pharmaceutical companies. If the Company is unable to secure adequate additional funding, its business,
operating results, financial condition and cash flows may be materially and adversely affected.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements and notes are
representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies
conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the
preparation of the financial statements. The preparation of financial statements requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets and liabilities
at the date of the financial statements. Actual results could differ from those estimates.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation and Comprehensive Income</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany balances and transactions have been
eliminated. The Company's financial statements are prepared using the accrual method of accounting.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S.
GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information
and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The
interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto included in the Company's Form 10-K for the year ended December 31, 2018. The unaudited interim condensed consolidated
financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a
fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible
for the unaudited interim consolidated financial statements included in this report. The results of operations of any interim period
are not necessarily indicative of the results for the full year.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Promotional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising expenses consist primarily
of costs incurred in the design, development, and printing of Company literature and marketing materials. The Company expenses
all advertising expenditures as incurred. There were no advertising expenses for the years ended December 31, 2018 and 2017, respectively.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid
investments with original maturities of three months or less to be cash equivalents.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid
investments with original maturities of three months or less to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's cash and cash equivalents,
marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains
substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal
Deposit Insurance Corporation up to $250,000. The Company had balances totaling $14,000 in excess of this limit at June 30, 2019.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's cash and cash equivalents,
marketable securities and accounts receivable are monitored for exposure to concentrations of credit risk. The Company maintains
substantially all of its cash balances in a limited number of financial institutions. The balances are each insured by the Federal
Deposit Insurance Corporation up to $250,000. The Company had no balances in excess of this limit at December 31, 2018.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock Based Compensation to Employees</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its stock-based
compensation for employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718.&#160;&#160;The Company
recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued
to employees and non-employees over the related vesting period.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company granted no stock options
during the six months ended June 30, 2019 and 2018, respectively</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its stock-based
compensation for employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 718. The Company recognizes
in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees
and non-employees over the related vesting period.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company granted no stock options
during the years ended December 31, 2018 and 2017, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_LongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our long-lived assets include property,
plant and equipment, capitalized costs of filing patent applications and other indefinite lived intangible assets. We evaluate
our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance with ASC 360, whenever events
or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Estimates of future cash flows
and timing of events for evaluating long-lived assets for impairment are based upon management&#8217;s judgment. If any of our
intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying
amount of the assets over its fair value.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Applicable long-lived assets are amortized
or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or
the statutory or contractual term in the case of patents. Estimates of useful lives and periods of expected revenue generation
are reviewed periodically for appropriateness and are based upon management&#8217;s judgment.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our long-lived assets include property,
plant and equipment, capitalized costs of filing patent applications and other indefinite lived intangible assets. We evaluate
our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance with ASC 360, whenever events
or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Estimates of future cash flows
and timing of events for evaluating long-lived assets for impairment are based upon management&#8217;s judgment. If any of our
intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying
amount of the assets over its fair value.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Applicable long-lived assets are amortized
or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or
the statutory or contractual term in the case of patents. Estimates of useful lives and periods of expected revenue generation
are reviewed periodically for appropriateness and are based upon management&#8217;s judgment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long Lived Assets</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's long-lived assets currently
consist of indefinite lived intangible assets associated with IPR&#38;D (&#8220;In-Process Research &#38; Development&#8221;) projects
and related capitalized patents acquired in the acquisition of Georgetown Translational Pharmaceuticals, Inc. as described in Note
2 below. &#160;Intangible assets associated with IPR&#38;D projects are not amortized until approval by the Food and Drug Administration
(FDA) is obtained in a major market subject to certain specified conditions and management judgment. The useful life of an amortizing
asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates indefinite lived
intangible assets for impairment at least annually and whenever impairment indicators are present in accordance with ASC 350. When
necessary, the Company records an impairment loss for the amount by which the fair value is less than the carrying value of these
assets. The fair value of intangible assets other than goodwill is typically determined using the &#8220;relief from royalty method&#8221;,
specifically the discounted cash flow method utilizing Level 3 fair value inputs. Some of the more significant estimates and assumptions
inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of
competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&#38;D assets,
as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the
projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs impairment testing
for all other long-lived assets whenever impairment indicators are present. When necessary, the Company calculates the undiscounted
value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying
amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's long-lived assets currently
consist of indefinite lived intangible assets associated with IPR&#38;D (&#8220;In-Process Research &#38; Development&#8221;) projects
and related capitalized patents acquired in the acquisition of Georgetown Translational Pharmaceuticals, Inc. as described in Note
3 below. Intangible assets associated with IPR&#38;D projects are not amortized until approval by the Food and Drug Administration
(FDA) is obtained in a major market subject to certain specified conditions and management judgment. The useful life of an amortizing
asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates indefinite lived
intangible assets for impairment at least annually and whenever impairment indicators are present in accordance with ASC 350. When
necessary, the Company records an impairment loss for the amount by which the fair value is less than the carrying value of these
assets. The fair value of intangible assets other than goodwill is typically determined using the &#8220;relief from royalty method&#8221;,
specifically the discounted cash flow method utilizing Level 3 fair value inputs. Some of the more significant estimates and assumptions
inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of
competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&#38;D assets,
as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the
projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs impairment testing
for all other long-lived assets whenever impairment indicators are present. When necessary, the Company calculates the undiscounted
value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying
amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value.</p>



<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes
using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future
tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior
periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not
be realized.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes
using the asset and liability approach, whereby deferred income tax assets and liabilities are recognized for the estimated future
tax effects, based on current enacted tax laws, of temporary differences between financial and tax reporting for current and prior
periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the corresponding future tax benefits may not
be realized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net income (loss) per share is
computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.
Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common
shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion
of outstanding stock options and warrants during the period. The weighted average number of potentially dilutive common shares
excluded from the calculation of net income (loss) per share totaled in 39,416,352 and 3,390,120 as of June 30, 2019 and 2018,
respectively.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net income (loss) per share is
computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.
Diluted net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common
shares outstanding during the period, plus the potential dilutive effect of common shares issuable upon exercise or conversion
of outstanding stock options and warrants during the period.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic and diluted
net loss per share for the years ended December 31, 2018 and 2017 excludes the common stock equivalents of the following potentially
dilutive securities because their inclusion would be anti-dilutive:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 78%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Exercise of common stock warrants</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Conversion of preferred stock into common stock</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Conversion of convertible debentures into common stock</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">5,704,543</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Exercise of common stock options</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">8,682,368</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,164,905</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Acquired patents are capitalized at their
acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications
are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that
are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are
not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the
patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident
increase in the value of the patents are capitalized.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Capitalized cost for pending patents
are amortized on a straight-line basis over the remaining twenty year legal life of each patent after the costs have been incurred.
Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining
statutory life, estimated economic life or ten years.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Acquired patents are capitalized at their
acquisition cost or fair value. The legal costs, patent registration fees and models and drawings required for filing patent applications
are capitalized if they relate to commercially viable technologies. Commercially viable technologies are those technologies that
are projected to generate future positive cash flows in the near term. Legal costs associated with patent applications that are
not determined to be commercially viable are expensed as incurred. All research and development costs incurred in developing the
patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense to the extent of an evident
increase in the value of the patents are capitalized.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Capitalized costs for pending patents
are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after the costs have been incurred.
Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter of the patent's remaining
statutory life, estimated economic life or ten years.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets is stated at cost. Depreciation
is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10&#160;years for machinery
and equipment and the shorter of the lease term or estimated economic life for leasehold improvements.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets are stated at cost. Depreciation
is computed on a straight-line basis over the estimated useful lives of the assets, which are 3 to 10 years for machinery and equipment
and the shorter of the lease term or estimated economic life for leasehold improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reported in the
balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair
value because of the short period of time between the origination of such instruments and their expected realization and their
current market rate of interest.&#160; The three levels are defined as follows:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company&#8217;s Level 2 valuation amounts consist of warrants and beneficial conversion features arising from the issuance of convertible securities and in accordance with ASC 815-40.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts reported in the
balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of fair
value because of the short period of time between the origination of such instruments and their expected realization and their
current market rate of interest. The three levels are defined as follows:</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. The Company&#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value represents fair value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 43px; padding-left: 5.25pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. The Company&#8217;s Level 2 liabilities consist of liabilities arising from the issuance of convertible securities and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent with that of a government-issued security of a similar maturity. There were no such liabilities at December 31, 2018.</font></td></tr>
</table>
<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed
as incurred and reported as research and development expense. Research and development costs totaling $1 million and $6.7 million
for the six months ended June 30, 2019 and 2018, respectively.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed
as incurred and reported as research and development expense. Research and development costs totaled $9.1 million and $1.1 million
for the years ended December 31, 2018 and 2017, respectively. Research and development costs for the year ended December 31, 2018
included non-cash compensation of $6.8 million.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>License Revenue</u></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-refundable, up-front fees that are
not contingent on any future performance by us, and require no consequential continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We defer
recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right, product
or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent
of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research
and development services that are required because our know-how and expertise related to the technology is proprietary to us, or
can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Payments related to substantive, performance-based
milestones in a research and development arrangement are recognized as revenue upon the achievement of the milestones as specified
in the underlying agreements when they represent the culmination of the earnings process. As of June 30, 2019, the Company has
not generated any licensing revenue.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued new guidance related to accounting for leases, Accounting Standards codification Topic
842 (ASC 842). We adopted the new guidance on January 1, 2019 using the modified retrospective approach and the optional transition
method. Under this adoption method, comparative prior periods were not adjusted and continue to be reported with our historical
accounting policy. The primary impact of adopting this standard was the recognition of $173 thousand in operating lease liabilities
and $165 thousand in right of use assets.</p><span></span>
</td>
<td class="text"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases.&#8221; This
ASU requires all lessees to be recognized on the balance sheet as right to use assets and lease liabilities for the rights and
obligations created by lease arrangements with terms greater than 12 months. The amendments in this ASU are effective for fiscal
years beginning after December 15, 2018 and for interim periods therein. The Company is in the process of assessing the impact
the adoption this ASU will have on its consolidated financial position, results of operations and cash flows. At a minimum, total
assets and total liabilities will increase in the period the ASU is adopted. Early adoption of this ASU is permitted. At December
31, 2018, the Company&#8217;s undiscounted future minimum payments outstanding for lease obligations (including those currently
included as capital lease obligations) were approximately $200,878.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No.
2014-09, &#8220;Revenue from Contracts with Customers: Topic 606.&#8221; This ASU replaces nearly all existing U.S. GAAP guidance
on revenue recognition. The standard prescribes a five-step model for recognizing revenue, the application of which will require
significant judgment. The amendments in this ASU are effective for fiscal years beginning after December 15, 2017, and for interim
periods therein. The provisions of this ASU may be applied retroactively or on a modified retrospective (cumulative effect) basis.
The Company adopted the standard using the modified retrospective approach beginning January 1, 2018. Adoption of this ASU did
not have a significant impact on the Company&#8217;s consolidated financial position, results of operations and cash flows.</p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6762223856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Deferred
Taxes</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The significant
components of net deferred income tax assets for the Company are (in thousands):</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>December
    31,</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
    tax assets:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 75%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Federal
    net operating loss carryforward</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">25,306,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,949,000</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Intellectual
    Property</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">61,787,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    Interest</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">129,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Patent
    amortization</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">6,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Deferred
    tax asseets before valuation</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">87,227,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,955,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Valuation
    allowance</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(87,227,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(15,955,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Net
    deferred income tax assets</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Generally
accepted accounting principles requires that the tax benefit of net operating losses, temporary differences and credit carryforwards
be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization
of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward
period. Because of the Company's history of operating losses, management has provided a valuation allowance equal to its net deferred
tax assets. The valuation allowance increased by approximately $71,270,000 during the year ended December 31, 2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Tax
Carryforward</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">At
December 31, 2018, the Company had net operating loss carryforwards of approximately $84,354,000 to reduce United States federal
taxable income in future years. These carryforwards expire from 2019 through 2038.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company is no longer subject to U.S. and state tax examinations for years ending before the fiscal year ended December 31, 2014.
Management does not believe there will be any material changes in our unrecognized tax positions over the next twelve months.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax
expense. There was no accrued interest or penalties associated with any unrecognized tax benefits, nor was any interest expense
recognized during the years ended December 31, 2018 and 2017.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6604637936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
Expenses are comprised of the following:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;December
    31,</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 75%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Research
    &#38; Development</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">585,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    Interest</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">432,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Professional
    Fees</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">162,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">62,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Consulting
    and Advisory Services</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">161,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Board
    of Directors Service Costs</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">94,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Payroll
    and Benefits</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">21,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">39,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><b>Accrued
    Expenses</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif"><b>1,455,000</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif"><b>101,000</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>


<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752528832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - The Company and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Business</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic
Data changed its incorporation to the State of Delaware in 1972. and changed its name to DDI Pharmaceuticals, Inc. in 1985. In
1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,
Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based off our proprietary Natural Killer (NK) cell engager (Tri-specific Killer Engager (TriKE) &#38; Tetra-specific Killer Engager
(TetraKE)) and bi-specific Antibody Drug Conjugate (bispecific-ADC) technology platforms. Our TriKE and TetraKE platforms generate
proprietary moieties designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer, or
NK, cells. Once bound to a NK cell, our moieties are designed to stimulate the NK cell and precisely direct it to one or more
specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell&#8217;s
death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target tumor antigens on hematologic
malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in an
outpatient setting and are expected to have reasonably low cost of goods. Our bispecific-ADC platform can generate product candidates
that are ligand-directed single-chain fusion proteins that simultaneously target two tumor antigens. We believe our bispecific-ADC
moieties represents the next generation of ADCs.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Going
Concern</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company&#8217;s current operations have focused on business planning, raising capital, establishing an intellectual property portfolio,
hiring, and conducting preclinical studies and clinical trials. The Company does not have any product candidates approved for
sale and has not generated any revenue from product sales. The Company has sustained operating losses since inception and expects
such losses to continue over the foreseeable future.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
financial statements of the Company have been prepared on a goingconcern basis, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments
that might be necessary should the Company be unable to continue in existence.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company has incurred substantial losses and negative cash flows from operations since its inception and has an accumulated deficit
of $536 million and cash of $264 thousand as of June 30, 2019. The Company anticipates incurring additional losses until such
time, if ever, that it can generate significant sales of its products currently in development. Substantial additional financing
will be needed by the Company to fund its operations and to commercially develop its product candidates. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Management
is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include
but are not limited to: public offerings of equity and/or debt securities, payments from potential strategic research and development,
and licensing and/or marketing arrangements with pharmaceutical companies. If the Company is unable to secure adequate additional
funding, its business, operating results, financial condition and cash flows may be materially and adversely affected.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Use
of Estimates</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.
These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently
applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities revenues and expenses and disclosures of contingent assets
and liabilities at the date of the financial statements. Actual results could differ from those estimates.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Basis
of Consolidation and Comprehensive Income</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany
balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Basis
of Presentation</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles
generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission
(&#8220;SEC&#8221;). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements
have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with
the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December
31, 2018. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments
that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash
flows for the periods presented. The Company is responsible for the unaudited interim consolidated financial statements included
in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Cash
and Cash Equivalents</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Concentrations
of Credit Risk</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations
of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The
balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company had balances totaling $14,000
in excess of this limit at June 30, 2019.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Stock
Based Compensation to Employees</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
718.&#160;&#160;The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based
compensation issued to employees and non-employees over the related vesting period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company granted no stock options during the six months ended June 30, 2019 and 2018, respectively</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Long-Lived
Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Our
long-lived assets include property, plant and equipment, capitalized costs of filing patent applications and other indefinite
lived intangible assets. We evaluate our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance
with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.
Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&#8217;s
judgment. If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized
is the excess of the carrying amount of the assets over its fair value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Applicable
long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the
assets will generate revenue, or the statutory or contractual term in the case of patents. Estimates of useful lives and periods
of expected revenue generation are reviewed periodically for appropriateness and are based upon management&#8217;s judgment.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Impairment
of Long-Lived Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company's long-lived assets currently consist of indefinite lived intangible assets associated with IPR&#38;D (&#8220;In-Process
Research &#38; Development&#8221;) projects and related capitalized patents acquired in the acquisition of Georgetown Translational
Pharmaceuticals, Inc. as described in Note 2 below. &#160;Intangible assets associated with IPR&#38;D projects are not amortized
until approval by the Food and Drug Administration (FDA) is obtained in a major market subject to certain specified conditions
and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially
all of the cash flows are expected to be generated.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company evaluates indefinite lived intangible assets for impairment at least annually and whenever impairment indicators are present
in accordance with ASC 350. When necessary, the Company records an impairment loss for the amount by which the fair value is less
than the carrying value of these assets. The fair value of intangible assets other than goodwill is typically determined using
the &#8220;relief from royalty method&#8221;, specifically the discounted cash flow method utilizing Level 3 fair value inputs.
Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected
net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact
of technological risk associated with IPR&#38;D assets, as well as the selection of a long-term growth rate; the discount rate,
which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the
geographic diversity of the projected cash flows.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company performs impairment testing for all other long-lived assets whenever impairment indicators are present. When necessary,
the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares
this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for
the excess of book value over fair value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Income
Taxes</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are
recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial
and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the
corresponding future tax benefits may not be realized.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Net
Income (Loss) per Share</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Basic
net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares
outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the
weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable
upon exercise or conversion of outstanding stock options and warrants during the period. The weighted average number of potentially
dilutive common shares excluded from the calculation of net income (loss) per share totaled in 39,416,352 and 3,390,120 as of
June 30, 2019 and 2018, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Patents</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Acquired
patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings
required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable
technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated
with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development
costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense
to the extent of an evident increase in the value of the patents are capitalized.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Capitalized
cost for pending patents are amortized on a straight-line basis over the remaining twenty year legal life of each patent after
the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter
of the patent's remaining statutory life, estimated economic life or ten years.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fixed
Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Fixed
assets is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which
are 3 to 10&#160;years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold
improvements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fair
Value</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments
and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and
their expected realization and their current market rate of interest.&#160; The three levels are defined as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
    The Company&#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value
    represents fair value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument. The Company&#8217;s Level 2 valuation amounts consist of warrants and beneficial conversion features arising from
    the issuance of convertible securities and in accordance with ASC 815-40.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Research
and Development</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred and reported as research and development expense. Research and development costs
totaling $1 million and $6.7 million for the six months ended June 30, 2019 and 2018, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Revenue
Recognition</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><u>License
Revenue</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements are multiple element
arrangements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Non-refundable,
up-front fees that are not contingent on any future performance by us, and require no consequential continuing involvement on
our part, are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered.&#160;&#160;We
defer recognition of non-refundable upfront fees if we have continuing performance obligations without which the technology, right,
product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent
of our performance under the other elements of the arrangement. In addition, if we have continuing involvement through research
and development services that are required because our know-how and expertise related to the technology is proprietary to us,
or can only be performed by us, then such up-front fees are deferred and recognized over the period of continuing involvement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Payments
related to substantive, performance-based milestones in a research and development arrangement are recognized as revenue upon
the achievement of the milestones as specified in the underlying agreements when they represent the culmination of the earnings
process. As of June 30, 2019, the Company has not generated any licensing revenue.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued new guidance related to accounting for leases,
Accounting Standards codification Topic 842 (ASC 842). We adopted the new guidance on January 1, 2019 using the modified retrospective
approach and the optional transition method. Under this adoption method, comparative prior periods were not adjusted and continue
to be reported with our historical accounting policy. The primary impact of adopting this standard was the recognition of $173
thousand in operating lease liabilities and $165 thousand in right of use assets.</font></p><span></span>
</td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Advertising
and promotional fees</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Advertising
expenses consist primarily of costs incurred in the design, development, and printing of Company literature and marketing materials.
The Company expenses all advertising expenditures as incurred. There were no advertising expenses for the years ended December
31, 2018 and 2017, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Cash
and Cash Equivalents</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Concentrations
of Credit Risk</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company's cash and cash equivalents, marketable securities and accounts receivable are monitored for exposure to concentrations
of credit risk. The Company maintains substantially all of its cash balances in a limited number of financial institutions. The
balances are each insured by the Federal Deposit Insurance Corporation up to $250,000. The Company had no balances in excess of
this limit at December 31, 2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Stock
Based Compensation to Employees</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company accounts for its stock-based compensation for employees in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
718. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation
issued to employees and non-employees over the related vesting period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company granted no stock options during the years ended December 31, 2018 and 2017, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Long-Lived
Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Our
long-lived assets include property, plant and equipment, capitalized costs of filing patent applications and other indefinite
lived intangible assets. We evaluate our long-lived assets for impairment, other than indefinite lived intangible assets, in accordance
with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.
Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&#8217;s
judgment. If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized
is the excess of the carrying amount of the assets over its fair value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Applicable
long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the
assets will generate revenue, or the statutory or contractual term in the case of patents. Estimates of useful lives and periods
of expected revenue generation are reviewed periodically for appropriateness and are based upon management&#8217;s judgment.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Impairment
of Long-Lived Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company's long-lived assets currently consist of indefinite lived intangible assets associated with IPR&#38;D (&#8220;In-Process
Research &#38; Development&#8221;) projects and related capitalized patents acquired in the acquisition of Georgetown Translational
Pharmaceuticals, Inc. as described in Note 3 below. Intangible assets associated with IPR&#38;D projects are not amortized until
approval by the Food and Drug Administration (FDA) is obtained in a major market subject to certain specified conditions and management
judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all
of the cash flows are expected to be generated.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company evaluates indefinite lived intangible assets for impairment at least annually and whenever impairment indicators are present
in accordance with ASC 350. When necessary, the Company records an impairment loss for the amount by which the fair value is less
than the carrying value of these assets. The fair value of intangible assets other than goodwill is typically determined using
the &#8220;relief from royalty method&#8221;, specifically the discounted cash flow method utilizing Level 3 fair value inputs.
Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected
net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact
of technological risk associated with IPR&#38;D assets, as well as the selection of a long-term growth rate; the discount rate,
which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the
geographic diversity of the projected cash flows.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company performs impairment testing for all other long-lived assets whenever impairment indicators are present. When necessary,
the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares
this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for
the excess of book value over fair value.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Income
Taxes</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability approach, whereby deferred income tax assets and liabilities are
recognized for the estimated future tax effects, based on current enacted tax laws, of temporary differences between financial
and tax reporting for current and prior periods. Deferred tax assets are reduced, if necessary, by a valuation allowance if the
corresponding future tax benefits may not be realized.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Net
Income (Loss) per Share</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Basic
net income (loss) per share is computed by dividing the net loss for the period by the weighted average number of common shares
outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss for the period by the
weighted average number of common shares outstanding during the period, plus the potential dilutive effect of common shares issuable
upon exercise or conversion of outstanding stock options and warrants during the period.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
computation of basic and diluted net loss per share for the years ended December 31, 2018 and 2017 excludes the common stock equivalents
of the following potentially dilutive securities because their inclusion would be anti-dilutive:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>December
    31,</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 75%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    of common stock warrants</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Conversion
    of preferred stock into common stock</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Conversion
    of convertible debentures into common stock</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">5,704,543</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercise
    of common stock options</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">8,682,368</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,164,905</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Patents</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Acquired
patents are capitalized at their acquisition cost or fair value. The legal costs, patent registration fees and models and drawings
required for filing patent applications are capitalized if they relate to commercially viable technologies. Commercially viable
technologies are those technologies that are projected to generate future positive cash flows in the near term. Legal costs associated
with patent applications that are not determined to be commercially viable are expensed as incurred. All research and development
costs incurred in developing the patentable idea are expensed as incurred. Legal fees from the costs incurred in successful defense
to the extent of an evident increase in the value of the patents are capitalized.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Capitalized
costs for pending patents are amortized on a straight-line basis over the remaining twenty-year legal life of each patent after
the costs have been incurred. Once each patent is issued, capitalized costs are amortized on a straight-line basis over the shorter
of the patent's remaining statutory life, estimated economic life or ten years.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fixed
Assets</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Fixed
assets are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, which
are 3 to 10 years for machinery and equipment and the shorter of the lease term or estimated economic life for leasehold improvements.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fair
Value</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
carrying amounts reported in the balance sheets for receivables and current liabilities each qualify as financial instruments
and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and
their expected realization and their current market rate of interest. The three levels are defined as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
    The Company&#8217;s Level 1 assets include cash equivalents, primarily institutional money market funds, whose carrying value
    represents fair value because of their short-term maturities of the investments held by these funds.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 43px; padding-left: 5.25pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument. The Company&#8217;s Level 2 liabilities consist of liabilities arising from the issuance of convertible securities
    and in accordance with ASC 815-40: a warrant liability for detachable warrants, as well as an accrued derivative liability
    for the beneficial conversion feature. These liabilities are remeasured each reporting period. Fair value is determined using
    the Black-Scholes valuation model based on observable market inputs, such as share price data and a discount rate consistent
    with that of a government-issued security of a similar maturity. There were no such liabilities at December 31, 2018.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 44px; padding-left: 6pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Research
and Development</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred and reported as research and development expense. Research and development costs
totaled $9.1 million and $1.1 million for the years ended December 31, 2018 and 2017, respectively. Research and development costs
for the year ended December 31, 2018 included non-cash compensation of $6.8 million.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Standards</u></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;)
No. 2016-02, &#8220;Leases.&#8221; This ASU requires all lessees to be recognized on the balance sheet as right to use assets
and lease liabilities for the rights and obligations created by lease arrangements with terms greater than 12 months. The amendments
in this ASU are effective for fiscal years beginning after December 15, 2018 and for interim periods therein. The Company is in
the process of assessing the impact the adoption this ASU will have on its consolidated financial position, results of operations
and cash flows. At a minimum, total assets and total liabilities will increase in the period the ASU is adopted. Early adoption
of this ASU is permitted. At December 31, 2018, the Company&#8217;s undiscounted future minimum payments outstanding for lease
obligations (including those currently included as capital lease obligations) were approximately $200,878.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers: Topic 606.&#8221; This ASU replaces nearly
all existing U.S. GAAP guidance on revenue recognition. The standard prescribes a five-step model for recognizing revenue, the
application of which will require significant judgment. The amendments in this ASU are effective for fiscal years beginning after
December 15, 2017, and for interim periods therein. The provisions of this ASU may be applied retroactively or on a modified retrospective
(cumulative effect) basis. The Company adopted the standard using the modified retrospective approach beginning January 1, 2018.
Adoption of this ASU did not have a significant impact on the Company&#8217;s consolidated financial position, results of operations
and cash flows.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769409632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 3,251<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 6,724<span></span>
</td>
<td class="nump">$ 9,067<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">5,347<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
<td class="nump">134,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Loss on impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,279<span></span>
</td>
<td class="nump">5,157<span></span>
</td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">12,317<span></span>
</td>
<td class="nump">250,069<span></span>
</td>
<td class="nump">135,570<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(2,279)<span></span>
</td>
<td class="num">(5,157)<span></span>
</td>
<td class="num">(6,335)<span></span>
</td>
<td class="num">(12,317)<span></span>
</td>
<td class="num">(250,069)<span></span>
</td>
<td class="num">(135,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of assets</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(479)<span></span>
</td>
<td class="num">(3,924)<span></span>
</td>
<td class="num">(933)<span></span>
</td>
<td class="num">(6,855)<span></span>
</td>
<td class="num">(9,117)<span></span>
</td>
<td class="num">(8,602)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(3,924)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="num">(6,855)<span></span>
</td>
<td class="num">(9,117)<span></span>
</td>
<td class="num">(8,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes', window );">Loss before provision for income taxes</a></td>
<td class="num">(2,789)<span></span>
</td>
<td class="num">(9,081)<span></span>
</td>
<td class="num">(7,299)<span></span>
</td>
<td class="num">(19,172)<span></span>
</td>
<td class="num">(259,186)<span></span>
</td>
<td class="num">(144,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,789)<span></span>
</td>
<td class="num">$ (9,081)<span></span>
</td>
<td class="num">$ (7,299)<span></span>
</td>
<td class="num">$ (19,172)<span></span>
</td>
<td class="num">$ (259,186)<span></span>
</td>
<td class="num">$ (144,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (.05)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (.14)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (5.16)<span></span>
</td>
<td class="num">$ (8.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">51,918,252<span></span>
</td>
<td class="nump">50,117,977<span></span>
</td>
<td class="nump">51,507,849<span></span>
</td>
<td class="nump">50,117,977<span></span>
</td>
<td class="nump">50,240<span></span>
</td>
<td class="nump">16,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncomeLossFromContinuingOperationsBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>39
<FILENAME>0001654954-19-010735-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-19-010735-xbrl.zip
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M/.@O68KMPC#?<Q_XAP'.&J#?-B=9+_1;YRF;.?P#!7_;?&8ST&^-X\P!?ZJ
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MWSQ4=61?MW6V>;!6EVMUH4+A!^H<_@=5NGLW0$R\%K$?>66[?3W(UBQJFHL
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MN&,8?&UR'OPFFPQCO+N<-(<"'H+]$0@>J,O 780[=N+HT0T 7I7N@7HMO!
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MP34W;;7;;</_#M2CP9\CTAU/T*2+WR(UI()>>BU)V*1.5%[H=H'OT =,-@_
MO$ +O?V#E!1R%(-]#U #61*%Y_H-.E>;/Q0-GXFLRW"*-"9)N=GM-IK-)JO@
M((;+?E2+-SN!'_,EM06@68[4#PDM&B9#C\5  +?RG-^K.-53#.34N<F 2>MG
MD9F*[VB.)*[2=M!2>-5]36Y(L"@4IGA*GY5O!EP7<?"HN%WAE4,02\#.T$[
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M;,.E 2=4Y4AK&$X%+Y*Z!0V&)V/6.3N]^&$>X.E=7IE9RINS4<9]@E\J\U_
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MQVQA/4[T[71/F\>!OKL25-LZ@I]1U17>@G>U1Q=TH #ND#IQ'FJGVSJV$[4
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M$(F&@/'"P4H147ARD,4Q; B>I+<GY'\3 5%*Q#0$Q,$_/G68NS@/?GH'9 4
M^JD/!XDGC ^TVJI()\(%DH0*<\*("WMB,4"?'^POI*.Z=0,BG.1.B-02R2Z)
M!*\&N.*_A":"P'=O 8'31V*?KL1KN.,LD4B+=(+7R+\?@-0%(<O$Y"$*WJ*T
M5G<]B46"W]R[04;\&3\<9L2MZ04$QD3*=B<"P])X.>&7!\(;&2^\-$L0*2/
M8B#4F-8$++R-XI@GWP#6 I9_&D^0I2,UPPL$H#9^SM@+I!55$C;!@5@;P_\
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M2^KG+M]WY]XC,KF822E[N(J_\%XEO$/7QW2,^$]1RDU3:_&%4$+;%"LB!ER
M>Z2[F#]$6> Y]YAUA@G#,05MU:(ZVR 9W DO"\1;YY7_VFDUVMTF\<-A!EA&
M3^/),"A\4YB\C+EO#(N!R*]\\PT$0[Z'4D9R@[@R/ &/G)4.M_3C=O/4^1(Z
MO[IP&TZKJYY_'S?RJ\1<EU$(D!(-U*/5AG--*3*(J@C,U1W<!/ >M3-"),OL
M=\GL+R<QJ <==>4S.3U^ 4J$RWG)\Q@\\K=!%(:"NOOS]X@SC$#\N#LSY8:
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M@R2WD!NZ YY4-W1H6*T^0+-94/<"#C9I]&<U"M838<(*&*Y <'!#"/K0G&5
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MCH50 V6C6&:W1)3QCTAG9#M4R\HZ)[BV8U^@ELH>>\5 6Q#'H8PL?_63/Z]
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M.I7>"E1<N 0.<.A>[D[B?U<*$=M_!?&B9E/TBT,H*KWERY/MACG KH76_G&
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ME(C'A(O8C_)U4]N2">5)Z(Q6"8P.Q5#-R;TO'O0F,"4DD!YY3)N=Q'A$NI?
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MZQ^MM2A+C;DU)M$0E344 1 D2"^@CZ(U2!;M(X<XX-]_9"%/'-&C&TI@ G@
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MW4;M"&/3P)J@))CK $,UQ^\[H)SB&KL#?EIT.)(\NLWZ"D'!O:K(A=+[X#L
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MS\_)H9D DPV_L;S9>=8C[<'G;DTZ1H8U\Y?/GV OV'B*%N*V&(5?Z\;3>10
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M'Q@UHRCP>T2()(?D2>;]\) (P?AR VJOY7)^-)IA2!//SEX;;6A2.KKE%0K
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M.2^W!%RJS=^S'H$>F<0)O@V+)S?4N7%370%_#*-X"/M:GS@,.%6WQ02!2WS
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M-6O!&U.9[8J(/#MM-E]@4UI@=3 6EFZM38"A+P$OU-W?-E'S?+4- ;@II*T
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M2U+\:1&$'Y4&XW_[\:D;!_Y/^+_PS_\/4$L#!!0    ( !6!+4\+6"-3<@L
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MK@*1!528$7?&MYIIG@%TD,5Z[52-1CLY;F8, ]$C=#QTV,@Y<.E(D<LQ!3.
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MD\\,H3YGL0:$^]&W\) _6'Q^GQ]ZJVG-H"UY"R/[R#_(/_+_,XXZ^4N> G[
M?:1.#Y_)0Z87%4Y&8U^>]55E0X;[%Q7 ;FPEIS]_ ],.)B,_(9&B#:>'%<Z+
MWH@;3D0XS,U)R9UN!B%TC)F (51-E$\$""(D>R?3#)+M0->I;L-DW^FM:S*P
M8/\[VGHGY6_52.A]ZQJYT&&_DZG7:2M;-1B&SKH&SX^V[V3OS:R1K+GQ^>IJ
M>L Z_KYX"/L<#*=,H"!WH-MTMC^ZE>".NDJ4@45^LQ(^2Q99=MUJV <3^=9!
M=0,E4C>LIT3"MX$2QAL&=%KP94SR@Y5R%U7 >%_!$C>H]K6,5>P+GI18J:A-
MM,G?-;"Y.DK6!OH4N&:A2%?)<MY'C+*O-&5?L8]?J<QFBFRLQ5SG4_$)FTIG
MGZS5:[.,R1<KE;)V?^%,K-]5$J:HF\"WY3TDOKE"!8#RLHO?HGWL'>7\EM%1
M%%B'$*FE1ZFO<)\R//?:M#3@HK(9*_%]^>CXHB)8*"=J>5G*&7 0ZCVJ=<8+
M67P[1537BX[97U1<ACUY;CE:CJ+*$0T@DF33EL CR0X>"WL<YOU0BOC :#A.
M2 F0&#W!>2@;:O?E=H,&*OOU-*8!6!9? *3>B)5Y?W5M#^9BYHK->#?WA8=[
M;^V*Z+.0I_1DT,_7\H6&N;0=XXX&@SO857J7G,O[(^2#T.DCGH@K'RQ+S%Y)
MM89]D2'153EG(I&Q!5.ZL%_$5[#$>_+A+PZX:O!2)G4'T3'QJVE*TW&FZF*8
M%X=Y<1;X@TK_MH*.TAO:YC/<OY/LM=T647#9$O\]7+;,JGOHY\JPZ !4"R(\
MIJ['X>\GF+F$2[-@%>UA5MB%VVEKI4NC:%24R*-\6YUP,]E_Q$Z805X9F.L:
M;3'$[''HQ%V'W\LYF0OL?<)D,(2_ES!%.P.L7"+OCKMU"%-7M[W&V]]7K76[
MMIQ@H5IIN06<HIQ7*Y=,NZ5,OK@Q=_0O<N%:'*5=(M,U?]$^;4UI[9"QR*7O
MPU*>QC,+966-V2Y=&$A<93G:_<P%"H]#D#(8:J.RQ,0->4L+HU;A>$09P]24
MIK2V/6".'>8.;_ S]NE85B8FZ:N*3XF_KR'RGJ+0ES,>3'*7WC/AE$V[F#T3
M-QU\JXC*:MP5E2%%_X8P[ K*>*SR->7IU+B"IJRFQ0LX[C!0]D&N7HE!VII-
M0R?! /0M3>GV1YP-L^>+-MV7>73DD&!+&M;S&M;+I6$CKV&C7!H>YC4\+)>&
M1WD-C\JEX7%>P^-R:7B2U_"D7!J>YC4\+9>&S;R&S7)I:-<T4W:M9#KJEI62
MK2NV9F&Q2[:RV)JEQ2[9VF)K%A>[9*N+K5E>[)*M+[9F@;%+ML+8FB7&+MD:
M8VL6&;MDJXRM66;LDJTS=<TZ4R_9.E/7K#/U$JTSL&\EF+<Z#/<Q@[VGRJ3,
MJVPF*8D%OZZV8!G)FUN0;+WGLEE)QG7>DF*D;VY1]FGQO-=;@: 9U>>M6Y_M
MS2W5 A(__"@ W2+EF]NSY#G_#>X!6<@P7XZ8F?S-+3/]JY1+D"G_DU-B5C%:
M)_Z4V/3FZ;([XLH#K0_X&0=AFH?-%Y<V01[]&XX.99(S?4<I>A>IP^@SD7WM
MEC+-*TT;\I;6%RI_DSQB[( ^[+_88;<D@-:)X_/%3EN<OG0=5T67&]_,I7/$
M-J3].=P4G];8BI-RLDKG(MU]#;G9W4A3.I/,)X07C2M*73HS\P<]%TTS4?P!
MS%G:'PN1EL[ S'*S] ":88DJP/.&)I]7HY>WX>/_ 5!+ P04    "  5@2U/
M#CM C5\,  #ZE@  %0   &=T8G M,C Q.3 V,S!?8V%L+GAM;-5=6W/;NA%^
M[TS_ ZK3,TT>:-T2)_*)>T:VG(QGG%BU[/9,7S(P"5F80Q$*0=E6?WT!7B21
M! %0$@7$#[[(V.5^^RT7BPN)3[^_SGWPC$**27#>ZIYT6@ %+O%P\'3>>I@X
MP\GE]74+T @&'O1)@,Y; 6G]_L^__@6PKT]_<QSP&2/?.P,CXCK7P93\!K[!
M.3H#7U" 0AB1\#?P;^@OV2?_^N,ZB-AG;H2?$?LTN>H9>'?2.X7 <3243L@R
M=-%:8W?0^W#:!5_N+\:@<]KO]#K= 9AT3UZG[*HC&+$F_*-?>Z,._];MWW=/
MS_J#L][I?S6O%\%H2=?7Z[Q^['0&G4ZGEXA_\G'PYQG_]@@I LR7 3U[I?B\
M-8NBQ5F[_?+R<O+2/R'A4[O7Z73;?WR]F;@S-(<.#KA/7=3*I+@6D5QW,!BT
MX_]F34LM7Q]#/[M&OYV9L];,_HLE[;<LH?B,QN;=$!=&<4@H+P,J6_"_G*R9
MPS]RNCVGS^BA7BMS?NS!D/CH#DT!__EP=[V^ZE/TB,EB!L,Y/'')O,W_WV8<
M+><HB(:!=Q5$.%IQPE@+;B_#$"N<A6AZWF+B"X<' (\-?M5?=&2CU8)%.<7S
MA<]\TM[=T OH<[].9@A%5&69L'$SIHQAR%PP0Q%VH5_++J'DP8SD-QOB[-#;
MZ>V")P_&BM)Q<JG#&W<[G43$_7-&?(\EL!&:8A='VD9*I1OQY"6DL\\^>:GE
MR)+0P4S[1B+4=2[)? &#E<HD8>.#FM++M+.,,%G.YS!<,8KP4X 9,Y E"M<E
M2Y8I@J<Q\1E72.G&_;0>%%R?]64LM3_A1U_/;J' 04UZYXS0H_)V*;<\J!'O
M'49 N$3>U>L"!53/-Y5"!S7MU+E#/KL//99JH]5]" /*ZR6-/*@G?5!C/SC;
MR>SJQY)UJ#IFRN0.:N#'Y$*WB]@'[&;\#PR94]2]L9;P04T=L%N/?8#NX:M>
M/ H%#INF.SR-S7$4=PK, 9<DSEEL@*"9!_4T'-9HUE_,6 I#M]--EOV*HAGQ
MM"Q6BQ_6W)XS63Y2]&/)/'3UC#1C4R)FN'MLMIMLM+NL;\X]Y!WE ]4*K0.H
M;[873"ZW4U^8%SU.#M<W5U-%<_E<WU2)V!%SN[Z]=?08OEE'*(+8;R@Q%93;
M ?4;#W,^V=8HYM)5&A@P[ )(+MEL*JT1:RK9XR33&@;KZCBJX=U#6-XU8GKO
M$*;WFN_$:H2(3*YQ VLE"2T%1^QY:SBYEJ+C0ZA%PVX:&QHX!L617QU2M+7(
MC'>A[R[]>";[AOV=DT"O$0H\M!X3< #[+YBPC[F:3O+5!0[(I+9_A8$'$A4@
MIZ-)Z\4+(SES>\S&]>PU^YT%#V4UBL=GPD J#U(%J:69K3YQ<_;Y?.&+A'FJ
M4_/BU:TII(_Q$M>2.D\0+MH\!-K(CVCV21P43J>;KG3]DG[\?4@I,^!R&?(U
ME.P"/GQ$?GS9[VF[0K.V.8/Y(@"_%=D//D?W#/WXYHPNV7VX8F$=+XI6 ]$4
M+P+<BIYAZ (2>B@\;ZV[9ABZN9@I+SNF+=J4%[%<C8-99&3RTY#,9?Y.?4MV
M@;+-"[.B!5X0?II%L?4&>1R': %Q5E\J ["BN1Y//:,\29%:QTN"Z!L)7+V<
ML-W2H-F;):+4+!2Q&LI?\CTC7PCQ7K#O5T/1D[8C*92I*<1;'5=8%WXCM" 4
MLS2F'8;5$G8D!R5?*LC6<30.R0*%T6KLPZ1^8[W/@E<Y+-)D&5PFI<=5WS17
M.M"MXRO=@!(\W2!(T1TWZ7;Z0)/T4$V80DR/L7>F&=,";QUE"3A5WVM+EU3A
M>G%QI.5J,ZE:BN,G2,PW&#YB'T<8J4=THK8F SZ9EZ!CN.++,^H!:45[TS=$
M-07%H)("MBZTTN6 .A$F$3%]N]=A20[;.J)N<(!NIY<A\K#T[M]N9;KXTJ9#
M!,XZ!BY)\,QJ1#X XVM]RONDJKWI DN;%3E@Z_@9H2EB%GIWS,@DE)04243T
M6'IOGB4E;.N(RI?N&="5DBV5G!YEI^8ITW. =;SQ):>LKMG:^LOA^I!2/,7(
M4Y)82XD>HQ_,,[J#:ZRC=PNLUO#"JJ*\LK#X:0J\ZEWJ919$;<VN^21]4&R7
M8J5.V-AT)$D>$2@M^E1!M2ZB^"8'$NAP4FYI>B2G34@52.O8&'JL-&.XH3^&
MV+L.+N$"1U"R>%4I8'I8I\V- K)U%-WQ33,!\JY@&+#JC Y==SE?QKUYX>')
M,ELZLJ9'?MK$Z3O".@Z_XH"$\;:C"(6(2A@KMS0]YM/FIPJD=6QLU5]\IW>-
M$D<M:;IFT,5679+:O7:R(S[5TY95,#^UBRAOV-_'VNLG?ME ;N-?7W_C'WB3
MT_>VV4V+BI<2Y$"\DX'8* )D"C:JP)N' "Y97XZ\MP;W-*ZG38H/14NFBC9-
MC=85%+&PY[OZ1N@9^23>6I":)BLII&*F\U\E':5B0@.]=3W7!/D^WU@5OUC(
M9[8/O3D.,(V27>%*\G3E36=Y71;K^<,Z.K^1@&1(O[#:EMX0*LT@E0*F1U^Z
MA"D0"QAR+%D62!Z2X>9J)/CMQM9DQ#*"JA4 \?L];*)E.XX27,K<)Q$Q"(3?
M!)R2VV"$:;PUDQ%Z.U5MR5*(F8XY)3V%R-/R@G7I.QOH*D.OU-!T_UJ7GPJD
M%N:%>/NY,E$7FNUD</GI-_X2QN\;O9^9UY.'^);,S9N!RP6:DA )7EVS92=7
MM9,FXW>^B( LFG9&96T"2&U,[XL+5H=.9?.QE0+&$X*,-I7Q6LG@Z#,IFB\<
MS$U$O->:B.#S$-LJ_P%*D^E-SZB4WTZ8PW&J/Z'"-8%8E243*BP4N4WCD#QC
MYI^+U0-%WG6P+DZ'_.6YB@T!=73\]+V5@11?DZ#B(%"8;&Q+[A-V^Z$+R+#Q
MM\*PA)=[6EPPMU+1WH+4OA]=<D=8Q]MP3L((_P\F0XCX!3B8QMO?QR&:X^6\
MFD(-4=,3+7NSJ>T>ZXAE.2/D6Q-'*/G)4$<S%&Z@*\;,NO*F%\3WIKB>H^P;
MQ)7M+SR_PB=Z2\]*U"%>3Y_IE?<& J&.(ZU+ /G4]1D','"9&RX)C5^8D^4Q
MV9.,VAI,;]L^<)Y7.\LZMD=H$2(7*ZJN?"O36[/W9DT$VCIF9*&UV[VGR]Q'
M>YG3<8IU3)I<?1C8R^6NRQ&F)[^/O)S<[=A+X1$7FBL6 OC3-T/?)\%3Y0Q_
MOHFFTVV<V"F#L33AE2OB_ NSZ@PBBI*:_%D\TZ/K'?M2GVK(N^,X4:)$DVV+
M9X)V\)EU]W.%$ZZ#9T3W7"P0ZC#Y/!M<Q8LV]V3H_ECB$%6^'JH::AT=EBXS
M2*@M/A57VV'VY;4*)ZR'%WO$MU"'T?W(BY2PV^GVD\O5P*HE+(U="6VE[<ER
M9]@7J0RKBY 7[^K0HZ]:PM(E,WWZ5,ZPKA\=KZ/MAL! ,9,C;&SIPE@-SJI=
M8-_=)GX=\QB%F'C%NJZ:R'I:3"?573"7=Q[4K9FM? JN.5?([A?KDM96ELT>
M/HTW*Z3[LO2Z'K&DZ71V (9UW;-/B#>W"MY<B,M&$'8]#"H^_#>WT^\#/YP"
M4]<G=!DB]@>7 ?STBOL9 FO1)O<E[GG<;P[.1R&<7AY.? A'>I5X+^;F.F!S
M(;"Y4M/HQ8<&YX -A,#XT[LYT:8M+1PIO&UBMR,TD3^;F\@T;5OU\<(Y,[M"
M,_G.W50<E!^O;<IDC=.&<[;WA+;SW;JI'A K GE-3:.0'D:<L[\OM/]#O-MX
M>S]T\6T(35FN/J X9_X[H?D?,_-!JB?.+QM-38,0'V.<,_R]T/!!G#VX*"@\
M_=%89Z1WFG'.]E-Q#]6)MZ6O=<4^+VAK'(W&2<<Y*!6=+<](B2+>&VWU0)FN
MQH%(SD+. 1!WKW%:VB@ F0;[B@9I\= 5]['[%0_@3?9;P^_+.-3YR-L>Z8F[
M]'T]DEST+7CS,!F!OQ_!+ZK#EG.8]>N#-1*#'94,B;A:D'=71\0D.Z@YAT-<
M-11[KR-:7NO(YAP4<06A[LR."&[_DYMSB,6EQ[XI)+VDS>XHG[69\XNXK#F0
M7\#ZXD?PD.*4Z!QJ<064C1'-V*\\/CJ'0%P"B;N'XT6I]HG2.2SB@D?50=B#
MJBN$U1=7+9JP0-<"8#TQ,'%IH@NL=^P^719[?7%Q4N[4CQ=M>@=9YT#H5B8F
MTEJ]PZUSL':O4H['UH[G7>=PBFN3&CB/2ZC^P=@YE!43*-NS#D%YUJ'(9;IX
MP;\]0HK8)_\'4$L#!!0    ( !6!+4^5FS^)^Q(  'HT 0 5    9W1B<"TR
M,#$Y,#8S,%]D968N>&UL[5W=<]NX$7_O3/\'UM=.[QX4?3AV8E_2CF+9&74<
MR[6<WDU?/) (6;BC"!T_;*M_?0%^2*0$@"!%"J#-/#BVA 5W][=8 +L+XM,_
M7Q:6\00=%V'[\U'W7>?(@/84F\A^_'ST?=SJCR^&PR/#]8!M @O;\/.1C8_^
M^8\__\D@_S[]I=4RKA"TS'-C@*>MH3W#/QLW8 '/C:_0A@[PL/.S\1]@^>23
M?_\ZM#WRV=1#3Y!\&C[UW'C_KG<*C%9+HM,Q]ITI7/?8/>M]..T:7^^_W!J=
MT^-.K],],\;==R\S\M0!\$@3^M'?>H,._=$]ON^>GA^?G?=._ROY/ ]XOKM^
M7N?E8Z=SUNET>B'Y)PO9OY_3'Q/@0H/HTG;/7UST^6CN><OS=OOY^?G=\_$[
M[#RV>YU.M_WKM^OQ= X7H(5LJM,I/(JI:"\LNN[9V5D[^#9NNM/R9>)8\3..
MVS$[ZY[)MZ:W)D@V/FF'7R:;(D'7":9==.X&DESC*? "Z\GDR."VH'^UXF8M
M^E&KVVL=$R1=\RC&*5"V@RUX!V<&_?_[W7#]U$=O@O!R#IP%>#?%BS;]ODW@
M]!?0]OJV>6E[R%M1;$D+RB^1(>AP[L#9YR-"OFQ16Z%F1)_Z@PRMMUJ2 >&B
MQ=(B.FD79_0+L*A>QW,(/3>+,V;C:EBY!0Y1P1QZ: JL7'PQ*4MCDHY+2-%Q
M1[/1DOH9@DJFXL14Y3,WFHT]//U]CBV3^+H!G*$I\J29%%)7HLD+X,ZO+/R<
M2Y$[1*6Q=H,]V&U=X,42V*LLEIB-2V6E%_=./,+87RR LR(0H4<;$60 <133
M*?:)I[ ?;[%%L(*9:MROUU*%.R;3'G'MCVABR?'-)"B5I?>M 9QD#I?=EJ4R
M<=(B #@^-"]?EM!VY73#)2J5M=/6';3(.#2)J_56]PZP7;JTDO"#<M2E,ONA
ME71FEW_X9$*585-$5RJ#'\,'C9:!#LA@_ 4X1"G9L[$4<:FLGI&A1SZ ]^!%
MSAZ9!.6ZZ0YU8POD!9,"4< %#GP6V4M(^D&Y'LIEFLP7<^+"X&BV\;+?H#?'
MIA3'V>3ELMMKC?V)"__PB88NGZ"D;0K(%$^/U4Z3E4Z7^=FY!W2B_.Y*F58)
MW5<["X:/*S07IDD/X\/EV97LHCI_+L^J@.R OEV>WSS]*!ZL ^@!9%7DF+8Z
MUT/4&VKF-"Y7J<P[3ZE@PU!$(#%EM:XTAZUET1[&F>9@6+:/@S+>+8/SKA+6
M>V6PWJM^$LMA(B*ZRAG,Y22D.CC@S)M#R;DZ.KP(N6 HUF-%&T=[>^>7!Q3I
M7D3, V<:\\]JG&2#DWV)DT T[7(2<#<G73A3?P);)B):=H.,1_2@I(+6O2#;
M:Y.F[:A-F]E!]7RO']8R\0*@G$SO4A^ X^!)K05<3*"3D]TT:?6\ LO*QV%
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M7S#<;=$L$[!7; $^$*8'R*4U6\1?D3\HC=$EO]S/H;$FK9C)7LPD?9N*OU@
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MN_%$;P4^9M_QMWLYWL%>;LQB7?R6Z6/9"_X4O&U:?->?$)GBE_T=#"LIZ3+
M8U_QET/,@\*YOJS7WKZL5X@EY_;AY)V]]NZ=O<W;MYNB_S=0]&_^YKOA*"?[
MT7 X#!/#BZQZR(!?6EF' O)UH_FA@2(ZT:VT4\!V5JVN!*FB<O]"P."\PG'K
MB]2&&ZM$5.NJ^T.@?L 2>]?Q$J"3O[8!)Q\]C*?0!@["MPY\0MAWK=4=7&*'
M;/6X6!.R+"I%A??R8P[G$N4@GE<*KCNR&X]FEHVYBI 2$*BZW*\(2EEB:!JO
M[IMFH$M@W0)D#NT+L$0>L$3K&R:!]H49(KYYV*B=Y>[HILN&9GQW&;%&?^%;
M1%ZRR9NA*1+< I=-JSU@DB+HN>9<1QUOH#> #GH* @-]UX5$;C!!%O)6WR"@
MNW!S9-_1"^QHL>07X"+WNXTG+G2>Z+I\:"]]SR7?8^)^+!1$4+\2M5QCUQW:
MX65W0SM6$=\>U/"CO8TI5 MWA:74;G=NBB:23ONV.:!7+8HJHC,(M;<$&?YY
MD$GD#J+/Z8\)<"'YY/]02P,$%     @ %8$M3R*^L/\],   S<T" !4   !G
M=&)P+3(P,3DP-C,P7VQA8BYX;6SE??MSX\B1YN\7<?]#;>_=S4R$-"UUC]O3
M/9YU4*]>>M6B+*EGUN?8F("(HE1K$*#Q4$O^Z[>J\"" >@(DJY)M1WC$)C,3
M7Q:^RGIG_>&/S\L(/>$T(TG\\ZOC[X]>(1S/DY#$#S^_^GQ[.+D]G4Y?H2P/
MXC"(DAC__"I.7OWQW_[W_T+T?W_XE\-#=$%P%'Y 9\G\<!HODI_05;#$']!'
M'.,TR)/T)_1+$!7TFS__YS3.Z7?SG#QA^FWYU _HA^_?O O0X:&%T=ND2.>X
ML7C\_LWOWQVCCW<GU^CHW=NC-T?'[]'M\??/"_K4LR"G(NRK__OF[(C]Y_CM
MW?&[#V_??WCS[O];/B\/\B)KGG?T_./1T?NCHZ,WI?H?(A+_[0/[SWV0843+
M,LX^/&?DYU>/>;[Z\/KUER]?OO_R]OLD?7C]YNCH^/5_?KJ\G3_B97!(8E:F
M<_RJUF)69'K'[]^_?\U_K44%R>?[-*J?\?9U#:>Q3'\E&OD6DHQ\R#B\RV0>
MY)P2QL<@I03[UV$M=LB^.CQ^<_B6OIXL?%47/B_!-(GP#5X@[N:'_&5%:9:1
MY2IBH/AWCRE>R,%$:?J:Z;^.\0-]XR%[T'OVH.-W[$'_6GU]&=SCZ!5BDI]O
MIDJ_WG=L54JO78.]QBE)PO-X'.J^MB?XM.ZD^08.M/6=NW"7Y$$T"GQ;TSGL
M*SRNQ-=Z[DN:-@-X7$FW-'<".Q<A#RY>>;E&[,M+^JD#$3_G. YQ6(-D)C01
MF#^!-PR5[<9Z,N_8C5@T3U*I[]SD(LCNN=TB.WP(@M5KUFJ^QE&>U=\<LF\.
MCXZK\/VOU=>_3;X$:7A'GS)Y)EG] .[=SZ\4,J_[:)GT)*TA!^G<X'<E\7J>
MT%9KE1]&90F7ZHLT62H?715*HA#X+;IO[)0E1Q^E -P12W'&.R:#7EP;M:[$
M*E3+B$JQ7AF.#S_?OOHW+H.8$/HK$_NO/[Q>F_)'B%^#- WB_!->WN-4X5Y/
MQB4AI/#:A.@(@"&$#%6?$)4,#!K<YLG\;[,5ZT-JJ2"1<TD')<PV)00A,+10
M(>M3@\NA4C"#0A#:A"]QG)]&09;-%ARBIA'1R+LEC %VES@*84 $TB/L$XF+
MH62!2D9!:GANZ: !9Z?7U"1.4QQRA/K8H]-P2BHS] ZMU.)PB&7$*,0HKH%.
M-V730WY?<H1-"'&&L.FA"M"?+.AA%G?!#5O0C!@F6>^LL 2HH,2?@ 28.E:>
M_[T@^<MILEPE,?UG9M-JR76\M%PZ^-+62Z;@G5)#4/9Y58JBM2RHAFQ "^:_
MZ;)MLT"&)0MP?>HTHF4/" 9C*)&726RFBT3.)5>4,-M$$83 L$2%3.@C<SE(
M_)B$(6%#OR"Z#D@XC4^#%<F#2,L5@X[323P;^)U)/9T"&#[9H!0F_1H=Q)0.
MIS&JU& P[0;G 8EQ>!ZD,8D?,BW%5,(NN:4'W":57!(,F[3P!!K-Y\6RB-@B
M"CK#"S(G0*8-)W%.0A(5;(? +9X7*64[SLZ?YU$1XO""OCK6:2MROC@]6]3.
M7N/T]C%(\<F+W(!N<6*73W0:)7=?=)T8N[O'@:E3N_=1J)@M!;36V-+X1#$U
M<OZ,TSG)\&S1ZN)4JPGR"&ZOYFRJ9( 3S92)A8YW+@X$*@QU*TTV9SLO.Z89
MG[K]4FGOB%.G25SM*ILMNL.K:9PGI@'+.!/.N#;2N89W _5A<' <:'%P5%MA
MC%PUH^F2E(1:ZM#4 3O+SSFYC_ 9OL=Q7M!BLV.E5M4+&RV<D;)0HP>/?6:P
M>M;-U_HH; PX(Y\TF%=KLP-;VYZ6W\96ZH*^K>VHP"":-4[KEC:!M.P^"?^[
MR'(V7YY=).GI(_4 3V,Z'DP*VO6,'ZY3$L_)*M+NYQIFP^U4T0CWNE-' PQX
M9^PFJ,6II<8&6B0I*JW0J(C6=E!C:)<K)EF:MPA-_]4G,_WJM]LYCH.4)+0K
M\D22(HM>;O J27,<2F.HG8H+J@X!SYAI(^^=B - 2E94*G%4R_MCU0W.ZO7$
M=7U0$DHK[8I+%I!K&FE$03#(C*]/GAO*G6P;K:NBKW:6S L.)P[/:03,7]CA
MH'3))WPF]UG.#C/)>A%V>L[Z:T/<:'IL-DK>:3,4:9] M2JBNJA41BWM;42B
MK Y%&9Y__Y \O0XQ89'H1_:!<>['5A"B7_U6PKC!#X1!CW-V%*WGMEK,!:=,
M(!F%5#+>&6, )G3K2TZL9?G)0(^\.*5L38-H&H?X^3_PB]([0<XM,Q0PN]3H
M"0'BAAR9@AR5,.+2B(I[H4<=RMB1$(E?W9]=D4$&JN9 ^S<0KUX"2-E>,!FO
MK[DYY<G..6N<Z<FY?O%2F'T&=(1 44&&3,F)4IAV(T)^^-P+/2842<C07$3!
M@\2QWN^NZ""%5=.@\R.(UR]#)$R8U#*("7EYV:=%FC*0))L'T5]PD*K#@5K4
M%05,8&LVJ.1 $,, 3EAX*,51*8^8@M_P4/5N2ECE? N)'\HT%^K.D$+<<8]2
M"[K7L93*@F"0!< ^BZ99-33])D.-1I6;!%66_NB13A<DPNDII?1#DJH')#TI
MM^210NQRIB,"B"HR7(J!"!=%M:Q'1IPO<?I 2?HQ3;[DCVR75!"KF:&0=LL0
M+>0N4Z2B@!BCPZ=@3JV"2AU4*7FDT.TRB**3(B,QSM1-4T_*+66D$+M4Z8@
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M/EV9A;J3AO*$QL7R'HP5-0.$LI<D9OEG>717#G#:(F['BB*X[NAP_3L8VDA
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M1:.6T]D/.Q<Z\QUZ%3"LL\,I;'Y?:U79>Y)EPB@71.@"@VF%Y9>$V#7'=KH
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M99<GLLLV>??"CE!&+:<'G^Q<Z)R$TJN B6MV.&672%=,^_8RR;+OV#V*B!N
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M2<J@2H</D6HM5*OMB#0G29"&LT6=TB6K'L=3O,E<T\L[HXP-[(8Q.F$8A+%
M*"1R9"IL--0HU51!7 U&4U9G^JFN)6PM.^A;,PL]IWD ;-WH9 (P*7GGWE"D
MXG'L%VH[X@'K!,=X0?2\VWV7P^[-*(4!3KH8H:KZM,!V)$I7[2=L4\P#/]]R
M\B)<5SKYPJ)BN:0^6Z^]WU#*720I^U&UBK.CA_E/4K>M C/GK]OT26""VT[=
MZU>^^NK<EM)75_^NBN4]3G=?VO5S]K36=8MI1Q6N?(C3NK;"*4G"VSQ(<UW#
MM2LGA1K7WI3%=Z><X3EF"NCM\0&BU>'''0V=C!YF!A<_\@VET_B:E^C'-,FD
M0Z[=/,?94&V7Q=0,\7;Q$.\MV*X]$R[-89(8RF5S&\8/VDXO,&&[;!K?=Q2I
MI$_:IT9+4U3;;+8DC_%>Q7;OFY"<IY0$4\W8ON5IEM$1XUF1LD/;9?/.5^';
MAW_JG=/*6C3"D--*,MK13AT8; 4.Q<="[S.X^=W35,^>]M'=3BV5O?3S.'3;
M1U=-2HF]]#\5,49OCW@/_3V06+AA<9ROSX/L=(PL><X^=3>4Q;3-^B<\!$X<
MWI%GBC#-3R=]M56N%5=^Q>Q<)@XG3S@-'G#WI%<210M74\;60/:ITHXOZ!VU
MJI8HOIIJ/]KU?ERHM5&ECFI]Q W\4\4%O^_JJXP 'JO]5SX-;N&ZA\EQ1_5]
MV"SG+NK\-A& JO?;+]I!=7][CX>V=\.]Z_L]HV\J#LDDJX^*/AC&7M7VD86\
MU2H_$,-75^_'^0]]I6'34JE]]EKY!X+8JZH_JH"W6O$'(?CJJOT8[[_BQ1FH
MH\RO>R''RO5_]N4=#W-*UD\'U>1LMTAWM$#T534R6W5[BVM*@%GH?:L\N%,G
M._936)*H<JMN<]O\V$V[$L^R76S:'?4<.)MV-R@F^TV[(QX"I2;MVL$1,WV
M([#'':B.8N_[DC$Q?N G+!UO154%WJU-$6TQVG)?KI*X=*=,P#V-LSPM>/4P
M;;)R^%S0T7AL,6X4G8<^=.^C]4B''>_5VF+M;"'EO@LNS_)'G-X]!E619+1P
MGG!&0TQON,$;K#,:#)O;;K?U3G8*$72==_!R-@H/.\2W]Y%D]V4#).BT+Y2)
MPWKH5^7[TR5;M-5T5T4'N;*N.59JWC<N#L<J)+SF=R+41^+998[-0+\RL"..
MB;<\R'R323GCCAIBPQ-1! 8GE+A4:U%HQ201CWY[.D#U=&;HK?<WOGO?A%2N
M_&=^WTH5.5KWKAP@#"VIQKVY4.X'+[O=X&5 6/KDTR3F(;8(HCN<+M_H7H]K
M),Y7FOP4M5#%W<* %0*\^*X\PA!41QC2V@":KRV@B"SVM;W9@X518,1TZ+&1
MCKC3\3EH-V#[ST>79S:_NH51M8OF;E#KNKG]9Q'4J.:VQYWC%,9V#U5GW!C:
M+$FYP6!^RN^7NPN>L<TDD4[:V>#>#+D9Y*M%O3>O=OBD-W&\1X>HU$1<%<9P
MK;X(L>63@DI6&BZ'/Q;0V]%2(^Z=5O88A2N"ZBLGUW=-?H#%K.:*S?7]@$F6
M\=NQJD/9_<U"HRSX8-X UV1,M% 'QTQ[S,*^"AQ2C8A?E)K4RBBBVFC>4@=*
MWNN48<Y?V)W)^23F2U&RZX[&&/!*7:-C6N8JM>$2UP2YSUMV#TX4X7+ZI%8&
MRE*^'FI=@TMAOX&S#5@?(YDDM*&O%N5^7*PDN/ Q2<(O)(IHU:!(J0.$+;_S
MGVQ+06O"*]\LG-.R4*,/-^*908N76.0T(*)@F:0Y^0<?7T-EJV2SN4G8+P/[
MV[[UDH!9I=EY+1F5H'M,>W@8/051 9E0O]3X)E&4? EBY>$U*TVO5%.[HN6=
MJ 9M.[@]Y#XQ&T$4U)) >7B%K8<67-0KTUI@M=2B<G #VAJ<,']'AZQA'=)(
M.8>WCFS.YGBMKE^V4O,XZVN^C-E"!\HX8"#>/9H7'CQ9!V5N;MA4W![,O V>
M:+O:APDVM5>79$GRH-P=$W_.5-VO(09@\$_EF!T?^]I[P$\%Y(%\9>NI*Y("
M&C.<!BOJ5W2)@PQG%P4[5OB)Q&19+.OSJF>%X7KS829<\G>,<VT&#]$'P^$1
MH/LLAI/3Q<J9:7SW)?D+#E)5>S[8"CB2BBX.YNG:Q'Y15< MLO7-T7ZQE3X3
M;X.O+3L0&2NX.8:SC9&]8VT?N82WQWO$VTU* R _1W-ROWBHX-Y=0C71LA1'
M$3.!5I46#$YRMR9Q>$,A!5%UV;6B)!2R+CFGA=OFF%00#*=TZ/H<8C)L/,-$
M?-T*'X:$C:6"Z#H@X32NJH2LW!6B\+:@FX *2_&-/&(*B,2H4O'T4F[8Q&&,
MP_,@94=VLLE\7BR+B"V$G.$%F1/I6,NL!>]5#< LV4!1BZ)*%D;<;;(*7.'\
M#*?DJ9S\9:L#ER2X)Q')7S[1*$%;FW 6W^ Y'4E2WT^"C&2?X^0^P^D3VRT^
MC5=%GM'?*6&H$I_R^$A+B\VL3.-Y5(1L:VA=<HH"]@7&9<OAM\#;5= /$C!M
MGU?W^_'A])&= &'!O,JI@!H,GL)Z#?@:I_61%#*G784S$A6Y_#95@PJ\@&X+
M6,B$4.DAJHBXIJ\.$5_%U4QI=@0 G?&4XQ):32YU@"HYKX5\105-Y;R6 5?4
M$FBJTEZ+>BUP=3&#*UQ#D7HJQKH%(5@7(40I0,6K =<OZI:H[X#1@F(H<9A%
M;5/&OHXLLQQ4CTD4XC0K4ZK)2EB4^NT', 6M 2?-N%6)?H-*833)\Y3<%SE/
M])8GZ#J 077:;[)[.R8=F)5"#U534U 0A]6[\_22:(/>;%)@(Y.,#4WDL4DA
M"BASE0FAN%%M+8^X OJV5/G.T^MH=IU4\ZWZW5VU$*!:H<8F7"33E'PMZKO,
MR^V*EXJ##!(QB.4N0:<N^6J#)B>]+\K7Y\8T"R4]$4#%KD(F.VW)Y&JN XCV
MY;O7E+I2&%#YFS%J8W[-_TK)5Q7@TT3MI&G2CFM?"%##J\8F=%NYY('M]2\[
MC3OSE"UQGN'R[S2^3O$J(*$V$.EU -4,:ZABJ"H5T+>UZG=L[KG2]AS 1*_X
MT>2F15-/#]EI@GZ!6L"6KY';0.L>@-=9J"N<GP;9XW6:/)$0AR<OGS.V'K)V
M<9Z3)^5<B;TVH+<Z K1L8SFS@6HCZ/X%?<OLT!?\7?O=-K8\O=]Z\]%=,IG3
M06Z*!V7EL-<&]'Y'@!9/J9<FV 1.9:1)T'& N)V#9N* FX)5?:?\LH*QU5>B
M#>CUC@ ]L/HVIN!4W]GB,@GBTR23MZP2,4!O3(=.6?.2!6+2B(M[VSNU:J"S
M$Y491<?F=66O0"4+Z#T8(8I["E>MU\%54*4#*]Y=D#B(YV/CG40;T%L; 7I@
MO&M,^8]W#"5MH=D?UK0^!1%C7WFO7K\W+GO#0_0!O>-1L(5-2NP-LTX)_]"R
M<X!*2T@R(/$WB"Q/ME\G$9F_W.'G_"1*YG]3#!NELH#>GQ&B9&A8'<NG+X?K
MH+]6?YDRXMK_M:>)IRWOMU?.L.W^T=#F[1QZ+)T-/.2W2* V M2"P)J+MEP%
M TW*4]05DLZ,X@%JDEE7<%!S01$'!)7;F:&\NY<$;YW?VWL\H/#HP^LQ/,]L
MB5[BX7.R'-%7RW;)]<;.*3\0P]?$^[&N[Y3\+5#_!#6@]L(?_P<A^)K8/\[Q
MG7*_@027^:/OQ,W4+:Z06G1G#P' W]W[)J7HEA^V+ZP;>J?[5E@X^"+Y/6;E
M:%^WP=*A#]\7UOXSW_V^QW7!1;%LH]KL$*>G?OC&]S/X9YTE0&7&<BJ/ZD-\
M7 7*J]A>-F_ +TF#UNJ-K?-[3S3YO=M?7=)/].OZ*_H?-K:@W_P/4$L#!!0
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M5PZ&I- 8"HB3I_$2UB5P_'2TQ=TU_T6;CG%YT/V:)_RDU^\M(Z/YS^>4A#3
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M=I4GN>8#-BKO.9236R>W'2E?.M1L!G=4!FM?(+K&WA,.<(212-':KN&B]V7
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M\4HRF+VMKJ!(MW; MH9TB51; KI0$?MVPK_ID:G0L?!QQF@\G4E'7 )TM:[
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M<"TR,#$Y,#8S,"YX;6Q02P$"% ,4    "  5@2U/"U@C4W(+  !&=   $0
M            @ &"P@  9W1B<"TR,#$Y,#8S,"YX<V102P$"% ,4    "  5
M@2U/#CM C5\,  #ZE@  %0              @ $CS@  9W1B<"TR,#$Y,#8S
M,%]C86PN>&UL4$L! A0#%     @ %8$M3Y6;/XG[$@  >C0! !4
M     ( !M=H  &=T8G M,C Q.3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( !6!
M+4\BOK#_/3   ,W- @ 5              "  >/M  !G=&)P+3(P,3DP-C,P
M7VQA8BYX;6Q02P$"% ,4    "  5@2U/FJ6;@M@C  "=8@( %0
M    @ %3'@$ 9W1B<"TR,#$Y,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$
' %Y" 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769685888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - The Company and Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">39,416,352<span></span>
</td>
<td class="nump">3,390,120<span></span>
</td>
<td class="nump">8,682,368<span></span>
</td>
<td class="nump">1,164,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockWarrantsMember', window );">Exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfPreferredStockIntoCommonStockMember', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,659<span></span>
</td>
<td class="nump">1,163,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfConvertibleDebenturesMember', window );">Conversion of convertible debentures into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockOptionsMember', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ConversionOfConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_ExerciseOfCommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6638484592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>&#160;December
    31,</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 75%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Research
    &#38; Development</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">585,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accrued
    Interest</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">432,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Professional
    Fees</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">162,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">62,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Consulting
    and Advisory Services</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">161,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Board
    of Directors Service Costs</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">94,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Payroll
    and Benefits</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">21,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">39,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif"><b>Accrued
    Expenses</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif"><b>1,455,000</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif"><b>101,000</b></font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758827216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock Options and Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of June 30, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of June 30, 2019</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of June 30, 2019</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">$ 1,320.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">1,020.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of June 30, 2019</a></td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">1,320.00<span></span>
</td>
<td class="nump">1,320.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">$ 1,428.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6640092144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Change of Accounting Method<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_Note6ChangeInPriorYearFinancialsAbstract', window );"><strong>Note 11 - Change Of Accounting Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Change of Accounting Method</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Adoption
of ASU 2017-11</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
connection with the securities purchase agreements and debt transactions during the year ended December 31, 2017, the Company
issued warrants to purchase common stock with a five-year term. Upon issuance of the warrants, the Company evaluated the note
agreement to determine if the agreement contained any embedded components that would qualify the agreement as a derivative. The
Company identified certain put features embedded in the warrants that potentially could result in a net cash settlement in the
event of a fundamental transaction, requiring the Company to classify the warrants as a derivative liability. The Company changed
its method of accounting for the debt and warrants through the early adoption of ASU 2017-11 on January 1, 2018 on a retrospective
basis. Accordingly, the Company recorded the warrant derivative and conversion option derivative liabilities to additional paid
in capital upon issuance.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
following table provides a summary of the derivative liability activity as a result of the adoption of ASU 2017-11 (in thousands,
except per share data):</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Consolidated
    Balance Sheet</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>December
    31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Previously
    Reported</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Revisions</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Revised
    Report</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 62%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Additional
    Paid-in Capital</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">519,702,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,603,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">521,305,000</font></td>
    <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Deficit</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(267,896,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(1,603,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(269,499,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Consolidated
    Statement of Operations</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>For
    the Year Ended December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Previously
    Reported</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Revisions</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Revised
    Report</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 62%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Change
    in Warrant Liability</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">925,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(925,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 3%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Earnings
    per Share</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(8.54</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(0.06</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(8.60</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
2018, the down round provisions of certain of the notes was triggered. The Company calculated the value of the down round feature
on that date and determined there to be no additional cost to be reported.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_Note6ChangeInPriorYearFinancialsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_Note6ChangeInPriorYearFinancialsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6592008288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Stock</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
the first six months of 2019, the Company issued 1,994,405 shares of common stock upon conversion of $1,045,453 in principal and
interest on senior convertible notes.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Preferred
Stock</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company designated 2,000,000 shares of Series J Preferred Stock. Shares of Series J Preferred Stock will
have the same voting rights as shares of common stock with each share of Series J Preferred Stock entitled to one vote at a meeting
of the shareholders of the Corporation. Shares of Series J Preferred Stock will not be entitled to receive any dividends, unless
and until specifically declared by our board of directors. The holders of the Series J Preferred Stock will participate, on an
as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Each share of the Series J Preferred Stock
is convertible into one share of our common stock at any time at the option of the holder.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On
the same day, the Board issued 1,513, 548 of those shares in exchange for the cancellation of debt.&#160; In the first quarter
of 2019, it was discovered that a certificate of designation with respect to the Series J Preferred Stock had never been filed
with the Office of the Secretary of State for the State of Delaware.&#160; Legal research determined that despite the fact the
Company had issued shares of Series J Preferred Stock, those shares had, in fact, never existed.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">To
remedy the situation, on April 4, 2019, the Company filed a certificate of designation with the Office of the Secretary State
for the State of Delaware designating a series of preferred stock as Series J-1 Preferred Stock.&#160; On April 19, 2019, the
Company issued 2,353,548 of those shares.&#160; The issuance was in lieu of the preferred stock that should have been issued on
September 1, 2017, and in settlement for not receiving preferred stock until 20 months after the debt for which the stock was
issued was cancelled. The Company reflected an expense in general and administrative costs in the quarter ended June 30, 2019
totaling $1,140,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
Shares are convertible into shares of common stock of the Registrant at the rate of $0.60 per share. &#160;The issuance was exempt
from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the same Act since the
issuance of the Shares did not involve any public offering. &#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif; background-color: white">350,000
of the Series J shares of preferred stock had been previously converted into 350,000 shares of common stock in December 2017.</font></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Stock
Split</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
July 2017, the Company approved a one for three hundred reverse stock split.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Shares</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
July 2017, the Company amended its articles of incorporation to change the number of authorized common shares to 750,000,000 shares
of $.001 par value stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Stock</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company entered into an Agreement and Plan of Merger whereby it acquired 100% of the issued and outstanding
capital stock of Georgetown Translational Pharmaceuticals, Inc. (GTP). GTP is a biotechnology company focused on acquiring or
discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS disease (Neurology and Pain)
and shepherding the products through the FDA approval process to the NDA. In exchange for the ownership of GTP, the Company issued
a total of 16,927,878 shares of its common stock to the three prior owners of GTP which represents 33% of the issued and outstanding
capital stock of the Company.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the six months ended June 30, 2017 the Registrant has issued a total of 390,279 shares of common stock to a total of eleven entities
or individuals in exchange for the cancellation of debt in the total amount of $2,025,000 and interest in the total amount of
$486,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
August 2017, the Company issued a total of 17,287,625 shares of common stock in exchange for the cancellation of debt in the total
amount of $17,141,000 and interest in the total amount of $4,693,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
August 2017, the Company issued 496,855 shares of common stock upon the exercise of warrants on a cashless basis.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
August 2017, the Company converted 25,000 Series H and 1,666,667 Series I shares of preferred stock into 5,327,734 shares of common
stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
December 2017, the Company converted 350,000 Series J shares of preferred stock into 350,000 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the quarter ended September 30, 2018, the Company issued 110,000 shares of common stock upon conversion of $220,000 of senior
convertible notes.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the quarter ended December 31, 2018, the Company issued 52,500 shares of common stock upon conversion of $105,000 of senior convertible
notes.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During
the quarter ended December 31, 2018, the Company issued a total of 245,000 shares of Rule 144 restricted common stock in full
settlement of outstanding legal matters, and 125,000 shares of Rule 144 restricted common stock in connection with consulting
services.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Preferred
Stock</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
96,230 shares of Series C preferred stock are convertible into 111 shares of the Company's common stock at the option of the holders
at any time. The conversion ratio is based on the average closing bid price of the common stock for the fifteen consecutive trading
days ending on the date immediately preceding the date notice of conversion is given, but cannot be less than .20 or more than
..2889 common shares for each Series C preferred share. The conversion ratio may be adjusted under certain circumstances such as
stock splits or stock dividends. The Company has the right to automatically convert the Series C preferred stock into common stock
if the Company lists its shares of common stock on the Nasdaq National Market and the average closing bid price of the Company's
common stock on the Nasdaq National Market for 15 consecutive trading days exceeds $3,000.00. Each share of Series C preferred
stock is entitled to the number of votes equal to .26 divided by the average closing bid price of the Company's common stock during
the fifteen consecutive trading days immediately prior to the date such shares of Series C preferred stock were purchased. In
the event of liquidation, the holders of the Series C preferred stock shall participate on an equal basis with the holders of
the common stock (as if the Series C preferred stock had converted into common stock) in any distribution of any of the assets
or surplus funds of the Company. The holders of Series C preferred stock are entitled to noncumulative dividends if and when declared
by the Company's board of directors. No dividends to Series C preferred stockholders were issued or unpaid through December 31,
2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
December 4, 2008, the Company entered into and closed an Agreement (the &#8220;Bristol Agreement&#8221;) with Bristol Investment
Fund, Ltd. pursuant to which Bristol agreed to cancel the debt payable by the Company to Bristol in the amount of approximately
$20,000 in consideration of the Company issuing Bristol 25,000 shares of Series G Convertible Preferred Stock, which such shares
carry a stated value equal to $1.00 per share (the &#8220;Series G Stock&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Series G Stock is convertible, at any time at the option of the holder, into common shares of the Company based on a conversion
price equal to the lesser of $2.50 or 60% of the average of the three lowest trading prices occurring at any time during the 20
trading days preceding the conversion. The Series G Stock, as amended, shall have voting rights on an as converted basis multiplied
by 100.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
the event of any liquidation or winding up of the Company, the holders of Series G Stock will be entitled to receive, in preference
to holders of common stock, an amount equal to the stated value plus interest of 15% per year.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Series G Stock restricts the ability of the holder to convert the Series G Stock and receive shares of the Company&#8217;s common
stock such that the number of shares of the Company common stock held by Bristol and its affiliates after such conversion does
not exceed 4.9% of the Company&#8217;s then issued and outstanding shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
October 13, 2009 the Company was informed by Theorem Group, LLC that it had purchased all of the outstanding Series G Preferred
Stock and Theorem gave notice to the Company that it intended to exercise its ability to vote on all shareholder matters utilizing
the super voting privileges provided by the Series G Stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Effective
February 10, 2010, the Company issued 25,000 shares of its new Series H Convertible Preferred Stock (the &#8220;Series H Preferred&#8221;)
to Theorem Group, LLC, a California limited liability company (the &#8220;Stockholder&#8221;), in exchange for the 25,000 shares
of Series G Stock then owned by the Stockholder. The foregoing exchange was effected pursuant to that certain Exchange Agreement,
dated February 10, 2010, between the Company and the Stockholder (the &#8220;Exchange Agreement&#8221;).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Certificate of Designation of the Series H Preferred is based on, and substantially similar to the form and substance of the Certificate
of Designation of the Series G Preferred. Some of the corrections, changes and differences between the Certificate of Designation
of the Series G Preferred and the Certificate of Designation of the Series H Preferred include the following:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">a.</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As
    previously disclosed, the holder of the Series H Preferred is entitled to vote with the common stock, and is entitled to a
    number of votes equal to (i) the number of shares of common stock it can convert into (without any restrictions or limitations
    on such conversion), (ii) multiplied by 100.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">b.</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
    holder of the Series H Preferred cannot convert such preferred stock into shares of common stock if the holder and its affiliates
    after such conversion would own more than 9.9% of the Company&#8217;s then issued and outstanding shares of common stock.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: top; width: 48px; padding-left: 0.25in; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">c.</font></td>
    <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
    Series G Preferred contained a limitation that the holder of the Series G Preferred could not convert such preferred shares
    into more than 19.999% of the issued and outstanding shares of common stock without the approval of the stockholders if the
    rules of the principal market on which the common stock is traded would prohibit such a conversion. Since the rules of the
    Company&#8217;s principal market did not require such a limitation, that provision has been deleted.</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
August 2017, the Company converted 25,000 Series H stock into 5,119,401 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
November 8, 2010, the Company sold 1,666,667 shares of the Company&#8217;s Series I Preferred Stock, $.001 par value, at a price
of $0.15 per share ($250,000).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
holder of the Series I Preferred Stock will be entitled to receive, out of funds legally available, dividends in cash at the annual
rate of 8.0% of the Preference Amount ($0.15), when, as, and if declared by the Board. No dividends or other distributions shall
be made with respect to any shares of junior stock until dividends in the same amount per share on the Series I Preferred Stock
shall have been declared and paid or set apart during that fiscal year. Dividends on the Series I Preferred Stock shall not be
cumulative and no right shall accrue to the Series I Preferred Stock by reason of the fact that the Company may fail to declare
or pay dividends on the Series I Preferred Stock in the amount of the Dividend Rate per share or in any amount in any previous
fiscal year of the Company, whether or not the earnings of the Company in that previous fiscal year were sufficient to pay such
dividends in whole or in part.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Each
share of Series I Preferred Stock shall entitle the holder thereof to such number of votes per share as shall equal the number
of shares of Common Stock (rounded to the nearest whole number) into which such share of Series I Preferred Stock is then convertible.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Upon
any liquidation of the Company, subject to the rights of any series of Preferred Stock that may from time to time come into existence,
before any distribution or payment shall be made to the holders of any Junior Stock, the holders of the shares of Series I Preferred
Stock then outstanding shall be entitled to receive and be paid out of the assets of the Company legally available for distribution
to its stockholders liquidating distributions in cash or property at its fair market value as determined by the Board in the amount
of $0.15 per share (as adjusted for any stock dividends, combinations or splits with respect to such shares).</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Shares
of Series I Preferred Stock may, at the option of the holder thereof, be converted at any time or from time to time into fully
paid and non-assessable shares of Common Stock. The number of shares of Common Stock which a holder of shares of Series I Preferred
Stock shall be entitled to receive upon conversion of such shares shall be the product obtained by multiplying the Conversion
Rate by the number of shares of Series I Preferred Stock being converted. Initially, the Series I Preferred Stock is convertible
into 6,667 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
the event that the per-share Market Price of the Common Stock over a period of 20 consecutive trading days is equal to at least
130% of the initial conversion price (130% of $0.15), all outstanding shares of Series I Preferred Stock shall be converted automatically
into the number of shares of Common Stock into which such shares of Series I Preferred Stock are then convertible without any
further action by the holders of such shares and whether or not the certificates representing such shares of Series I Preferred
Stock are surrendered to the Company or its transfer agent.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
August 2017, the Company converted 1,666,667 Series I shares of preferred stock into 208,333 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company authorized 2,000,000 shares of Series J Preferred Stock. Shares of Series J Preferred Stock will
have the same voting rights as shares of common stock with each share of Series J Preferred Stock entitled to one vote at a meeting
of the shareholders of the Corporation. Shares of Series J Preferred Stock will not be entitled to receive any dividends, unless
and until specifically declared by our board of directors. The holders of the Series J Preferred Stock will participate, on an
as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Each share of the Series J Preferred Stock
is convertible into one share of our common stock at any time at the option of the holder.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017 the Company issued a total of 700,278 shares of Series J Preferred Stock in exchange for the cancellation of
debt in the total amount of $840,000.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017 the Company issued 5,046 shares of Series J Preferred Stock upon the exercise of warrants on a cashless basis.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017 the Company also issued 600,000 shares of Series J Preferred Stock to one entity as payment for $720,000 of
consulting services provided to the Company.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
December 2017, the Company converted 350,000 Series J shares of preferred stock into 350,000 shares of common stock.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Common
Stock Warrants</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Warrant
transactions for the years ended December 31, 2018 and 2017 are as follows:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
    Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2016</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15,550</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">135.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">486,351</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(501,901</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">15.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    Warrants:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Stock
Options</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
Company reserved 1,333 shares of its common stock at December 31, 2014 for issuance under the 2014 Stock Incentive Plan (the &#8220;2014
Plan&#8221;). The 2014 Plan, approval by stockholders in May 2015, permits the Company to grant stock options to acquire shares
of the Company's common stock, award stock bonuses of the Company's common stock, and grant stock appreciation rights. At December
31, 2018, 87 shares of common stock were available for grant and options to purchase 1,246 shares of common stock are outstanding
under the 2014 Plan.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
following table summarizes stock option transactions for the years ended December 31, 2018 and 2017:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
    of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
    Exercise Price</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 76%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2016</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(133</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,020.00</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Exercisable
    Options:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2018</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">December
    31, 2017</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,428.00</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
weighted-average fair value of options granted was approximately $1,469,000 and $1,770,000 for 2018 and 2017, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
following table summarizes information about all outstanding and exercisable stock options at December 31, 2018:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Outstanding
    Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Exercisable
    Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    <b>Range of Exercise Prices</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    <b>Number of Options</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Remaining</b></font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Contractual
        Life</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Exercise Price</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Number
        of Options</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted-Average
        Exercise Price</b></font></p></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td style="vertical-align: bottom; width: 1%; text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;
    $750.00 to $2,225.00&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.49</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 3%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 1%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,320.00</font></td>
    <td style="vertical-align: bottom; width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758777072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock Options and Warrants (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable as of June 30, 2019</a></td>
<td class="nump">1,813,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercisable as of June 30, 2019</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">486,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(501,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of June 30, 2019</a></td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813,053<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2018</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 135.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="nump">15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of June 30, 2019</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercisable as of June 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentExercisableAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635579216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6774099600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,299)<span></span>
</td>
<td class="num">$ (19,172)<span></span>
</td>
<td class="num">$ (259,186)<span></span>
</td>
<td class="num">$ (144,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Loss on impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense for options and warrants issued to employees and non-employees</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">6,489<span></span>
</td>
<td class="nump">9,696<span></span>
</td>
<td class="nump">130,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">6,855<span></span>
</td>
<td class="nump">8,663<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_NoteAllonges', window );">Note Allonges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">2,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of loan costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(581)<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,048)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(10,677)<span></span>
</td>
<td class="num">(5,430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">2,352<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
<td class="nump">15,145<span></span>
</td>
<td class="nump">5,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Loan costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,415)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">6,522<span></span>
</td>
<td class="nump">10,197<span></span>
</td>
<td class="nump">5,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Minority Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS - Beginning of period</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS - End of period</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes', window );">Issuance of common stock upon conversion of convertible notes</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest', window );">Issuance of common stock upon conversion of accrued interest</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock', window );">Acquisition of intangibles through issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">253,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_IssuanceOfCommonStockForDebt', window );">Issuance of common stock for debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AcquisitionOfIntangiblesThroughIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfCommonStockForDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfCommonStockForDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfCommonStockUponConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfCommonStockUponConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_NoteAllonges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_NoteAllonges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772334240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">25,262<span></span>
</td>
<td class="nump">25,262<span></span>
</td>
<td class="nump">253,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-to-use asset</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">25,421<span></span>
</td>
<td class="nump">25,309<span></span>
</td>
<td class="nump">253,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">25,707<span></span>
</td>
<td class="nump">25,399<span></span>
</td>
<td class="nump">254,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Note payable to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debentures</a></td>
<td class="nump">12,170<span></span>
</td>
<td class="nump">10,673<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">16,731<span></span>
</td>
<td class="nump">14,029<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,731<span></span>
</td>
<td class="nump">14,029<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 750,000,000 shares authorized; and 52,644,882 and 50,650,478 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">545,073<span></span>
</td>
<td class="nump">540,171<span></span>
</td>
<td class="nump">521,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(535,984)<span></span>
</td>
<td class="num">(528,685)<span></span>
</td>
<td class="num">(269,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,976<span></span>
</td>
<td class="nump">11,370<span></span>
</td>
<td class="nump">251,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">25,707<span></span>
</td>
<td class="nump">25,399<span></span>
</td>
<td class="nump">254,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized:</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember', window );">Series J</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock - $0.001 par value; 15,000,000 shares authorized:</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752957488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><b><i>Leases</i></b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As
described in&#160;<i>Note 1. Nature of Operations and Summary of Significant Accounting Policies</i>, we adopted new lease accounting
guidance effective January 1, 2019.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">We
determine if a contractual arrangement is a lease at inception. Our lease arrangements provide the Company the right to utilize
certain specified tangible assets for a period of time in exchange for consideration. Our leases primarily relate to building
office space. Our leases currently consist solely of operating leases. Leases with an initial term of 12 months or less are not
recorded on the balance sheet.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">We
recognize a lease liability and a right of use asset at the lease commencement date based on the present value of the future lease
payments over the lease term discounted using our incremental borrowing rate. Implicit interest rates within our lease arrangements
are rarely determinable. Right of use assets also include, if applicable, prepaid lease payments and initial direct costs, less
incentives received.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">We
recognize operating lease expense on a straight-line basis over the term of the lease within selling general and administrative
expenses.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Our
leases do not contain any material residual value guarantees or material restrictive covenants. Some of our leases include optional
renewal periods or termination provisions which we assess at inception to determine the term of the lease, subject to reassessment
in certain circumstances.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
following table summarizes the Company&#8217;s future minimum lease commitments as of June 30, 2019:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Year
    ending December 31:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 88%; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2019</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">34,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2020</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">71,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2021</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">61,000
    </font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">166,000
    </font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Rent
expense for the six months ended June 30, 2019&#160;and&#160;2018&#160;was&#160;$35,000&#160;and&#160;$54,000, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><b>Employment
Agreements</b></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
October 18, 2018, the Company entered into a Consultant Agreement with Anthony Cataldo. The term of the Consultant Agreement shall
remain in effect until September 30, 2019. This Agreement supersedes the Consultant Agreement dated February 14, 2018 and will
pay Mr. Cataldo $25,000 per month during the term of the Agreement.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
October 19, 2018, the Company entered into an Executive Employment Agreement with Dr. Urbanski, reflecting his current position
as Chief Executive Officer of the Company. Under the terms of this agreement, Dr. Urbanski&#8217;s annual salary is essentially
unchanged from his previous positions. Dr. Urbanski is also entitled to participate in the Company&#8217;s bonus plans. Under
the Executive Employment Agreement, the Company has agreed that upon shareholder approval of a Stock Option Plan, it will recommend
to the Board that the Company grant Dr. Urbanski a Non-Qualified stock option to purchase 2,971,102 shares of the Company&#8217;s
common stock having an exercise equal to the fair market value of the shares on the date of the Agreement. The stock option grant
would vest according to the following schedule: (i) 1,250,000 fully vested shares upon signing of the agreement, (ii) 1,250,000
shares on January 1, 2019, and (iii) 471,102 shares on January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his position
as Chief Executive Officer, President and Chairman of the Board.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
April 3, 2019, the Company entered into the Separation Agreement with Dr. Urbanski in connection with his resignation as the Company&#8217;s
Chief Executive Officer. Pursuant to the terms of the Separation Agreement&#160;Dr. Urbanski will receive six months&#8217; salary
of $212,500 paid in two installments and the Company will reimburse the premiums associated with Dr.&#160;Urbanski&#8217;s continuation
health coverage for six months following his resignation. The Settlement Agreement also contains a release by Mr.&#160;Ali of
any claims against the Company arising from or relating to his employment and customary confidentiality, non-disparagement and
cooperation covenants.</font></p><span></span>
</td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Leases</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
September 1, 2017, the Company entered into a three-year lease agreement for its office in Washington, D.C. In addition to minimum
rent, certain leases require payment of real estate taxes, insurance, common area maintenance charges and other executory costs.
The Company recognizes rent expense under such arrangements on a straight-line basis over the effective term of each lease. This
lease was terminated as of June 30, 2018.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
October 1, 2018, the Company entered into a three-year lease agreement for its office in Westlake Village, CA. In addition to
minimum rent, certain leases require payment of real estate taxes, insurance, common area maintenance charges and other executory
costs. The Company recognizes rent expense under such arrangements on a straight-line basis over the effective term of each lease.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The
following table summarizes the Company&#8217;s future minimum lease commitments as of December 31, 2018 (in thousands):</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Year
    ending December 31:</font></td>
    <td colspan="3" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 88%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2019</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">69,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2020</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">71,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2021</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">61,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">201,000</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Rent
expense for the years ended December 31, 2018 and 2017 was $69,000 and $9,000, respectively.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Employment
Agreements</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 18, 2018, the Company entered into
a Consultant Agreement with Anthony Cataldo. The term of the Consultant Agreement shall remain in effect until September 30, 2019.
This Agreement supersedes the Consultant Agreement dated February 14, 2018 and will pay Mr. Cataldo $25,000 per month during the
term of the Agreement.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 19, 2018, the Company entered into
an Executive Employment Agreement with Dr. Urbanski, reflecting his current position as Chief Executive Officer of the Company.
Under the terms of this agreement, Dr. Urbanski&#8217;s annual salary is essentially unchanged from his previous positions. Dr.
Urbanski is also entitled to participate in the Company&#8217;s bonus plans. Under the Executive Employment Agreement, the Company
has agreed that upon shareholder approval of a Stock Option Plan, it will recommend to the Board that the Company grant Dr. Urbanski
a Non-Qualified stock option to purchase 2,971,102 shares of the Company&#8217;s common stock having an exercise equal to the fair
market value of the shares on the date of the Agreement. The stock option grant would vest according to the following schedule:
(i) 1,250,000 fully vested shares upon signing of the agreement, (ii) 1,250,000 shares on January 1, 2019, and (iii) 471,102 shares
on January 1, 2020. On March 15, 2019, Dr, Urbanski resigned his position as Chief Executive Officer, President and Chairman of
the Board.</p>



<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6762242848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On
December 21, 2018, Dr. Raymond Urbanski, Chief Executive Officer and Chairman of the Board, provided a short-term loan of $100,000
to meet immediate capital needs. The loan matured on January 20, 2019 and carries an interest rate of 5%. The loan was repaid
in January, 2019.</font></p>



<p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645933280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock Options and Warrants (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_StockOptionsAndWarrantsDetailsAbstract', window );"><strong>Stock Options And Warrants Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ExercisePriceRange', window );">Exercise price range</a></td>
<td class="text"> $750.00 to $2,225.00 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1,320.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockOptionsAndWarrantsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockOptionsAndWarrantsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752864928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6762217872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Business</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
1965, the corporate predecessor of GT Biopharma, Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic
Data changed its incorporation to the State of Delaware in 1972; and changed its name to DDI Pharmaceuticals, Inc. in 1985. In
1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International,
Inc. In July 2017, the Company changed its name to GT Biopharma, Inc.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products
based off our proprietary Natural Killer (NK) cell engager (Tri-specific Killer Engager (TriKE) &#38; Tetra-specific Killer Engager
(TetraKE)) and bi-specific Antibody Drug Conjugate (bispecific-ADC) technology platforms. Our TriKE and TetraKE platforms generate
proprietary moieties designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer, or
NK, cells. Once bound to an NK cell, our moieties are designed to stimulate the NK cell and precisely direct it to one or more
specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell&#8217;s
death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target tumor antigens on hematologic
malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in an
outpatient setting and are expected to have reasonably low cost of goods. Our bispecific-ADC platform can generate product candidates
that are ligand-directed single-chain fusion proteins that simultaneously target two tumor antigens. We believe our bispecific-ADC
moieties represents the next generation of ADCs.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Also,
in connection with the acquisition of Georgetown Translational Pharmaceuticals on September 1, 2017, we acquired a portfolio of
IPR&#38;D CNS assets consisting of innovative reformulations and/or repurposing of existing therapies. These CNS assets address
disease states such as chronic neuropathic pain, myasthenia gravis and motion sickness.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Basis
of Consolidation and Comprehensive Income</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
accompanying consolidated financial statements include the accounts of GT Biopharma, Inc. and its subsidiaries. All intercompany
balances and transactions have been eliminated. The Company's financial statements are prepared using the accrual method of accounting.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Going
Concern</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As
shown in the accompanying consolidated financial statements, the Company has incurred an accumulated deficit of $528,685,000 through
December 31, 2018. On a consolidated basis, the Company had cash and cash equivalents of $60,000 at December 31, 2018. The Company's
plan is to raise additional capital until such time that the Company generates sufficient revenues to cover its cash flow needs
and/or it achieves profitability. However, the Company cannot assure that it will accomplish this task and there are many factors
that may prevent the Company from reaching its goal of profitability.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
current rate of cash usage raises substantial doubt about the Company&#8217;s ability to continue as a going concern, absent any
sources of significant cash flows. In an effort to mitigate this near-term concern the Company intends to seek additional equity
or debt financing to obtain sufficient funds to sustain operations. However, the Company cannot provide assurance that it will
successfully obtain equity or debt or other financing, if any, sufficient to finance its goals or that the Company will generate
future product related revenues. The Company&#8217;s financial statements do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that
the Company cannot continue in existence.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Use
of Estimates</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity.
These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently
applied in the preparation of the financial statements. The preparation of financial statements requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosures of contingent assets
and liabilities at the date of the financial statements. Actual results could differ from those estimates.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>Segment
Information</i></font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the
Company has viewed its operations and manages its business as one segment operating in the United States of America.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6765548752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">52,644,882<span></span>
</td>
<td class="nump">50,650,478<span></span>
</td>
<td class="nump">50,117,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">52,644,882<span></span>
</td>
<td class="nump">50,650,478<span></span>
</td>
<td class="nump">50,117,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember', window );">Series J</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">2,353,548<span></span>
</td>
<td class="nump">2,353,548<span></span>
</td>
<td class="nump">1,163,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">2,353,548<span></span>
</td>
<td class="nump">2,353,548<span></span>
</td>
<td class="nump">1,163,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesJPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6760785648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ResearchDevelopment', window );">Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_ConsultingAndAdvisoryServices', window );">Consulting and Advisory Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_BoardOfDirectorsServiceCosts', window );">Board of Directors Service Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Expenses</a></td>
<td class="nump">$ 2,665<span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_BoardOfDirectorsServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_BoardOfDirectorsServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConsultingAndAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConsultingAndAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6633898160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease commitments</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Year
    ending December 31:</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 88%; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2019</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">34,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2020</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">71,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;2021</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">61,000
    </font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">166,000
    </font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Year
    ending December 31:</font></td>
    <td colspan="3" style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 88%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2019</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 9%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">69,000</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2020</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">71,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">2021</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">61,000</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">201,000</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6608371200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - The Company and Summary of Significant Accounting Policies (Tables) (USD $)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract', window );"><strong>Note 2 - Company And Summary Of Significant Accounting Policies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially dilutive securities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2018</b></font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 78%; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Exercise of common stock warrants</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,813,053</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 1%; line-height: 107%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Conversion of preferred stock into common stock</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,163,659</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Conversion of convertible debentures into common stock</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">5,704,543</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">Exercise of common stock options</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,113</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,246</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">8,682,368</font></td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt double; text-align: right; line-height: 107%"><font style="font: 8pt Times New Roman, Times, Serif">1,164,905</font></td>
    <td style="line-height: 107%">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_Note1CompanyAndSummaryOfSignificantAccountingPoliciesTablesUsdAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
